





Division of Extramural Activities Annual Report 2012



Subtype-specific gene expression signatures

MYD88 L265P*	BCL2 t(14;18)
CD79B*; CD79A*	EZH2*
SPIB amp	MEF2B*; MEF2C*
BCL2 amp	MDM2 amp
	miR-17-92 amp
	SGK1*
CDKN2A del	PTEN*/del
INK4a/ARF del	S1PR2*
TNFAIP3*/del	GNA13*
PRDM1*/del	TNFRSF14*/del
	FAS*/del

Subtype-specific genetic aberrations




Subtype-specific targeted therapy

Molecular Diagnosis of Lymphoid Malignancies

Diffuse large B cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is diagnosed in more than 20,000 individuals per year in the United States. Currently, the diagnosis of DLBCL is based on tumor histology, and all patients are given a standard chemotherapeutic regimen (CHOP) plus Rituximab (R-CHOP). Substantial clinical heterogeneity exists within this diagnostic category, with only ~50 percent of individuals cured by R-CHOP. This heterogeneity has been explained, in part, by the fact that DLBCL is comprised of two molecularly distinct diseases that were originally identified by their unique gene expression signatures (**top panel**). These subtypes, termed Activated B Cell-like (ABC) DLBCL, and Germinal Center B Cell-like (GCB) DLBCL, arise from different stages of normal B cell differentiation, which accounts in part for their distinctive gene expression signatures. With R-CHOP chemotherapy, ABC DLBCL has, at best, a 40 percent cure rate as compared with 75 percent for GCB DLBCL.

These DLBCL subtypes acquire separate somatic genetic aberrations, thus supporting the view that they represent pathogenetically distinct diseases (middle panel). Various genomic alterations—including point mutations (asterisks), translocations, amplifications, and deletions—are preferentially or exclusively observed in one DLBCL subtype or the other. These genetic events in turn engage different cellular pathways that promote proliferation and/or survival of the malignant cell. In ABC DLBCL, the pro-survival NF- κ B pathway is constitutively activated by gain-of-function mutations targeting the B cell receptor subunits CD79B and CD79A and the signaling adapters CARD11 and MYD88, as well as by loss-of-function mutations targeting *TNFAIP3*, which encodes the negative regulator of the NF- κ B pathway A20. Conversely, GCB DLBCL tumors acquire various mutations that activate the pro-survival and pro-growth PI(3) kinase pathway, including inactivating mutations and deletions of *PTEN*, as well as amplification of the mir-17-92 microRNA cluster, which down-regulates expression of *PTEN*.

Knowledge of these oncogenic pathways is leading to new therapeutic strategies for these DLBCL subtypes. In ABC DLBCL, a subset of tumors rely upon a “chronic active” form of B cell receptor signaling, which is augmented by the mutations in the CD79B and CD79A subunits of the B cell receptor (lower panel). B cell receptor activation triggers a cascade of kinases, including several SRC-family kinases (SFKs), SYK, BTK, and PKC β . PKC β phosphorylates and activates the adapter CARD11, leading to activation of I κ B kinase (IKK), the central regulator of the NF- κ B pathway. The BTK kinase inhibitor, Ibrutinib, suppresses chronic active B cell receptor signaling in ABC DLBCL. In early phase clinical trials in relapsed/refractory DLBCL, Ibrutinib has induced complete and partial remissions, the vast majority of which have occurred in patients with ABC DLBCL. Future therapeutic regimens in DLBCL need to be tailored to the oncogenic addictions that define and separate the ABC and GCB subtypes.



Images and narrative are courtesy of Dr. Louis M. Staudt, Director, Center for Cancer Genomics, National Cancer Institute, National Institutes of Health

Contents

Introduction	1
Overview of the Division of Extramural Activities.	3
Special Activities in the Office of the Director, DEA	4
Program Coordination: A Resource for New Funding Initiatives	6
Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications	7
Peer Review — The Next Step	9
NCI Grant and RFA/Cooperative Agreement Funding	17
Supporting Peer Review Consultants.	19
DEA's Role in Advisory Activities	21
Committee Management Activities	23
Portfolio Tracking and Analysis	25
Information Resources Management	29
Organizational Structure of the Division of Extramural Activities.	31

Figures

Figure 1. Receipt and Referral of NCI Grant Applications, FY2008 – 2012	7
Figure 2. DEA Review Workload, FY2008 – 2012	10
Figure 3. P01, SPORE, and Other Multi-Project Research Applications Reviewed, FY2008 – 2012	12
Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed, FY2008 – 2012	14
Figure 5. Technology Initiatives Applications Reviewed, FY2008 – 2012	15
Figure 6. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area, FY2011	17
Figure 7. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area, FY2012	18
Figure 8. BSA Approved RFA/Cooperative Agreement Funding Concept Set-Asides by Division/Office/Center	18
Figure 9. FY2012 Success Rates for Applications in High Incidence Cancers	27
Figure 10. FY2012 Success Rates for Applications in Selected Special Interest Categories.	28

Tables

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2012, Sorted by Date of Publication	42
Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2012, Sorted by Division/Office/Center.	43
Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2012, Sorted by Date of Publication	44
Table 3a. Program Announcements (PAs) Published by the NCI in FY2012, Sorted by Date of Publication	46
Table 3b. Program Announcements (PAs) Published by the NCI in FY2012, Sorted by Division/Office/Center.	47
Table 4. NCI Participation in Trans-NIH Program Announcements (PAs) in FY2012, Sorted by Date of Publication	48

Table 5.	Applications Received for Referral by the NCI/DEA in FY2012, Sorted by Mechanism	50
Table 6.	Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2012, Sorted by Mechanism	52
Table 7.	Applications Reviewed by NCI Initial Review Group (IRG) Subcommittees and Special Emphasis Panels (SEPs) in FY2012	53
Table 8.	Summary of Investigator-Initiated Program Project (P01) Applications Reviewed	53
Table 9.	Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2012	53
Table 10.	Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2012	54
Table 11.	Program Announcements (PAs) Reviewed by the NCI/DEA in FY2012	55
Table 12.	Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2012	57
Table 13.	Summary of NCI Grant Awards by Mechanism in FY2012	59
Table 14.	Average Total Cost and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism from FY2008 - FY2012	61
Table 15.	NCI Organ and Related Site-Specific Dollars for FY2008 - FY2012 – Annual Percent Change	64
Table 16.	NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change	72
Table 17.	NCI Funding of Foreign Research Grants in FY2012	91
Table 18.	Foreign Components of U.S. Domestic Research Grants in FY2012.	94

Appendixes

Appendix A:	Activities of the National Cancer Advisory Board (NCAB)	96
Appendix B:	Activities of the Board of Scientific Advisors (BSA)	97
Appendix C:	List of Chartered Committees	98
Appendix D:	NCI Initial Review Group Consultants	111
Appendix E:	NCI Grant Mechanisms and Descriptions	162
Appendix F:	Glossary of Acronyms	172
Appendix G:	Cancer Information Sources on the Internet	174

Introduction



The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research before funding and for conducting systematic surveillance of that research after funding. The Division solicits advice from individuals and/or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is critically important to science in that it allows good ideas to surface and to be judged on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

The DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, and conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA) with distinguished scientists from outside the NCI and representatives from the advocacy community advises the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; and (3) extramural training opportunities for NCI program and review staff.

As a Division, we: evaluate the content of all extramural research funded by the NCI and annually track the NCI research portfolio of more than 7,800 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized analyses of the costs, goals, and


accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. The DEA: monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division also: coordinates, for the NCI, the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of the DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2012 (1 October 2011 - 30 September 2012) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actually engaged in research for assistance in selecting the best research and training projects. We sincerely want to thank the more than 2,100 researchers, clinicians, and advocates who gave unselfishly of their time in FY2012 and have contributed to the continuing success of NCI's peer review and advisory activities.

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities

Division of Extramural Activities



Overview of the Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grants review by the National Cancer Advisory Board (NCAB) and the concept review of all new and reissued Requests for Applications (RFAs) and research and development (R&D) Requests for Proposals (RFPs) with the Board of Scientific Advisors (BSA).

The **Committee Management Office** (CMO) provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, and chartered review groups, and it serves as an NIH service center for the National Center for Complementary and Alternative Medicine, the NIH Council of Councils, and a Department of Health and Human Services (HHS) chartered advisory committee. The CMO provides policy guidance and assistance to ensure that the NCI and client HHS/NIH Institutes, Centers, and Offices operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, PAs, Notices, and RFPs, and, finally, through the peer review of grant and cooperative agreement applications and contract proposals. The **Office of Referral, Review, and Program Coordination** (ORRPC), with four branches, was established for: (1) coordination of the development and issuance of NCI program initiatives; (2) execution of grant referral; and (3) management of NCI review activities. Review activities include the organization and management of peer review for all applications and proposals received in response to RFAs, R&D RFPs, Program Announcements with Special Receipt (PARs), and multi-compo-

nent grant initiatives. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program divisions, offices, and centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as to the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The **Research Analysis and Evaluation Branch** (RAEB) works closely with the NCI Office of Budget and Finance to provide budget-linked portfolio data for NCI grants and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. This Branch has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to staff, advisory groups, and applicants. To facilitate this evaluation, the **Office of Extramural Applications** (OEA), through the **Applied Information Systems Branch** (AISB), maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public Internet (<http://deainfo.nci.nih.gov/funding.htm>) and NCI limited-access Intranet versions. Both RAEB and AISB were actively involved in elevating the DEA Funded Research Portfolio website to become the NCI Funded Research Portfolio (NFRP) website (<http://fundedresearch.cancer.gov>).

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD ensures that the NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that a grantee believes the proposed study does not warrant or require inclusion of women or persons from minority groups, he or she can apply for a waiver of this requirement. The DEA Director is the Appeals Officer for the NCI and has the authority to grant waivers. In FY2012, 26 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA Director and designees work to address concerns

about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2012, 10 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity, HHS, and referred to the Director, DEA. Six cases were closed, and two cases were found to involve research misconduct.*

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO), which resides in the DEA OD, develops and coordinates the training of Program, Review, and other extramural staff. The mission of PRESTO is to increase the knowledge base of new and experienced staff members and optimize their effectiveness in supporting the goals of NCI. To accomplish this mission, PRESTO: (1) designs and implements a broad-based curriculum for Program and Review staff; (2) provides training on specialized topics related to understanding of and compliance with NIH policies; and (3) identifies and develops resources to facilitate individual learning and performance. PRESTO also collaborates with the NCI Office of Grants Administration, the Trans-NCI Extramural Awareness Group (TEAG), and the NCI Office of Workforce Management and Development to provide customized job-related training and career development opportunities. Finally, PRESTO monitors the participation of extramural staff in NIH- and NCI-sponsored training

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

activities as well as continuously evaluates the efficacy of these activities.

During FY2012, PRESTO developed and/or conducted the following activities:

- A NCI-specific curriculum for extramural staff, consisting of an online narrated overview of the NCI Extramural Program and face-to-face sessions on the grants process.
- Forums on core administrative responsibilities, including ones related to the NCAB Closed Session, Funding Opportunity Announcement Development and Production, Federal Advisory Committee Act (FACA), and Conflict of Interest.
- A State-of-the-Science forum with emphasis on NCI-supported activities.
- A New Employee Handbook for NCI Extramural Staff, as well as a quarterly PRESTO newsletter.
- Several DEA Brown Bag meetings focused on SRO-related activities.
- A training website (<http://deaintranet.nci.nih.gov/presto/index.htm>) on the DEA intranet.
- A survey of NCI extramural staff to identify training needs, along with the establishment of a liaison group consisting of NCI Division/Office/Center (DOC) representatives.
- Meetings with Program Divisions to introduce PRESTO and provide a refresher on the appeals process.

PRESTO also collaborated with TEAG in the production of the NCI Program Official (PO) Best Practices Handbook, and co-sponsored a forum with TEAG on the NCI Grants Budget process.

During FY2013, PRESTO will continue to provide a variety of training opportunities for NCI extramural staff, and will create online resources (e.g., screencasts) to assist extramural staff in their job functions.

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements, which comprise both RFAs and Program Announcements (PAs). Specifically, members of the **Program Coordination and Referral Branch** (PCRB) provide expert assistance to NCI program staff members as they work to develop and publish new (and reissue) FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, all new and reissued NCI FOAs, Notices, and various associated guidelines are reviewed, edited as needed, and cleared through the DEA, under PCRB coordination, before being forwarded to the NIH Office of Extramural Research for approval and publication in the *NIH Guide for Grants and Contracts* and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in proper format. PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and **1b** show the variety of RFAs issued by the NCI in FY2012, and **Table 2** lists RFAs issued by other NIH institutes or centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2012, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.


PCRB staff members continue to provide relevant information and timely updates to all NCI extramural staff members on activities and results related to the requirements for and uses of electronic grant applications. The Branch also serves as a direct source of guidance on this topic for program directors at the NCI and applicants in the extramural scientific community. The Referral Office (RO) staff persons in PCRB collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Web-based Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of use by NCI staff members and quality of service for the NCI's grant applicants and awardees. In addition to performing their program coordination and referral responsibilities, PCRB Health Scientist Administrators also served as Scientific Review Officers (SROs) in managing the reviews of 427 student loan repayment program (LRP) contract proposals in FY2012.

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2012, a total of 13,733 grant applications were submitted to the NCI for funding with appropriated funds (see Figure 1 and Table 5). Applications for 50 different types of funding award mechanisms (Appendix E) were received, including the Investigator-Initiated Research Project (R01), Career Development Awards (K series), Research Program Project (P01), Cancer Center Support Grant (CCSG, P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) Grant (R41/R42), Small Business Innovation Research (SBIR) Grant (R43/R44), and U-series (Cooperative Agreement) mechanisms.

All applications submitted to the National Institutes of Health (NIH) are assigned to an Institute or Center (IC). The IC in turn has a structure in place to address internal assignments. DEA's **Program Coordination and Referral Branch** is responsible for receipt, referral, and assignment of applications as well as for program (i.e., scientific initiative and funding opportunity) development functions. Upon receipt of primary and secondary assignments of applications to the NCI by the NIH Center for Scientific Review (CSR), the DEA Referral Officers (ROs): (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance; and (3) whenever necessary, negotiate transfers of grant applications to and from other NIH ICs and even other HHS

**Figure 1. Receipt and Referral of NCI Grant Applications*
FY2008 - 2012**



*Includes NCI Primary and Secondary applications received and referred.

research funding agencies, such as the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control and Prevention (CDC).

The ROs distribute all of the applications that are to be directly reviewed by NCI DEA-managed peer review groups. These applications include those for P01, Planning Grants (P20), Cancer Centers (P30), Specialized Centers (P50), Conference Grants (R13), Small Grants, certain Phased Innovation Grants (R21/R33), Training Grants (T32 and R25), K-series Career Development Grants, certain R01 Research Project Grants (such as large multi-site clinical trials), and Cooperative Agreement applications.

The first point of contact for applicants is often the RO. The RO is the receipt point for Letters of Intent (LOIs) from potential applicants for multi-component P01 and R13 grants and applications for Academic Research Enhance-

ment Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant award support. Additionally, applicants contact the Referral Office for information about NCI programs, their eligibility to apply the relevance of their proposed research to the missions of various NCI programs, and the names and contact information of NCI program staff members to guide them through the application process.

DEA's RO serves as the primary NCI contact locus for the extramural scientific community in need of information related to funding opportunities, mechanisms, policies, processes, procedures, new initiatives announced as RFAs or PAs, and the peer review process. In addition, the ROs assist members of the extramural community in navigating NIH and NCI Web pages to obtain current grants-related information, forms, and guidelines.

Peer Review—The Next Step

Once applications are referred to the NCI and the appropriate program, they must be reviewed. The high caliber of NCI-sponsored research is maintained through a peer review process in which experts in the appropriate fields review and score the merit of research grant applications and contract proposals. The peer review mechanism helps to ensure that the NCI uses its resources wisely and funds research that has the potential to make a significant contribution to science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The peer review system of the NIH consists of two sequential levels of review mandated by statute. The first level is of grant applications assigned to the NCI. This review is performed by either an NIH CSR study section, a chartered NCI Initial Review Group (IRG) subcommittee, or an NCI Special Emphasis Panel (SEP), whose primary purpose is to review and evaluate the scientific merit/impact of research grant and cooperative agreement applications. The second level of review, which is for program relevance, is conducted by the National Cancer Advisory Board (NCAB).

Most investigators are familiar with the NIH CSR study sections, which have primary responsibility for managing the peer review of R01 grant and Fellowship (F) applications. It is less widely known, however, that grant applications representing requests for more than 50 percent of the NCI's extramural budget are reviewed by chartered IRGs and SEPs that are directly formed and managed within the NCI by the DEA. Peer review managed by either the CSR or the DEA is usually determined by the choice of grant mechanism.

The NCI has no direct input into the selection of peer reviewers who serve on CSR study sections. In contrast, members of the NCI IRG and SEPs are selected by DEA review staff, with suggestions from NCI program staff. All chartered DEA review subcommittee members are approved by the Director, DEA, based on their knowledge of the various disciplines and fields related to cancer. The NCI has five active IRG specialized review subcommittees; for example, Subcommittee A reviews Cancer Center grant applications and Subcommittee I reviews career development applications. (The membership of NCI-chartered subcommittees may be found in [Appendix C](#) and at <http://deainfo.nci.nih.gov/advisory/irg.htm>.) IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs may be formed to review grant applications received in response to RFAs and PARs, other specialized applications, or R&D contract proposals received in response to RFPs. Members of such panels are selected on a one-time, as-needed basis to review specific grant and cooperative agreement applications, or contract proposals. Additional information about NCI SEPs can be accessed at <http://deainfo.nci.nih.gov/advisory/sep.htm>.

Both the SEPs and IRGs provide advice on the scientific and technical merit of applications for research and research training grants, cooperative agreements, and contract proposals relating to scientific areas relevant to cancer. DEA SROs manage the scientific reviews of grant applications and R&D contract proposals, including the selection of peer reviewers and the overall administration of the peer review process.

The peer review of grant applications generally occurs in the fall, winter, and spring prior to the February, June, and September NCAB meetings, respectively.

Review Workload


In FY2012, the DEA organized, managed, and reported the review of a total of 2,514 grant and cooperative agreement applications (Table 6) and 659 contract proposals (Table 12) assigned to the NCI for funding with appropriated dollars. The total number of grant, cooperative agreement applications, and contract proposals reviewed in FY2012 was 3,173 (Figure 2). Table 7 provides a summary of the applications reviewed by NCI IRG subcommittees and SEPs. Thirteen meetings of the NCI IRG subcommittees and 105 SEPs were convened to review grant applications and contract proposals of various types. In addition, there were 10 site visits and 53 other review-associated meetings, such as orientation teleconferences, applicant interviews, and fact-finding review panel workgroups. Approximately 2,148 peer reviewers and expert

consultants served on the NCI DEA-managed IRG subcommittees, SEPs, and workgroups in FY2012 (see Appendixes C and D). Members were selected because they are authorities in relevant fields of biomedical research or because they represent informed consumer perspectives.

Peer Review Functions

The Office of Referral, Review, and Program Coordination (ORRPC) is responsible for the coordination and management of the review of grant applications, cooperative agreement applications, and contract proposals for the Institute, and it includes three review branches, a referral branch, and the Office of the Associate Director. The review branches are responsible for organizing, managing, and reporting the scientific peer review of applications for a wide variety of grant

**Figure 2. DEA Review Workload*
FY2008 - 2012**



*Withdrawn applications are not included. LRP contracts are not included in the RFAs.

mechanisms and topics. Reviews are conducted by one of the five subcommittees of the NCI IRG or by one of the specially convened SEPs as shown in [Table 7](#).

The [Research Programs Review Branch](#) (RPRB) and the [Resources and Training Review Branch](#) (RTRB) are primarily responsible for the peer review of a variety of unsolicited multi-component, cancer training, and career development grant applications (see [Table 6](#)). The RPRB has primary responsibility for review of unsolicited P01 and SPORE applications involving translational research focused on various disease sites. The RTRB has primary responsibility for review of applications for cancer centers, cancer training, and career development, as well as for managing the five NCI IRG subcommittees (see [Appendix D](#)).

Reviews conducted by the RTRB, including those of the Cancer Center Support Grant (CCSG) applications, involve a two-tier initial peer review process. Normally, the first tier of the review involves a site visit to the applicant's institution by an expert review panel. This review format provides an opportunity for the reviewers to question the applicants directly to clarify issues in the application, thereby enhancing the review process. The review panel members prepare a draft review report, which is then considered, along with the written application, by the relevant NCI IRG for final impact scoring of the CCSG application. Subcommittee A is the "parent IRG subcommittee" for the P30 CCSG applications. The other four subcommittees of the NCI IRG (Subcommittees F, G, I, and J) review all of the career development, training, and education grant applications submitted to the NCI.

The [Special Review and Logistics Branch](#) (SRLB) organizes and manages peer review primarily for grant applications in response to most of NCI's RFAs, specialized PARs, and R&D contract proposals submitted in response to RFPs; all of these reviews are conducted by SEPs. In addition, the Program Coordination and Referral Branch often collaborates with the review branches to assist

in the review of special initiatives and also has responsibility for the review of conference grant and loan repayment program applications.

SROs in these review units prepare the summary statements, which present the peer reviewers' written evaluations of and recommendations for the applications considered at each review committee meeting. Each principal investigator (applicant) for an application also receives the summary statement as do the NCAB members for a second-level review.

Research Programs Review Branch

Program Project (P01) Applications

A significant proportion of the effort of the RPRB during FY2012 was associated with the review of unsolicited P01 applications. During FY2012, the SROs in the RPRB organized and managed the review of 77 new, renewal (recompeting), resubmitted (amended), and revised (competitive supplement) P01 applications (see [Table 8](#)). Approximately 56 percent of the applications were proposing new multidisciplinary research programs, and 36 percent of the applications were amended ([Table 8](#)). Thirty five (46%) of the 77 applications were referred to NCI's Division of Cancer Treatment and Diagnosis (DCTD) (see [Table 9](#)). The 77 applications requested \$186,372,920 in total costs for the first year (see [Table 9](#)) and \$1,062,717,984 in total costs for all years. Of the 77 P01 applications reviewed in FY2012, 15 (20%) included multiple PIs.

P01 applications are reviewed in groups of up to 10 applications by a one-tier, "paper only" review process. All review panels are constituted as SEPs, with reviewers recruited based on the expertise needed for the applications being reviewed. The applications are grouped based on science, typically into three to four SEPs. The groupings vary depending on the number of applications that are received and the science proposed. A SEP may include applications representing a continuum of research from basic through translational to pre-clinical and clinical studies. The SEP reviewers

evaluate and score projects, cores, and integration, and then assign the overall impact score to each application.

Specialized Programs of Research Excellence (SPORE, P50)


The other major responsibility for RPRB during FY2012 was the peer review of applications received for the NCI SPORE. These large, complex, multidisciplinary P50 research center applications focus on translational research directly applicable to human disease in various organ sites. During FY2012, the RPRB organized and managed six SEPs for the review of a total of 41 SPORE applications (see [Figure 3](#)). These 41 applications addressed multiple organ sites, with the following distribution of applications: Brain (3); Breast (7); Endometrial (1); Gastrointestinal (GI)(8); Head and Neck (HN) (1); Leukemia (2); Lymphoma (4); Lung (3); Liver (1); Prostate (6); Skin (3); and Thyroid (2).

Overall, 20 (49%) of the 41 applications were for new SPOREs, and 21 (51%) of the 41 applications were renewal applications. The applications requested \$102,226,685 in total costs for the first year of support and \$524,816,257 in total costs for all years.

The disease sites addressed in SPORE applications for each review round continued to be very varied. Seven applications addressing six different disease sites were reviewed for the February 2012 NCAB meeting, 25 applications addressing 10 disease sites were reviewed for the June 2012 NCAB meeting, and nine applications addressing six disease sites were reviewed for the September 2012 NCAB meeting.

Potential applicants for both P01 and SPORE grants are strongly encouraged to have pre-submission conferences with the appropriate NCI program (and review) staff members so that they fully understand the guidelines, requirements,

Figure 3. P01, SPORE, and Other Multi-Project Research Applications Reviewed* FY2008 - 2012



*Withdrawn applications are not included.

and goals of these complex applications. SROs from RPRB routinely participate in these pre-submission conferences to ensure that applicants also understand the formatting requirements, the review process, the special review criteria, and the special scoring paradigms for these applications.

Resources and Training Review Branch

In FY2012, the RTRB administered the five NCI IRG subcommittees (A, F, G, I, and J). The RTRB has the responsibility for the reviews of applications for cancer centers, institutional training and education programs, and career development awards. Its staff members also participate in the reviews of applications for other funding mechanisms handled by the DEA.

The reviews conducted by the RTRB subcommittees are of two types: (1) the complex, multidisciplinary applications, such as Cancer Center Support Grants (CCSG) and (2) single component training and career development applications. The review formats for the CCSG applications generally involve a two-step initial review. The first step of the review involves a site visit to the applicant institution. Each group of experts serves as a fact-finding body to clarify any information or issues related to the application through discussion with the applicants. This site visit committee prepares a draft report that is presented, with the full application, for discussion, evaluation, and final scoring by parent subcommittee, NCI IRG Subcommittee A. Scoring by a parent subcommittee provides a more uniform evaluation of applications than scoring by individual review teams. During FY2012, Subcommittee A reviewed 10 CCSG applications. The single component career development, training, and education grant applications submitted to the NCI are reviewed by Subcommittees F, G, I, and J.

Training and Career Development

Between 2007 and 2009, the number of applications for career development awards had declined. However, the significant increase from

385 applications in 2009 to 474 in 2010 is stabilized to 435 in 2012. The number of training grant applications is 152 in 2012 (see [Figure 4](#)).

National Clinical Trials Network (NCTN)


Late in FY2010, the NCI initiated an effort to upgrade the Clinical Trials Cooperative Group Program into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The overall goal of the NCTN Program is to conduct definitive, randomized, late phase clinical treatment trials and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials, as part of the NCI's overall clinical research program for adults and children with cancer.

In July 2012, six FOAs were posted soliciting applications for Network Group Operations Centers; Network Group Statistics and Data Management Centers; Network Group Integrated Translational Science Centers; Lead Academic Participating Site Centers; Network Radiotherapy and Imaging Core Services Centers; and a Canadian Collaborating Clinical Trials Network. It is anticipated that the NCI will review these applications during the summer of FY2013.

Other RTRB Activities

To assist reviewers in preparing for their participation in peer review, Reviewer Guides are maintained for all of the application types reviewed by the RTRB. These Reviewer Guides were updated for the newly reissued FOAs and for electronic receipt. This resource was especially helpful for the subcommittee members who evaluate Training and Career Development grant applications, because most reviewers on each subcommittee review several types of applications. The Reviewer Guides contain general information on peer review and NIH rules regarding the use of human subjects in research, as well as specific instructions for each of the mechanisms to be reviewed by that subcommittee. These mechanism-specific guides have been completed for all education, training, and career development types

**Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed*
FY2008 - 2012**



CD Mechanisms: K01, K05, K07, K08, K18, K22, K23, K24, K25, K99. T&E Mechanisms: K12, R25, T32.

*Withdrawn applications are not included.

of applications that are reviewed in the RTRB, and for the Cancer Centers applications that are evaluated by Subcommittee A.

Special Review and Logistics Branch

The SRLB organizes and manages peer review primarily for grant applications submitted in response to NCI RFAs and specialized PARs as well as for contract proposals submitted in response to specific RFPs. The reviews are conducted with SEPs and involve recruiting scientists with the appropriate expertise for each review meeting. During FY2012, the DEA reviewed 2,514 applications received in response to 16 RFAs and 46 PAs/PARs.

Following approval of RFA concepts by the NCI Scientific Program Leaders (SPL) and the BSA, program staff members prepare RFAs for publication in the *NIH Guide for Grants and Contracts*. DEA staff members, including members of the

SRLB, assist in critically reading the draft documents and in providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute and approved by the BSA, whereas for a PAR, there is no dollar set-aside and no requirement for BSA review. **Table 10** lists the RFAs and number of related applications that were reviewed by the DEA in FY2012. **Table 11** presents the number of applications submitted in response to PAs or PARs, the review of which is shared by the SRLB, the RPRB, and the RTRB. The Institute also issues RFP solicitations seeking offers for contracts to support activities targeted to highly specific institute goals.

Technology Research Applications

The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Develop-

mental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where “proof-of-principle” of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In FY2012, 131 technology applications for Exploratory/Developmental grants (R21) and Exploratory/Developmental Phase II grants (R33) were reviewed under 4 RFAs (see [Figure 5](#)).


The Small Business Innovation Research (SBIR) program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, there was the first issuance of the SBIR Phase II Bridge Award RFA designed to “bridge the gap” between the

end of the Phase II award and commercial development. That program continued in 2012. Ten R44 applications were reviewed for SBIR Phase II B Bridge Awards. In 2012, a PAR entitled “Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology,” invited applications for cooperative agreement SBIR (U43/U44) awards. Forty-eight U43 and one U44 were reviewed in DEA for this initiative.

Research Answers to NCI’s Provocative Questions

The 2012 activities in the SRLB are very notable for the review of a large number of applications submitted in response to RFAs for “Research Answers to NCI’s Provocative Questions.” In 2011, following input from the scientific community through focus groups, forums, and online postings, 24 perplexing scientific questions in cancer prevention, detection, diagnosis, and treatment in need of research answers were identified.

**Figure 5. Technology Initiatives Applications Reviewed*
FY2008 - 2012**



*Withdrawn applications are not included.

Four hundred and twenty (420) R01 Research Project and 325 R21 Exploratory/Developmental applications in five thematic areas were submitted in response to two RFAs (CA11-011 and CA11-012). The applications were reviewed using a two-stage initial review format. The first stage review of applications was conducted by mail-in reviews to assess the technical merit of each application followed by an in-person review meeting to assign a final impact score to each application based on the impact and significance of the science. The RFAs will be reissued for FY2013.

Small Grant Programs

Several small grant (R03) PAR program initiatives stimulated increased interest in the applicant community. These initiatives provided support for many new investigators and pilot studies in cancer prevention (PAR-11-079); cancer epidemiology (PAR-08-237; reissued as PAR-12-039); and behavior research in cancer control (PAR-09-003; reissued as PAR-12-035). In FY2011, there were 428 applications submitted in response to the three initiatives. In FY2012, those same ini-

tiatives attracted 455 applications. In FY2012, an additional 139 R03 applications were submitted under other Program Announcements and were reviewed in CSR.

Research and Development Contract Proposals

The DEA SRLB, RPRB, RTRB, and PCRB reviewed 659 R&D contract proposals (including 427 Loan Repayment Program applications) received in response to 38 RFPs. Of those 38 RFPs, 35 were part of the Omnibus Solicitation for Small Business Innovation Research (SBIR) published each fall (Phase I and II topics) (see [Table 12](#)). During review, several elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards result from the RFP solicitation. Phase II SBIR proposals are submitted by Phase I awardees at the request of the Institute. To facilitate the contract review process, the SRLB has been working with the staff of DEA's Applied Information Systems Branch to develop a series of Web-based documents to be used for contract peer review.

NCI Grant and RFA/Cooperative Agreement Funding


The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, it provides concept review for NCI-sponsored RFAs. **Figures 6 and 7** show total NCI Grant and RFA funding according to scientific concept area in FY2011 and FY2012. **Figure 8** shows RFA concepts that the BSA approved from FY2009 through FY2012 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2012. In **Table 14**, a comparison is made of the average

cost and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10, and U19 grants and cooperative agreements awarded in FY2008 through FY2012 according to the extramural divisions, offices, and centers.


Trends in grant funding according to scientific discipline and organ site are provided in **Tables 15 and 16**. **Table 17** reports NCI's funding of foreign research grants in FY2012, and **Table 18** reports foreign components of U.S. Domestic research grants in FY2012. **Note:** Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year.

Figure 6. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area FY2011




Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 7. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area FY2012



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 8. BSA Approved RFA/Cooperative Agreement Funding Concept Set-Asides by Division/Office/Center



Legend:

DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
OD	Office of the Director
OD-OCG	Office of the Director - Office of Cancer Genomics
OD-OCTR	Office of the Director - Office of Centers, Training, and Resources
OD-CRCHD	Office of the Director - Center to Reduce Cancer Health Disparities
OD-OHAM	Office of the Director - Office of HIV and AIDS Malignancy
OD-CSSI	Office of the Director - Center for Strategic Scientific Initiatives
OD-OBRR	Office of the Director - Office of Biorepositories and Biospecimen Research
OD-SBIRDC	Office of the Director - Small Business Innovation Research Development Center
TRANS-1	NCI (DCCPS), Trans-NIH
TRANS-2	NCI (DCTD), Trans-NIH

* Indicates co-funding among NCI Divisions/Offices/Centers.

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's **Scientific Review and Evaluation Activities (SREA)** unit, residing within the NCI **Committee Management Office**, supports the NCI peer review process by compensating consultants for their services on the NCI IRG subcommittees or SEPs and by reimbursing for their travel and other expenses (see **Appendixes C and D**). The SREA staff also approves and processes payments for other activities related to review, including hotel contracts, teleconferencing services, and contract-supported ticketing services.

The NCI SREA program is a multi-million dollar program. The staff members of CMO continue to oversee the successful reconciliation of peer review costs charged against the SREA account, identify erroneous charges, and keep an extensive tracking sheet on all costs related to approximately 128 peer review-associated meetings, which all contribute to successfully managing the budget. The CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure there are enough funds to cover all NCI peer review activities.

During FY2012, approximately 2,184 consultants were paid honoraria and a flat-rate reimbursement for meals and incidental expenses for serving at more than 135 peer review meetings (**Appendix D**). There were 3,297 instances of honoraria and flat rate payments to NCI's peer review consultants. The SREA staff works diligently to ensure reviewers are reimbursed in a timely manner and, when appropriate, contacts every reviewer with an unpaid or returned reimbursement status. The SROs have expressed their gratitude to the members of the SREA team for tracking the reviewers' payments and, when necessary, helping reviewers complete their Secure Payee Registration System (SPRS) registration. Due to

these proactive efforts by the SREA staff, only 23 of 3,297 instances of honoraria and flat-rate payments owed to NCI peer review consultants were not paid in FY2012.

On January 3, 2012, the "HHS Policy on Promoting Efficient Spending: Use of Appropriated Funds for Conferences and Meetings, Food, Promotional Items, and Printing, and Publications" was issued. These new policies support the Executive Order on Promoting Efficient Spending (EO 13589) from the President, as a way to minimize administrative costs to perform our mission critical functions in the most efficient, cost-effective way. These policies went into effect immediately at the National Institutes of Health (NIH) and over the 2012 fiscal year, NCI DEA did achieve significant cost savings in regards to peer review meeting spending.

The NCI continued to be a participant in the Hotel Centralization Program with the NIH SREA Management and Service Center in FY2012. The NIH SREA Management and Service Center conducts the final review and processing of all NCI peer review meeting hotel contracts and invoices. The SREA staff, however, is responsible for ensuring that all hotel charges are valid and accurate before all hotel invoices are processed for payment by the NIH SREA Management and Service Center. Teleconference meeting costs and airline tickets were paid expeditiously throughout the year, and SREA staff ensured the timely review and approval of 77 hotel contracts and 80 hotel invoices.

The CMO and its SREA program created new training materials and conducted training sessions for NCI DEA staff. These training sessions encompass all facets of the peer review process as it related to the committee management office and SREA. The Committee Management Activities section includes the specific training sessions that were held in FY2012.

The SREA staff collaborates with the DEA ORRPC Associate Director, Branch Chiefs, and Scientific Review Officers on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities, and they initiate changes and improvements whenever warranted. The NCI Committee Management Procedures for Peer

Review Meetings training book, which contains detailed guidelines, policies, and procedures for all aspects of SREA activities, is updated as needed. This training book is given to all NCI SROs and Extramural Support Assistants (ESAs) as a reference guide for important CMO and SREA policies and procedures that are integral to the peer review process and the NCI's mission.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most far-reaching role the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees (see [Appendix C](#)). The memberships and activities of these advisory bodies are coordinated by the **Office of the Director, DEA**, and the **Committee Management Office, DEA**, in consultation with the **NCI Director**. A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include conducting the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the Board of Scientific Advisors (BSA), the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI. Under the various chartered committees, working groups are formed to address and make recommendations on several important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See [Appendixes A](#) and [B](#) for highlights of the activities of these Boards in FY2012 and [Appendix C](#) for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the Presidentially appointed NCAB. The Board advises the Department of Health and Human Services (HHS) Secretary and the NCI Director on issues related to the entire National Cancer Program and

provides a second level of review for grant applications referred to the NCI and for the Food and Drug Administration (FDA) (see [Appendix A](#)).

President's Cancer Panel (PCP). The PCP consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program, and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The BSA represents the scientific community's voice in NCI-supported extramural science. The Board, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs and policies, and it reviews concepts for new research opportunities and solicitations to ensure that those concepts are meritorious and consistent with the Institute's mission (see [Appendix B](#)).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiology. The two BSCs, managed through the Office of the Director (OD), NCI, advise the Institute leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG). These groups of scientific experts from outside the NCI evaluate the performance and productivity of NCI staff scientists through periodic site visits to intramural laboratories and provide evaluation and advice on the course of research for each Laboratory and Branch.

Director's Consumer Liaison Group (DCLG). The **DCLG** advises the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the **DCLG** will conduct these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the **DCLG** will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The **CTAC** advises and makes recommendations to the NCI Director, NCI Deputy Directors, and the NCI Division/Office/Center (DOC) Directors on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, the Committee makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. **CTAC** also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all clinical trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and related science.

NCI Frederick Advisory Committee (NFAC). The **NFAC** will provide advice and make recommendations to the Director, NCI, and the Associate Director, NCI-Frederick, on the optimal use of the NCI-Frederick facility to rapidly meet the most urgent needs of the Institute. The NCI facility in

Frederick, Maryland, was established in 1972 as a Government-owned Contractor-operated facility. In 1975, the facility was designated as a Federally Funded Research and Development Center (FFRDC) to provide a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. The FFRDC has been renamed the Frederick National Laboratory for Cancer Research (FNLRC). The Committee will review major new projects proposed to be conducted at NCI-Frederick and advise the Director, NCI, and Associate Director, NCI-Frederick, about the intrinsic merit of the projects and about whether they should be done at the Frederick facility.

NCI Initial Review Group (IRG). The **IRG**, composed of four active subcommittees, reviews grant for centers, research projects, and research training activities in the areas of cancer cause, prevention, diagnosis, treatment, and control. Members may be appointed as standing committee members with overlapping terms of up to 6 years, or as "temporary" members with all of the rights and obligations of committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts or *ad hoc* members to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The **SEPs** advise the NCI Director and the DEA Director regarding research grant and cooperative agreement applications, contract proposals, and concept reviews relating to basic and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership of a **SEP** is fluid, with individuals designated to serve for individual meetings rather than for fixed terms. These individuals have all of the rights and obligations of committee membership, including the right to vote on recommendations.

Committee Management Activities

The NCI Committee Management Office (CMO) is critical to the continued success of all NCI Federal advisory committee activities, including Boards, Advisory Committees, subcommittees, working groups, review panels, and so on. The CMO is located in the Office of the Director, Division of Extramural Activities (DEA), NCI. This office continues to provide expert advice to the Director, NCI; Deputy Directors, NCI; the Director, DEA, NCI; and other senior-level Institute/Center/Client staff on all rules, regulations, guidelines, policies, procedures, etc. governing the Federal Advisory Committee Act (FACA). The CMO also is an established service center for the management of other Institutes' Federal advisory committees. Currently, the CMO serves as the Service Center for the NIH Council of Councils (CoC).

The CMO successfully manages 14 Federal advisory committees and numerous subcommittees and working groups. The Office also is responsible for providing logistical planning and support of the following: four National Cancer Advisory Board meetings, three Board of Scientific Advisors meetings, and two NCI-Frederick Advisory Committee meetings as well as numerous subcommittees and working groups.

As a service center for the Office of the Director, NIH, the CMO continued to provide exceptional service to this Client-Institute on the management of its Federal advisory committees. The CMO effectively managed a comprehensive ethics program in support of CoC. Ethics services include analysis and review of Special Government Employee (SGE) OGE-450s of new CoC advisory committee members and preparation of recusal lists and waivers/addendums of current members. Additionally, the CMO prepares charter renewals, analyzes potential nominees, and prepares nomination slates, *Federal Register* notices, and annual and fiscal year reports.

Highlights of CMO activities in FY2012 include the following:

- **OFACP Internal Review:** The NIH Office of Federal Advisory Committee Policy (OFACP) conducted a review of the NCI Service Center Advisory Board files. OFACP's review cited the CMO as having developed superior checklists that are utilized for Official Meeting files, nomination slates, and Board member personnel files. Other comments were that files are highly effective and very commendable.
- **Archive and Scanning Project:** The CMO led an effort to archive and scan FACA files in the NCI Service Center CMO file room. This included providing policy guidance to staff on the disposition of historical Advisory Board documents and working with AISB staff to create an L Scan Drive to hold all scanned electronic Official Meeting Files of NCI Advisory Boards and nomination slates. In part, this effort came about because of the move to the NCI Shady Grove Facility. The National Archives, however, is working on changing the disposition of FACA files so that they can be maintained electronically instead of in hardcopy. When this is implemented, the NCI CMO will be in a good position to quickly and effectively adhere to this policy.
- **HHS Policy on Promoting Efficient Spending: Use of Appropriated Funds for Conferences and Meetings, Food, Promotional Items, and Printing and Publications (January & June 2012):** The CMO provided guidance to DEA staff regarding light refreshments and the holding of peer review meetings in Federal space. Guidance included the amendments of hotel contracts to remove light refreshments and review of current hotel contracts to deter-

mine whether they could be grandfathered in. The CMO worked closely with SRO staff, CSR SREA Director, and ARC staff to ensure that the impact of this new policy did not delay the processing of DEA peer review hotel contracts.

- **Organizational Establishment of the NCI Center for Cancer Training:** The CMO provided guidance to the NCI Office of Management Policy and Compliance regarding FACA compliance as it relates to a reorganization of the Cancer Centers Training Branch.
- **Closure of Program Advisory Committees Meetings:** Program Advisory Committees are typically not closed to the public. In 2012, the CMO worked with OFACP and OGC lawyers to appropriately justify and receive approval for the closure of several NCI Board meetings.
- Met with the ORRPC Associate Director on several occasions to discuss SREA issues; and met with several new DFO/Executive Secretaries to orient them on their roles and responsibilities related to the Advisory Committees and discuss the policies and procedures. The CMO also participated in several conference calls to discuss various topics such as NIH Ethic's procedures for SGEs.
- Responded to several FOIA requests, and oversaw travel authorizations and vouchers for more than 100 SGE travel instances.
- The Committee Management IMPAC II Module is an integral part of the day-to-day

activities in the management of Advisory Committees. As such, the CMO regularly provides feedback to the Committee Management Users Group Representative on potential modifications to the Module. NCI CMO staff also participated in several NIH pilots throughout the year.

- Participated in numerous meetings providing expert advice on working groups, FACA, and SGE rules and regulations.
- Responded to requests from senior NCI and Client staff on various non-FACA meetings and working group concerns.

The CMO conducted several training sessions and participated in curriculum development and as panelists during FY2012. Training highlights include the following:

- NCI Extramural Staff Training Curriculum – Panelist and Training
- PRESTO-NCI/DEA Peer Review Reference Guide for ESAs
- CMO staff participated in a DiSC® assessment and training session. The purpose was to improve teambuilding, understand behaviors, effective communication, and conflict management.
- PRESTO-Sponsored Brown Bag Training titled “DEA FACA and SREA Training”
- PRESTO-Sponsored FACA Training to NCI Extramural Staff

Portfolio Tracking and Analysis

The DEA's Research Analysis and Evaluation Branch (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs to collect and maintain consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's research funding portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio. The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff members analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding from FY2008 through FY2012 for selected organ sites and SIC Codes are presented in **Tables 15** and **16**. In addition, RAEB staff members serve as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

FY2012 Highlights

- The RAEB provided numerous portfolio analyses, for example:
 - For NIH briefing materials on amyloidosis, angiogenesis, lymphatic disease, and for cell phones and brain cancer risk.
 - For a briefing by NIH Director Dr. Francis Collins on Precision Medicine.
 - For the U.S. Global Climate Change Research Program; the RAEB determined that the NCI funded no grants or contracts that had direct relevance to Global Climate change.
 - For NCI Program Directors on pharmacogenetics, translational genitourinary projects, and Hispanic Serving Institutions.
- Indexed and coded nearly 16,000 funded and unfunded applications.
- Supported the NCI-Funded Research Portfolio (NFRP) website by providing scientific indexing for NCI-funded extramural projects (<http://fundedresearch.cancer.gov>).
- Supported the ICR Partners (ICRP), a group of international cancer funding organizations, by coding NCI extramural projects to the Common Scientific Outline (CSO) and participating in the ICRP.
- Began indexing to the CSO for cancer grants funded by other NIH institutes for the ICRP.
- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group to prepare data for biennial reporting of NCI compliance with Congressional Health Disparities reporting requirements, and represented the NCI on the NIH Population Tracking Users Group. Served as NCI Subject Matter Expert on the Population Tracking Redesign Working Group.

- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation SIG.
- Continued data quality comparison checks with DCTD program staff for RAEB multi-project clinical trials coding.

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2012, the NCI allocated \$17.9 million to support 102 grants received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total funding support in [Table 17](#). Canadian institutions received the most funding from the NCI, with 39 grants totaling \$9.1 million. U10 and R01 are the most common mechanisms funded; U10s

with 39 grants receiving \$1.8 million and R01s with 35 grants receiving \$7.6 million. Disease areas receiving the most NCI funding to foreign institutions were Breast (\$3.8 million), Lung (\$2.2 million), and Kidney (\$1.2 million).

In FY2012, the NCI supported 265 U.S. domestic grants with 450 foreign components. These grants are listed in [Table 18](#) by country, mechanism, and number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Institutions in Canada, the United Kingdom, Australia, China, and Germany are the NCI’s most frequent collaborators, with 63, 39, 32, 25, and 23 grants, respectively. R01 is the most common funding mechanism used for collaborations, with 260 grants.

FY2012 Funding of Foreign Institutions

(See [Table 17](#) for more information.)

Country	Grants #	Funding \$
Canada	39	\$9,156,417
France	9	\$3,816,351
United Kingdom	6	\$1,208,491
Israel	7	\$1,200,016
Australia	8	\$903,821
India	2	\$391,342
Belgium	24	\$275,468
Spain	1	\$224,100
Netherlands	1	\$217,377
Ireland	1	\$184,409
Switzerland	3	\$176,961
Republic of South Korea	1	\$171,049


Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following graphs and tables illustrate success rates for selected Special Interest Categories and for the highest incidence cancers. The highest incidence cancer rankings are from the SEER rank of top 15 cancer sites, 2004-2008, age-adjusted incidence for all races and sexes.

Success rates were calculated by dividing the total number of applications newly funded in 2012 (type 1 and 2 grants) for that research category (SIC or Organ Site) by the total number of applications for that research category (see [Figures 9](#) and [10](#)).

Figure 9. FY2012 Success Rates for Applications in High Incidence Cancers*


Sorted by Success Rate



Cancer Organ Site	SEER Rank*	Types 1 & 2 Funded in 2012 for This Site	Total Applications Received in 2012 for This Site	2012 Success Rate for This Site	Total Funding for Types 1 & 2 in 2012 for This Site
Uterus	9	27	73	36.99%	\$3,338,446
Kidney	8	41	134	30.60%	\$4,564,219
Non-Hodgkin Lymphoma	7	86	332	25.90%	\$18,802,660
Leukemia	10	143	568	25.18%	\$40,963,099
Oral Cavity and Pharynx	13	24	98	24.49%	\$3,188,797
Colon and Rectum	4	177	839	21.10%	\$49,948,091
Melanoma	6	95	484	19.63%	\$18,373,238
Liver	15	72	379	19%	\$14,821,114
Lung	3	177	932	18.99%	\$49,944,858
Pancreas	11	96	590	16.27%	\$22,474,124
Stomach	14	6	37	16.22%	\$755,246
Breast	2	353	2185	16.16%	\$113,088,277
Prostate	1	160	1000	16%	\$38,921,836
Thyroid	12	10	67	14.93%	\$1,840,051
Bladder	5	23	166	13.86%	\$5,947,159

*SEER rank of top 15 cancer sites 2004-2008 age-adjusted incidence for all races and sexes.

Figure 10. FY2012 Success Rates for Applications in Selected Special Interest Categories
Sorted by Success Rate



Special Interest Category	Types 1 & 2 Funded in 2012 for This SIC	Total Applications Received in 2012 for This SIC	2012 Success Rate for This SIC	Total Funding for Types 1 & 2 in 2012 for This SIC
Oncogenes	342	1,319	25.93%	\$92,214,207
Genomics	239	940	25.43%	\$71,164,087
Prevention	254	1,059	23.98%	\$73,608,142
Inflammation	113	515	21.94%	\$25,337,500
Early Detection	171	796	21.48%	\$45,020,896
Angiogenesis	80	383	20.89%	\$16,315,401
Obesity	58	288	20.14%	\$16,848,578
Biomarkers	346	1,761	19.65%	\$94,832,885
Metastasis	278	1,441	19.29%	\$67,830,491
Diagnosis	368	1,997	18.43%	\$117,035,115
Therapy	789	4,462	17.68%	\$271,278,695

Information Resources Management

The **Applied Information Systems Branch** (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and, serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report. For FY2012, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Planned, tested, and deployed WebEx and Cisco Movi clients while working closely with the CBIIT Unified Communications team for the successful teleconference implementation at the September NCAB meeting.
- Completed the Annual Assessment (AA)/Continuous Monitoring and Contingency Plan Table-Top Exercise with NCI and DEA staff for the DEA General Support System (GSS) and Fiscal Linked Analysis of

Research Emphasis (FLARE) Security Assurances (formerly C&A).

- Replaced 25 Windows-XP computers with Windows-7 computers while ensuring the migration of all user data and settings.
- Created a new docking configuration to provide and maintain software updates for 15 laptop computers simultaneously in ready-status mode for short-term issue to DEA staff.

Application Development Projects

- Completed the prototype for the RAEB (Research Analysis and Evaluation Branch) online application, which includes: a fully standards compliant Web front end; database containing FLARE data; and a series of end-user accessible datasets, complete with dynamic graphing capable of displaying success rates and statistical analysis of RAEB disease coding data.
- Produced special reports for the Provocative Review Team (winner of NCI Director's Award) with a customized display of review scores.
- Created/maintained Referral History Reports for the Program Coordination and Referral Branch (PCRB), which helps reduce the number of re-referrals; and created special reports to track OMNIBUS referrals.
- Worked with NIH eRA application development staff in completing the migration of the NCAB Early Concurrence voting system to the eRA system.
- Successfully launched the Mailing/Shipping module as part of the RPDU (Review Processing and Distribution Unit) application.
- Completed business transition of the Glossary application to a new owner (Program and Review Extramural Staff Training Office (PRESTO)) as well as the consolidation of terms/data from multiple sources. Worked with PRESTO to implement administrative enhancements.

- Successfully piloted and then deployed for NCI program staff the Concept to Awards Tracking System (CATS).
- Completed final modifications to the Funding Opportunities Application (FOA) data interchange between PCRB and OEFIA to enable up-to-date status reporting for OEFIA staff.
- Deployed a public Web blog for the NCI Director for comment on “Awards of R01 and R21 Grants in FY 2011.”
- Upgraded the AISB application infrastructure to support new NIH eRA document services in the retrieval and display of eRA (IMPAC II) data.
- Redesigned and implemented new USA.gov search and retrieval screens for the DEA Internet Web pages.
- Implemented the Include function in the Inter- and Intranet HTML pages to streamline page updates.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch’s (RAEB) Scientific Coding and Analysis

- Completed enhancements and upgrades to the FLARE system and environment, including: Women’s Health Report (by subproject); new Basic and Applied (BAD) Coding Module; conversion of reports (using “BIRT” tool), which will replace the current spreadsheet-based Crystal reports; improvement in the subproject data validation and integration processes; redesign of the RAEB FLARE GUI; and enhancements to the IRDB Download Day 2 Performance.
- Created reports/data collections for disseminating FLARE data that included: BAD Codes report; AIDS report by subproject; and reports to OBF for the Office of AIDS Research (OAR).
- Work also was completed on integration of RAEB coding data into the NCI IMPAC II

Extension (I2E) database; and enabling data electronically for Cancer Centers Branch — Office of the Deputy Director for Extramural Science staff for P30 Ratio reporting.

- Tasks involving subproject coding reporting produced the following: IMPACII Subproject Data — discrepancy reports to OGA using biweekly tracked subproject data during the FLARE IRDB download time and in FLARE; produced the FY2012 Final Women’s Health Report and AIDS Report by subproject for the first time in 2012.

User Training

AISB staff provided user training/materials in the following areas: SharePoint; Adobe Connect, and Goto meetings for PRESTO and the Office of the Director, DEA teams; Screencast; the RPDU application Mailing/Shipping module; and coordinated NCI Records Management Training for DEA.

AISB Staff Involvement

AISB staff were involved with many NCI and NIH information systems and information technology groups and organizations, including:

- International Cancer Research Portfolio (ICRP) Data Meetings
- NCI BAD codes (Basic and Applied) Working Group
- NCI Coding QA/QC Team
- NCI Division, Office, and Center Contacts IT Group
- NCI Science Management Workspace (SMW)
- NCI SMW Special Interest Groups (Business Information Systems and COTS software)
- NIH Electronic Council Book and Query View Reporting (ECB/QVR) Steering Committee
- NIH eRA Technical Users Group (eTUG)
- NIH Review Users Group (RUG)

Organizational Structure of the Division of Extramural Activities

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership (SPL) Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D.	Director
Vacant	Deputy Director
Peter Wirth, Ph.D.	Assistant Director
Ricardo Rawle, M.B.A.	Special Assistant to the Director
Barbara Hider	Secretary
Judi Ziegler	Secretary

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees, and serves as an NIH service center for the NIH National Center for Complementary and Alternative Medicine, the NIH Council of Councils, and a HHS chartered advisory committee to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Acts as a Service Center to provide advisory committee policy and management services to the Office of Biotechnology Activities, Office of the Director, NIH, and the NCCAM.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal Advisory Committees; coordinates activities with all other NCI Advisory Committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB, NFAC, and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as special government employees.
- Provides administrative support for the peer review system by compensating consultants for their services on NCI IRG subcommittees and SEPs, reimbursing consultants for travel and other expenses, and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris	Committee Management Officer
Andrea Collins	Deputy Committee Management Officer
Linda Southworth	Senior Committee Management Specialist
Malaika Staff	Senior Committee Management Specialist
Natasha Copeland	Committee Management Specialist
Hing Lee	Committee Management Specialist
Alonda Lord	Committee Management Specialist
Kate Reardon	Committee Management Specialist
Kimberly Taylor	Committee Management Specialist

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff (e.g., in the Division of Extramural Activities Support) upon request.
- Identifies and develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with other entities (including NCI Office of Workforce Management and Development) to provide customized job-related training and career development opportunities.
- Monitors participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D.	Chief
Ivan Ding, M.D.	Health Scientist Administrator
Peter Wirth, Ph.D.	Health Scientist Administrator
Gregory Jones	Program Analyst
Elena Kusterer	Program Analyst
Cecily Nelson, M.S.	Program Analyst
Denise Santeufemio	Program Analyst

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the SRLB, RTRB, RPRB, and PCRB.

Shamala Srinivas, Ph.D.	Associate Director
Paul Gallourakis	Special Assistant to the Associate Director
Catherine Battistone	Program Analyst
Linda Brown	Program Specialist
Linda Coleman	Committee Management Specialist

Special Review and Logistics Branch

- Plans, manages, and assists in the scientific merit review of special grant and cooperative agreement applications (received in response to RFAs and PARs) and the technical merit review of contract proposals (received in response to RFPs).
- Identifies and recommends appropriate review committee members and site visitors, as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.
- Coordinates second-level review activities of the NCAB with staff of other NCI Divisions, other Branches of the Division, and the NCI Office of Grants Administration.
- Provides logistical support for primary- and second-level review activities in support of other Division and Institute units.

Kirt Vener, Ph.D. Chief
 Thomas Vollberg, Ph.D. Deputy Chief

Special Review Unit

Kenneth Bielat, Ph.D. Scientific Review Officer
 Eun-Ah Cho, Ph.D. Scientific Review Officer
 Donald Coppock, Ph.D. Scientific Review Officer
 Jeffrey DeClue, Ph.D. Scientific Review Officer
 Gerald Lovinger, Ph.D. Scientific Review Officer
 Savvas Makrides, Ph.D. .. Scientific Review Officer
 Isis Mikhail, Ph.D.‡ Scientific Review Officer
 Thu Nguyen Program Analyst
 Lalita Palekar, Ph.D.* Scientific Review Officer
 Joyce Pegues, Ph.D. Scientific Review Officer
 Marvin Salin, Ph.D. Scientific Review Officer
 Ellen Schwartz, Ph.D. Scientific Review Officer
 Cliff Schweinfest, Ph.D. Scientific Review Officer
 Viatcheslav Soldatenkov, Ph.D. Scientific Review Officer
 Adriana Stoica, Ph.D. Scientific Review Officer
 Thomas Winters Ph.D.† Scientific Review Officer
 Zhiqiang Zou, Ph.D. Scientific Review Officer
 Rosalind Niamke Lead Staff Assistant
 Donnell Wilson Lead Staff Assistant
 Alisha Brown Staff Assistant
 Alicia Craig Staff Assistant
 Bratati Chowdhury Staff Assistant

*Retired in 2012.

†Joined in 2012.

‡On detail from December 2012.

Grace Hughitt..... Staff Assistant
James Thomas Staff Assistant
Etsegenet Abebe Staff Assistant
Hanh Julie Hoang..... Staff Assistant

Review Processing and Distribution Unit

Adrian Bishop Mail and File Clerk
Sanjeeb Choudhry..... Mail and File Clerk
Robert Kruth..... Mail and File Clerk
Clara Murphy Program Assistant

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts*, and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers resubmission (amended) and renewal (competing continuation, Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI program and review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to review and program staff.
- Receives Letters of Intent from applicants (principal investigators) intending to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Directors for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D.	Chief
David Contois	Referral Officer, NCI/NIH Referral Liaison
Anandarup Gupta, Ph.D.	RFA/PA Coordinator, Scientific Review Officer
Leota Hall	Referral Officer, NCI/NIH Referral Liaison
Natacha P. Lassègue	Program Analyst
Bratin Saha, Ph.D.	Referral Officer, Scientific Review Officer
Jan Woynarowski, Ph.D.	RFA/PA Coordinator, Scientific Review Officer

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by Special Emphasis Panels.
- Identifies and recommends appropriate review committee members for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers and other DEA Branches.

Olivia Bartlett, Ph.D.	Chief
Virginia Wray, Ph.D.	Deputy Chief
Shakeel Ahmad, Ph.D.	Scientific Review Officer
Caterina Bianco Ph.D.*	Scientific Review Officer
Monica Congo	Program Specialist
Majed Hamawy, Ph.D., M.B.A.	Scientific Review Officer
Jeannette Korczak, Ph.D.†	Scientific Review Officer
Wlodek Lopaczynski, M.D., Ph.D.	Scientific Review Officer
Caron Lyman, Ph.D.	Scientific Review Officer
David Ransom, Ph.D.	Scientific Review Officer
Delia Tang, Ph.D.	Scientific Review Officer

*Joined in June 2012.

†Reassigned from the RTRB.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, training, education, and career development grant and cooperative agreement applications by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D...... Chief
Lynn Amende, Ph.D. Scientific Review Officer
Gail Bryant, M.D...... Scientific Review Officer
Jeannette Korczak, Ph.D.* Scientific Review Officer
Ilda McKenna, Ph.D. Scientific Review Officer
Timothy Meeker, M.D. Scientific Review Officer
Sergei Radaev, Ph.D. Scientific Review Officer
Sonya Roberson, Ph.D...... Scientific Review Officer

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch and the Applied Information Systems Branch.
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP..... Associate Director
Justin Rhoderick Program Analyst

Research Analysis and Evaluation Branch

- Serves as the Institute’s officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston..... Chief
Edward Kyle..... Deputy Chief

*Reassigned to the RPRB in 2012.

Research Documentation

- Analyzes and indexes grants and contracts for the Branch’s computerized systems.
- Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of NCI’s grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle	Lead Biologist/Team Leader
Beth Buschling	Biologist
Beverly Johnson, M.S.	Biologist
Ernestyne Watkins, M.S.	Biologist
Bernard Whitfield	Biologist
Tyrone Wilson	Biologist

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts in-depth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.
- Manages RAEB’s FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB’s computer applications to meet the Branch’s needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S.	Lead Biologist/Team Leader
Clarissa Douglas	Program Specialist
William Clark, M.S.	Biologist
Rajasri Roy, Ph.D.	Epidemiologist
Vacant	Biological Statistician

Applied Information Systems Branch

- Fulfills the information technology (IT) requirements of the Division by coordinating information resources management (IRM) activities with other relevant NCI and NIH units, and by providing high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti..... **Chief**

Application Development Team

- Analyzes and coordinates life-cycle software development for the Division.
- Develops and designs applications to support the Division's business processes, including user guides.
- Coordinates security assessment and authorization for the Division's general support system applications.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Formulates system development policy, and oversees eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and training for specific DEA applications.

Todd Hardin..... **Team Leader**

Teresa Park..... **Information Technology Specialist**

Vivien Yeh*..... **Information Technology Specialist**

*Joined in 2012.

Information Management Team

- Designs and maintains the Division’s Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Coordinates security assessment and authorization for systems and applications developed and implemented for the Research Analysis and Evaluation Branch (RAEB).
- Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the RAEB in the areas of scientific coding and analysis.
- Administers and implements purchasing for the Division’s computer hardware/software, maintenance, and supplies.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the Web.

Elaine Taylor **Team Leader**
Michael Hu..... **Information Technology Specialist**
Joshua Rhoderick..... **Information Technology Specialist**
Lorrie Smith..... **Information Technology Specialist**

Operations Team

- Administers and maintains the Division’s application, database, and Web servers.
- Oversees and provides guidance for IT security policies and regulations.
- Coordinates and implements the Division’s security assessment and authorization policies for the server environment.
- Manages the software application environment for development, testing, and production.
- Coordinates network connectivity for the Division with CBIIT.
- Provides user and technical support and training for desktop and laptop computers, office automation products and applications.
- Plans and recommends purchases of all IT-related equipment for the Division.
- Maintains accountable IT equipment inventory for the Division.
- Develops and maintains policies for the use of office automation technology.

Richard Florence..... **Team Leader**
Roderick James..... **Information Technology Specialist**
Raymond Vidal..... **Information Technology Specialist**

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2012
Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/28/2011	CA12-001	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
12/13/2011	CA12-501	U24	The Chernobyl Tissue Bank—Coordinating Center (Limited Competition)	DCB
12/21/2011	CA12-002	R21	Early-Stage Innovative Technology Development for Cancer Research	CSSI
	CA12-003	R33	Validation and Advanced Development of Emerging Technologies for Cancer Research	
	CA12-005		Validation and Advanced Development of Emerging Technologies in Biospecimen Science	
	CA12-004	R21	Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	
1/5/2012	CA12-502	UM1	Pediatric Phase 1/Pilot Consortium (Limited Competition)	DCTD
3/30/2012	CA12-503	U24	A Data Resource for Analyzing Blood and Marrow Transplants (Limited Competition)	CSSI
	CA12-006	U01	Cancer Target Discovery and Development (CTDD) Network	
6/8/2012	CA12-008	U10	Minority-Based Community Clinical Oncology Program Groups	DCP
	CA12-007		Community Clinical Oncology Program Groups	
7/23/2012	CA12-012	U10	NCI National Clinical Trials Network—Network Group Integrated Translational Science Centers	DCTD
	CA12-010		NCI National Clinical Trials Network—Network Group Operations Centers	
	CA12-014	U24	NCI National Clinical Trials Network—Network Radiotherapy and Imaging Core Services Centers	
	CA12-013	U10	NCI National Clinical Trials Network—Network Lead Academic Participating Sites	
	CA12-011		NCI National Clinical Trials Network—Network Group Statistics and Data Management Centers	
	CA12-504		NCI National Clinical Trials Network—Canadian Collaborating Clinical Trials Network (Limited Competition)	
8/17/2012	CA12-023	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
9/21/2012	CA12-019	R01	Research Answers to NCI's Provocative Questions—Group C	CSSI
	CA12-021		Research Answers to NCI's Provocative Questions—Group D	
	CA12-015		Research Answers to NCI's Provocative Questions—Group A	
	CA12-017		Research Answers to NCI's Provocative Questions—Group B	
	CA12-020	R21	Research Answers to NCI's Provocative Questions—Group C	
	CA12-016		Research Answers to NCI's Provocative Questions—Group A	
	CA12-018		Research Answers to NCI's Provocative Questions—Group B	
	CA12-022		Research Answers to NCI's Provocative Questions—Group D	

Source: Office of Referral, Review and Program Coordination.

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2012
Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication	
CSSI	CA12-002	R21	Early-Stage Innovative Technology Development for Cancer Research	12/21/2011	
	CA12-003	R33	Validation and Advanced Development of Emerging Technologies for Cancer Research		
	CA12-005		Validation and Advanced Development of Emerging Technologies in Biospecimen Science		
	CA12-004	R21	Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	9/21/2012	
	CA12-006	U01	Cancer Target Discovery and Development (CTDD) Network		
	CA12-019	R01	Research Answers to NCI's Provocative Questions—Group C		
	CA12-021		Research Answers to NCI's Provocative Questions—Group D		
	CA12-015		Research Answers to NCI's Provocative Questions—Group A		
	CA12-017		Research Answers to NCI's Provocative Questions—Group B		
	CA12-020	R21	Research Answers to NCI's Provocative Questions—Group C		
	CA12-016		Research Answers to NCI's Provocative Questions—Group A		
	CA12-018		Research Answers to NCI's Provocative Questions—Group B		
	CA12-022		Research Answers to NCI's Provocative Questions—Group D		
DCB	CA12-501		U24	The Chernobyl Tissue Bank—Coordinating Center (Limited Competition)	12/13/2011
DCP	CA12-008	U10	Minority-Based Community Clinical Oncology Program Groups	6/8/2012	
	CA12-007		Community Clinical Oncology Program Groups		
DCTD	CA12-502	UM1	Pediatric Phase 1/Pilot Consortium (Limited Competition)	1/5/2012	
	CA12-503	U24	A Data Resource for Analyzing Blood and Marrow Transplants (Limited Competition)	3/30/2012	
	CA12-012	U10	NCI National Clinical Trials Network—Network Group Integrated Translational Science Centers	7/23/2012	
	CA12-010		NCI National Clinical Trials Network—Network Group Operations Centers		
	CA12-014	U24	NCI National Clinical Trials Network—Network Radiotherapy and Imaging Core Services Centers		
	CA12-013	U10	NCI National Clinical Trials Network—Network Lead Academic Participating Sites		
	CA12-011		NCI National Clinical Trials Network—Network Group Statistics and Data Management Centers		
	CA12-504		NCI National Clinical Trials Network—Canadian Collaborating Clinical Trials Network (Limited Competition)		
SBIRDC	CA12-001	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization		10/28/2011
	CA12-023		SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization		8/17/2012

Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2012
Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/7/2011	RM11-023	R01	Phased Economic Studies Ancillary to Completed or Ongoing Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments	*
10/7/2011	RM11-024	R21, R33	Phased Economic Studies Ancillary to Planned Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments	*
11/10/2011	RM11-007	DP5	NIH Director's Early Independence Awards	*
11/17/2011	RM11-019	R01	Technology Development to Enable Large Scale Metabolomics Analyses	*
11/18/2011	OD12-001	SI2	Lasker Clinical Research Scholars Program	
11/22/2011	RM11-022	UH2, UH3	Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease	*
11/23/2011	RM11-014	R21	Exceptionally Innovative Tools and Technologies for Single Cell Analysis	*
	RM11-013	U01	Studies to Evaluate Cellular Heterogeneity Using Transcriptional Profiling of Single Cells	*
	RM12-001	U18	Stem/Progenitor Cell-Derived Human Micro-organs and -tissues	*
	RM11-015	R01	Accelerating the Integration and Translation of Technologies to Characterize Biological Processes at the Single Cell Level	*
11/29/2011	AI12-002	U01	Women's Interagency HIV Study (WIHS-V) (Limited Competition)	OHAM
11/30/2011	RM11-017	K01	Mentored Research Scientist Development Award in Metabolomics	*
	RM11-018	R25	Development of Courses or Workshops in Metabolomics	*
12/2/2011	RM11-020	U01	Metabolomics Data Repository and Coordinating Center (DRCC)	*
	RM11-016	U24	Regional Comprehensive Metabolomics Resource Cores (RCMRC)	*
12/21/2011	RM12-003	UH2, UH3	Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants	*
	RM12-004	U01	Human Health and Heredity in Africa (H3Africa): Research Grants	*
1/24/2012	RM11-021	U54	NIH Health Care Systems Research Collaboratory-Coordinating Center	*
	RM12-002	UH2, UH3	NIH Health Care Systems Research Collaboratory—Pragmatic Clinical Trials Demonstration Projects	*
1/27/2012	AI12-004	UM1	Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV-Associated Infections in Adults	OHAM
2/6/2012	AR12-007	R01	Ancillary Domain Validation Patient-Reported Outcomes Measurement Information System (PROMIS) Studies	DCTD
2/29/2012	OD12-003	R43, R44	Small Business Alzheimer's Disease Research	SBIRDC
	OD12-004	R41, R42		
4/4/2012	AI12-021	R01	U.S.-China Program for Biomedical Collaborative Research	OHAM
6/13/2012	RM12-005	U01	Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program	*
	AI12-033	R21	U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-Morbidities	OHAM

continued

*All Divisions, Centers, and Offices may participate.

Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2012
Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
6/29/2012	RM12-017	R01	NIH Director's Transformative Research Awards	*
7/10/2012	DA13-003	P50	Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act	DCCPS
7/13/2012	RM12-018	DP5	NIH Director's Early Independence Awards	*
8/3/2012	RM12-010	U54	Data Management and Resource Repository (DMRR) on Extracellular RNA	*
	RM12-013	UH2, UH3	Clinical Utility of Extracellular RNA for Biomarker Development	*
	RM12-011	U01	Reference Profiles of Human Extracellular RNA	*
	RM12-014	UH2, UH3	Clinical Utility of Extracellular RNA for Therapy Development	*
	RM12-012	U19	Extracellular RNA Biogenesis, Biodistribution, Uptake, and Effector Function	*
8/7/2012	RM12-019	R01	Development and Application of Systems Approaches for Analyzing the Impact of Genomic Variation on Tissue Transcriptomes	*
	RM12-016	DP2	2013 NIH Director's New Innovator Award Program	*
	RM12-015	DP1	2013 NIH Director's Pioneer Award Program	*
8/22/2012	RM12-008	UH2, UH3	Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants	*
	RM12-006	U54	Human Heredity and Health in Africa (H3Africa): Collaborative Centers	*
	RM12-007	U01	Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants	*
9/11/2012	LM12-002	R24	Basic Social and Behavioral Research on Culture, Health, and Wellbeing	DCCPS

*All Divisions, Centers, and Offices may participate.

Source: Office of Referral, Review and Program Coordination.

Table 3a. Program Announcements (PAs) Published by the NCI in FY2012*Sorted by Date of Publication*

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center
10/21/2011	PAR12-005	P01	National Cancer Institute Program Project Applications	ALL DIVISIONS
11/9/2011	PAR12-010	R01	NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act	OHAM
	PAR12-011	U01		
11/16/2011	PA12-014	R21	Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens From Multi-Site Cancer Trials	DCTD
	PA12-013	R01		
11/28/2011	PAR12-039	R03	Small Grants Program for Cancer Epidemiology	DCCPS
12/1/2011	PAR12-049	R25	Cancer Education Grants Program	CCT
12/9/2011	PAR12-055	U54	Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)	CRCHD
12/15/2011	PAR12-051	K08	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	CCT
	PAR12-052	K23	NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	
	PAR12-050	K01	NCI Mentored Research Scientist Development Award to Promote Diversity	
12/16/2011	PAR12-062	K22	The NCI Transition Career Development Award to Promote Diversity	CCT
12/21/2011	PAR12-065	K05	NCI Established Investigator Award in Cancer Prevention and Control	CCT
	PAR12-035	R03	Small Grants for Behavioral Research in Cancer Control	DCCPS
12/22/2011	PAR12-067	K07	Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award	CCT
	PA12-082	R01	Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy	DCTD DCP
PA12-083	R21			
2/2/2012	PAR12-096	R21	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research	CRCHD
	PAR12-095	U01	Basic Cancer Research in Cancer Health Disparities	
	PAR12-094	R21	Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities	
3/15/2012	PAR12-121	K22	The NCI Transition Career Development Award	CCT
3/26/2012	PAR12-140	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	DCB/DCP
3/29/2012	PAR12-144	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	Trans NCI
	PAR12-145	R21	NCI Exploratory/Developmental Research Grant Program (NCI Omnibus)	Trans NCI
6/5/2012	PA12-196	R44	Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR)	OD
6/19/2012	PA12-214	R21	Identifying Non-coding RNA Targets for Early Detection of Cancer	DCP
	PA12-213	R01		
6/28/2012	PA12-221	R01	Biomarkers for Early Detection of Hematopoietic Malignancies	DCP
	PA12-220	R21		
7/10/2012	PAR12-229	R21	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival	DCP DCCPS
	PAR12-228	R01		
8/29/2012	PA12-275	R01	Examination of Survivorship Care Planning Efficacy and Impact	DCCPS
	PA12-274	R21		
9/19/2012	PAR12-286	R01	Revisions for Early-Stage Development of Informatics Technology	DCB DCCPS
	PAR12-289	U01		
	PAR12-290	P01		
	PAR12-287	U24		DCTD/DCCPS
	PAR12-288	U01		DCTD/DCP DCCPS
9/25/2012	PAR12-296	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	DCTD
9/26/2012	PAR12-298	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	OCC

Source: Office of Referral, Review and Program Coordination.

Table 3b. Program Announcements (PAs) Published by the NCI in FY2012*Sorted by Division, Office, and Center*

Division, Office, and Center	PA/PAR	Mechanism	Title	Date of Publication
ALL DIVISIONS	PAR12-005	P01	National Cancer Institute Program Project Applications	10/21/2011
	PAR12-049	R25	Cancer Education Grants Program	12/1/2011
	PAR12-051	K08	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	
	PAR12-052	K23	NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	12/15/2011
CCT	PAR12-050	K01	NCI Mentored Research Scientist Development Award to Promote Diversity	
	PAR12-062	K22	The NCI Transition Career Development Award to Promote Diversity	12/16/2011
	PAR12-065	K05	NCI Established Investigator Award in Cancer Prevention and Control	12/21/2011
	PAR12-067	K07	Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award	12/22/2011
	PAR12-121	K22	The NCI Transition Career Development Award	3/15/2012
	PAR12-055	U54	Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Limited Competition)	12/9/2011
CRCHD	PAR12-096	R21	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research	
	PAR12-095	U01	Basic Cancer Research in Cancer Health Disparities	2/2/2012
	PAR12-094	R21	Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities	
DCB DCCPS	PAR12-289	U01	Revisions for Early-Stage Development of Informatics Technology	
	PAR12-286	R01	Revisions for Early-Stage Development of Informatics Technology	9/19/2012
	PAR12-290	P01	Revisions for Early-Stage Development of Informatics Technology	
DCB/DCP	PAR12-140	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	3/26/2012
	PAR12-039	R03	Small Grants Program for Cancer Epidemiology	11/28/2011
DCCPS	PAR12-035	R03	Small Grants for Behavioral Research in Cancer Control	12/22/2011
	PA12-275	R01	Examination of Survivorship Care Planning Efficacy and Impact	8/29/2012
	PA12-274	R21	Examination of Survivorship Care Planning Efficacy and Impact	
	PA12-214	R21	Identifying Non-coding RNA Targets for Early Detection of Cancer	6/19/2012
DCP	PA12-213	R01	Identifying Non-coding RNA Targets for Early Detection of Cancer	
	PA12-221	R01	Biomarkers for Early Detection of Hematopoietic Malignancies	6/28/2012
	PA12-220	R21	Biomarkers for Early Detection of Hematopoietic Malignancies	
DCP DCCPS	PA12-229	R21	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival	7/10/2012
	PA12-228	R01	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival	
	PAR12-287	U24	Advanced Development of Informatics Technology	9/19/2012
	PA12-014	R21	Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens From Multi-Site Cancer Trials	11/16/2011
DCTD	PA12-013	R01	Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens From Multi-Site Cancer Trials	
	PAR12-296	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	9/25/2012
DCTD/DCP	PA12-082	R01	Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy	1/17/2012
	PA12-083	R21	Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy	
DCTD/DCP DCCPS	PAR12-288	U01	Early-Stage Development of Informatics Technology	9/19/2012
OCC	PAR12-298	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	9/26/2012
OD	PA12-196	R44	Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR)	6/5/2012
OHAM	PAR12-010	R01	NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act	11/9/2011
	PAR12-011	U01	NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act	
TRANS NCI	PAR12-144	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	3/29/2012
	PAR12-145	R21	NCI Exploratory/Developmental Research Grant Program (NCI Omnibus)	
DCCPS	PAR12-035	R03	Small Grants for Behavioral Research in Cancer Control	12/22/2011

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2012
Sorted by Date of Publication

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
10/7/2011	PAR12-001	R01	Collaborations with National Centers for Biomedical Computing	DCB	NIH
11/2/2011	PA12-006	R15	Academic Research Enhancement Award (Parent R15)		NIH
11/18/2011	PA12-024	R01	Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care	DCCPS	OBSSR
	PA12-022	R01	Practical Interventions to Improve Medication Adherence in Primary Care	DCCPS	OBSSR
12/13/2011	PAR12-058	R01	Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes	DCTD	NIMH
	PAR12-059	R21			
	PAR12-060	R01	Solicitation of Validated Hits for the Discovery of <i>In Vivo</i> Chemical Probes	DCTD	NIMH
12/22/2011	PAR12-068	D43	Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions	OHAM	FIC
1/31/2012	PA12-089	R41, R42	PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications	SBIRDC	NCI
	PA12-090	R43, R44	New Technologies for Viral Hepatitis	SBIRDC	NIDDK
	PA12-091	R41, R42			
	PA12-088	R43, R44	PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA, and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	
2/1/2012	PAR12-092	X01	Resource Access for the Bridging Interventional Development Gaps Program		NIH
2/13/2012	PA12-100	333	Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Administrative Supplement)		NIH
2/16/2012	PAR12-108	X01	Assays for High Throughput Screening (HTS) to Discover Chemical Probes in the Molecular Libraries Probe Production Centers Network (MLPCN)		NIH
2/23/2012	PA12-111	R01	Research on the Health of LGBTI Populations	OHAM	NICHD
	PA12-112	R03			
	PA12-113	R21			
3/19/2012	PA12-119	333, P01, P20, P30, P50, R01, R15, 21, R33, R34, R37, U01, U54	Use-Oriented Basic Research: Change Mechanisms of Behavioral Social Interventions (Administrative Supplement)	DCCPS	NIH
3/21/2012	PA12-136	R01	Translational Research at the Aging/Cancer Interface (TRACI)	DCB	NIA/NCI
	PA12-135	R21			
3/23/2012	PA12-139	R21	Pilot and Feasibility Clinical Research Studies in Digestive Diseases and Nutrition	DCP	
3/29/2012	PA12-146	R01	Mechanisms of Alcohol-associated Cancers	DCP	
	PA12-147	R21			
4/6/2012	PA12-149	333, DP1, DP2, DP3, DP4, DP5, G12, K99, P01, P20, P30, P40, P41, P50, P60, R00, R01, R03, R15, R18, R21, R24, R34, R37, R41, R42, R43, R44, RC1 RC2, RC3, RC4, SC1, SC2, SC3 U01, U10, U18, U19, U34, U41, U42, U54, UM1, UP5	Research Supplements to Promote Diversity in Health-Related Research (Administrative Supplement)		NIH CDC NIOSH

continued

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2012
Sorted by Date of Publication

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
	PA12-150	DP1, DP2, DP3, DP4, DP5, G12, P01, P20, P30, P40, P41, P50, P51, P60, R01, R18, R24, R34, R37, R41, R42, R43, R44, RC1, RC2, RC3, RC4, U01, U10, U18, U19, U34, U41, U42, U54, UM1, UP5	Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Administrative Supplement)		
4/11/2012	PA12-158	333, P01, P30, P50, R01, U01	NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Administrative Supplement)	DEA	NIH
4/12/2012	PA12-161	R01	Basic Research on HIV Persistence	OHAM	NIH
	PA12-162	R21			
4/24/2012	PAR12-174	R21	Multidisciplinary Studies of HIV/AIDS and Aging (R21)	OHAM	NIH
	PAR12-175	R01			
	PAR12-176	R03			
5/2/2012	PA12-179	R21	Exploratory/Developmental Clinical Research Grants in Obesity	DCP	NIH
5/8/2012	PAR12-182	S06	Native American Research Centers for Health (NARCH)		NIH/HIS
6/6/2012	PAR12-197	R21	Improving Diet and Physical Activity Assessment	DCCPS	NIH
	PAR12-198	R01			
6/11/2012	PA12-202	333, D43, K01, K02, K23, P01, P20, P30, P50, R01, R15, R21, R24, R25, R33, R34, R37, U01, U10, U19, U54, UM1	Administrative Supplements for Health Impacts of Household Air Pollution on Womens Health and Child Survival (Administrative Supplement)	DCCPS	NIH
6/19/2012	PA12-212	R13, U13	NIH Support for Conferences and Scientific Meetings (Parent R13/U13)	DEA	NIH
7/24/2012	PAR12-243	R21	Ethical Issues in Research on HIV/AIDS and Its Co-Morbidities	OHAM	NIH
	PAR12-244	R01			
8/8/2012	PAR12-257	R01	Time-Sensitive Obesity Policy and Program Evaluation	DCCPS	NIH FDA
8/23/2012	PAR12-268	R03	Tobacco Control Regulatory Research		NIH
	PAR12-267	R01			
	PAR12-266	R21			
8/24/2012	PA12-270	777	Change of Grantee Organization (Type 7 Parent)	DCP	NIH
	PA12-269	666	Successor-in-Interest (Type 6 Parent)		
	PA12-271	R01	Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies		
9/11/2012	PA12-284	R21	Exploratory/Developmental Bioengineering Research Grants (EBRG)	DCTD	NIBIB

Source: Office of Referral, Review and Program Coordination.

Table 5. Applications Received for Referral by the NCI/DEA in FY2012*
Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by Board			Total Costs Requested First Year
			Feb	June	Sept	
International Training Grants in Epidemiology (FIC)	D43	12	0	12	0	\$3,280,563
NIH Director's New Innovator Awards	DP2	15	0	15	0	\$22,500,000
Early Independence Award	DP5	5	0	0	5	\$1,817,896
Individual Predoctoral National Research Service Award for M.D./Ph.D. Fellowships (ADAMHA)	F30	137	39	55	43	\$0
Predoctoral Individual National Research Service Award	F31	416	117	167	132	\$0
Postdoctoral Individual National Research Service Award	F32	434	124	154	156	\$0
National Research Service Award for Senior Fellows	F33	2	0	1	1	\$0
Research Scientist Development Award—Research and Training	K01	29	5	15	9	\$3,479,610
Research Scientist Award	K05	13	4	6	3	\$1,829,754
Academic/Teacher Award	K07	72	20	25	27	\$10,305,749
Clinical Investigator Award	K08	79	20	31	28	\$12,624,421
Physician Scientist Award (Program)	K12	31	6	25	0	\$15,090,454
Career Enhancement Award	K18	2	1	0	1	\$403,794
Career Transition Award	K22	44	11	17	16	\$6,535,873
Mentored Patient-Oriented Research Development Award	K23	30	10	11	9	\$5,136,229
Midcareer Investigator Award in Patient-Oriented Research	K24	12	3	4	5	\$2,157,141
Mentored Quantitative Research Career Development	K25	18	6	8	4	\$2,738,072
Career Transition Award	K99	193	63	80	50	\$20,563,463
Research Program Projects	P01	81	26	32	23	\$189,900,904
Exploratory Grants	P20	20	0	0	20	\$4,239,582
Center Core Grants	P30	20	15	3	2	\$71,334,911
Biotechnology Resource Grant Program	P41	1	0	1	0	\$371,250
Specialized Center	P50	41	7	25	9	\$102,226,685
Research Project	R01	6,265	1,806	2,437	2,022	\$3,013,181,444
Small Research Grants	R03	583	177	192	214	\$44,944,816
Conferences	R13	149	57	46	46	\$5,239,958
Academic Research Enhancement Awards (AREA)	R15	242	90	70	82	\$98,961,898
Exploratory/Developmental Grants	R21	2,732	927	1,028	777	\$611,461,460
Resource-Related Research Projects	R24	1	0	1	0	\$384,643
Education Projects	R25	86	36	26	24	\$33,613,939
Exploratory/Developmental Grants—Phase II	R33	35	1	2	32	\$14,999,707
Method to Extend Research in Time (MERIT) Award	R37	6	0	3	3	\$2,634,865
Small Business Technology Transfer (STTR) Grants—Phase I	R41	131	39	32	60	\$25,708,050
* Small Business Technology Transfer (STTR) Grants—Phase II	R42	18	4	7	7	\$7,843,824
Small Business Innovation Research Grants (SBIR)—Phase I	R43	1,067	381	326	360	\$224,505,708
Small Business Innovation Research Grants (SBIR)—Phase II	R44	197	61	73	63	\$98,215,184
High Priority, Short Term Project Award	R56	4	1	2	1	\$302,065

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 404 withdrawn applications that have been subtracted from the total count.

Table 5. Applications Received for Referral by the NCI/DEA in FY2012**Sorted by Mechanism*

Mechanism	Activity Code	Total by Activity	Applications by Board			Total Costs Requested First Year
			Feb	June	Sept	
Research Enhancement Award	SC1	16	5	6	5	\$5,054,325
Pilot Research Project	SC2	18	5	6	7	\$2,575,323
Intramural Clinical Scholar Research Award	SI2	3	0	0	3	\$0
Institutional National Research Service Award	T32	81	31	26	24	\$32,645,469
Research Project (Cooperative Agreements)	U01	261	130	95	36	\$246,875,320
Cooperative Clinical Research (Cooperative Agreements)	U10	35	35	0	0	\$77,197,476
Conference (Cooperative Agreement)	U13	1	0	1	0	\$74,180
Research Program (Cooperative Agreement)	U19	1	1	0	0	\$3,110,446
Resource-Related Research Project (Cooperative Agreements)	U24	2	0	1	1	\$4,250,000
Small Business Innovation Research (SBIR) Cooperative Agreements—Phase I	U43	48	16	0	32	\$9,771,227
Small Business Innovation Research (SBIR) Cooperative Agreements—Phase II	U44	1	0	0	1	\$524,187
Specialized Center (Cooperative Agreements)	U54	10	0	1	9	\$9,837,211
Exploratory/Developmental Cooperative Agreement—Phase I	UH2	3	0	2	1	\$1,364,371
Multi-Component Research Project Cooperative Agreements	UM1	30	8	12	10	\$63,589,373
Overall Totals		13,733	4,288	5,082	4,363	\$5,115,402,820

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 404 withdrawn applications that have been subtracted from the total count.

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2012*

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
Research Scientist Development Award - Research and Training	K01	29	5	15	9	\$3,479,610
Research Scientist Award	K05	13	4	6	3	\$1,829,754
Academic/Teacher Award	K07	72	20	25	27	\$10,305,749
Clinical Investigator Award	K08	65	17	24	24	\$10,534,912
Physician Scientist Award (Program)	K12	6	6	0	0	\$2,658,109
Career Enhancement Award	K18	2	1	0	1	\$403,794
Career Transition Award	K22	44	11	17	16	\$6,535,873
Mentored Patient-Oriented Research Development Award	K23	26	9	9	8	\$4,496,663
Midcareer Investigator Award in Patient-Oriented Research	K24	11	3	3	5	\$2,057,090
Mentored Quantitative Research Career Development	K25	16	4	8	4	\$2,418,426
Career Transition Award	K99	157	43	69	45	\$16,856,034
Research Program Projects	P01	77	24	31	22	\$188,405,944
Exploratory Grants	P20	20	0	0	20	\$4,239,582
Center Core Grants	P30	10	5	3	2	\$53,042,834
Specialized Center	P50	41	7	25	9	\$102,226,685
Research Project	R01	471	3	466	2	\$247,804,576
Small Research Grants	R03	455	139	148	168	\$35,236,770
Conferences	R13	86	30	29	27	\$2,560,581
Exploratory/Developmental Grants	R21	427	1	325	101	\$98,615,375
Education Projects	R25	70	25	21	24	\$21,240,814
Exploratory/Developmental Grants—Phase II	R33	30	0	0	30	\$13,093,196
Small Business Innovation Research Grants (SBIR)—Phase II	R44	10	0	4	6	\$9,526,237
High Priority, Short Term Project Award	R56	1	0	1	0	\$302,065
Institutional National Research Service Award	T32	76	27	26	23	\$29,117,588
Research Project (Cooperative Agreements)	U01	177	102	70	5	\$152,147,320
Cooperative Clinical Research (Cooperative Agreements)	U10	35	35	0	0	\$77,197,476
Research Program (Cooperative Agreement)	U19	1	1	0	0	\$3,110,446
Resource-Related Research Project (Cooperative Agreements)	U24	2	0	1	1	\$4,250,000
Small Business Innovation Research (SBIR) Cooperative Agreements—Phase I	U43	48	16	0	32	\$9,771,227
Small Business Innovation Research (SBIR) Cooperative Agreements—Phase II	U44	1	0	0	1	\$524,187
Specialized Center (Cooperative Agreements)	U54	5	0	1	4	\$7,955,557
Multi-Component Research Project (Cooperative Agreements)	UM1	30	8	12	10	\$63,589,373
Overall Totals		2,514	546	1,339	629	\$1,185,533,847

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 128 withdrawn applications that have been subtracted from the total count.

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs) in FY2012*

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	10	\$53,042,834
F - Institutional Training & Education	K99,R25,T32	206	\$45,074,846
G - Education	K01,K05,K12,K22,K24,R25	70	\$19,523,513
I - Transition to Independence	K01,K08,K18,K22,K25,K99	167	\$22,825,493
J - Career Development	K05,K07,K23,K24	103	\$15,466,737
Totals - NCI IRG Subcommittees		556	\$155,933,423
Total SEPs	K01, K05, K07, K08, K22, K23, K24, K99, P01, P20, P50, R01, R03, R13, R21, R25, R33, R44, R56, T32, U01, U10, U19, U24, U43, U44, U54, UM1	1,958	\$1,029,600,424
Totals		2,514	\$1,185,533,847

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 12 withdrawn applications that have been subtracted from the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed in FY2012*

Type of Application	Applications by Board			FY 2012 Total
	February 2012	June 2012	September 2012	
New	9	11	7	27
Resubmitted New	3	3	7	13
Renewal	8	8	3	19
Resubmitted Renewal	4	6	5	15
Revisions	0	3	0	3
Total	24	31	22	77

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 4 withdrawn applications that have been subtracted from the total count.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2012*

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Division of Cancer Biology (DCB)	29	\$56,375,713	\$272,627,592
Division of Cancer Control and Population Sciences (DCCPS)	10	\$34,651,781	\$278,372,378
Division of Cancer Prevention (DCP)	3	\$5,529,541	\$27,671,542
Division of Cancer Treatment and Diagnosis (DCTD)	35	\$89,815,885	\$484,046,472
Total	77	\$186,372,920	\$1,062,717,984

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 4 withdrawn applications that have been subtracted from the total count.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2012*

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Community Clinical Oncology Program Groups	CA11-006	U10	17	17	0	0	\$26,368,469
Community Clinical Oncology Program Research Bases	CA11-007	U10	9	9	0	0	\$43,796,214
Minority-Based Community Clinical Oncology Program Groups	CA11-008	U10	9	9	0	0	\$7,032,793
Alliance of Glycobiologists for Detection of Cancer	CA11-009	U01	30	0	30	0	\$16,047,812
Cancer Target Discovery and Development (CTDD) Network	CA11-010	U01	56	56	0	0	\$63,088,267
Research Answers to NCI's Provocative Questions	CA11-011	R01	420	0	420	0	\$223,500,023
	CA11-012	R21	325	0	325	0	\$71,054,751
Cancer Research Network: A Research Resource within Health Care Delivery System (Limited Competition)	CA11-502	U24	1	0	1	0	\$4,000,000
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	CA12-001	R44	10	0	4	6	\$9,526,237
Early-Stage Innovative Technology Development for Cancer Research	CA12-002	R21	89	0	0	89	\$23,930,622
Validation and Advanced Development of Emerging Technologies for Cancer Research	CA12-003	R33	27	0	0	27	\$11,789,481
Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	CA12-004	R21	12	0	0	12	\$3,392,502
Validation and Advanced Development of Emerging Technologies in Biospecimen Science	CA12-005	R33	3	0	0	3	\$1,303,715
The Chernobyl Tissue Bank—Coordinating Center (Limited Competition)	CA12-501	U24	1	0	0	1	\$250,000
Pediatric Phase 1/Pilot Consortium (Limited Competition)	CA12-502	UM1	1	0	0	1	\$3,470,000
International Tobacco and Health Research and Capacity Building Program	TW11-003	R01	43	0	43	0	\$14,042,377
		R56	1	0	1	0	\$302,065
Totals			1,054	91	824	139	\$522,895,328

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 82 withdrawn applications that have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2012*

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Career Enhancement Award for Stem Cell Research	PA09-110	K18	2	1	0	1	\$403,794
Developmental Projects in Complementary Approaches to Cancer Care and Treatment	PA09-167	R21	1	1	0	0	\$237,500
Research Project Grant (Parent)	PA10-067	R01	3	3	0	0	\$3,027,568
NIH Support for Conferences and Scientific Meetings (Parent)	PA10-071	R13	86	30	29	27	\$2,560,581
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent)	PA11-184	T32	76	27	26	23	\$29,117,588
Mentored Clinical Scientist Research Career Development Award (Parent)	PA11-193	K08	56	15	22	19	\$9,095,854
Mentored Patient-Oriented Research Career Development Award (Parent)	PA11-194	K23	21	8	5	8	\$3,695,730
Midcareer Investigator Award in Patient-Oriented Research (Parent)	PA11-195	K24	11	3	3	5	\$2,057,090
Mentored Quantitative Research Development Award (Parent)	PA11-196	K25	16	4	8	4	\$2,418,426
NIH Pathway to Independence Award (Parent)	PA11-197	K99	157	43	69	45	\$16,856,034
Research Project Grant (Parent)	PA11-260	R01	5	0	3	2	\$7,234,608
Pilot Studies in Pancreatic Cancer	PA11-298	R03	1	0	0	1	\$87,083
Cancer Education Grants Program	PAR08-120	R25	33	14	17	2	\$10,174,526
Small Grants Program for Cancer Epidemiology	PAR08-237	R03	88	48	40	0	\$6,832,890
Small Grants for Behavioral Research in Cancer Control	PAR09-003	R03	59	25	34	0	\$4,586,168
NCI Program Project Applications	PAR09-025	P01	77	24	31	22	\$186,372,920
		U19	1	1	0	0	\$3,110,446
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR09-050	K08	4	2	2	0	\$642,232
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR09-051	K23	5	1	4	0	\$800,933
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR09-052	K01	20	5	15	0	\$2,359,806
NCI Transition Career Development Award to Promote Diversity	PAR09-069	K22	9	4	5	0	\$1,476,351
Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award	PAR09-078	K07	45	20	25	0	\$6,529,646
Established Investigator Award in Cancer Prevention and Control	PAR09-088	K05	10	4	6	0	\$1,562,854
NCI Transition Career Development Award	PAR09-089	K22	27	7	12	8	\$3,979,156
Etiology, Prevention, and Treatment of Hepatocellular Carcinoma	PAR09-147	P01	1	1	0	0	\$1,275,910
Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership	PAR09-201	P20	20	0	0	20	\$4,239,582
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	PAR10-003	P50	41	7	25	9	\$102,226,685
		U54	1	0	1	0	\$2,499,998
Paul Calabresi Career Development Award for Clinical Oncology	PAR10-155	K12	6	6	0	0	\$2,658,109

continued

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 74 withdrawn applications that have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2012*

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
NCI Cancer Education and Career Development Program	PAR10-165	R25	18	11	4	3	\$5,974,245
Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	PAR10-286	U43	48	16	0	32	\$9,771,227
		U44	1	0	0	1	\$524,187
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	PAR11-005	P30	10	5	3	2	\$53,042,834
Cancer Prevention Research Small Grant Program	PAR11-079	R03	191	66	74	51	\$14,788,705
Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment	PAR11-146	U01	23	0	23	0	\$15,382,767
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR11-150	U01	16	6	5	5	\$10,212,728
Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	PAR11-151	U01	40	40	0	0	\$36,484,114
The Role of Microbial Metabolites in Cancer Prevention and Etiology	PAR11-152	U01	12	0	12	0	\$10,931,632
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	PAR11-167	UM1	29	8	12	9	\$60,119,373
NCI Program Project Applications	PAR12-005	P01	22	0	0	22	\$47,474,723
Small Grants for Behavioral Research in Cancer Control	PAR12-035	R03	30	0	0	30	\$2,278,034
Small Grants Program for Cancer Epidemiology	PAR12-039	R03	86	0	0	86	\$6,663,890
Cancer Education Grants Program	PAR12-049	R25	19	0	0	19	\$5,092,043
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR12-050	K01	9	0	0	9	\$1,119,804
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR12-051	K08	5	0	0	5	\$796,826
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Limited Competition)	PAR12-055	U54	4	0	0	4	\$5,455,559
NCI Transition Career Development Award to Promote Diversity	PAR12-062	K22	8	0	0	8	\$1,080,366
NCI Established Investigator Award in Cancer Prevention and Control	PAR12-065	K05	3	0	0	3	\$266,900
Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award	PAR12-067	K07	27	0	0	27	\$3,776,103
Totals			1,483	456	515	512	\$709,356,128

* Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. There were 74 withdrawn applications that have been subtracted from the total count.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2012*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
N01-CN-05014-69	Cancer Prevention Agent Development Program: Early Phase Clinical Research	Feb-12	8
Topic 257 (Phase II)	Biopsy Instruments and Devices that Preserve Molecular Profiles in Tumors	Feb-12	1
N01-CP-11015-63	HPV Type 16 Vaccine Trial in Costa Rica	Feb-12	1
Topic 255	Development of Anticancer Agents	Jun-12	32
Topic 277 (FT) (Phase I: 15) (Phase I & II: 3)	Development of Companion Diagnostics	Jun-12	21
Topic 291 (FT) (Phase I: 12) (Phase I & II: 6)	Development of Radiation Modulators for Use During Radiotherapy	Jun-12	24
Topic 300	Reformulation of Cancer Therapeutics Using Nanotechnology	Jun-12	11
Topic 301	Probing Tumor Microenvironment Using <i>In Vivo</i> Nanotechnology-Base Sensors	Jun-12	6
Topic 306	Development of Innovative Algorithms for Processing and Analysis of <i>In Vivo</i> Images	Jun-12	5
Topic 307	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Jun-12	8
Topic 308	Automated Collection, Storage, Analysis, and Reporting Systems for Dietary Images	Jun-12	9
Topic 309 (FT) (Phase I: 40) (Phase I & II: 5)	Development of Low-Cost, Small Sample Multi-Analyte Technologies for Cancer Diagnosis, Prognosis, and Early Detection	Jun-12	50
Topic 310	Simplified Tissue Microarray Instrument for Clinical and Research Settings (NIH Technology Transfer)	Jun-12	6
Topic 311	High Throughput Isolation fo Antigen Specific T-Cells for Cancer Therapy (NIH Technology Transfer)	Jun-12	0
Topic 312	Generation and Qualification of Site-Specific Post-Translationally Modified Protein for Use as Calibrators in Pharmacodynamic (PD) Assays	Jun-12	2
N01-CN-25000-78	Preclinical Pharmacology and Toxicology Studies	Jun-12	7
Topic 255 (Phase II)	Development of Anticancer Agents	Sep-12	7
Topic 257 (Phase II)	Biopsy Instruments and Devices that Preserve Molecular Profiles in Tumors	Sep-12	1
Topic 284 (Phase II)	Alternative Biospecimen Stabilization and Storage Solutions	Sep-12	1
Topic 258 (Phase II)	Innovative Devices to Protect Radiosensitive Organs and Structures During Radiation Therapy	Sep-12	1
Topic 266 (Phase II)	Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer	Sep-12	1
Topic 272 (Phase II)	Point of Care Analysis of Circulating Tumor Cells for Cancer Diagnostics, Prognosis, and Treatment	Sep-12	1
Topic 273 (Phase II)	Process Analytic Technologies (PAT) for Biologics: Innovative Methods for Monitoring and Analyzing Product Quality and Safety During Manufacture of Cancer Therapeutics	Sep-12	1
Topic 274 (Phase II)	Quantitative Cell-Based Imaging for Clinical Diagnosis and Treatment	Sep-12	2

continued

* The NCI reviewed a total of 659 proposals. The proposals were in response to SBIR Contract Solicitations—Phase I (146) and Fast Track Phase I/II (28), Phase II (32), RFP (26), and Loan Repayment (427)

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2012*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 275 (Phase II)	Development of Generic Antibodies for the Treatment of Cancer	Sep-12	3
Topic 276 (Phase II)	Development of Novel Medicinal Food Products for the Mitigation of the Side-Effects of Cancer Chemotherapy	Sep-12	1
Topic 277 (Phase II)	Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine in Cancer Therapy	Sep-12	4
Topic 279 (Phase II)	Facilitating the Transfer of Statistical Methodology into Practice	Sep-12	3
Topic 287 (Phase II)	Nanotechnology Sensing Platforms for Improved Cancer Detection	Sep-12	2
Topic 288 (Phase II)	Development of Alternative Affinity Capture Reagents for Cancer Proteomics Research	Sep-12	2
Topic 290 (Phase II)	siRNA Resource for Synthetic Lethal Screening of DNA Repair and Damage Signaling Networks	Sep-12	1
N01-CN-25002-78	Preclicinal <i>In Vivo</i> Efficacy and Intermediate Endpoints	Sep-12	5
N01-CN-25001-26	Preclinical <i>In Vitro</i> and <i>In Vivo</i> Agent Development Assays	Sep-12	5
L30	Loan Repayment	Aug-12	319
L40	Loan Repayment	Aug-12	108
Total			659

* The NCI reviewed a total of 659 proposals. The proposals were in response to SBIR Contract Solicitations—Phase I (146) and Fast Track Phase I/II (28), Phase II (32), RFP (26), and Loan Repayment (427)

Table 13. Summary of NCI Grant Awards by Mechanism in FY2012*†

Fund Type: Appropriated	Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
					Number	Dollars			
Research Project Grants									
	Traditional Research Grants – R01/RL1	3,526	1,318,483,374	373,932	54.48%	40.74%	4,155	620	14.92%
	Program Projects – P01	122	243,599,108	1,996,714	1.89%	7.53%	96	21	21.88%
	Small Grants – R03	172	13,132,383	76,351	2.66%	0.41%	506	101	19.96%
	Exploratory/Developmental Research – R21	439	86,383,990	196,774	6.78%	2.67%	1,897	200	10.54%
	Phased Innovation Grant (Phase 2) – R33	3	1,181,596	393,865	0.05%	0.04%	5	0	0.0%
	Pathway to Independence – R00	76	18,531,003	243,829	1.17%	0.57%	0	0	0.0%
	Exploratory/Development Cooperative Agreements – UH2/UH3	1	100,159	100,159	0.02%	0.0%	1	0	0.0%
	Merit Awards – R37	48	23,972,295	499,423	0.74%	0.74%	5	4	80.0%
	NIH Director Pioneer Award (NDPA) – DP1	7	7,288,587	1,041,227	0.11%	0.23%	0	0	0.0%
	NIH Director New Innovator Awards – DP2	2	4,583,750	2,291,875	0.03%	0.14%	2	2	100.0%
	Academic Research Enhancement Awards (AREA) – R15	19	7,772,257	409,066	0.29%	0.24%	163	19	11.66%
	Multi-Component Research Project Cooperative Agreements – UM1	5	13,466,541	2,693,308	0.08%	0.42%	16	5	31.25%
	Request for Applications	193	70,914,804	367,434	2.98%	2.19%	884	73	8.26%
	Cooperative Agreements – RFA – U01/ U19	133	134,041,999	1,007,835	2.06%	4.14%	87	15	17.24%
	Cooperative Agreements – U01/U19	85	54,487,586	641,030	1.31%	1.68%	156	25	16.03%
	Small Business Innovative Research	151	63,711,223	421,929	2.33%	1.97%	980	105	10.71%
	Small Business Technology Transfer – R41/R42	39	13,644,000	349,846	0.6%	0.42%	101	30	29.7%
	Program Evaluation – R01	0	75,329,000	75,329,000	0.0%	2.33%	0	0	0.0%
	Subtotal Research Project Grants	5,021	2,150,623,655	428,326	77.58%	66.45%	9,054	1,220	13.47%
Other Research									
	Clinical Cooperative Groups	128	225,582,018	1,762,360	1.98%	6.97%	35	26	74.29%
	Clinical Cooperative Groups – U10 Specials	0	3,600,000	3,600,000	0.0%	0.11%	0	0	0.0%
	Clinical Cooperative Groups – CCCT	0	659,887	659,887	0.0%	0.02%	0	0	0.0%
	Cooperative Conference Grants – U13	0	6,500	6,500	0.0%	0.0%	0	0	0.0%
	Conference Grants – R13	64	5,669,494	88,586	0.99%	0.18%	82	33	40.24%
	Continuing Education Training Grants – T15/RL9	1	100,323	100,323	0.02%	0.0%	0	0	0.0%
	Cancer Education Awards – R25	93	33,372,612	358,845	1.44%	1.03%	55	18	32.73%
	Research/Resource Grant – R24/U24	34	64,692,754	1,902,728	0.53%	2.0%	3	3	100.0%
	Research Enhancement Award – SC1	1	339,678	339,678	0.02%	0.01%	0	0	0.0%
	Subtotal Other Research	321	334,023,266	1,040,571	4.96%	10.32%	175	80	45.71%

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2012*†

Fund Type: Appropriated	Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
					Number	Dollars			
Centers									
	Core	83	272,115,151	3,278,496	1.28%	8.41%	36	19	52.78%
	Core – CCCT	0	4,968,442	4,968,442	0.0%	0.15%	0	0	0.0%
	Center for AIDS Research – CFAR – OHAM – P30	0	2,792,913	2,792,913	0.0%	0.09%	0	0	0.0%
	Spore Grants	54	113,454,248	2,101,005	0.83%	3.51%	32	7	21.88%
	Other P50/P20	22	33,437,764	1,519,898	0.34%	1.03%	1	1	100.0%
	Specialized Center (Cooperative Agreement)	113	186,020,211	1,646,197	1.75%	5.75%	7	3	42.86%
	Subtotal Centers	272	612,788,729	2,252,900	4.2%	18.93%	76	30	39.47%
NRSA									
	NRSA Institution	152	54,251,880	356,920	2.35%	1.68%	66	23	34.85%
	NRSA Fellowships	284	11,739,934	41,338	4.39%	0.36%	672	171	25.45%
	Subtotal NRSA	436	65,991,814	151,357	6.74%	2.04%	738	194	26.29%
Careers									
	Career Enhancement Award for Stem Cell Research – K18	1	117,208	117,208	0.02%	0.0%	2	0	0.0%
	Mentored Clinical Scientist – K08	105	16,479,431	156,947	1.62%	0.51%	54	22	40.74%
	Preventive Oncology Award – K07	76	10,940,744	143,957	1.17%	0.34%	64	4	6.25%
	Mentored Career Award – K12	18	13,397,570	744,309	0.28%	0.41%	6	3	50.0%
	Mentored Research Scientist Development Awards, Mentored Career Development to Promote Diversity/ Temin – K01	51	6,487,385	127,204	0.79%	0.2%	27	15	55.56%
	Clinical Research Track – K22	25	4,452,024	178,081	0.39%	0.14%	41	6	14.63%
	Mentored Patient-Oriented Research Career Development – K23	36	5,784,803	160,689	0.56%	0.18%	24	4	16.67%
	Mid-Career Investigator in Patient- Oriented Research – K24	17	3,034,687	178,511	0.26%	0.09%	9	5	55.56%
	Mentored Quantitative Research Career Development Award – K25	17	2,273,764	133,751	0.26%	0.07%	19	2	10.53%
	Established Investigator Award in Cancer Prevention and Control – K05	23	3,452,664	150,116	0.36%	0.11%	12	3	25.0%
	Pathway to Independence – K99	53	6,743,844	127,242	0.82%	0.21%	147	25	17.01%
	Subtotal Careers	422	73,164,124	173,375	6.52%	2.26%	405	89	21.98%
	Total:	6,472	3,236,591,588	500,091	100.0%	100.0%	10,448	1,613	15.44%

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

**Table 14. Average Total Cost*† and Number of Research Project Grant Awards
Sorted by Division, Office, Center, and Mechanism
From FY2008 - FY2012‡**

	FY 2008		FY 2009		FY 2010		FY 2011		FY 2012		Percent Change 2008 - 2012	
	No.	Avg. Cost	No.	Avg. Cost								
R01 Average Cost of Award												
NCI Overall	3,732	335	3,573	350	3,655	362	3,648	365	3,526	374	-5.52 %	11.64 %
DCB	1,923	298	1,792	308	1,783	313	1,748	317	1,660	323	-13.7 %	8.5 %
DCP	247	368	246	388	261	399	258	400	245	421	-0.8 %	14.3 %
DCTD	1,055	317	1,042	327	1,107	336	1,141	343	1,139	355	8.0 %	12.1 %
DCCPS	490	484	478	515	486	561	485	553	468	559	-4.5 %	15.6 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	17	917	15	977	18	911	16	901	14	924	-17.6 %	0.7 %
P01 Average Cost of Award												
NCI Overall	158	1,932	151	2,002	140	2,004	129	2,010	122	1,997	-22.78%	3.36%
DCB	58	1,675	60	1,729	56	1,783	53	1,804	54	1,771	-6.9 %	5.8 %
DCP	11	1,916	9	1,931	7	1,737	8	1,814	8	1,579	-27.3 %	-17.6 %
DCTD	77	2,069	69	2,215	64	2,188	58	2,164	49	2,194	-36.4 %	6.0 %
DCCPS	11	2,306	12	2,174	12	2,161	10	2,298	11	2,502	0.0 %	8.5 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	2,397	1	2,220	1	2,576	0	638	0	306	-100.0 %	-87.2 %
R03 Average Cost of Award												
NCI Overall	256	77	239	77	181	78	127	76	172	76	-32.81%	-1.3%
DCB	9	75	15	76	8	78	3	75	10	76	11.1 %	2.2 %
DCP	107	78	91	78	56	78	38	75	61	78	-43.0 %	0.6 %
DCTD	9	73	12	76	10	77	6	76	10	78	11.1 %	5.5 %
DCCPS	131	75	119	77	107	79	80	77	91	75	-30.5 %	-0.8%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	47	2	47	0	0	0	0	0	0	0.0 %	-100.0%
R21 Average Cost of Award												
NCI Overall	466	198	447	205	415	202	442	200	439	197	-5.79 %	-0.51%
DCB	74	183	75	193	77	188	79	181	80	187	8.1 %	2.2 %
DCP	55	169	50	174	50	187	51	183	54	188	-1.8 %	10.9 %
DCTD	248	214	236	218	198	218	207	220	188	215	-24.2 %	0.2 %
DCCPS	87	180	85	195	82	185	80	178	89	176	2.3 %	-2.0 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	2	230	1	204	8	217	25	205	28	186	1,300.0 %	-18.8 %

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† In thousands.

‡ Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2008 - FY2012‡

	FY 2008		FY 2009		FY 2010		FY 2011		FY 2012		Percent Change 2008 - 2012	
	No.	Avg. Cost	No.	Avg. Cost								
U01/U19 Average Cost of Award												
NCI Overall	125	906	110	1,035	131	1,091	130	1,062	132	989	5.6%	9.16%
DCB	23	870	28	776	28	776	29	721	28	714	21.7 %	-17.9 %
DCP	9	402	7	366	35	741	35	671	36	681	300.0 %	69.3 %
DCTD	56	1,051	39	1,417	28	1,461	26	1,313	23	939	-58.9 %	-10.6 %
DCCPS	32	564	32	678	23	1,598	23	1,752	22	1,761	-31.3 %	211.9 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	5	2,534	4	3,159	17	1,039	17	1,135	23	1,119	360.0 %	-55.8 %
R13 Average Cost of Award												
NCI Overall	92	34	80	36	95	76	92	65	64	89	-30.43%	161.76%
DCB	40	9	33	10	36	9	35	4	22	6	-45.0 %	-30.1 %
DCP	4	12	8	15	8	12	9	15	5	19	25.0 %	61.7 %
DCTD	24	11	19	13	19	12	16	11	14	14	-41.7 %	29.1 %
DCCPS	11	30	14	24	17	20	17	14	11	21	0.0 %	-29.8 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	13	162	6	307	15	418	15	349	12	418	-7.7 %	157.6 %
U10 Average Cost of Award												
NCI Overall	133	1,773	134	1,750	131	1,937	135	1,801	128	1,789	-3.76%	0.9%
DCP	72	1,275	73	1,254	71	1,330	77	1,160	75	1,165	4.2 %	-8.6 %
DCTD	61	2,360	61	2,344	60	2,655	58	2,653	53	2,671	-13.1 %	13.2 %
P30 Average Cost of Award												
NCI Overall	64	4,217	65	4,337	66	4,446	66	4,168	67	4,134	4.69%	-1.97%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	64	4,217	65	4,337	66	4,446	66	4,168	67	4,133	4.7 %	-2.0 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	0	0	0	0	0	0	0	0	100	0.0 %	100.0 %
P50 Average Cost of Award												
NCI Overall	60	2,055	71	1,967	75	2,081	74	1,979	69	2,010	15.0%	-2.19%
DCP	0	0	0	0	0	400	0	400	0	400	0.0 %	100.0 %
DCTD	60	2,051	64	2,025	65	2,101	64	1,999	59	2,044	-1.7 %	-0.3 %
DCCPS	0	0	7	1,334	10	1,847	10	1,739	10	1,686	100.0 %	100.0 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	262	0	766	0	617	0	701	0	813	0.0 %	210.3 %

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† In thousands.

‡ Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2008 - FY2012‡

	FY 2008		FY 2009		FY 2010		FY 2011		FY 2012		Percent Change 2008 - 2012	
	No.	Avg. Cost	No.	Avg. Cost								
SBIR Average Cost of Award												
NCI Overall	274	314	219	367	180	411	123	587	151	422	-44.89%	34.39%
CRCHD	0	0	0	0	0	85	0	83	0	0	0.0 %	0.0 %
DCB	23	268	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
DCP	16	318	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
DCTD	165	342	4	318	0	0	0	0	0	0	-100.0 %	-100.0 %
DCCPS	13	326	0	0	0	0	0	32	0	0	-100.0 %	-100.0 %
SBIRDC	57	251	215	368	180	411	123	586	151	422	164.9 %	68.1 %
STTR Average Cost of Award												
NCI Overall	38	297	42	277	27	431	21	562	39	350	2.63%	17.85%
DCB	3	189	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
DCP	3	325	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
DCTD	27	297	1	138	0	0	0	0	0	0	-100.0 %	-100.0 %
DCCPS	2	301	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
SBIRDC	0	0	0	0	0	0	21	562	39	350	100.0 %	100.0 %
STTRDC	3	368	41	280	27	431	0	0	0	0	-100.0 %	-100.0 %
U54 Average Cost of Award												
NCI Overall	44	1,802	56	1,939	93	1,453	101	1,523	103	1,709	134.09%	-5.16%
CRCHD	17	1,161	21	1,274	51	1,066	47	1,152	49	1,110	188.2 %	-4.3 %
CSSI	8	3,683	16	3,311	18	2,776	21	2,468	21	3,630	162.5 %	-1.4 %
DCB	15	1,407	15	1,327	20	1,492	22	1,400	22	1,441	46.7 %	2.4 %
DCCPS	4	2,242	4	2,238	4	230	11	1,551	11	1,244	175.0 %	-44.5 %

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Adrenal	<i>Number of Grants</i>	9	7	9	6	6	
	Relevant Grant Dollars	490,757	443,049	908,434	557,068	694,479	
	<i>Total Count</i>	9	7	9	6	6	
	Total Relevant Dollars	490,757	443,049	908,434	557,068	694,479	20.33
Anus	<i>Number of Grants</i>	13	17	14	16	18	
	Relevant Grant Dollars	1,717,104	2,585,470	1,996,111	2,740,690	2,539,326	
	<i>Number of Contracts</i>	5	5	‡	3	‡	
	Relevant Contract Dollars	744,588	778,300	‡	446,435	‡	
	<i>Total Count</i>	18	22	14	19	18	
Total Relevant Dollars	2,461,692	3,363,770	1,996,111	3,187,125	2,539,326	8.83	
Bladder	<i>Number of Grants</i>	230	219	208	176	143	
	Relevant Grant Dollars	20,612,527	20,834,546	18,941,518	15,777,763	18,493,415	
	<i>Number of Contracts</i>	17	16	3	1	1	
	Relevant Contract Dollars	417,443	340,792	25,113	176,266	749,947	
	<i>Total Count</i>	247	235	211	177	144	
Total Relevant Dollars	21,029,970	21,175,338	18,966,631	15,954,029	19,243,362	-1.25	
Bone Marrow	<i>Number of Grants</i>	101	75	92	76	55	
	Relevant Grant Dollars	15,453,422	16,586,714	13,124,422	17,343,897	8,938,608	
	<i>Total Count</i>	101	75	92	76	55	
	Total Relevant Dollars	15,453,422	16,586,714	13,124,422	17,343,897	8,938,608	-7.46
Bone, Cartilage	<i>Number of Grants</i>	110	84	98	90	72	
	Relevant Grant Dollars	16,585,539	16,835,159	18,014,359	14,539,162	10,824,238	
	<i>Number of Contracts</i>	1	‡	‡	‡	‡	
	Relevant Contract Dollars	10,529	‡	‡	‡	‡	
	<i>Total Count</i>	111	84	98	90	72	
Total Relevant Dollars	16,596,068	16,835,159	18,014,359	14,539,162	10,824,238	-9.10	
Brain	<i>Number of Grants</i>	536	464	498	500	512	
	Relevant Grant Dollars	121,777,889	125,530,253	131,178,363	143,786,108	148,032,345	
	<i>Number of Contracts</i>	15	14	3	3	5	
	Relevant Contract Dollars	436,218	215,004	217,734	698,895	672,916	
	<i>Total Count</i>	551	478	501	503	517	
Total Relevant Dollars	122,214,107	125,745,257	131,396,097	144,485,003	148,705,261	5.07	
Breast	<i>Number of Grants</i>	1,999	1,958	1,934	1,859	1,835	
	Relevant Grant Dollars	517,943,650	542,409,702	569,062,367	552,999,395	536,444,140	
	<i>Number of Contracts</i>	44	36	32	20	25	
	Relevant Contract Dollars	6,480,995	7,420,959	7,908,595	9,370,644	12,810,843	
	<i>Total Count</i>	2,043	1,994	1,966	1,879	1,860	
Total Relevant Dollars	524,424,645	549,830,661	576,970,962	562,370,039	549,254,983	1.23	
Central Nervous System	<i>Number of Grants</i>	70	42	43	35	51	
	Relevant Grant Dollars	8,892,769	5,765,488	6,255,071	5,370,246	4,169,107	
	<i>Number of Contracts</i>	1	1	‡	‡	‡	
	Relevant Contract Dollars	450,000	374,998	‡	‡	‡	
	<i>Total Count</i>	71	43	43	35	51	
Total Relevant Dollars	9,342,769	6,140,486	6,255,071	5,770,246	4,169,107	-16.98	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Cervix	Number of Grants	321	298	298	295	298	
	Relevant Grant Dollars	57,532,246	51,605,675	61,579,940	60,341,462	58,198,274	
	Number of Contracts	23	23	5	4	3	
	Relevant Contract Dollars	5,783,915	7,479,618	4,759,619	4,729,585	3,366,401	
	Total Count	344	321	303	299	301	
	Total Relevant Dollars	63,316,161	59,085,293	66,339,559	65,071,047	61,564,675	-0.43
Childhood Leukemia	Number of Grants	131	123	148	157	178	
	Relevant Grant Dollars	43,226,882	42,335,965	49,924,922	33,329,283	51,786,291	
	Total Count	131	123	148	157	178	
	Total Relevant Dollars	43,226,882	42,335,965	49,924,922	33,291,283	51,786,291	9.53
Colon, Rectum	Number of Grants	1,011	963	984	951	937	
	Relevant Grant Dollars	242,315,525	237,991,020	245,295,756	242,486,775	227,386,183	
	Number of Contracts	46	38	16	11	14	
	Relevant Contract Dollars	8,206,006	7,934,699	6,412,331	4,299,256	6,246,343	
	Total Count	1,057	1,001	1,000	962	951	
	Total Relevant Dollars	250,521,531	245,925,719	251,708,087	246,786,031	233,632,526	-1.69
Connective Tissue	Number of Grants	70	55	51	56	44	
	Relevant Grant Dollars	12,574,363	10,709,782	10,417,011	9,999,338	8,185,709	
	Total Count	70	55	51	56	44	
	Total Relevant Dollars	12,574,363	10,709,782	10,417,011	9,999,338	8,185,709	-9.93
Embryonic Tissue, Cells	Number of Grants	9	6	10	8	5	
	Relevant Grant Dollars	1,779,062	694,792	1,477,847	1,325,565	368,936	
	Total Count	9	6	10	8	5	
	Total Relevant Dollars	1,779,062	694,792	1,477,847	1,325,565	368,936	-7.68
Esophagus	Number of Grants	133	129	100	118	147	
	Relevant Grant Dollars	18,768,511	24,435,190	25,599,073	28,238,207	23,801,157	
	Number of Contracts	3	‡	‡	1	2	
	Relevant Contract Dollars	258,939	‡	‡	20,000	229,905	
	Total Count	136	129	100	119	149	
	Total Relevant Dollars	19,027,450	24,435,190	25,599,073	28,258,207	24,031,062	7.15
Eye	Number of Grants	13	11	13	12	14	
	Relevant Grant Dollars	1,850,716	1,910,869	2,168,685	2,161,882	2,008,983	
	Total Count	13	11	13	12	14	
	Total Relevant Dollars	1,850,716	1,910,869	2,168,685	2,161,882	2,008,983	2.34
Gall Bladder	Number of Grants	3	4	1	16	2	
	Relevant Grant Dollars	462,516	372,129	212,356	199,485	156,086	
	Total Count	3	4	1	16	2	
	Total Relevant Dollars	462,516	372,129	212,356	199,485	156,086	-22.57
Gastrointestinal Tract	Number of Grants	68	62	51	48	50	
	Relevant Grant Dollars	9,411,464	9,143,226	8,649,596	8,306,179	9,181,848	
	Number of Contracts	2	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	70	62	51	48	50	
	Total Relevant Dollars	9,411,464	9,143,226	8,649,596	8,306,179	9,181,848	-0.42

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Genital System, Female	<i>Number of Grants</i>	15	9	12	19	38	
	Relevant Grant Dollars	1,408,356	578,518	1,255,368	1,708,702	2,136,318	
	<i>Number of Contracts</i>	5	5	5	1	‡	
	Relevant Contract Dollars	651,232	666,439	336,493	187,496	‡	
	<i>Total Count</i>	20	14	17	20	38	
	Total Relevant Dollars	2,059,588	1,244,957	1,591,861	1,896,198	2,136,318	5.02
Genital System, Male	<i>Number of Grants</i>	7	6	6	5	6	
	Relevant Grant Dollars	1,304,477	1,466,575	549,031	334,581	350,827	
	<i>Number of Contracts</i>	5	5	5	‡	‡	
	Relevant Contract Dollars	651,232	666,439	336,493	‡	‡	
	<i>Total Count</i>	12	11	11	5	6	
	Total Relevant Dollars	1,955,709	2,133,014	885,524	334,581	350,827	-26.69
Head and Neck	<i>Number of Grants</i>	234	214	204	201	217	
	Relevant Grant Dollars	42,337,050	41,932,591	41,468,691	39,623,318	37,034,455	
	<i>Number of Contracts</i>	4	5	7	3	7	
	Relevant Contract Dollars	2,252,606	1,433,714	1,897,174	1,337,385	4,032,932	
	<i>Total Count</i>	238	219	211	204	224	
	Total Relevant Dollars	44,589,656	43,366,305	43,365,865	40,960,703	41,067,387	-2.01
Heart	<i>Number of Grants</i>	24	20	15	16	12	
	Relevant Grant Dollars	2,919,031	2,361,956	2,148,483	1,737,287	1,971,428	
	<i>Total Count</i>	24	20	15	16	12	
	Total Relevant Dollars	2,919,031	2,361,956	2,148,483	1,737,287	1,971,428	-8.45
Hodgkins Lymphoma	<i>Number of Grants</i>	91	72	54	77	94	
	Relevant Grant Dollars	15,616,622	13,631,008	9,846,229	8,994,562	9,649,890	
	<i>Number of Contracts</i>	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	<i>Total Count</i>	91	72	54	77	94	
	Total Relevant Dollars	15,616,622	13,631,008	9,846,229	8,994,562	9,649,890	-10.46
Kaposi Sarcoma	<i>Number of Grants</i>	99	81	92	87	82	
	Relevant Grant Dollars	20,543,363	18,551,830	17,444,041	20,205,869	19,241,042	
	<i>Number of Contracts</i>	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	<i>Total Count</i>	99	81	92	87	82	
	Total Relevant Dollars	20,543,363	18,551,830	17,444,041	20,205,869	19,241,042	-1.15
Kidney	<i>Number of Grants</i>	209	210	226	241	246	
	Relevant Grant Dollars	26,064,122	26,856,193	26,734,935	29,194,089	32,449,153	
	<i>Number of Contracts</i>	2	1	2	2	‡	
	Relevant Contract Dollars	‡	47,891	274,436	390,889	‡	
	<i>Total Count</i>	211	211	228	243	246	
	Total Relevant Dollars	26,064,122	26,904,084	27,009,371	29,584,978	32,449,153	5.71
Larynx	<i>Number of Grants</i>	4	5	3	4	6	
	Relevant Grant Dollars	94,951	387,226	99,159	203,215	464,533	
	<i>Total Count</i>	4	5	3	4	6	
	Total Relevant Dollars	94,951	387,226	99,159	203,215	464,533	116.74

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Leukemia	<i>Number of Grants</i>	735	703	680	683	724	
	Relevant Grant Dollars	187,378,267	192,236,365	210,799,140	199,610,401	208,324,142	
	<i>Number of Contracts</i>	3	2	3	4	2	
	Relevant Contract Dollars	159,480	228,944	1,495,139	1,098,646	213,752	
	Total Count	738	705	683	687	726	
	Total Relevant Dollars	187,537,747	192,465,309	212,294,279	200,709,047	208,537,894	2.84
Liver	<i>Number of Grants</i>	303	280	294	302	322	
	Relevant Grant Dollars	60,131,598	58,730,034	60,616,338	54,071,410	52,508,097	
	<i>Number of Contracts</i>	2	1	‡	1	2	
	Relevant Contract Dollars	46,630	124,807	‡	299,353	115,700	
	Total Count	305	281	294	303	324	
	Total Relevant Dollars	60,178,228	58,854,841	60,616,338	54,370,763	52,623,797	-3.18
Lung	<i>Number of Grants</i>	966	961	965	968	993	
	Relevant Grant Dollars	211,422,479	210,440,490	243,602,747	260,155,893	268,028,541	
	<i>Number of Contracts</i>	42	35	23	16	26	
	Relevant Contract Dollars	8,194,888	7,217,782	7,815,307	4,919,129	12,146,630	
	Total Count	1,008	996	988	984	1,019	
	Total Relevant Dollars	219,617,367	217,658,272	251,418,054	265,075,022	280,175,171	6.44
Lymph Node	<i>Number of Grants</i>	23	18	15	13	9	
	Relevant Grant Dollars	5,090,890	4,206,917	2,542,477	2,017,737	1,975,041	
	Total Count	23	18	15	13	9	
	Total Relevant Dollars	5,090,890	4,206,917	2,542,477	2,017,737	1,975,041	-19.92
Lymphatic System	<i>Number of Grants</i>	9	9	4	5	4	
	Relevant Grant Dollars	1,008,473	972,288	472,471	788,609	803,722	
	Total Count	9	9	4	5	4	
	Total Relevant Dollars	1,008,473	972,288	472,471	788,609	803,722	3.46
Melanoma	<i>Number of Grants</i>	506	454	457	435	423	
	Relevant Grant Dollars	91,542,259	86,581,615	85,429,532	96,537,993	99,713,846	
	<i>Number of Contracts</i>	2	2	4	1	2	
	Relevant Contract Dollars	‡	276,130	698,413	50,000	1,349,977	
	Total Count	508	456	461	436	425	
	Total Relevant Dollars	91,542,259	86,857,745	86,127,945	96,587,993	101,063,823	2.71
Mesothelioma	<i>Number of Grants</i>	19	18	15	16	18	
	Relevant Grant Dollars	5,258,514	4,954,819	5,530,460	3,457,493	4,863,814	
	Total Count	19	18	15	16	18	
	Total Relevant Dollars	5,258,514	4,954,819	5,530,460	3,457,493	4,863,814	2.26
Muscle	<i>Number of Grants</i>	42	37	37	48	58	
	Relevant Grant Dollars	7,152,012	6,535,783	6,049,875	8,018,193	6,914,232	
	Total Count	42	37	37	48	58	
	Total Relevant Dollars	7,152,012	6,535,783	6,049,875	8,018,193	6,914,232	0.68
Myeloma	<i>Number of Grants</i>	197	234	234	242	249	
	Relevant Grant Dollars	34,920,892	40,008,777	41,740,236	48,195,056	52,667,345	
	<i>Number of Contracts</i>	2	‡	1	‡	1	
	Relevant Contract Dollars	28,000	‡	199,860	‡	1,499,746	
	Total Count	199	234	235	242	250	
	Total Relevant Dollars	34,948,892	40,008,777	41,940,096	48,195,056	54,167,091	11.65

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Nervous System	Number of Grants	33	29	30	28	26	
	Relevant Grant Dollars	5,617,294	4,847,016	5,271,048	6,787,090	6,438,816	
	Number of Contracts	+	+	+	1	+	
	Relevant Contract Dollars	+	+	+	8,250	+	
	Total Count	33	29	30	29	26	
	Total Relevant Dollars	5,617,294	4,847,016	5,271,048	6,795,340	6,438,816	4.68
Neuroblastoma	Number of Grants	95	100	98	98	105	
	Relevant Grant Dollars	16,372,549	17,189,208	17,861,575	20,974,714	24,697,656	
	Number of Contracts	+	+	+	+	1	
	Relevant Contract Dollars	+	+	+	+	299,993	
	Total Count	95	100	98	98	106	
	Total Relevant Dollars	16,372,549	17,189,208	17,861,575	20,974,714	24,997,649	11.38
Non-Hodgkins Lymphoma	Number of Grants	570	523	455	472	473	
	Relevant Grant Dollars	102,077,543	100,604,178	97,937,059	101,566,115	93,857,913	
	Number of Contracts	+	+	+	1	1	
	Relevant Contract Dollars	+	+	+	1,500,000	125,000	
	Total Count	570	523	455	473	474	
	Total Relevant Dollars	102,077,543	100,604,178	97,937,059	103,066,115	93,982,913	-1.92
Nose, Nasal Passages	Number of Grants	10	10	14	8	10	
	Relevant Grant Dollars	835,744	676,153	1,627,236	904,491	1,117,904	
	Total Count	10	10	14	8	10	
	Total Relevant Dollars	835,744	676,153	1,627,236	904,491	1,117,904	25.19
Not Site Specific §	Number of Grants	2,304	2,196	2,079	1,952	1,889	
	Relevant Grant Dollars	595,117,368	604,058,911	608,746,346	573,631,342	572,734,563	
	Number of Contracts	214	186	162	166	192	
	Relevant Contract Dollars	357,711,859	432,722,194	191,360,124	192,657,199	187,026,369	
	Total Count	2,518	2,382	2,241	2,118	2,081	
	Total Relevant Dollars	952,829,227	1,036,781,105	800,106,470	766,288,541	759,760,932	-4.77
Oral Cavity	Number of Grants	43	49	52	49	59	
	Relevant Grant Dollars	5,505,263	8,783,998	11,138,288	8,209,050	11,657,227	
	Number of Contracts	1	+	+	+	+	
	Relevant Contract Dollars	1,188,000	+	+	+	+	
	Total Count	44	49	52	49	59	
	Total Relevant Dollars	6,693,263	8,783,998	11,138,288	8,209,050	11,657,227	18.44
Ovary	Number of Grants	419	398	413	413	385	
	Relevant Grant Dollars	81,047,163	92,438,385	96,565,010	96,600,440	95,732,146	
	Number of Contracts	16	16	11	6	7	
	Relevant Contract Dollars	5,782,543	6,099,306	5,217,503	2,015,726	2,496,203	
	Total Count	435	414	424	419	392	
	Total Relevant Dollars	86,829,706	98,537,691	101,782,513	98,616,166	98,228,349	3.32
Pancreas	Number of Grants	405	401	424	417	421	
	Relevant Grant Dollars	81,507,036	83,917,076	90,502,908	91,095,822	97,245,213	
	Number of Contracts	4	1	1	3	3	
	Relevant Contract Dollars	358,204	124,807	159,140	673,594	306,780	
	Total Count	409	402	425	420	424	
	Total Relevant Dollars	81,865,240	84,041,883	90,662,048	91,769,416	97,551,993	4.51

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

§Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies. There is no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Parathyroid	<i>Number of Grants</i>	3	4	2	1	2	
	Relevant Grant Dollars	167,518	103,991	‡	‡	216,587	
	<i>Total Count</i>	3	4	2	1	2	
	Total Relevant Dollars	167,518	103,991	‡	‡	216,587	35.18
Penis	<i>Number of Grants</i>	7	4	5	6	6	
	Relevant Grant Dollars	3,031,187	752,499	2,667,920	2,249,216	2,424,675	
	<i>Total Count</i>	7	4	5	6	6	
	Total Relevant Dollars	3,031,187	752,499	2,667,920	2,249,216	2,424,675	42.87
Pharynx	<i>Number of Grants</i>	32	52	14	18	74	
	Relevant Grant Dollars	2,785,503	4,449,521	1,521,576	1,692,375	3,427,507	
	<i>Number of Contracts</i>	1	‡	‡	‡	‡	
	Relevant Contract Dollars	1,188,000	‡	‡	‡	‡	
	<i>Total Count</i>	33	52	14	18	74	
Total Relevant Dollars	3,973,503	4,449,521	1,521,576	1,692,375	3,427,507	14.98	
Pituitary	<i>Number of Grants</i>	6	7	7	7	5	
	Relevant Grant Dollars	606,496	482,208	627,219	1,032,440	695,788	
	<i>Total Count</i>	6	7	7	7	5	
Total Relevant Dollars	606,496	482,208	627,219	1,032,440	695,788	10.39	
Prostate	<i>Number of Grants</i>	1,101	1,028	1,030	960	968	
	Relevant Grant Dollars	252,666,154	250,572,712	265,054,420	254,592,786	231,897,860	
	<i>Number of Contracts</i>	46	38	24	13	10	
	Relevant Contract Dollars	9,220,125	8,857,832	8,108,959	5,670,388	3,076,292	
	<i>Total Count</i>	1,147	1,066	1,054	973	978	
Total Relevant Dollars	261,886,279	259,430,544	273,163,379	260,263,174	234,974,152	-2.52	
Reticuloendothelial System	<i>Number of Grants</i>	49	30	24	23	12	
	Relevant Grant Dollars	8,704,661	7,424,753	4,220,047	4,207,337	3,007,301	
	<i>Total Count</i>	49	30	24	23	12	
Total Relevant Dollars	8,704,661	7,424,753	4,220,047	4,207,337	3,007,301	-21.67	
Respiratory System	<i>Number of Grants</i>	5	3	3	5	4	
	Relevant Grant Dollars	448,324	484,204	400,921	433,241	424,144	
	<i>Total Count</i>	5	3	3	5	4	
Total Relevant Dollars	448,324	484,204	400,921	433,241	424,144	-0.81	
Retinoblastoma	<i>Number of Grants</i>	25	23	20	14	13	
	Relevant Grant Dollars	4,536,603	3,582,106	2,599,952	2,291,465	2,335,494	
	<i>Total Count</i>	25	23	20	14	13	
Total Relevant Dollars	4,536,603	3,582,106	2,599,952	2,291,465	2,335,494	-14.60	
Salivary Glands	<i>Number of Grants</i>	4	4	5	2	3	
	Relevant Grant Dollars	216,951	219,489	281,931	122,931	582,113	
	<i>Total Count</i>	4	4	5	2	3	
Total Relevant Dollars	216,951	219,489	281,931	122,931	582,113	86.69	
Skin	<i>Number of Grants</i>	274	243	227	206	209	
	Relevant Grant Dollars	48,382,761	44,850,024	43,190,271	39,781,606	38,979,774	
	<i>Number of Contracts</i>	‡	1	‡	1	1	
	Relevant Contract Dollars	‡	200,000	‡	999,000	299,993	
	<i>Total Count</i>	274	244	227	207	210	
Total Relevant Dollars	48,382,761	45,050,024	43,190,271	40,780,606	39,279,767	-5.07	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Small Intestine	Number of Grants	23	21	19	21	22	
	Relevant Grant Dollars	1,913,855	2,322,269	2,154,757	2,523,663	2,601,072	
	Total Count	23	21	19	21	22	
	Total Relevant Dollars	1,913,855	2,322,269	2,154,757	2,523,663	2,601,072	8.74
Spleen	Number of Grants	5	4	3	1	‡	
	Relevant Grant Dollars	579,727	190,652	243,170	41,226	‡	
	Total Count	5	4	3	1	‡	
	Total Relevant Dollars	579,727	190,652	243,170	41,226	‡	-40.87
Stomach	Number of Grants	74	64	65	58	46	
	Relevant Grant Dollars	8,736,659	11,212,686	10,776,732	9,227,080	8,068,624	
	Number of Contracts	2	‡	‡	‡	2	
	Relevant Contract Dollars	21,086	‡	‡	‡	85,605	
	Total Count	76	64	65	58	48	
Total Relevant Dollars	8,757,745	11,212,686	10,776,732	9,227,080	8,154,229	-0.47	
Testis	Number of Grants	39	30	27	23	12	
	Relevant Grant Dollars	6,649,429	4,704,354	4,216,762	2,966,075	3,825,536	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	39	30	27	23	12	
Total Relevant Dollars	6,649,429	4,704,354	4,216,762	2,966,075	3,825,536	-10.07	
Thymus	Number of Grants	9	6	4	4	4	
	Relevant Grant Dollars	944,461	702,233	397,192	504,940	615,252	
	Total Count	9	6	4	4	4	
	Total Relevant Dollars	944,461	702,233	397,192	504,940	615,252	-5.03
Thyroid	Number of Grants	50	47	52	51	48	
	Relevant Grant Dollars	9,785,919	10,773,542	10,900,704	10,394,218	10,082,148	
	Number of Contracts	2	‡	‡	‡	‡	
	Relevant Contract Dollars	161,058	‡	‡	‡	‡	
	Total Count	52	47	52	51	48	
Total Relevant Dollars	9,946,977	10,773,542	10,900,704	10,394,218	10,082,148	0.46	
Trachea, Bronchus	Number of Grants	3	3	2	4	3	
	Relevant Grant Dollars	283,631	332,875	112,364	927,176	707,722	
	Total Count	3	3	2	4	3	
	Total Relevant Dollars	283,631	332,875	112,364	927,176	707,722	163.15
Uterus	Number of Grants	109	107	80	90	107	
	Relevant Grant Dollars	14,240,551	14,708,946	12,006,415	13,617,358	16,911,090	
	Number of Contracts	2	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	111	107	80	90	107	
Total Relevant Dollars	14,240,551	14,708,946	12,006,415	13,617,358	16,911,090	5.63	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Vagina	Number of Grants	5	3	4	5	5	
	Relevant Grant Dollars	395,049	374,910	275,471	284,762	336,623	
	Total Count	5	3	4	5	5	
	Total Relevant Dollars	395,049	374,910	275,471	284,762	336,623	-2.51
Vascular	Number of Grants	96	65	55	48	40	
	Relevant Grant Dollars	16,401,823	13,022,343	12,429,452	11,108,479	7,523,998	
	Total Count	96	65	55	48	40	
	Total Relevant Dollars	16,401,823	13,022,343	12,429,452	11,108,479	7,523,998	-17.01
Wilms Tumor	Number of Grants	17	16	15	17	14	
	Relevant Grant Dollars	3,748,439	4,249,920	3,792,626	3,166,418	2,563,467	
	Total Count	17	16	15	17	14	
	Total Relevant Dollars	3,748,439	4,249,920	3,792,626	3,166,418	2,563,467	-8.23

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Adoptive Cell Immunotherapy	Number of Grants	264	250	249	226	231	
	Relevant Grant Dollars	74,709,142	65,455,904	71,169,780	68,415,543	64,459,206	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	247,568	‡	
	Total Count	264	250	249	227	231	
	Total Relevant Dollars	74,709,142	65,455,904	71,169,780	68,663,011	64,459,206	-3.33
Advanced Manufacturing Technology	Number of Grants	26	16	15	13	10	
	Relevant Grant Dollars	4,715,021	3,032,054	3,285,087	2,770,889	2,945,075	
	Number of Contracts	6	7	1	‡	1	
	Relevant Contract Dollars	796,198	2,189,910	106,000	‡	498,626	
	Total Count	32	23	16	13	11	
	Total Relevant Dollars	5,511,219	5,221,964	3,391,087	2,770,889	3,443,701	-8.58
Aging	Number of Grants	1,511	1,311	1,066	854	689	
	Relevant Grant Dollars	152,249,919	135,080,359	113,349,368	99,438,832	79,998,304	
	Number of Contracts	39	26	7	5	2	
	Relevant Contract Dollars	5,277,985	4,221,489	2,424,616	631,073	82,113	
	Total Count	1,550	1,337	1,073	859	691	
	Total Relevant Dollars	157,527,904	139,301,848	115,773,984	100,069,905	80,080,417	-15.50
AIDS	Number of Grants	492	413	412	65	60	
	Relevant Grant Dollars	103,344,122	98,869,614	91,837,776	13,092,878	12,538,472	
	Number of Contracts	8	10	3	‡	‡	
	Relevant Contract Dollars	2,461,012	4,070,295	504,083	‡	‡	
	Total Count	500	423	415	65	60	
	Total Relevant Dollars	105,805,134	102,939,909	92,341,859	13,092,878	12,538,472	-25.76
Alternative Medicine, Direct	Number of Grants	369	371	373	347	343	
	Relevant Grant Dollars	97,318,620	85,029,188	89,420,040	83,106,708	73,033,996	
	Number of Contracts	4	3	2	‡	3	
	Relevant Contract Dollars	791	610	1,149,412	‡	266,500	
	Total Count	373	374	375	347	346	
	Total Relevant Dollars	97,319,411	85,029,798	90,569,452	83,106,708	73,300,496	-6.54
Alternative Medicine, Indirect	Number of Grants	57	48	44	47	31	
	Relevant Grant Dollars	13,189,399	8,017,376	8,714,472	8,363,143	6,981,196	
	Total Count	57	48	44	47	31	
	Total Relevant Dollars	13,189,399	8,017,376	8,714,472	8,363,143	6,981,196	-12.77
Alzheimers Dementia	Number of Grants	6	7	4	4	3	
	Relevant Grant Dollars	519,280	643,620	508,810	565,699	96,204	
	Total Count	6	7	4	4	3	
	Total Relevant Dollars	519,280	643,620	508,810	565,699	96,204	-17.20
Arctic Research	Number of Grants	7	5	3	3	5	
	Relevant Grant Dollars	965,121	593,726	684,462	692,817	570,649	
	Number of Contracts	‡	‡	‡	‡	1	
	Relevant Contract Dollars	‡	‡	‡	‡	471,532	
	Total Count	7	5	3	3	6	
	Total Relevant Dollars	965,121	593,726	684,462	692,817	1,042,181	7.11
Arthritis	Number of Grants	4	6	4	5	7	
	Relevant Grant Dollars	558,858	269,326	400,562	396,477	1,066,691	
	Total Count	4	6	4	5	7	
	Total Relevant Dollars	558,858	269,326	400,562	396,477	1,066,691	41.24

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Asbestos	Number of Grants	14	10	11	12	13	
	Relevant Grant Dollars	3,033,759	2,598,119	3,428,084	2,591,109	3,609,082	
	Total Count	14	10	11	12	13	
	Total Relevant Dollars	3,033,759	2,598,119	3,428,084	2,591,109	3,609,082	8.11
Ataxia Telangiectasia	Number of Grants	23	21	19	17	11	
	Relevant Grant Dollars	3,327,580	3,679,780	2,938,837	1,769,222	1,369,928	
	Total Count	23	21	19	17	11	
	Total Relevant Dollars	3,327,580	3,679,780	2,938,837	1,769,222	1,369,928	-17.98
Autoimmune Diseases	Number of Grants	55	45	37	35	33	
	Relevant Grant Dollars	6,844,086	5,221,927	4,320,535	4,076,442	3,767,007	
	Total Count	55	45	37	35	33	
	Total Relevant Dollars	6,844,086	5,221,927	4,320,535	4,076,442	3,767,007	-13.55
Behavior Research	Number of Grants	1,072	1,093	1,104	1,098	1,106	
	Relevant Grant Dollars	280,067,448	297,188,165	314,205,359	322,649,017	328,483,291	
	Number of Contracts	18	14	10	12	18	
	Relevant Contract Dollars	7,038,853	4,360,635	3,248,062	7,177,481	7,750,198	
	Total Count	1,090	1,107	1,114	1,110	1,124	
	Total Relevant Dollars	287,106,301	301,548,800	317,453,421	329,826,498	336,233,489	4.04
Bioengineering	Number of Grants	661	593	543	478	471	
	Relevant Grant Dollars	166,106,195	146,299,426	143,101,038	136,659,850	128,170,758	
	Number of Contracts	43	19	19	28	14	
	Relevant Contract Dollars	23,284,472	9,802,298	5,212,765	7,104,296	7,721,382	
	Total Count	704	612	562	506	485	
	Total Relevant Dollars	189,390,667	156,101,724	148,313,803	143,764,146	135,892,140	-7.78
Bioinformatics	Number of Grants	647	609	613	620	691	
	Relevant Grant Dollars	153,069,578	162,286,911	175,538,540	195,579,757	220,626,261	
	Number of Contracts	35	21	16	20	25	
	Relevant Contract Dollars	61,976,197	23,191,871	18,412,975	20,328,761	20,993,037	
	Total Count	682	630	629	640	716	
	Total Relevant Dollars	215,045,775	185,478,782	193,951,515	215,908,518	241,619,298	3.51
Biological Carcinogenesis Non-Viral	Number of Grants	61	68	65	68	75	
	Relevant Grant Dollars	10,028,377	13,031,273	13,043,584	14,509,921	15,387,505	
	Number of Contracts	1	‡	‡	‡	‡	
	Relevant Contract Dollars	11,788	‡	‡	‡	‡	
	Total Count	62	68	65	68	75	
	Total Relevant Dollars	10,040,165	13,031,273	13,043,584	14,509,921	15,387,505	11.79
Biologics/Biological Response Modifiers	Number of Grants	2,415	2,122	1,900	1,668	1,484	
	Relevant Grant Dollars	770,905,944	696,719,623	670,058,289	603,303,533	530,129,682	
	Number of Contracts	35	36	22	15	10	
	Relevant Contract Dollars	49,274,072	42,544,872	21,405,546	16,939,205	10,691,980	
	Total Count	2,450	2,158	1,922	1,683	1,494	
	Total Relevant Dollars	820,180,016	739,264,495	691,463,835	620,242,738	540,821,662	-9.86
Biomaterials Research	Number of Grants	156	131	141	114	104	
	Relevant Grant Dollars	29,002,753	27,561,068	21,212,069	17,519,246	15,414,009	
	Number of Contracts	9	‡	4	‡	2	
	Relevant Contract Dollars	876,528	‡	1,548,783	‡	1,186,186	
	Total Count	165	131	145	114	106	
	Total Relevant Dollars	29,879,281	27,561,068	22,760,852	17,519,246	16,600,195	-13.36

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Biomedical Computing	Number of Grants	430	467	532	542	596	
	Relevant Grant Dollars	91,622,068	113,451,117	137,845,989	144,567,142	164,726,922	
	Number of Contracts	52	21	19	30	31	
	Relevant Contract Dollars	62,638,913	61,682,516	61,163,296	76,247,799	53,261,742	
	Total Count	482	488	551	572	627	
	Total Relevant Dollars	154,260,981	175,133,633	199,009,285	220,814,941	217,988,664	9.21
Birth Defects	Number of Grants	75	61	64	56	46	
	Relevant Grant Dollars	12,667,124	11,547,343	12,310,466	10,773,700	8,086,859	
	Total Count	75	61	64	56	46	
	Total Relevant Dollars	12,667,124	11,547,343	12,310,466	10,773,700	8,086,859	-9.91
Bone Marrow Transplantation	Number of Grants	140	146	140	146	112	
	Relevant Grant Dollars	47,434,124	52,111,916	54,507,621	50,005,537	37,328,235	
	Number of Contracts	‡	1	‡	‡	‡	
	Relevant Contract Dollars	‡	49,496	‡	‡	‡	
	Total Count	140	147	140	146	112	
	Total Relevant Dollars	47,434,124	52,161,412	54,507,621	50,005,537	37,328,235	-4.79
Breast Cancer Detection	Number of Grants	525	508	498	458	441	
	Relevant Grant Dollars	108,220,945	104,769,617	99,759,605	91,023,962	88,105,336	
	Number of Contracts	28	22	13	15	12	
	Relevant Contract Dollars	2,767,443	2,928,506	3,632,816	6,478,783	5,863,578	
	Total Count	553	530	511	473	453	
	Total Relevant Dollars	110,988,388	107,698,123	103,392,421	97,502,745	93,968,914	-4.07
Breast Cancer Early Detection	Number of Grants	240	219	225	196	197	
	Relevant Grant Dollars	53,893,623	45,876,009	47,143,457	48,915,492	46,685,468	
	Number of Contracts	6	1	3	4	6	
	Relevant Contract Dollars	470,851	420,996	1,506,703	2,561,486	3,764,617	
	Total Count	246	220	228	200	203	
	Total Relevant Dollars	54,364,474	46,297,005	48,650,160	51,476,978	50,450,085	-1.49
Breast Cancer Education	Number of Grants	144	142	149	131	117	
	Relevant Grant Dollars	16,003,803	17,412,166	16,743,662	16,114,826	13,390,623	
	Total Count	144	142	149	131	117	
	Total Relevant Dollars	16,003,803	17,412,166	16,743,662	16,114,826	13,390,623	-3.92
Breast Cancer Epidemiology	Number of Grants	191	182	189	195	215	
	Relevant Grant Dollars	54,730,727	54,666,482	64,674,588	67,767,559	79,021,942	
	Number of Contracts	3	1	5	1	2	
	Relevant Contract Dollars	308,692	51,500	336,493	1,620,669	1,728,711	
	Total Count	194	183	194	196	217	
	Total Relevant Dollars	55,039,419	54,717,982	65,011,081	69,388,228	80,750,653	10.33
Breast Cancer Genetics	Number of Grants	429	429	453	482	510	
	Relevant Grant Dollars	97,895,528	104,276,046	116,708,177	116,790,479	130,302,574	
	Number of Contracts	3	8	5	6	5	
	Relevant Contract Dollars	1,064,606	2,655,595	2,418,766	2,277,691	2,143,190	
	Total Count	432	437	458	488	515	
	Total Relevant Dollars	98,960,134	106,931,641	119,126,943	119,068,170	132,445,764	7.66

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Breast Cancer Prevention	Number of Grants	237	223	211	193	190	
	Relevant Grant Dollars	24,443,078	23,625,542	20,573,617	19,425,993	18,454,078	
	Number of Contracts	‡	‡	‡	2	1	
	Relevant Contract Dollars	‡	‡	‡	161,745	35,700	
	Total Count	237	223	211	195	191	
	Total Relevant Dollars	24,443,078	23,625,542	20,573,617	19,587,738	18,489,778	-6.66
Breast Cancer Rehabilitation	Number of Grants	157	156	165	180	169	
	Relevant Grant Dollars	18,496,683	22,053,106	23,414,402	23,491,341	23,354,588	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	157	156	165	180	169	
	Total Relevant Dollars	18,496,683	22,053,106	23,414,402	23,491,341	23,354,588	6.29
Breast Cancer Screening	Number of Grants	190	182	194	178	178	
	Relevant Grant Dollars	22,935,243	21,132,490	22,564,554	24,098,034	26,090,155	
	Number of Contracts	‡	‡	‡	1	1	
	Relevant Contract Dollars	‡	‡	‡	1,599,992	1,400,000	
	Total Count	190	182	194	179	179	
	Total Relevant Dollars	22,935,243	21,132,490	22,564,554	25,698,026	27,490,155	4.94
Breast Cancer Treatment	Number of Grants	715	676	699	671	679	
	Relevant Grant Dollars	159,717,667	175,287,152	191,699,483	182,244,051	151,868,982	
	Number of Contracts	17	20	11	3	8	
	Relevant Contract Dollars	2,845,506	2,908,754	1,962,093	461,244	4,169,128	
	Total Count	732	696	710	674	687	
	Total Relevant Dollars	162,563,173	178,195,906	193,661,576	182,705,295	156,038,110	-0.49
Breast Cancer - Basic	Number of Grants	807	773	781	758	744	
	Relevant Grant Dollars	152,092,109	161,805,933	168,864,512	168,911,481	175,587,977	
	Number of Contracts	8	9	9	2	5	
	Relevant Contract Dollars	559,354	1,532,199	1,977,194	648,203	1,013,726	
	Total Count	815	782	790	760	749	
	Total Relevant Dollars	152,651,463	163,338,132	170,841,706	169,559,684	176,601,703	3.75
Cancer Survivorship	Number of Grants	604	596	627	669	669	
	Relevant Grant Dollars	189,504,238	197,965,376	233,784,991	244,829,411	247,349,527	
	Number of Contracts	26	22	7	11	13	
	Relevant Contract Dollars	3,743,947	2,901,978	2,202,035	10,974,854	12,698,851	
	Total Count	630	618	634	680	682	
	Total Relevant Dollars	193,248,185	200,867,354	235,987,026	255,804,265	260,048,378	7.87
Carcinogenesis, Environmental	Number of Grants	1,478	1,407	1,316	1,237	1,163	
	Relevant Grant Dollars	416,898,310	388,760,406	395,790,431	384,795,833	367,617,534	
	Number of Contracts	34	26	19	9	13	
	Relevant Contract Dollars	16,619,490	10,219,303	7,165,859	3,411,768	4,057,751	
	Total Count	1,512	1,433	1,335	1,246	1,176	
	Total Relevant Dollars	433,517,800	398,979,709	402,956,290	388,207,601	371,675,285	-3.72
Cervical Cancer Education	Number of Grants	48	42	49	44	39	
	Relevant Grant Dollars	6,078,672	5,288,307	6,669,506	6,289,116	6,569,930	
	Total Count	48	42	49	44	39	
	Total Relevant Dollars	6,078,672	5,288,307	6,669,506	6,289,116	6,569,930	2.97

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Chemoprevention	Number of Grants	603	581	554	513	521	
	Relevant Grant Dollars	127,214,057	122,199,190	110,809,302	110,334,008	106,270,652	
	Number of Contracts	26	20	9	9	9	
	Relevant Contract Dollars	30,237,119	34,586,263	14,907,908	12,224,778	7,745,895	
	Total Count	629	601	563	522	530	
	Total Relevant Dollars	157,451,176	156,785,453	125,717,210	122,558,786	114,016,547	-7.43
Chemoprevention, Clinical	Number of Grants	130	134	136	129	129	
	Relevant Grant Dollars	33,077,734	32,365,770	31,292,583	30,974,445	26,207,896	
	Number of Contracts	12	7	2	4	5	
	Relevant Contract Dollars	11,367,607	11,187,869	1,568,183	6,660,343	1,809,372	
	Total Count	142	141	138	133	134	
	Total Relevant Dollars	44,445,341	43,553,639	32,860,766	37,634,788	28,017,268	-9.40
Chemotherapy	Number of Grants	1,350	1,318	1,265	1,268	1,309	
	Relevant Grant Dollars	474,245,547	491,407,371	486,445,892	487,783,247	483,927,715	
	Number of Contracts	31	24	23	23	21	
	Relevant Contract Dollars	23,279,025	18,985,236	16,237,585	15,509,777	15,400,076	
	Total Count	1,381	1,342	1,288	1,291	1,330	
	Total Relevant Dollars	497,524,572	510,392,607	502,683,477	503,293,024	499,327,791	0.10
Child Health	Number of Grants	208	173	180	146	132	
	Relevant Grant Dollars	55,722,419	41,893,936	35,485,301	30,619,348	29,367,355	
	Number of Contracts	1	1	1	1	3	
	Relevant Contract Dollars	10,529	94,045	100,000	500,000	632,000	
	Total Count	209	174	181	147	135	
	Total Relevant Dollars	55,732,948	41,987,981	35,585,301	31,119,348	29,999,355	-14.02
Childhood Cancers	Number of Grants	504	477	495	517	532	
	Relevant Grant Dollars	164,775,607	163,353,861	166,272,586	165,281,278	177,934,130	
	Number of Contracts	5	1	1	1	2	
	Relevant Contract Dollars	1,431,001	1,990,858	2,938,868	2,791,925	2,999,993	
	Total Count	509	478	496	518	534	
	Total Relevant Dollars	166,206,608	165,344,719	169,211,454	168,073,203	180,934,123	2.20
Chronic Myeloproliferative Disorders	Number of Grants	124	115	129	143	143	
	Relevant Grant Dollars	31,066,792	31,864,056	33,259,274	40,413,091	38,980,403	
	Total Count	124	115	129	143	143	
	Total Relevant Dollars	31,066,792	31,864,056	33,259,274	40,413,091	38,980,403	6.23
Clinical Trials, Diagnosis	Number of Grants	180	177	158	157	142	
	Relevant Grant Dollars	52,919,647	46,050,747	49,365,161	50,104,212	38,090,132	
	Number of Contracts	20	15	14	3	2	
	Relevant Contract Dollars	22,227,173	20,599,926	21,295,518	4,929,393	2,264,053	
	Total Count	200	192	172	160	144	
	Total Relevant Dollars	75,146,820	66,650,673	70,660,679	55,033,605	40,354,185	-13.52
Clinical Trials, Other	Number of Grants	202	196	231	220	241	
	Relevant Grant Dollars	57,804,488	55,185,455	64,532,028	69,256,696	73,756,321	
	Number of Contracts	5	2	3	4	8	
	Relevant Contract Dollars	35,442,454	1,800,000	2,199,778	5,627,105	4,870,009	
	Total Count	207	198	234	224	249	
	Total Relevant Dollars	93,246,942	56,985,455	66,731,806	74,883,801	78,626,330	-1.14

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Clinical Trials, Prevention	Number of Grants	152	160	162	227	140	
	Relevant Grant Dollars	51,014,829	52,476,013	56,851,445	142,302,439	51,726,135	
	Number of Contracts	14	10	4	6	8	
	Relevant Contract Dollars	17,487,767	17,750,174	10,044,105	11,401,878	2,682,866	
	Total Count	166	170	166	233	148	
	Total Relevant Dollars	68,502,596	70,226,187	66,895,550	153,704,317	54,409,001	15.73
Clinical Trials, Therapy	Number of Grants	709	657	636	523	574	
	Relevant Grant Dollars	394,416,421	381,371,267	383,892,811	321,816,935	326,779,192	
	Number of Contracts	16	16	17	20	16	
	Relevant Contract Dollars	20,555,120	45,809,933	43,398,794	57,748,533	38,008,573	
	Total Count	725	673	653	543	590	
	Total Relevant Dollars	414,971,541	427,181,200	427,291,605	379,565,468	364,787,765	-3.02
Combined Treatment Modalities	Number of Grants	572	601	679	769	922	
	Relevant Grant Dollars	329,900,253	330,893,890	366,302,744	388,561,125	407,422,052	
	Number of Contracts	1	1	4	7	8	
	Relevant Contract Dollars	1,141,539	1,990,858	3,372,144	6,442,620	7,776,273	
	Total Count	573	602	683	776	930	
	Total Relevant Dollars	331,041,792	332,884,748	369,674,888	395,003,745	415,198,325	5.89
Cost Effectiveness	Number of Grants	177	172	173	177	181	
	Relevant Grant Dollars	27,408,881	27,223,170	27,186,831	29,938,700	29,528,911	
	Number of Contracts	5	3	2	1	1	
	Relevant Contract Dollars	791	610	186,230	248,461	2,479,561	
	Total Count	182	175	175	178	182	
	Total Relevant Dollars	27,409,672	27,223,780	27,373,061	30,187,161	32,008,472	4.05
Diabetes	Number of Grants	59	53	47	36	49	
	Relevant Grant Dollars	7,044,678	6,202,451	3,530,526	4,851,425	7,823,131	
	Total Count	59	53	47	36	49	
	Total Relevant Dollars	7,044,678	6,202,451	3,530,526	4,851,425	7,823,131	10.91
Diagnosis	Number of Grants	1,985	1,911	1,855	1,779	1,758	
	Relevant Grant Dollars	573,452,204	559,042,065	553,036,713	559,531,772	538,315,913	
	Number of Contracts	94	71	66	51	52	
	Relevant Contract Dollars	48,739,504	36,236,631	38,373,345	24,273,760	32,848,866	
	Total Count	2,079	1,982	1,921	1,830	1,810	
	Total Relevant Dollars	622,191,708	595,278,696	591,410,058	583,805,532	571,164,779	-2.11
Diethylstilbestrol	Number of Grants	3	‡	2	3	3	
	Relevant Grant Dollars	405,296	‡	210,443	330,257	323,182	
	Number of Contracts	5	5	5	‡	‡	
	Relevant Contract Dollars	1,302,461	1,332,877	1,345,965	‡	‡	
	Total Count	8	5	7	3	3	
	Total Relevant Dollars	1,707,757	1,332,877	1,556,408	330,257	323,182	-21.53
Dioxin	Number of Grants	10	10	12	13	9	
	Relevant Grant Dollars	1,364,134	1,268,488	1,736,256	869,725	936,088	
	Total Count	10	10	12	13	9	
	Total Relevant Dollars	1,364,134	1,268,488	1,736,256	869,725	936,088	-3.10

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
DNA Repair	Number of Grants	699	633	600	555	540	
	Relevant Grant Dollars	135,428,622	122,923,808	128,813,944	122,952,777	111,276,907	
	Number of Contracts	‡	‡	2	‡	1	
	Relevant Contract Dollars	‡	‡	399,599	‡	999,596	
	Total Count	699	633	602	555	541	
	Total Relevant Dollars	135,428,622	122,923,808	129,213,543	122,952,777	112,276,503	-4.41
Drug Development	Number of Grants	2,077	2,087	2,091	2,095	2,233	
	Relevant Grant Dollars	526,752,390	538,758,282	550,899,818	582,044,480	593,685,849	
	Number of Contracts	86	75	82	84	69	
	Relevant Contract Dollars	89,847,891	51,239,667	50,932,059	44,439,383	58,367,271	
	Total Count	2,163	2,162	2,173	2,179	2,302	
	Total Relevant Dollars	616,600,281	589,997,949	601,831,877	626,483,863	652,053,120	1.47
Drug Discovery	Number of Grants	366	364	377	380	426	
	Relevant Grant Dollars	79,667,568	81,268,839	74,170,074	71,551,561	77,078,178	
	Number of Contracts	18	11	18	11	7	
	Relevant Contract Dollars	9,345,219	13,478,230	11,779,829	2,805,286	2,752,844	
	Total Count	384	375	395	391	433	
	Total Relevant Dollars	89,012,787	94,747,069	85,949,903	74,356,847	79,831,022	-2.24
Drug Resistance	Number of Grants	646	631	634	638	697	
	Relevant Grant Dollars	109,833,907	111,827,085	117,323,805	126,166,864	137,912,021	
	Number of Contracts	‡	1	2	2	2	
	Relevant Contract Dollars	‡	37,181	395,550	388,667	399,349	
	Total Count	646	632	636	640	699	
	Total Relevant Dollars	109,833,907	111,864,266	117,719,355	126,555,531	138,311,370	5.97
Drugs – Natural Products	Number of Grants	647	634	640	603	577	
	Relevant Grant Dollars	134,532,430	150,196,945	143,114,167	140,027,475	123,779,207	
	Number of Contracts	5	4	4	5	2	
	Relevant Contract Dollars	240,346	593,175	1,375,565	1,298,440	396,938	
	Total Count	652	638	644	608	579	
	Total Relevant Dollars	134,772,776	150,790,120	144,489,732	141,325,915	124,176,145	-1.65
Early Detection	Number of Grants	936	869	839	799	788	
	Relevant Grant Dollars	240,604,537	222,168,970	227,060,938	231,169,872	220,140,713	
	Number of Contracts	40	20	17	10	17	
	Relevant Contract Dollars	23,057,128	21,156,276	21,353,066	9,463,743	15,164,662	
	Total Count	976	889	856	809	805	
	Total Relevant Dollars	263,661,665	243,325,246	248,414,004	240,633,615	235,305,375	-2.74
Effectiveness Research	Number of Grants	135	156	199	241	329	
	Relevant Grant Dollars	38,991,088	52,087,249	59,933,366	88,645,132	95,620,963	
	Number of Contracts	4	1	2	2	7	
	Relevant Contract Dollars	216,123	252,597	560,081	303,094	5,463,193	
	Total Count	139	157	201	243	336	
	Total Relevant Dollars	39,207,211	52,339,846	60,493,447	88,948,226	101,084,156	27.44
Endocrinology	Number of Grants	846	787	716	669	619	
	Relevant Grant Dollars	152,810,901	160,349,292	144,586,939	134,691,456	127,583,367	
	Number of Contracts	8	6	5	2	4	
	Relevant Contract Dollars	1,442,461	2,042,874	1,345,965	365,780	813,140	
	Total Count	854	793	721	671	623	
	Total Relevant Dollars	154,253,362	162,392,166	145,932,904	135,057,236	128,396,507	-4.31

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Energy Balance	Number of Grants	117	109	104	105	112	
	Relevant Grant Dollars	37,250,439	34,684,820	30,844,556	33,474,016	32,621,115	
	Number of Contracts	5	2	1	‡	‡	
	Relevant Contract Dollars	1,916,049	1,575,000	4,885	‡	‡	
	Total Count	122	111	105	105	112	
	Total Relevant Dollars	39,166,488	36,259,820	30,849,441	33,474,016	32,621,115	-4.10
Epidemiology	Number of Grants	184	203	238	248	257	
	Relevant Grant Dollars	35,362,320	48,391,387	58,955,769	58,456,327	75,023,578	
	Number of Contracts	12	11	12	9	19	
	Relevant Contract Dollars	40,155,271	6,923,651	7,967,822	6,370,296	13,162,987	
	Total Count	196	214	250	257	276	
	Total Relevant Dollars	75,517,591	55,315,038	66,923,591	64,826,623	88,186,565	6.78
Epidemiology, Biochemical	Number of Grants	581	560	544	513	525	
	Relevant Grant Dollars	187,522,766	186,146,991	207,004,532	196,371,213	200,458,114	
	Number of Contracts	10	11	9	10	10	
	Relevant Contract Dollars	13,132,622	22,350,084	22,230,209	27,302,955	32,063,034	
	Total Count	591	571	553	523	535	
	Total Relevant Dollars	200,655,388	208,497,075	229,234,741	223,674,168	232,521,148	3.85
Epidemiology, Environmental	Number of Grants	534	518	487	442	402	
	Relevant Grant Dollars	165,826,605	157,183,612	169,765,154	158,195,340	146,924,987	
	Number of Contracts	24	21	16	10	14	
	Relevant Contract Dollars	16,439,893	24,581,051	24,953,396	22,833,401	27,082,561	
	Total Count	558	539	503	452	416	
	Total Relevant Dollars	182,266,498	181,764,663	194,718,550	181,028,741	174,007,548	-1.01
Epigenetics	Number of Grants	699	722	771	859	893	
	Relevant Grant Dollars	115,349,385	139,887,622	161,834,223	182,952,932	197,448,892	
	Number of Contracts	2	4	3	‡	1	
	Relevant Contract Dollars	302,567	653,292	549,598	‡	80,000	
	Total Count	701	726	774	859	894	
	Total Relevant Dollars	115,651,952	140,540,914	162,383,821	182,952,932	197,528,892	14.42
Gene Mapping, Human	Number of Grants	554	493	436	402	349	
	Relevant Grant Dollars	119,648,785	153,658,315	158,894,763	149,903,735	112,977,260	
	Total Count	554	493	436	402	349	
	Total Relevant Dollars	119,648,785	153,658,315	158,894,763	149,903,735	112,977,260	0.39
Gene Mapping, Non-Human	Number of Grants	327	274	243	215	183	
	Relevant Grant Dollars	49,897,071	40,329,713	37,746,569	35,807,176	30,805,418	
	Total Count	327	274	243	215	183	
	Total Relevant Dollars	49,897,071	40,329,713	37,746,569	35,807,176	30,805,418	-11.17
Gene Transfer, Clinical	Number of Grants	58	37	28	33	28	
	Relevant Grant Dollars	9,063,499	11,261,635	8,086,568	8,242,594	6,398,890	
	Total Count	58	37	28	33	28	
	Total Relevant Dollars	9,063,499	11,261,635	8,086,568	8,242,594	6,398,890	-6.09
Genetic Testing Research, Human	Number of Grants	460	380	335	286	250	
	Relevant Grant Dollars	153,581,370	128,833,823	115,367,220	97,622,451	78,970,309	
	Number of Contracts	4	3	3	4	4	
	Relevant Contract Dollars	1,064,606	1,308,355	1,325,744	1,531,022	2,838,423	
	Total Count	464	383	338	290	254	
	Total Relevant Dollars	154,645,976	130,142,178	116,692,964	99,153,473	81,808,732	-14.68

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific SIC.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Genomics	Number of Grants	603	758	837	936	1,090	
	Relevant Grant Dollars	160,617,624	233,634,493	276,653,749	312,504,344	355,990,253	
	Number of Contracts	7	11	9	10	9	
	Relevant Contract Dollars	37,387,078	2,893,716	2,573,478	3,992,902	3,769,491	
	Total Count	610	769	846	946	1,099	
	Total Relevant Dollars	198,004,702	236,528,209	279,227,227	316,497,246	359,759,744	16.13
Health Literacy	Number of Grants	74	78	93	104	107	
	Relevant Grant Dollars	14,713,919	19,259,445	21,151,000	23,322,845	25,702,360	
	Number of Contracts	6	2	1	1	1	
	Relevant Contract Dollars	462,228	2,242,507	2,225,682	2,034,678	2,026,250	
	Total Count	80	80	94	105	108	
	Total Relevant Dollars	15,176,147	21,501,952	23,376,682	25,357,523	27,728,610	17.06
Health Promotion	Number of Grants	567	550	535	492	459	
	Relevant Grant Dollars	188,789,768	189,856,649	156,169,759	158,653,454	152,900,603	
	Number of Contracts	31	29	12	5	9	
	Relevant Contract Dollars	17,490,115	12,155,514	8,239,835	4,853,740	5,078,162	
	Total Count	598	579	547	497	468	
	Total Relevant Dollars	206,279,883	202,012,163	164,409,594	163,507,194	157,978,765	-6.15
Health Care Delivery	Number of Grants	233	260	323	361	370	
	Relevant Grant Dollars	58,703,422	79,491,611	99,249,496	111,213,954	116,521,815	
	Number of Contracts	19	7	9	10	12	
	Relevant Contract Dollars	4,471,971	4,206,677	4,637,640	6,239,884	6,285,437	
	Total Count	252	267	332	371	382	
	Total Relevant Dollars	63,175,393	83,698,288	103,887,136	117,453,838	122,807,252	18.56
Helicobacter	Number of Grants	39	39	34	33	32	
	Relevant Grant Dollars	5,876,269	8,224,164	8,078,008	8,081,826	7,685,880	
	Number of Contracts	1	‡	‡	‡	‡	
	Relevant Contract Dollars	11,788	‡	‡	‡	‡	
	Total Count	40	39	34	33	32	
	Total Relevant Dollars	5,888,057	8,224,164	8,078,008	8,081,826	7,685,880	8.26
Hematology	Number of Grants	1,646	1,531	1,472	1,423	1,440	
	Relevant Grant Dollars	468,003,334	451,773,304	466,847,932	464,441,339	454,740,603	
	Number of Contracts	10	6	6	6	7	
	Relevant Contract Dollars	1,465,173	906,834	1,967,879	2,797,458	3,100,209	
	Total Count	1,656	1,537	1,478	1,429	1,447	
	Total Relevant Dollars	469,468,507	452,680,138	468,815,811	467,238,797	457,840,812	-0.59
Hematopoietic Stem Cell Research	Number of Grants	486	467	396	465	449	
	Relevant Grant Dollars	114,552,753	114,121,151	113,380,226	122,611,326	105,983,734	
	Number of Contracts	5	5	1	‡	‡	
	Relevant Contract Dollars	1,177,713	727,386	999,936	‡	‡	
	Total Count	491	472	397	465	449	
	Total Relevant Dollars	115,730,466	114,848,537	114,380,162	122,611,326	105,983,734	-1.88
Hormone Replacement Therapy	Number of Grants	49	41	33	31	23	
	Relevant Grant Dollars	6,714,658	7,098,888	3,175,346	3,987,675	2,695,611	
	Total Count	49	41	33	31	23	
	Total Relevant Dollars	6,714,658	7,098,888	3,175,346	3,987,675	2,695,611	-14.09

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Hospice	Number of Grants	57	45	45	33	34	
	Relevant Grant Dollars	9,075,982	8,363,251	9,344,380	8,276,000	7,183,290	
	Number of Contracts	4	‡	1	‡	‡	
	Relevant Contract Dollars	612,259	‡	999,998	‡	‡	
	Total Count	61	45	46	33	34	
	Total Relevant Dollars	9,688,241	8,363,251	10,344,378	8,276,000	7,183,290	-5.80
Human Genome	Number of Grants	219	408	533	631	762	
	Relevant Grant Dollars	72,721,075	157,617,076	224,387,803	262,277,096	303,194,306	
	Number of Contracts	1	3	2	2	4	
	Relevant Contract Dollars	149,975	2,392,888	2,260,666	1,398,722	1,744,057	
	Total Count	220	411	535	633	766	
	Total Relevant Dollars	72,871,050	160,009,964	226,648,469	263,675,818	304,938,363	48.30
Iatrogenesis	Number of Grants	288	275	257	247	264	
	Relevant Grant Dollars	55,716,691	65,399,334	61,577,955	62,271,326	70,740,383	
	Number of Contracts	6	7	5	3	4	
	Relevant Contract Dollars	2,202,346	2,532,672	1,345,965	487,983	1,406,258	
	Total Count	294	282	262	250	268	
	Total Relevant Dollars	57,919,037	67,932,006	62,923,920	62,759,309	72,146,641	6.15
Imaging	Number of Grants	1,100	1,047	1,045	1,012	1,014	
	Relevant Grant Dollars	300,082,605	289,428,387	298,744,722	309,142,019	287,214,478	
	Number of Contracts	40	27	32	20	14	
	Relevant Contract Dollars	32,833,674	18,714,802	21,851,672	7,316,896	7,351,691	
	Total Count	1,140	1,074	1,077	1,032	1,028	
	Total Relevant Dollars	332,916,279	308,143,189	320,596,394	316,458,915	294,566,169	-2.90
Immunization	Number of Grants	477	420	442	449	469	
	Relevant Grant Dollars	116,732,773	109,830,817	116,267,543	122,814,703	127,780,151	
	Number of Contracts	1	2	‡	4	1	
	Relevant Contract Dollars	14,808,841	1,370,729	‡	3,429,651	1,996,084	
	Total Count	478	422	442	453	470	
	Total Relevant Dollars	131,541,614	111,201,546	116,267,543	126,244,354	129,776,235	0.12
Inflammation	Number of Grants	328	365	418	467	532	
	Relevant Grant Dollars	59,043,221	66,040,358	81,746,863	99,553,973	113,039,549	
	Number of Contracts	1	1	‡	‡	‡	
	Relevant Contract Dollars	7,404,421	98,991	‡	‡	‡	
	Total Count	329	366	418	467	532	
	Total Relevant Dollars	66,447,642	66,139,349	81,746,863	99,553,973	113,039,549	14.62
Information Dissemination	Number of Grants	902	853	861	835	787	
	Relevant Grant Dollars	246,350,342	247,182,186	231,787,714	237,305,178	247,159,725	
	Number of Contracts	72	57	38	36	56	
	Relevant Contract Dollars	74,153,319	72,776,903	72,642,039	70,246,091	76,556,706	
	Total Count	974	910	899	871	843	
	Total Relevant Dollars	320,503,661	319,959,089	304,429,753	307,551,269	323,716,431	0.31
Metastasis	Number of Grants	1,585	1,574	1,527	1,534	1,543	
	Relevant Grant Dollars	346,736,699	365,861,233	361,870,802	381,229,457	370,139,067	
	Number of Contracts	8	8	7	6	6	
	Relevant Contract Dollars	1,033,247	1,183,914	1,325,290	1,024,332	3,434,990	
	Total Count	1,593	1,582	1,534	1,540	1,549	
	Total Relevant Dollars	347,769,946	367,045,147	363,196,092	382,253,789	373,574,057	1.87

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific SIC.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Mind/Body Research	Number of Grants	83	82	75	83	83	
	Relevant Grant Dollars	13,979,085	14,158,379	17,883,028	16,149,064	18,436,251	
	Number of Contracts	‡	‡	‡	‡	2	
	Relevant Contract Dollars	‡	‡	‡	‡	89,759	
	Total Count	83	82	75	83	85	
	Total Relevant Dollars	13,979,085	14,158,379	17,883,028	16,149,064	18,526,010	8.15
Molecular Disease	Number of Grants	4,996	5,003	4,962	4,879	4,945	
	Relevant Grant Dollars	1,563,937,623	1,615,324,573	1,670,263,492	1,660,747,605	1,646,243,216	
	Number of Contracts	23	35	31	35	34	
	Relevant Contract Dollars	7,309,485	12,253,807	9,144,621	14,337,338	19,893,543	
	Total Count	5,019	5,038	4,993	4,914	4,979	
	Total Relevant Dollars	1,571,247,108	1,627,578,380	1,679,408,113	1,675,084,943	1,666,136,759	1.49
Molecular Imaging	Number of Grants	523	617	650	701	724	
	Relevant Grant Dollars	147,326,896	174,956,716	164,707,342	181,500,075	184,280,121	
	Number of Contracts	9	11	15	15	4	
	Relevant Contract Dollars	1,650,977	2,239,610	4,042,324	5,602,005	798,078	
	Total Count	532	628	665	716	728	
	Total Relevant Dollars	148,977,873	177,196,326	168,749,666	187,102,080	185,078,199	5.99
Molecular Targeted Prevention	Number of Grants	219	237	252	248	269	
	Relevant Grant Dollars	39,335,671	46,986,672	39,235,184	47,765,297	47,214,496	
	Number of Contracts	1	‡	1	1	2	
	Relevant Contract Dollars	74,930	‡	74,750	248,461	212,500	
	Total Count	220	237	253	249	271	
	Total Relevant Dollars	39,410,601	46,986,672	39,309,934	48,013,758	47,426,996	5.95
Molecular Targeted Therapy	Number of Grants	1,405	1,483	1,515	1,577	1,775	
	Relevant Grant Dollars	393,453,935	404,674,238	407,096,513	442,319,529	475,531,951	
	Number of Contracts	19	9	21	18	18	
	Relevant Contract Dollars	2,742,385	2,305,444	6,175,491	7,588,080	12,174,642	
	Total Count	1,424	1,492	1,536	1,595	1,793	
	Total Relevant Dollars	396,196,320	406,979,682	413,272,004	449,907,609	487,706,593	5.38
Nanotechnology	Number of Grants	496	430	461	444	480	
	Relevant Grant Dollars	114,866,489	113,651,594	122,072,696	119,336,493	121,450,044	
	Number of Contracts	22	10	20	11	14	
	Relevant Contract Dollars	38,850,232	3,523,067	7,338,362	5,161,598	7,104,793	
	Total Count	518	440	481	455	494	
	Total Relevant Dollars	153,716,721	117,174,661	129,411,058	124,498,091	128,554,837	-3.47
Neurofibromatosis	Number of Grants	27	26	34	15	15	
	Relevant Grant Dollars	4,166,356	6,209,557	7,560,557	2,915,817	2,745,637	
	Total Count	27	26	34	15	15	
	Total Relevant Dollars	4,166,356	6,209,557	7,560,557	2,915,817	2,745,637	0.88
Nursing Research	Number of Grants	71	58	54	49	45	
	Relevant Grant Dollars	14,422,508	12,056,800	13,918,717	11,599,142	11,366,624	
	Total Count	71	58	54	49	45	
	Total Relevant Dollars	14,422,508	12,056,800	13,918,717	11,599,142	11,366,624	-4.91

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Nutrition	Number of Grants	887	866	830	779	735	
	Relevant Grant Dollars	208,303,563	202,932,362	198,165,748	201,597,394	176,394,674	
	Number of Contracts	19	16	14	5	19	
	Relevant Contract Dollars	4,410,022	13,115,073	13,792,873	9,069,226	12,900,479	
	Total Count	906	882	844	784	754	
	Total Relevant Dollars	212,713,585	216,047,435	211,958,621	210,666,620	189,295,153	-2.77
Nutrition-Fiber	Number of Grants	29	21	19	19	13	
	Relevant Grant Dollars	7,461,435	6,750,851	2,058,728	3,019,322	1,881,369	
	Number of Contracts	‡	‡	‡	‡	1	
	Relevant Contract Dollars	‡	‡	‡	‡	56,250	
	Total Count	29	21	19	19	14	
	Total Relevant Dollars	7,461,435	6,750,851	2,058,728	3,019,322	1,937,619	-17.05
Nutrition Monitoring	Number of Grants	52	46	45	42	36	
	Relevant Grant Dollars	12,732,118	14,363,776	11,311,406	15,194,549	9,995,060	
	Number of Contracts	4	3	‡	‡	7	
	Relevant Contract Dollars	898,128	800,214	‡	‡	1,107,515	
	Total Count	56	49	45	42	43	
	Total Relevant Dollars	13,630,246	15,163,990	11,311,406	15,194,549	11,102,575	-1.69
Obesity	Number of Grants	235	232	251	251	258	
	Relevant Grant Dollars	49,154,604	52,150,701	47,992,367	58,308,346	63,008,280	
	Number of Contracts	7	5	‡	3	4	
	Relevant Contract Dollars	899,253	801,220	‡	698,394	1,012,349	
	Total Count	242	237	251	254	262	
	Total Relevant Dollars	50,053,857	52,951,921	47,992,367	59,006,740	64,020,629	6.97
Occupational Cancer	Number of Grants	64	51	57	49	42	
	Relevant Grant Dollars	9,326,436	8,119,594	10,901,093	8,727,377	7,737,704	
	Number of Contracts	6	3	2	‡	‡	
	Relevant Contract Dollars	1,695,741	850,154	224,000	‡	‡	
	Total Count	70	54	59	49	42	
	Total Relevant Dollars	11,022,177	8,969,748	11,125,093	8,727,377	7,737,704	-6.87
Oncogenes	Number of Grants	2,354	2,194	2,031	1,934	1,883	
	Relevant Grant Dollars	552,856,295	518,552,721	515,190,558	498,144,267	473,323,034	
	Number of Contracts	4	6	3	5	8	
	Relevant Contract Dollars	1,347,905	2,229,506	2,074,867	1,072,456	2,534,277	
	Total Count	2,358	2,200	2,034	1,939	1,891	
	Total Relevant Dollars	554,204,200	520,782,227	517,265,425	499,216,723	475,857,311	-3.72
Organ Transplant Research	Number of Grants	199	192	182	194	164	
	Relevant Grant Dollars	64,935,205	65,966,217	66,404,117	67,155,158	49,923,229	
	Number of Contracts	‡	1	‡	‡	‡	
	Relevant Contract Dollars	‡	49,496	‡	‡	‡	
	Total Count	199	193	182	194	164	
	Total Relevant Dollars	64,935,205	66,015,713	66,404,117	67,155,158	49,923,229	-5.57
Osteoporosis	Number of Grants	8	9	8	6	6	
	Relevant Grant Dollars	1,596,851	913,593	411,172	317,668	925,324	
	Total Count	8	9	8	6	6	
	Total Relevant Dollars	1,596,851	913,593	411,172	317,668	925,324	17.69

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Pain	Number of Grants	170	161	147	152	154	
	Relevant Grant Dollars	16,642,839	16,576,535	16,468,439	16,300,996	18,155,638	
	Number of Contracts	2	‡	2	‡	‡	
	Relevant Contract Dollars	230,355	‡	1,299,610	‡	‡	
	Total Count	172	161	149	152	154	
	Total Relevant Dollars	16,873,194	16,576,535	17,768,049	16,300,996	18,155,638	2.14
Palliative Care	Number of Grants	186	167	161	153	153	
	Relevant Grant Dollars	24,209,640	22,111,289	20,897,707	21,247,383	21,916,672	
	Number of Contracts	5	‡	2	1	1	
	Relevant Contract Dollars	612,259	‡	2,198,445	52,655	21,000	
	Total Count	191	167	163	154	154	
	Total Relevant Dollars	24,821,899	22,111,289	23,096,152	21,300,038	21,937,672	-2.81
PAP Testing	Number of Grants	117	105	106	105	111	
	Relevant Grant Dollars	13,323,361	10,352,147	10,627,523	11,695,680	11,312,785	
	Number of Contracts	‡	‡	1	‡	‡	
	Relevant Contract Dollars	‡	‡	45,000	‡	‡	
	Total Count	117	105	107	105	111	
	Total Relevant Dollars	13,323,361	10,352,147	10,672,523	11,695,680	11,312,785	-3.22
Pediatric Research	Number of Grants	685	685	685	581	636	
	Relevant Grant Dollars	208,184,370	212,351,643	212,337,590	146,844,741	179,363,922	
	Number of Contracts	6	3	7	2	5	
	Relevant Contract Dollars	1,471,436	2,134,899	4,384,833	3,291,925	3,631,993	
	Total Count	691	688	692	583	641	
	Total Relevant Dollars	209,655,806	214,486,542	216,722,423	150,136,666	182,995,915	-1.37
Personalized Health Care	Number of Grants	652	632	630	638	685	
	Relevant Grant Dollars	214,006,481	199,252,033	183,230,229	180,445,101	184,951,025	
	Number of Contracts	15	17	21	17	20	
	Relevant Contract Dollars	33,822,151	35,742,085	37,543,010	32,351,821	37,283,739	
	Total Count	667	649	651	655	705	
	Total Relevant Dollars	247,828,632	234,994,118	220,773,239	212,796,922	222,234,764	-2.60
Pesticides	Number of Grants	21	14	12	13	10	
	Relevant Grant Dollars	1,508,700	909,530	531,371	471,294	460,087	
	Number of Contracts	2	2	2	‡	‡	
	Relevant Contract Dollars	845,205	701,197	224,000	‡	‡	
	Total Count	23	16	14	13	10	
	Total Relevant Dollars	2,353,905	1,610,727	755,371	471,294	460,087	-31.27
Pharmacogenetics	Number of Grants	319	310	312	276	266	
	Relevant Grant Dollars	74,057,323	70,646,463	53,813,379	52,795,552	54,346,257	
	Number of Contracts	3	2	‡	1	2	
	Relevant Contract Dollars	1,039,064	150,000	‡	193,637	670,000	
	Total Count	322	312	312	277	268	
	Total Relevant Dollars	75,096,387	70,796,463	53,813,379	52,989,189	55,016,257	-6.86
Prevention	Number of Grants	1,293	1,294	1,246	1,220	1,235	
	Relevant Grant Dollars	356,228,797	346,953,036	324,621,692	332,988,470	338,729,425	
	Number of Contracts	43	36	20	23	35	
	Relevant Contract Dollars	41,680,021	46,984,156	28,993,208	30,211,780	25,780,603	
	Total Count	1,336	1,330	1,266	1,243	1,270	
	Total Relevant Dollars	397,908,818	393,937,192	353,614,900	363,200,250	364,510,028	-2.04

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Proteomics	Number of Grants	542	543	564	648	718	
	Relevant Grant Dollars	99,199,104	98,691,096	105,713,144	128,504,517	143,749,069	
	Number of Contracts	23	14	13	12	8	
	Relevant Contract Dollars	39,204,878	4,666,075	3,710,715	2,364,169	3,506,652	
	Total Count	565	557	577	660	726	
	Total Relevant Dollars	138,403,982	103,357,171	109,423,859	130,868,686	147,255,721	3.17
Radiation, Electromagnetic Fields	Number of Grants	7	5	5	5	2	
	Relevant Grant Dollars	821,382	235,460	794,902	274,880	208,400	
	Total Count	7	5	5	5	2	
	Total Relevant Dollars	821,382	235,460	794,902	274,880	208,400	19.16
Radiation, Ionizing	Number of Grants	192	143	137	118	109	
	Relevant Grant Dollars	31,992,559	24,747,402	24,942,689	22,587,580	20,437,132	
	Number of Contracts	6	1	‡	‡	1	
	Relevant Contract Dollars	940,864	200,000	‡	‡	91,808	
	Total Count	198	144	137	118	110	
	Total Relevant Dollars	32,933,423	24,947,402	24,942,689	22,587,580	20,528,940	-10.71
Radiation, Ionizing Diagnosis	Number of Grants	231	236	284	288	297	
	Relevant Grant Dollars	50,150,240	60,711,962	67,228,830	83,355,570	78,440,948	
	Number of Contracts	5	3	2	6	4	
	Relevant Contract Dollars	270,167	465,803	1,127,414	3,682,723	2,664,706	
	Total Count	236	239	286	294	301	
	Total Relevant Dollars	50,420,407	61,177,765	68,356,244	87,038,293	81,105,654	13.30
Radiation, Ionizing Radiotherapy	Number of Grants	680	635	605	594	595	
	Relevant Grant Dollars	207,665,565	199,422,427	197,773,842	215,668,304	178,645,894	
	Number of Contracts	4	4	3	6	6	
	Relevant Contract Dollars	47,500	545,157	226,116	852,523	1,860,053	
	Total Count	684	639	608	600	601	
	Total Relevant Dollars	207,713,065	199,967,584	197,999,958	216,520,827	180,505,947	-3.00
Radiation, Low-Level Ionizing	Number of Grants	23	20	16	15	11	
	Relevant Grant Dollars	6,004,368	6,500,454	3,564,004	2,684,415	2,790,815	
	Number of Contracts	‡	1	‡	‡	‡	
	Relevant Contract Dollars	‡	200,000	‡	‡	‡	
	Total Count	23	21	16	15	11	
	Total Relevant Dollars	6,004,368	6,700,454	3,564,004	2,684,415	2,790,815	-13.98
Radiation, Magnetic Resonance Imaging	Number of Grants	360	324	309	311	316	
	Relevant Grant Dollars	80,540,821	75,059,941	71,053,694	72,516,747	66,373,621	
	Number of Contracts	3	3	2	3	4	
	Relevant Contract Dollars	217,673	416,415	625,760	810,966	1,649,709	
	Total Count	363	327	311	314	320	
	Total Relevant Dollars	80,758,494	75,476,356	71,679,454	73,327,713	68,023,330	-4.13
Radiation, Mammography	Number of Grants	205	203	211	186	183	
	Relevant Grant Dollars	28,042,754	31,642,663	26,824,376	30,249,026	29,124,083	
	Number of Contracts	2	1	1	2	1	
	Relevant Contract Dollars	452	464	999,985	1,845,486	1,400,000	
	Total Count	207	204	212	188	184	
	Total Relevant Dollars	28,043,206	31,643,127	27,824,361	32,094,512	30,524,083	2.81

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Radiation, Non-Ionizing	Number of Grants	219	177	167	160	149	
	Relevant Grant Dollars	32,101,143	27,357,488	26,918,563	26,910,915	25,283,118	
	Number of Contracts	‡	‡	3	1	1	
	Relevant Contract Dollars	‡	‡	476,414	999,000	137,350	
	Total Count	219	177	170	161	150	
	Total Relevant Dollars	32,101,143	27,357,488	27,394,977	27,909,915	25,420,468	-5.42
Radiation, Non-Ionizing Diagnosis	Number of Grants	514	502	471	467	491	
	Relevant Grant Dollars	132,398,533	136,372,426	125,702,669	131,948,820	126,670,584	
	Number of Contracts	4	3	9	5	6	
	Relevant Contract Dollars	446,969	416,415	1,675,452	1,260,269	2,735,231	
	Total Count	518	505	480	472	497	
	Total Relevant Dollars	132,845,502	136,788,841	127,378,121	133,209,089	129,405,815	-0.55
Radiation, Non-Ionizing Radiotherapy	Number of Grants	152	161	195	190	187	
	Relevant Grant Dollars	31,373,416	41,460,636	40,077,552	48,439,155	45,869,628	
	Number of Contracts	1	1	3	‡	1	
	Relevant Contract Dollars	181,796	199,735	599,386	‡	1,499,896	
	Total Count	153	162	198	190	188	
	Total Relevant Dollars	31,555,212	41,660,371	40,676,938	48,439,155	47,369,524	11.63
Radiation, UV	Number of Grants	189	152	149	144	133	
	Relevant Grant Dollars	27,465,174	23,732,686	23,686,597	24,555,465	23,909,838	
	Number of Contracts	‡	‡	3	1	1	
	Relevant Contract Dollars	‡	‡	476,414	‡	137,350	
	Total Count	189	152	152	145	134	
	Total Relevant Dollars	27,465,174	23,732,686	24,163,011	25,554,465	24,047,188	-2.98
Radon	Number of Grants	6	5	2	3	5	
	Relevant Grant Dollars	2,177,728	1,976,301	48,624	326,441	490,407	
	Total Count	6	5	2	3	5	
	Total Relevant Dollars	2,177,728	1,976,301	48,624	326,441	490,407	128.70
Rare Diseases	Number of Grants	183	138	140	119	100	
	Relevant Grant Dollars	30,770,735	26,634,147	29,192,350	23,592,946	18,712,924	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	183	138	140	119	100	
	Total Relevant Dollars	30,770,735	26,634,147	29,192,350	23,592,946	18,712,924	-10.93
Rehabilitation	Number of Grants	215	221	221	230	234	
	Relevant Grant Dollars	33,557,701	37,960,259	38,584,600	40,748,671	45,308,533	
	Number of Contracts	16	14	2	1	1	
	Relevant Contract Dollars	1,508,881	1,131,599	76,452	52,655	21,000	
	Total Count	231	235	223	231	235	
	Total Relevant Dollars	35,066,582	39,091,858	38,661,052	40,801,326	45,329,533	6.75
Rural Populations	Number of Grants	106	95	103	103	100	
	Relevant Grant Dollars	35,317,988	38,996,059	35,157,309	34,658,560	31,874,931	
	Number of Contracts	13	12	12	10	8	
	Relevant Contract Dollars	11,397,326	9,846,502	10,416,108	8,535,867	7,269,316	
	Total Count	119	107	115	113	108	
	Total Relevant Dollars	46,715,314	48,842,561	45,573,417	43,194,427	39,144,247	-4.18

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Sexually Transmitted Diseases	Number of Grants	215	192	183	185	175	
	Relevant Grant Dollars	35,502,090	31,951,321	30,488,788	29,789,110	28,189,148	
	Number of Contracts	1	1	2	1	1	
	Relevant Contract Dollars	3,621,135	3,701,779	4,439,576	3,836,717	870,317	
	Total Count	216	193	185	186	176	
	Total Relevant Dollars	39,123,225	35,653,100	34,928,364	33,625,827	29,059,465	-7.05
Sleep Disorders	Number of Grants	65	54	70	64	54	
	Relevant Grant Dollars	7,576,158	7,775,308	9,183,149	7,810,486	6,729,657	
	Number of Contracts	‡	‡	‡	‡	1	
	Relevant Contract Dollars	‡	‡	‡	‡	300,000	
	Total Count	65	54	70	64	55	
	Total Relevant Dollars	7,576,158	7,775,308	9,183,149	7,810,486	7,029,657	-1.05
Small Molecules	Number of Grants	429	386	407	416	513	
	Relevant Grant Dollars	77,887,805	73,465,245	70,693,138	81,708,151	100,631,305	
	Number of Contracts	4	1	10	9	4	
	Relevant Contract Dollars	843,000	30,860	2,203,593	3,726,105	1,449,375	
	Total Count	433	387	417	425	517	
	Total Relevant Dollars	78,730,805	73,496,105	72,896,731	85,434,256	102,080,680	7.30
Smokeless Tobacco	Number of Grants	24	26	34	19	24	
	Relevant Grant Dollars	3,957,700	5,933,701	6,896,702	4,743,669	5,175,673	
	Number of Contracts	1	‡	1	1	1	
	Relevant Contract Dollars	1,800,000	‡	453,965	385,000	385,000	
	Total Count	25	26	35	20	25	
	Total Relevant Dollars	5,757,700	5,933,701	7,350,667	5,128,669	5,560,673	1.28
Smoking, Passive	Number of Grants	32	30	24	15	14	
	Relevant Grant Dollars	4,887,736	3,425,541	3,459,579	2,250,884	2,491,604	
	Number of Contracts	‡	‡	1	1	1	
	Relevant Contract Dollars	‡	‡	453,965	385,000	385,000	
	Total Count	32	30	25	16	15	
	Total Relevant Dollars	4,887,736	3,425,541	3,913,544	2,635,884	2,876,604	-9.80
Structural Biology	Number of Grants	1,610	1,456	1,337	1,242	1,199	
	Relevant Grant Dollars	310,422,424	280,014,980	269,191,027	258,099,045	235,455,633	
	Number of Contracts	16	17	11	15	3	
	Relevant Contract Dollars	39,571,941	2,434,109	1,512,388	1,522,607	615,101	
	Total Count	1,626	1,473	1,348	1,257	1,202	
	Total Relevant Dollars	349,994,365	282,449,089	270,703,415	259,621,652	236,070,734	-9.16
Surgery	Number of Grants	390	352	327	333	328	
	Relevant Grant Dollars	66,059,380	63,498,562	72,591,577	85,655,815	76,917,479	
	Number of Contracts	‡	‡	2	2	3	
	Relevant Contract Dollars	‡	‡	1,200,000	373,417	545,979	
	Total Count	390	352	329	335	331	
	Total Relevant Dollars	66,059,380	63,498,562	73,791,577	86,029,232	77,463,458	4.74
Taxol	Number of Grants	290	284	305	285	273	
	Relevant Grant Dollars	62,261,243	68,741,615	73,441,347	70,198,681	60,447,024	
	Number of Contracts	‡	‡	1	‡	1	
	Relevant Contract Dollars	‡	‡	50,000	‡	199,714	
	Total Count	290	284	306	285	274	
	Total Relevant Dollars	62,261,243	68,741,615	73,491,347	70,198,681	60,646,738	-0.19

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Telehealth	Number of Grants	399	364	351	311	292	
	Relevant Grant Dollars	74,370,113	76,214,970	83,738,070	76,191,259	76,478,419	
	Number of Contracts	39	26	10	11	7	
	Relevant Contract Dollars	24,501,587	15,922,057	12,502,513	11,912,660	9,755,606	
	Total Count	438	390	361	322	299	
	Total Relevant Dollars	98,871,700	92,137,027	96,240,583	88,103,919	86,234,025	-3.23
Therapy	Number of Grants	3,842	3,736	3,668	3,626	3,738	
	Relevant Grant Dollars	1,256,647,167	1,253,530,990	1,289,919,675	1,295,238,778	1,293,761,000	
	Number of Contracts	112	104	102	94	92	
	Relevant Contract Dollars	68,675,001	100,995,788	97,314,391	93,641,732	88,810,315	
	Total Count	3,954	3,840	3,770	3,720	3,830	
	Total Relevant Dollars	1,325,322,168	1,354,526,778	1,387,234,066	1,388,880,510	1,382,571,315	1.07
Tobacco	Number of Grants	465	493	470	449	416	
	Relevant Grant Dollars	107,012,253	106,446,317	121,389,946	127,614,366	122,594,345	
	Number of Contracts	5	7	8	4	4	
	Relevant Contract Dollars	2,762,640	804,235	2,479,840	1,419,652	1,302,350	
	Total Count	470	500	478	453	420	
	Total Relevant Dollars	109,774,893	107,250,552	123,869,786	129,034,018	123,896,695	3.35
Tobacco Use Behavior	Number of Grants	219	250	250	239	259	
	Relevant Grant Dollars	61,173,821	65,696,233	81,176,603	83,456,895	87,985,064	
	Number of Contracts	‡	2	4	2	4	
	Relevant Contract Dollars	‡	144,041	1,868,571	1,320,000	1,302,350	
	Total Count	219	252	254	241	263	
	Total Relevant Dollars	61,173,821	65,840,274	83,045,174	84,776,895	89,287,414	10.29
Tropical Diseases	Number of Grants	36	31	29	25	21	
	Relevant Grant Dollars	8,218,552	7,697,801	6,535,704	5,619,635	5,588,012	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	36	31	29	25	21	
	Total Relevant Dollars	8,218,552	7,697,801	6,535,704	5,619,635	5,588,012	-9.00
Tumor Markers	Number of Grants	996	846	731	626	508	
	Relevant Grant Dollars	252,452,493	218,547,902	189,955,095	161,691,676	124,259,866	
	Number of Contracts	29	19	12	4	3	
	Relevant Contract Dollars	4,923,691	6,788,354	4,365,645	2,569,530	2,693,245	
	Total Count	1,025	865	743	630	511	
	Total Relevant Dollars	257,376,184	225,336,256	194,320,740	164,531,206	126,953,111	-16.10
Underserved Populations	Number of Grants	568	563	607	595	585	
	Relevant Grant Dollars	173,480,427	193,637,731	210,560,355	210,385,470	216,074,187	
	Number of Contracts	38	34	21	16	16	
	Relevant Contract Dollars	15,803,363	14,072,123	12,245,405	10,306,244	11,469,992	
	Total Count	606	597	628	611	601	
	Total Relevant Dollars	189,283,790	207,709,854	222,805,760	220,691,714	227,544,179	4.79
Vaccine Development	Number of Grants	171	168	163	159	151	
	Relevant Grant Dollars	25,020,169	27,688,541	21,218,754	21,105,678	20,714,291	
	Number of Contracts	‡	2	‡	1	‡	
	Relevant Contract Dollars	‡	1,370,729	‡	199,988	‡	
	Total Count	171	170	163	160	151	
	Total Relevant Dollars	25,020,169	29,059,270	21,218,754	21,305,666	20,714,291	-3.30

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Vaccine Production	Number of Grants	8	4	8	6	3	
	Relevant Grant Dollars	1,733,938	1,679,991	1,046,919	661,049	589,530	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	1,499,001	‡	
	Total Count	8	4	8	7	3	
	Total Relevant Dollars	1,733,938	1,679,991	1,046,919	2,160,050	589,530	-1.79
Vaccine Research	Number of Grants	211	201	201	195	183	
	Relevant Grant Dollars	34,486,715	37,047,110	33,377,072	34,117,779	31,279,880	
	Number of Contracts	2	1	1	2	1	
	Relevant Contract Dollars	14,808,841	30,860	23,100	1,502,003	1,996,084	
	Total Count	213	202	202	197	184	
	Total Relevant Dollars	49,295,556	37,077,970	33,400,172	35,619,782	33,275,964	-8.73
Vaccine Testing	Number of Grants	151	138	130	111	101	
	Relevant Grant Dollars	34,603,697	29,771,312	21,759,604	18,745,944	17,217,816	
	Number of Contracts	1	1	1	1	1	
	Relevant Contract Dollars	3,621,135	3,701,779	4,394,576	3,836,717	870,317	
	Total Count	152	139	131	112	102	
	Total Relevant Dollars	38,224,832	33,473,091	26,154,180	22,582,661	18,088,133	-16.96
Virus – Cancer Research	Number of Grants	613	558	541	505	481	
	Relevant Grant Dollars	158,577,860	151,074,096	153,628,908	142,438,045	133,815,083	
	Number of Contracts	3	3	3	1	4	
	Relevant Contract Dollars	18,429,976	5,230,139	4,549,461	3,836,717	4,066,305	
	Total Count	616	561	544	506	485	
	Total Relevant Dollars	177,007,836	156,304,235	158,178,369	146,274,762	137,881,388	-5.94
Virus – Epstein-Barr	Number of Grants	115	110	110	104	96	
	Relevant Grant Dollars	26,897,323	26,563,416	24,362,117	24,499,924	22,756,337	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	115	110	110	104	96	
	Total Relevant Dollars	26,897,323	26,563,416	24,362,117	24,499,924	22,756,337	-4.02
Virus – Genital Herpes	Number of Grants	6	4	4	4	3	
	Relevant Grant Dollars	540,230	477,647	379,575	372,188	290,654	
	Total Count	6	4	4	4	3	
	Total Relevant Dollars	540,230	477,647	379,575	372,188	290,654	-13.99
Virus – Hepatitis B	Number of Grants	50	54	51	50	42	
	Relevant Grant Dollars	11,387,036	12,166,996	11,337,066	6,370,613	4,928,799	
	Total Count	50	54	51	50	42	
	Total Relevant Dollars	11,387,036	12,166,996	11,337,066	6,370,613	4,928,799	-16.6
Virus – Hepatitis C	Number of Grants	38	35	34	31	40	
	Relevant Grant Dollars	5,322,764	6,405,143	5,719,779	4,600,379	5,332,014	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	38	35	34	31	40	
	Total Relevant Dollars	5,322,764	6,405,143	5,719,779	4,600,379	5,332,014	1.49

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2008 - FY2012 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.	
Virus – Herpes	Number of Grants	228	208	206	190	182		
	Relevant Grant Dollars	56,793,367	54,527,236	47,274,246	48,127,519	44,080,597		
	Number of Contracts	‡	‡	‡	‡	‡		
	Relevant Contract Dollars	‡	‡	‡	‡	‡		
	Total Count	228	208	206	190	182		
	Total Relevant Dollars	56,793,367	54,527,236	47,274,246	48,127,519	44,080,597	-5.97	
Virus – HHV8	Number of Grants	94	81	87	78	74		
	Relevant Grant Dollars	23,036,760	19,737,355	18,532,843	17,725,584	15,764,211		
	Number of Contracts	‡	‡	‡	‡	‡		
	Relevant Contract Dollars	‡	‡	‡	‡	‡		
	Total Count	94	81	87	78	74		
	Total Relevant Dollars	23,036,760	19,737,355	18,532,843	17,725,584	15,764,211	-8.96	
Virus – HTLV-I	Number of Grants	27	23	22	24	22		
	Relevant Grant Dollars	6,797,477	7,313,840	6,183,612	6,171,762	6,563,215		
	Number of Contracts	‡	‡	‡	‡	‡		
	Relevant Contract Dollars	‡	‡	‡	‡	‡		
	Total Count	27	23	22	24	22		
	Total Relevant Dollars	6,797,477	7,313,840	6,183,612	6,171,762	6,563,215	-0.43	
Virus – HTLV-II	Number of Grants	4	1	‡	2	1		
	Relevant Grant Dollars	409,579	135,552	‡	2,000	171,471		
	Total Count	4	1	‡	2	1		
	Total Relevant Dollars	409,579	135,552	‡	2,000	171,471	2769.37	
	Virus – Papilloma	Number of Grants	178	166	169	168	165	
		Relevant Grant Dollars	43,565,517	39,602,459	46,214,177	43,559,761	41,276,749	
Number of Contracts		1	3	1	1	3		
Relevant Contract Dollars		3,621,135	5,230,139	4,394,576	3,836,717	3,866,401		
Total Count		179	169	170	169	168		
Total Relevant Dollars		47,186,652	44,832,598	50,608,753	47,396,478	45,143,150	-0.8	
Virus – Papova	Number of Grants	221	206	207	200	190		
	Relevant Grant Dollars	54,680,936	49,970,034	55,528,827	52,541,742	49,415,531		
	Number of Contracts	1	3	2	1	3		
	Relevant Contract Dollars	3,621,135	5,230,139	4,544,576	3,836,717	3,866,401		
	Total Count	222	209	209	201	193		
	Total Relevant Dollars	58,302,071	55,200,173	60,073,403	56,378,459	53,281,932	-2.03	
Virus – SV40	Number of Grants	40	36	29	25	21		
	Relevant Grant Dollars	7,172,313	5,967,645	5,171,617	5,163,432	3,525,677		
	Total Count	40	36	29	25	21		
	Total Relevant Dollars	7,172,313	5,967,645	5,171,617	5,163,432	3,525,677	-15.5	
	Vitamin A	Number of Grants	102	89	66	55	42	
		Relevant Grant Dollars	16,421,451	11,622,987	8,863,103	9,150,008	6,336,364	
Number of Contracts		1	1	1	1	‡		
Relevant Contract Dollars		178,904	300,000	391,285	99,917	‡		
Total Count		103	90	67	56	42		
Total Relevant Dollars		16,600,355	11,922,987	9,254,388	9,249,925	6,336,364	-20.53	
Vitamin C	Number of Grants	26	24	21	15	16		
	Relevant Grant Dollars	2,020,753	2,234,318	1,843,823	1,106,973	1,323,825		
	Total Count	26	24	21	15	16		
	Total Relevant Dollars	2,020,753	2,234,318	1,843,823	1,106,973	1,323,825	-6.82	

continued

* Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2008 - FY2012 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2008	2009	2010	2011	2012	Average Percent Change/Yr.
Vitamin D	<i>Number of Grants</i>	‡	32	45	70	76	
	Relevant Grant Dollars	‡	9,218,013	11,837,723	20,457,495	20,791,513	
	<i>Number of Contracts</i>	‡	1	‡	‡	1	
	Relevant Contract Dollars	‡	200,000	‡	‡	56,250	
	<i>Total Count</i>	‡	33	45	70	77	
	Total Relevant Dollars	‡	9,418,013	11,837,723	20,457,495	20,847,763	33.47
Vitamins, Other	<i>Number of Grants</i>	103	72	55	44	25	
	Relevant Grant Dollars	20,299,917	15,499,403	12,310,882	10,076,781	6,252,528	
	<i>Number of Contracts</i>	‡	‡	‡	‡	1	
	Relevant Contract Dollars	‡	‡	‡	‡	56,250	
	<i>Total Count</i>	103	72	55	44	26	
	Total Relevant Dollars	20,299,917	15,499,403	12,310,882	10,076,781	6,308,778	-24.94

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific SIC.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2012

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/Cancer Site	Mechanism								Totals
	F31	R01	R03	R21	R37	U01	U10	U24	
AUSTRALIA									
<i>Grants #</i>		4			4				8
<i>Funding \$</i>		673,620			230,201				903,821
Colon, Rectum		148,197							148,197
Hodgkins Lymphoma					39,134				39,134
Leukocytes					115,101				115,101
Lung		259,967							259,967
Melanoma		117,259							117,259
Myeloma					36,832				36,832
Non-Hodgkins Lymphoma					39,134				39,134
Pancreas		148,197							148,197
BELGIUM									
<i>Grants #</i>							24		24
<i>Funding \$</i>							275,468		275,468
Bone, Cartilage							2,354		2,354
Brain							7,063		7,063
Breast							72,989		72,989
Central Nervous System							2,354		2,354
Cervix							2,354		2,354
Childhood Leukemia							28,254		28,254
Colon, Rectum							14,127		14,127
Esophagus							2,354		2,354
Head and Neck							2,354		2,354
Hodgkins Lymphoma							2,354		2,354
Kidney							9,418		9,418

continued

Table 17. NCI Funding of Foreign Research Grants in FY2012*(This table reports extramural grants only; intramural grants and contracts are excluded.)*

Country/Cancer Site	Mechanism								
	F31	R01	R03	R21	R37	U01	U10	U24	Totals
BELGIUM (continued)									
Leukemia							28,254		28,254
Liver							2,354		2,354
Lung							18,836		18,836
Muscle							2,354		2,354
Myeloma							11,772		11,772
Neuroblastoma							7,063		7,063
Non-Hodgkins Lymphoma							2,354		2,354
Not Site Specific*							7,063		7,063
Ovary							18,836		18,836
Pharynx							2,354		2,354
Prostrate							18,836		18,836
Urinary System							2,354		2,354
Uterus							7,063		7,063
CANADA									
<i>Grants #</i>		15	3	1	2	2	15	1	39
<i>Funding \$</i>		3,931,991	86,703	224,959	332,792	890,442	1,592,780	2,096,750	9,156,417
Bone Marrow		192,346							192,346
Breast		1,150,928				166,396	1,463,909		2,781,233
Cervix							13,907		13,907
Connective Tissue			43,351						43,351
Genital System, Female							1,319		1,319
Hodgkins Lymphoma							1,319		1,319
Kidney							9,230		9,230
Leukemia		634,748					1,319		636,067
Lung		992,299				166,396	11,867		1,170,562
Melanoma		105,739							105,739
Myeloma							21,097		21,097
Non-Hodgkins Lymphoma			21,676						21,676
Not Site Specific*		485,780	21,676			700,154	6,593	2,096,750	3,310,953
Ovary						190,288	55,627		245,915
Prostate		370,151		224,959			1,319		596,429
Urinary System							5,274		5,274
FRANCE									
<i>Grants #</i>			2			7			9
<i>Funding \$</i>			64,431			3,751,920			3,816,351
Bladder							125,040		125,040
Breast			6,831						6,831
Kidney							1,195,864		1,195,864
Lung							1,790,251		1,790,251
Melanoma			57,600						57,600
Nose, Nasal Passages							28,622		28,622
Not Site Specific*							583,521		583,521
Pharynx							28,622		28,622
INDIA									
<i>Grants #</i>		2							2
<i>Funding \$</i>		391,342							391,342
Breast		195,671							195,671
Cervix		195,671							195,671

continued

* Not Site Specific denotes research NOT on a particular type of cancer/cancer site (e.g., basic research examining a role of a protein in cellular DNA damage in a bacteria/worm/fruit fly/non-cancer cell system).

Table 17. NCI Funding of Foreign Research Grants in FY2012*(This table reports extramural grants only; intramural grants and contracts are excluded.)*

Country/Cancer Site	Mechanism								Totals
IRELAND	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		1							1
Funding \$		184,409							184,409
Neuroblastoma		184,409							184,409
ISRAEL	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		4			3				7
Funding \$		750,664			449,352				1,200,016
Breast					230,201				230,201
Colon, Rectum		86,885			54,788				141,673
Lung					164,363				164,363
Not Site Specific*		474,123							474,123
Ovary		102,771							102,771
Prostate		86,885							86,885
REPUBLIC OF SOUTH KOREA	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		1							1
Funding \$		171,049							171,049
Lung		171,049							171,049
NETHERLANDS	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		1							1
Funding \$		217,377							217,377
Colon, Rectum		217,377							217,377
SPAIN	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		1							1
Funding \$		224,100							224,100
Melanoma		224,100							224,100
SWITZERLAND	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #		3							3
Funding \$		176,961							176,961
Non-Hodgkins Lymphoma		88,481							88,481
Nose, Nasal Passages		44,240							44,240
Pharynx		44,240							44,240
UNITED KINGDOM	F31	R01	R03	R21	R37	U01	U10	U24	Totals
Grants #	1	3	1					1	6
Funding \$	42,232	875,214	49,300					241,745	1,208,491
Breast	42,232	438,107	49,300						529,639
Lung		437,107							437,107
Thyroid								241,745	241,745
Total Grants	1	35	6	1	9	9	39	2	102
Total \$ Per Grant type	42,232	7,596,727	200,434	224,959	1,012,345	4,642,362	1,868,248	2,338,495	17,925,802

* Not Site Specific denotes research NOT on a particular type of cancer/cancer site (e.g., basic research examining a role of a protein in cellular DNA damage in a bacteria/worm/fruit fly/non-cancer cell system).

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2012*(This table reports extramural grants only; intramural grants and contracts are excluded.)*

Country	Funding Mechanism																				Sub-total			
	D43	F30	F32	K01	K05	K07	K08	K22	K23	N44	P01	R00	R01	R03	R13	R15	R21	R37	R42	R43		U01	U24	UM1
Africa (unspecified)												1									1			2
Argentina				1								1										1		3
Asia (unspecified)												1	1			1								3
Australia			1	1	1						1	22					1				2	2	1	32
Austria												3										1		4
Bangladesh												2												2
Belgium												1										1		2
Brazil												2									1	1		4
Cameroon	1																							1
Canada				1			1	1	1	1	39	2	4		4	1		1	6	2				63
Caribbean (unspecified)											1													1
Central America (unspecified)											1													1
Chile											1													1
China					1						15	2	1		1	1		1	1	2				25
Colombia			1								1											1		3
Costa Rica																					1			1
Czech Republic											2										1	1		4
Denmark											4										1	1		6
Dominican Republic											1													1
Egypt											2											1		3
Europe (unspecified)											2					1								3
Finland											4											1		5
France											6	1							1	3	1			12
Germany											15		1	2					1	2	2			23
Greece											3					1								4
Haiti											1					1								2
Hungary																						2		2
India				1							2					1			1	1				6
Iran																						1		1
Iceland																					1			1
Ireland											3											1		4
Israel											1	9	1				1					2		14
Italy		1		1							7	1	2								1	2		15
Japan											9				1							1		11
Kenya	1	1									2					1					2		7	
Kuwait																						1		1
Latin America (unspecified)																		1						1
Malaysia																					1	1		2
Mexico											4											1		5
Middle East (unspecified)											1													1

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2012*(This table reports extramural grants only; intramural grants and contracts are excluded.)*

Country	Funding Mechanism																							Sub-total
	D43	F30	F32	K01	K05	K07	K08	K22	K23	N44	P01	R00	R01	R03	R13	R15	R21	R37	R42	R43	U01	U24	UM1	
Morocco												1												1
Netherlands											1	9			1		1				5	1		18
New Zealand												3										2		5
Nigeria	1		1																			1		3
North America (unspecified)												1												1
Norway												5									3			8
Oceania (unspecified)												1												1
Pakistan																						1		1
Panama																						1		1
Peru													1		1									2
Philippines												1												1
Poland												1										1		2
Portugal												1										1		2
Romania																						1		1
Russia												3										1	2	6
Rwanda	1																							1
Saudi Arabia																							1	1
Serbia												1												1
Singapore						1						4										1		6
Slovenia																						1		1
South Africa	1											1				2					1	2		7
South America (unspecified)												1												1
South Korea																						1		1
Spain												6			1					1		2		10
Sweden												9		1							2	2		14
Switzerland							1					4									1	2		8
Taiwan												3										1		4
Tanzania	1																							1
Thailand												2												2
Turkey												2										1		3
Uganda	2								1			2									3			8
United Kingdom												29	1	1		1		1		4	2			39
Uruguay																						1		1
Venezuela																						1		1
Vietnam												1												1
Zambia	1											1												2
Zimbabwe																						2		2
Totals	9	2	3	2	4	2	1	1	1	1	3	1	260	10	10	2	20	4	1	6	48	58	1	450*

* Because many grants and contracts have multiple foreign contributors, the total count (450) is greater than the total number of grants and contracts (265).

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting *ex officio* members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 12,293 applications in 2012 requesting \$3,450,548,168 in direct costs with appropriated funds.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2012, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- NIH Diversity Report
- Overview: Center for Cancer Genomics
- U.S. Prevention Task Force Recommendation on PSA
- Status Report: Center for Cancer Research
- Status Report: Division of Cancer Epidemiology and Genetics
- Update: Recent Actions, Re-Organization, and Initiatives
- Current and Future Perspectives on Cancer Prevention Research

- Annual Delegations of Authority
- Update: Cooperative Groups Reorganization
- Frederick National Laboratory for Cancer Research (FNLCR) Strategic Plan
- Improving Efficiency in NCI/CTEP Sponsored Clinical Trials, Central Institutional Review Board (IRB) and Unified Data Collection
- Update: National Cancer Informatics Program
- Bypass Budget Overview
- NCAB Subcommittee Reports: Cancer Centers, Clinical Investigations, and Global Cancer Research

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at <http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2012:

- Report of the NCI Director
- NCI/Congressional Relations
- Perspectives on the BSA
- Status Report: caBIG[®] Oversight *Ad Hoc* Subcommittee
- BSA RFA Annual Concept Report
- Update: The Chernobyl Tissue Bank
- Overview: NCI Center for Global Health
- Frederick National Laboratory for Cancer Research (FNLCR) Strategic Plan

RFA/Cooperative Agreements Approved

Office of the Director

- AIDS and Cancer Specimen Resources
- Innovative Molecular Analysis Technologies Program

Division of Cancer Treatment and Diagnosis

- Data Resource for Blood and Marrow Transplants
- Pediatric Phase I/Pilot Consortium NCI Clinical Trials Network

Appendix C: List of Chartered Committees

President's Cancer Panel

Chair

Barbara K. Rimer, Dr.P.H.The University of North Carolina at Chapel Hill

Members

Mr. Hill Harper Author, Actor, Philanthropist
Owen N. Witte, M.D.University of California at Los Angeles

Executive Secretary

Abby B. Sandler, Ph.D. National Cancer Institute

National Cancer Advisory Board

Current Chair

Tyler E. Jacks, Ph.D.†.....Massachusetts Institute of Technology

Past Chair

Bruce A. Chabner, M.D.* Massachusetts General Hospital Cancer Center

Members

Anthony Atala, M.D.* Wake Forest University
Victoria L. Champion, D.N.S.Indiana University
David C. Christiani, M.D., M.P.H.† Harvard School of Public Health
Donald S. Coffey, Ph.D.*The Johns Hopkins University
Marcia R. Cruz-Correa, M.D., Ph.D. University of Puerto Rico
Kevin J. Cullen, M.D. University of Maryland
Judy E. Garber, M.D., M.P.H.† Dana-Farber Cancer Institute
William H. Goodwin, Jr., M.B.A.CCA Industries, Inc.
Waun K. Hong, M.D.The University of Texas MD Anderson Cancer Center
Mr. Robert A. Ingram* Hatteras Venture Partners
Elizabeth M. Jaffe, M.D.† The Johns Hopkins University School of Medicine
Beth Y. Karlan, M.D.†Cedar-Sinai Medical Center
Judith S. Kaur, M.D.* Mayo Comprehensive Cancer Center
Ms. Mary Vaughan Lester University of California, San Francisco Foundation
H. Kim Lyerly, M.D.Duke University
Karen M. Meneses, Ph.D.* University of Alabama at Birmingham
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P. University of Chicago
Jennifer A. Pietenpol, Ph.D. Vanderbilt University
Mack Roach III, M.D., F.A.C.R.† University of California, San Francisco
Jonathan M. Samet, M.D., M.S. University of Southern California Keck School of Medicine
Charles L. Sawyers, M.D.† Memorial Sloan-Kettering Cancer Center
William R. Sellers, M.D.Novartis Institutes for Biomedical Research, Inc.

*Retired March 9, 2012.

†Appointed August 31, 2012.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.	National Institute of Environmental Health Sciences, NIH
Francis S. Collins, M.D., Ph.D.	National Institutes of Health
Margaret A. Hamburg, M.D.	U.S. Food and Drug Administration
John P. Holdren, Ph.D.	Office of Science and Technology Policy
John Howard, M.D., M.P.H., J.D., L.L.M.	National Institute for Occupational Safety and Health
Lisa Jackson, M.S.	U.S. Environmental Protection Agency
The Honorable Dr. Michael J. Kussman.	U.S. Department of Veterans Affairs
Anna Palmisano, Ph.D.	U.S. Department of Energy
The Honorable Kathleen Sebelius, M.P.A.	U.S. Department of Health and Human Services
The Honorable Hilda L. Solis	U.S. Department of Labor
Inez Tenenbaum, M.Ed.	U.S. Consumer Product Safety Commission
Jonathan Woodson, M.D.	U.S. Department of Defense

Alternates to Ex Officio Members of the National Cancer Advisory Board

Michael A. Babich, Ph.D.	U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H.	OSHA/U.S. Department of Labor
Vincent J. Coglian, Ph.D.	U.S. Environmental Protection Agency
Michael Kelley, M.D., F.A.C.P.	U.S. Department of Veterans Affairs
Aubrey Miller, M.D.	National Institutes of Environmental Health Sciences, NIH
Richard Pazdur, M.D.	U.S. Food and Drug Administration
Craig D. Shriver, M.D., F.A.C.S., COL., M.C.	U.S. Department of Defense
Michael Stebbins, Ph.D.	Office of Science and Technology Policy
Marie H. Sweeney, Ph.D., M.P.H.	National Institute for Occupational Safety and Health
Lawrence A. Tabak, D.D.S., Ph.D.	National Institutes of Health
Sharlene Weatherwax, Ph.D.	U.S. Department of Energy

Executive Secretary

Paulette S. Gray, Ph.D.	National Cancer Institute
------------------------------	---------------------------

NCI – Frederick Advisory Committee

Chair

Zach H. Hall, Ph.D.	University of California, San Francisco
--------------------------	---

Members

J. Carl Barrett, Ph.D.	AstraZeneca Pharmaceutical
David Botstein, Ph.D.	Princeton University
Vicki L. Colvin, Ph.D.*	Rice University
Levi A. Garraway, M.D., Ph.D.	Harvard Medical School
Beatrice Hahn, M.D.	The University of Pennsylvania

*Pending.

Appendix C: List of Chartered Committees

Monica J. Justice, Ph.D.	Baylor College of Medicine
Lawrence J. Marnett, Ph.D.	Vanderbilt University
Jill P. Mesirov, Ph.D.	The Broad Institute of MIT and Harvard
Garry P. Nolan, Ph.D.	Stanford University
Kenneth Olden, Ph.D., Sc.D., L.H.D.	U.S. Environmental Protection Agency
Kenneth J. Pienta, M.D.	The Johns Hopkins University
Steven T. Rosen, M.D., F.A.C.P.	Northwestern University

Representatives

Joe W. Gray, Ph.D.	Oregon Health and Science University
Thomas A. Look, M.D.	Dana-Farber Cancer Institute
Jennifer A. Pietenpol, Ph.D.	Vanderbilt University
Cheryl Willman, M.D.	The University of New Mexico

Ex Officio Members of the NCI – Frederick Advisory Committee

John Czajkowski, M.P.A.	National Cancer Institute
James H. Doroshow, M.D.	National Cancer Institute
Joseph F. Fraumeni, Jr., M.D.	National Cancer Institute
Paulette S. Gray, Ph.D.	National Cancer Institute
Douglas R. Lowy, M.D.	National Cancer Institute
Alan Rabson, M.D.	National Cancer Institute
Craig W. Reynolds, Ph.D.	National Cancer Institute
Margaret A. Tucker, M.D.	National Cancer Institute
Robert H. Wiltout, Ph.D.	National Cancer Institute

Executive Secretary

Thomas M. Vollberg, Sr., Ph.D.	National Cancer Institute
-------------------------------------	---------------------------

NCI Board of Scientific Advisors

Chair

Todd R. Golub, M.D.	The Broad Institute of MIT and Harvard University
--------------------------	---

Members

Francis Ali-Osman, D.Sc.	Duke University Medical Center
Christine B. Ambrosone, Ph.D.	Roswell Park Cancer Institute
Ethan M. Basch, M.D., M.Sc.	University of North Carolina at Chapel Hill
Sangeeta N. Bhatia, M.D., Ph.D.	Massachusetts Institute of Technology
Andrea Califano, Ph.D.	Columbia University Medical Center
Michael A. Caligiuri, M.D.	The Ohio State University Comprehensive Cancer Center
Arul M. Chinnaiyan, M.D., Ph.D.	University of Michigan Medical School
Curt I. Civin, M.D.	University of Maryland
Graham A. Colditz, M.D., Dr.P.H.	Washington University School of Medicine
Chi V. Dang, M.D., Ph.D.	The University of Pennsylvania

Robert B. Diasio, M.D.	Mayo Clinic Cancer Center
Daniel C. DiMaio, M.D., Ph.D.	Yale University School of Medicine
Jeffrey A. Drebin, M.D., Ph.D, F.A.C.S.	The University of Pennsylvania
Brian J. Druker, M.D.	Oregon Health and Science University
Karen M. Emmons, Ph.D.	Harvard School of Public Health
Betty R. Ferrell, Ph.D., RN, F.A.A.N.	City of Hope National Medical Center
Kathleen M. Foley, M.D.	Memorial Sloan-Kettering Cancer Center
Sanjiv S. Gambhir, M.D., Ph.D.	Stanford University
Stanton L. Gerson, M.D.	Case Western Reserve University
Joe W. Gray, Ph.D.	Oregon Health and Science University
Chanita Hughes-Halbert, Ph.D.	Medical University of South Carolina
Mary J. Hendrix, Ph.D.	Northwestern University
Timothy J. Kinsella, M.D.	Rhode Island Hospital
Joshua LaBaer, M.D., Ph.D.	Arizona State University
Theodore S. Lawrence, M.D., Ph.D.	University of Michigan
Mr. Donald Listwin	Canary Foundation
Maria E. Martinez, Ph.D., M.P.H.	University of California, San Diego
James L. Omel, M.D.	Self-Employed
Luis F. Parada, Ph.D.	The University of Texas Southwestern Medical Center
Martine F. Roussel (Sherr), Ph.D.	St. Jude Children’s Research Hospital
Stuart L. Schreiber, Ph.D.	The Broad Institute of Harvard and MIT
Kevin M. Shannon, M.D.	University of California, San Francisco
Mary L. Smith, J.D., M.B.A.	Research Advocacy Network
Lincoln Stein, M.D., Ph.D.	Ontario Institute for Cancer Research
Bruce W. Stillman, Ph.D.	Cold Spring Harbor Laboratory
Victor J. Strecher, Ph.D., M.P.H.	University of Michigan
Louise C. Strong, M.D.	The University of Texas MD Anderson Cancer Center
Frank M. Torti, M.D., M.P.H.	University of Connecticut Health Center
Gregory L. Verdine, Ph.D.	Harvard University
Cheryl L. Walker, Ph.D., A.T.S., F.A.A.S.*	Texas A&M Health Science Center
Irving L. Weissman, M.D.	Stanford University

Executive Secretary

Paulette S. Gray, Ph.D.	National Cancer Institute
------------------------------	---------------------------

*Pending.

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D., F.A.C.P.The University of Texas MD Anderson Cancer Center

Members

Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia
Susan G. Arbuck, M.D., M.Sc., F.A.C.P.Susan G. Arbuck, LLC
Monica M. Bertagnolli, M.D. Dana-Farber Cancer Institute
Ms. Susan G. Braun The V Foundation for Cancer Research
Curt I. Civin, M.D. University of Maryland
Kenneth H. Cowan, Ph.D. University of Nebraska Medical Center
Kevin J. Cullen, M.D. University of Maryland
Nancy E. Davidson, M.D. University of Pittsburgh
Olivera J. Finn, Ph.D. University of Pittsburgh
J. Philip Kuebler, M.D., Ph.D. Columbus Oncology Associates, Inc.
Scott M. Lippman, M.D. University of California, San Diego
Mary S. McCabe, R.N., M.A. Memorial Sloan-Kettering Cancer Center
Lisa A. Newman, M.D., M.P.H., F.A.C.S. University of Michigan Comprehensive
Cancer Center
Ms. Nancy Roach C3: Colorectal Cancer Coalition
Daniel J. Sargent, Ph.D. Mayo Clinic Foundation
Mitchell D. Schnall, M.D., Ph.D. The University of Pennsylvania Medical Center
Peter G. Shields, M.D. The Ohio State University Comprehensive Cancer Center
George W. Sledge, Jr., M.D. Stanford University
Joel E. Tepper, M.D. The University of North Carolina at Chapel Hill
Gillian M. Thomas, M.D., F.R.C.P.C., F.R.C.R. University of Toronto
Frank M. Torti, M.D., M.P.H. University of Connecticut Health Center
Miguel A. Villalona-Calero, M.D. The Ohio State University
George J. Weiner, M.D. Holden Comprehensive Cancer Center

Ex Officio Members

James H. Doroshow, M.D. National Cancer Institute
Paulette S. Gray, Ph.D. National Cancer Institute
Rosemarie B. Hakim, Ph.D. U.S. Centers for Medicare and Medicaid Services
Lee J. Helman, M.D. National Cancer Institute
Michael J. Kelley, M.D. U.S. Department of Veterans Affairs
Richard Pazdur, M.D. U.S. Food and Drug Administration
Alan S. Rabson, M.D. National Cancer Institute

Executive Secretary

Sheila A. Prindiville, M.D., M.P.H. National Cancer Institute

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Ethan Dmitrovsky, M.D. Dartmouth Medical School

Members

Edgar Ben-Josef, M.D.The University of Pennsylvania
 Jonine L. Bernstein, Ph.D.* Memorial Sloan-Kettering Cancer Center
 Arthur W. Blackstock, Jr., M.D. Wake Forest University
 Bruce R. Blazer, M.D.University of Minnesota
 Tim Byers, M.D.University of Colorado Cancer Center
 Susan M. Chang, M.D.University of California, San Francisco
 Susan L. Cohn, M.D.* University of Chicago
 William E. Evans, Pharm.D.St. Jude Children’s Research Hospital
 Jo L. Freudenheim, Ph.D.The State University of New York at Buffalo
 Judy E. Garber, M.D., M.P.H. Dana-Farber Cancer Institute
 Marc T. Goodman, Ph.D, M.P.H. Cedars-Sinai Medical Center
 Bernard Harlow, Ph.D. University of Minnesota, Twin Cities
 Carl June, M.D.The University of Pennsylvania
 Karen L. Kelly, M.D. University of California, Davis Medical Center
 Hongzhe Lee, Ph.D.The University of Pennsylvania
 Alexandra M. Levine, M.D., M.A.C.P. City of Hope National Medical Center
 Sanford Markowitz, M.D., Ph.D. Case Western Reserve University
 Augusto Ochoa, M.D. Louisiana State University Health Sciences Center
 Kenneth Offit, M.D., M.P.H. Memorial Sloan-Kettering Cancer Center
 Raphael E. Pollock, M.D., Ph.D.The University of Texas MD Anderson Cancer Center
 David Poplack, M.D. Baylor College of Medicine
 Jeremy N. Rich, M.D., M.H.Sc.* Case Western Reserve University
 Ms. Nancy Roach C3: Colorectal Cancer Coalition
 Thomas Rohan, M.D., Ph.D. Albert Einstein College of Medicine of Yeshiva University
 Thomas A. Sellers, Ph.D. University of South Florida
 Darryl K. Shibata, M.D.University of Southern California
 Walter M. Stadler, M.D., F.A.C.P* University of Chicago Medical Center
 Robert E. Tigelaar, M.D. Yale University
 Walter J. Urba, M.D., Ph.D. Providence Portland Medical Center
 Elizabeth Ward, Ph.D. American Cancer Society
 Louis M. Weiner, M.D.*Georgetown University Medical Center
 George Wilding, M.D. University of Wisconsin
 Cheryl L. Willman, M.D.The University of New Mexico Cancer Research Facility

Executive Secretary

Brian E. Wojcik, Ph.D. National Cancer Institute

*Pending.

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Joan W. Conaway, Ph.D.Stowers Institute for Medical Research

Members

Paul D. Bieniasz, Ph.D.Rockefeller University
 John C. Cambier, Ph.D.University of Colorado, Denver
 Lawrence Corey, M.D.Fred Hutchinson Cancer Research Center
 Sara A. Courtneidge, Ph.D.Sanford-Burnham Medical Research Institute
 Norman Drinkwater, Ph.D.University of Wisconsin, Madison
 Nelson Fausto, M.D.†University of Washington
 Errol Friedberg, M.D.University of Texas Southwestern Medical Center
 Joanna Groden, Ph.D.The Ohio State University
 Daria J. Hazuda, Ph.D.Merck and Company Inc.
 Eric Hunter, Ph.D.Emory University
 Stephen D. Hursting, Ph.D., M.P.H.*University of Texas at Austin
 Chris M. Ireland, Ph.D.University of Utah
 Alexandra L. Joyner, Ph.D.Memorial Sloan-Kettering Cancer Center
 Marcelo G. Kazanietz, Ph.D.The University of Pennsylvania
 Robert E. Lewis, Ph.D.University of Nebraska Medical Center
 Jonathan D. Licht, M.D.Northwestern University Feinberg School of Medicine
 Thomas A. Look, Jr., M.D.Dana-Farber Cancer Institute
 Ian G. Macara, Ph.D.Vanderbilt University Medical Center
 Nita J. Maihle, Ph.D.Yale University
 Lynn M. Matrisian, Ph.D.Vanderbilt University
 Roeland Nusse, Ph.D.*Stanford University
 Suzanne Ostrand-Rosenberg, Ph.D.University of Maryland, Baltimore County
 Ann Marie Pendergast, Ph.D.Duke University Medical Center
 Thomas L. Poulos, Ph.D.University of California, Irvine
 James H. Prestegard, Ph.D.University of Georgia
 Kenneth L. Rock, M.D.University of Massachusetts Medical School
 Tzyy-Choou Wu, M.D., Ph.D.*The Johns Hopkins University School of Medicine
 James A. Wells, Ph.D.*University of California, San Francisco
 Wayne M. Yokoyama, M.D.Washington University School of Medicine
 Virginia A. Zakian, Ph.D.Princeton University
 Dong-Er Zhang, Ph.D.*University of California, San Diego

Executive Secretary

Florence E. Farber, Ph.D.National Cancer Institute

*Pending.

†Deceased.

NCI Director's Consumer Liaison Group

Chair

Ms. Gwen E. Darien Pathways Project

Members

Jeffrey Allen, Ph.D. Friends of Cancer Research
David F. Arons, J.D. National Brain Tumor Society
Ms. Susan G. Braun, M.A. The V Foundation for Cancer Research
Adam M. Clark, Ph.D. U.S. Department of Health and Human Services
Joya Delgado Harris, M.P.H. American Cancer Society
Linda S. House, M.S., R.N. Cancer Support Community
Cheryl Jernigan, C.P.A., FACHE Susan G. Komen for the Cure
Jeffrey A. Kaufman, M.B.A. Adenoid Cystic Carcinoma Research Foundation
Michelle T. McMurry-Heath, M.D., Ph.D. U.S. Food and Drug Administration
Deborah Morosini, M.D. AstraZeneca Pharmaceutical
Phyllis Pettit Nassi, M.S.W. University of Utah
Jon G. Retzlaff, M.P.A., M.B.A. American Association for Cancer Research
Ms. Wendy K.D. Selig Melanoma Research Alliance
Mr. Josh Sommer The Chordoma Foundation
Andrea E. Ferris Stern, M.B.A. LUNgevity Foundation
Max N. Wallace, J.D. Accelerate Brain Cancer Cure, Inc.

Executive Secretary

Kelli K. Marciel, M.A. National Cancer Institute

Subcommittee F—Manpower and Training

Chair

Herbert Chen, M.D. University of Wisconsin

Past Chair

Mark A. Nelson, Ph.D. The University of Arizona

Members

- Steven P. Balk, M.D., Ph.D. Harvard Medical School
- Moray J. Campbell, Ph.D. Roswell Park Cancer Institute
- Cathy S. Carlson, D.V.M., Ph.D. University of Minnesota
- Fong-Fong Chu, Ph.D. Beckman Research Institute of City of Hope
- Daniel Donoghue, Ph.D. University of California, San Diego
- Henry S. Friedman, M.D. Duke University Medical Center
- Juan Fueyo-Margareto, M.D. The University of Texas MD Anderson Cancer Center
- Rebecca S. Hartley, Ph.D. The University of New Mexico Health Sciences Center
- Marlene L. Hauck, D.V.M., Ph.D. North Carolina State University
- Mark R. Kelley, Ph.D. Indiana University
- Annette R. Khaled, Ph.D. University of Central Florida
- Molly F. Kulesz-Martin, Ph.D. Oregon Health and Science University
- Edmund C. Lattime, Ph.D. University of Medicine and Dentistry of New Jersey-
Robert Wood Johnson Medical School
- Stephen L. Lessnick, M.D., Ph.D. University of Utah
- Christopher I. Li, M.D., Ph.D. Fred Hutchinson Cancer Research Center
- Nipun B. Merchant, M.D., FACS Vanderbilt University
- Funda Meric-Bernstam, M.D. The University of Texas MD Anderson Cancer Center
- Babatunde O. Oyajobi, M.D., Ph.D. The University of Texas Health Sciences Center
at San Antonio
- Janet S. Rader, M.D., FACOG Medical College of Wisconsin
- Gavin P. Robertson, Ph.D. The Pennsylvania State University
- Mary Beth Terry, Ph.D. Columbia University
- Gayle E. Woloschak, Ph.D. Northwestern University
- Yu-Chung Yang, Ph.D. Case Western Reserve University

Scientific Review Officer

Timothy C. Meeker, M.D. National Cancer Institute

Subcommittee G—Education*

Chair

Georgia Robins Sadler, Ph.D.University of California, San Diego

Members

Lucile L. Adams-Campbell, Ph.D.Georgetown University Medical Center
Barbara L. Anderson, Ph.D. The Ohio State University
Dee M. Baldwin, Ph.D., R.N., F.A.A.N.University of North Carolina at Charlotte
John C. Byrd, M.D. The Ohio State University Comprehensive Cancer Center
Shine Chang, Ph.D.The University of Texas MD Anderson Cancer Center
Phyllis A. Gimotty, Ph.D.The University of Pennsylvania
Gail G. Harrison, Ph.D. University of California, Los Angeles
Judy Kasey Houlette, M.A. Friend for Life Cancer Support Network
Daniel C. Hughes, Ph.D. The University of Texas Health Science Center
Aminah Jatoi, M.D.Mayo Clinic
E. Melinda Mahabee-Gittens, M.D. Cincinnati Children’s Hospital Medical Center
Gertraud Maskarinec, M.D., Ph.D.University of Hawaii Cancer Research Center
Arthur M. Michalek, Ph.D. Roswell Park Cancer Institute
R. Sean Morrison, M.D.Mount Sinai School of Medicine
Polly A. Newcomb, Ph.D.Fred Hutchinson Cancer Research Center
Timothy Pearman, Ph.D. Tulane University School of Medicine
Mark P. Pfeifer, M.D. University of Louisville Hospital
Edward A. Sausville, M.D., Ph.D. University of Maryland
Peter C. Trask, Ph.D.Sanofi-Aventis

Scientific Review Officer

Jeannette F. Korczak, Ph.D. National Cancer Institute

*Subcommittee G was inactivated on April 30, 2012.

Subcommittee I—Career Development

Chair

William E. Gillanders, M.D. Washington University School of Medicine

Members

Deepak Bastia, Ph.D. Medical University of South Carolina
 Sujit Basu M.D., Ph.D. The Ohio State University
 Jennifer Clarke, Ph.D. University of Miami
 James M. Ford, M.D. Stanford University
 Jessica J. Kandel, M.D. Columbia University
 Charles Keller, M.D. Oregon Health and Science University
 John M. Lehman, Ph.D. East Carolina University
 Sophie A. Lelievre, D.V.M., Ph.D. Purdue University
 Anna E. Loshkin, Ph.D. The University of Pittsburgh
 Daniela E. Matei, M.D. Indiana University
 Carlos S. Moreno, Ph.D. Emory University
 Neil Osheroﬀ, Ph.D. Vanderbilt University Medical Center
 Keith D. Paulsen, Ph.D. Dartmouth College
 Manuel L. Penichet, M.D., Ph.D. University of California, Los Angeles
 Rajagopal Ramesh, Ph.D. University of Oklahoma
 Richard D. Schulick, M.D. The Johns Hopkins University
 Tiffany N. Seagroves, Ph.D. University of Tennessee Health Science Center
 David B. Solit, M.D. Memorial Sloan-Kettering Cancer Center
 Bakhos A. Tannous, Ph.D. Massachusetts General Hospital/Harvard Medical School
 Robert A. Winn, M.D. University of Colorado
 Wen-Cheng Xiong, Ph.D., M.D. Medical College of Georgia
 Yu-Chung Yang, Ph.D. Case Western Reserve

Scientific Review Officer

Sergei Radaev, Ph.D. National Cancer Institute

Subcommittee J—Population and Patient-Oriented Training

Chair

Johanna W. Lampe, Ph.D. Fred Hutchinson Cancer Research Center

Members

Barbara L. Andersen, Ph.D. The Ohio State University
Michael A. Andrykowski, Ph.D. University of Kentucky
Virginia F. Borges, M.D., MM.Sc. University of Colorado, Denver
Michael Bouvet, M.D. University of California, San Diego-Moores Cancer Center
John C. Byrd, M.D., Ph.D. The Ohio State University
Mary E. Cooley, Ph.D. Dana-Farber Cancer Institute
Michael E. Hagansee, M.D., Ph.D. Louisiana State University
Raymond J. Hohl, M.D., Ph.D. University of Iowa
Shawna V. Hudson, Ph.D. University of Medicine and Dentistry of New Jersey-
Robert Wood Johnson Medical School
Paul B. Jacobson, Ph.D. H. Lee Moffitt Cancer Center and Research Institute
Beverly L. Laird, Ph.D. 3D Medical Concepts, L.L.C.
Christopher H. Lowrey, M.D. Dartmouth Medical School
Gertraud Maskarinec, M.D., Ph.D., M.P.H. University of Hawaii
Guy H. Montgomery, Ph.D. Mount Sinai School of Medicine
Chaya S. Moskowitz, Ph.D. Memorial Sloan-Kettering Cancer Center
Kirsten B. Moysich, Ph.D. Roswell Park Cancer Institute
C. Daniel Mullins, Ph.D. University of Maryland
Frank J. Penedo, Ph.D. University of Miami
Lillian L. Siu, M.D. Princess Margaret Hospital
Scott A. Waldman, M.D., Ph.D. Thomas Jefferson University
Zuo-Feng Zhang, M.D., Ph.D., M.P.H. University of California, Los Angeles

Scientific Review Officer

Ilda M. Melo, Ph.D. National Cancer Institute

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2012

A

Abrams, Scott I., Ph.D. Roswell Park Cancer Institute
Akman, Steven A., M.D. Wake Forest University
Akpouriaye, Emmanuel T., Ph.D. Providence Portland Medical Center
Alberg, Anthony J., Ph.D., M.P.H. Medical University of South Carolina
Albertson, Donna G., Ph.D. University of California, San Francisco
Allman, David M., Ph.D. The University of Pennsylvania
Andrykowski, Michael A., Ph.D. University of Kentucky

B

Badawi, Ramsey D., Ph.D. University of California, Davis
Berger, Franklin G., Ph.D. University of South Carolina, Columbia
Boise, Lawrence H., Ph.D. Emory University
Bovbjerg, Dana H., Ph.D. The University of Pittsburgh
Buchsbaum, Donald J., Ph.D. The University of Alabama at Birmingham
Byrd, John C., M.D., Ph.D. The Ohio State University

C

Chang, Eric C., Ph.D. Baylor College of Medicine
Chang, Shine, Ph.D. The University of Texas MD Anderson Cancer Center
Chen, George T.Y., Ph.D. Massachusetts General Hospital
Chen, Moon S.C., Ph.D., M.P.H. University of California, Davis
Chen, Suzie, Ph.D. Rutgers, The State University of New Jersey
Chu, Edward, M.D. The University of Pittsburgh
Clarke, Jennifer P., Ph.D. University of Miami Miller School of Medicine
Coleman, William B., Ph.D. The University of North Carolina at Chapel Hill
Corry, Peter M., Ph.D. University of Arkansas for Medical Sciences, Little Rock

D

Daskalakis, Constantine, Sc.D. Thomas Jefferson University
Datta, Kaustubh, Ph.D. University of Nebraska Medical Center
Deininger, Prescott L., Ph.D. Tulane University

E

Elmer, Patricia J., Ph.D. Kaiser Foundation Research Institute

F

Ferrone, Soldano, M.D., Ph.D. The University of Pittsburgh
 Figlin, Robert A., M.D. Cedars-Sinai Medical Center
 Foreman, Kimberly E., Ph.D. Loyola University, Chicago
 Freeman, Michael L., Ph.D. Vanderbilt University
 Friedberg, Joseph S., M.D. The University of Pennsylvania
 Friese, Christopher R., Ph.D., R.N. University Of Michigan, Ann Arbor

G

Gapstur, Susan M., Ph.D., M.P.H. American Cancer Society
 Geahlen, Robert L., Ph.D. Purdue University, West Lafayette
 Gillanders, William E., M.D. Washington University
 Given, Barbara A., Ph.D., R.N. Michigan State University
 Glunde, Kristine, Ph.D. The Johns Hopkins University
 Grandis, Jennifer R., M.D. The University of Pittsburgh
 Grunberg, Steven M., M.D. The University of Vermont and State Agricultural College

H

Haase, Joan E., Ph.D., M.S.N. Indiana University-Purdue University, Indianapolis
 Hartmann, Lynn C., M.D. Mayo Clinic
 Hatcher, Jennifer, Ph.D. University of Kentucky
 He, Xiaolin, Ph.D. Northwestern University
 Henry, Roland G., Ph.D. University of California, San Francisco
 Heslop, Helen E., M.D. Baylor College of Medicine
 Hochwald, Steven N., M.D. University of Florida
 Hoopes, Jack, D.V.M., Ph.D. Dartmouth College
 Huang, Tim H.M., Ph.D. The University of Texas Health Science Center at San Antonio
 Hughes, Daniel C., Ph.D. The University of Texas Health Science Center at San Antonio
 Hyslop, Terry, Ph.D. Thomas Jefferson University

I

Ibrahim, Joseph G., Ph.D. University of North Carolina at Chapel Hill
 Isom, Harriet C., Ph.D. Pennsylvania State University, Milton S. Hershey
 Medical Center

J

Jatoi, Aminah, M.D. Mayo Clinic
 Jeraj, Robert, Ph.D. University of Wisconsin, Madison
 Joiner, Michael C., Ph.D. Wayne State University

K

Katz, Steven J., M.D., M.P.H. University of Michigan, Ann Arbor
 Kaufman, Russel E., M.D. The Wistar Institute

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2012

Keller, Charles, M.D. Oregon Health & Science University
Killackey, Maureen A., M.D. Memorial Sloan-Kettering Cancer Center
Kimler, Bruce F., Ph.D. The University of Kansas Medical Center
Kitchell, Barbara E., D.V.M., Ph.D. Michigan State University
Kong, Ah-Ng T., Ph.D. Rutgers, The State University of New Jersey
Koniaris, Leonidas G., M.D. Thomas Jefferson University
Kowalski, Jeanne, Ph.D. Emory University
Kwon, Eugene D., M.D. Mayo Clinic

L

Lake, Douglas, Ph.D. Arizona State University, Tempe
Lang, James C., Ph.D. The Ohio State University
Lannigan, Deborah, Ph.D. Vanderbilt University
Lee, Jeannette Y., Ph.D. University of Arkansas for Medical Sciences, Little Rock
Lehman, John M., Ph.D. East Carolina University
Lelievre, Sophie A., D.V.M., Ph.D. Purdue University, West Lafayette
Lessnick, Stephen L., M.D., Ph.D. The University of Utah
Lever, Susan Z., Ph.D. University of Missouri, Columbia
Loffredo, Christopher A., Ph.D. Georgetown University

M

Malkas, Linda H., Ph.D. City of Hope National Medical Center
Maskarinec, Gertraud, M.D., Ph.D. The University of Hawaii at Manoa
Matei, Daniela E., M.D. Indiana University-Purdue University, Indianapolis
McGuire, Deborah B., Ph.D., R.N. University of Maryland, Baltimore
McMillan, Susan C., Ph.D., M.S.N. University of South Florida
McWeeney, Shannon K., Ph.D. Oregon Health & Science University
Meric-Bernstam, Funda, M.D. The University of Texas MD Anderson Cancer Center
Meyers, Craig M., Ph.D. Pennsylvania State University, Milton S. Hershey Medical Center
Meyn, Raymond E., Ph.D. The University of Texas MD Anderson Cancer Center
Michor, Franziska, Ph.D. Dana-Farber Cancer Institute
Mikkelsen, Ross B., Ph.D. Virginia Commonwealth University
Miller, Donald M., M.D., Ph.D. University of Louisville
Milosavljevic, Aleksandar, Ph.D. Baylor College of Medicine
Mitchell, Beverly S., M.D. Association of American Cancer Institutes
Mohanty, Pritiraj, Ph.D. Boston University
Mukhtar, Hasan, Ph.D. University of Wisconsin, Madison
Mule, James J., Ph.D. H. Lee Moffitt Cancer Center & Research Institute

N

Newcomb, Polly A., Ph.D., M.P.H. Fred Hutchinson Cancer Research Center
Normolle, Daniel P., Ph.D. The University of Pittsburgh
Norris, James S., Ph.D. Medical University of South Carolina
Nwogu, Chukwumere E., M.D., Ph.D. Roswell Park Cancer Institute

O

Osheroff, Neil, Ph.D. Vanderbilt University

P

Pal, Soumitro, Ph.D. Children’s Hospital Boston
 Pascal, John, Ph.D. Thomas Jefferson University
 Passaniti, Antonino, Ph.D. University of Maryland, Baltimore
 Paulsen, Keith D., Ph.D. Dartmouth College
 Pearman, Timothy P., Ph.D. Northwestern University
 Pfeifer, Mark P., M.D. University of Louisville
 Phillips, Mark H., Ph.D. University of Washington
 Piazza, Gary A., Ph.D. University of South Alabama
 Pieper, Russell O., Ph.D. University of California, San Francisco
 Politi, Katerina A., Ph.D. Yale University

R

Ramalingam, Suresh S., M.D. Emory University
 Ramaswamy, Sridhar, M.D. Massachusetts General Hospital
 Robertson, Erle S., Ph.D. The University of Pennsylvania

S

Samlowski, Wolfram E., M.D. University of Nevada, Reno
 Schmidt, Edward E., Ph.D. The Montana State University
 Seagroves, Tiffany N., Ph.D. The University of Tennessee Health Science Center
 Seo, Youngho, Ph.D. University of California, San Francisco
 Siminoff, Laura A., Ph.D. Virginia Commonwealth University
 Singh, Pomila, Ph.D. The University of Texas Medical Branch at Galveston
 Snetselaar, Linda G., Ph.D. The University of Iowa
 Solit, David B., M.D. Memorial Sloan-Kettering Cancer Center
 Spanjaard, Remco, Ph.D. Boston University Medical Campus

T

Tan, Ming T., Ph.D. Georgetown University
 Tannous, Bakhos A., Ph.D. Massachusetts General Hospital
 Troester, Melissa A., Ph.D., M.P.H. University of Massachusetts, Amherst

V

Vedeckis, Wayne V., Ph.D. Louisiana State University Health Sciences Center
 Vij, Neeraj, Ph.D. The Johns Hopkins University

W

Wang, Shizhen E., Ph.D. City of Hope National Medical Center
Weiner, George J., M.D. The University of Iowa
Weiss, Geoffrey R., M.D. University of Virginia
Wheatley, Barnarese P., D.Ed., M.P.H. Alameda County Medical Center
Wiley, Patti, M.B.A. On The Wings of Angels
Wilkinson, Joanne E., M.D. Boston University School of Medicine
Winn, Robert A., M.D. University of Colorado, Denver
Woloschak, Gayle E., Ph.D. Northwestern University

Y

Yamashiro, Darrell J., M.D., Ph.D. Columbia University Health Sciences Campus
Yang, Yu-Chung, Ph.D. Case Western Reserve University
Yee, Douglas, M.D. University of Minnesota
Yeudall, William A., D.D.S., Ph.D. Virginia Commonwealth University

Z

Zaika, Alexander I., Ph.D. Vanderbilt University
Zhou, Daohong, M.D. University of Arkansas for Medical Sciences, Little Rock

Total number of Reviewers: 137

2. Consultants Serving as *Ad Hoc* Committee Members on Non-FACA/IRG Meetings in FY2012

A

Adams-Campbell, Lucile L., Ph.D. Georgetown University
Adjei, Alex A., M.D., Ph.D. Roswell Park Cancer Institute
Aisner, Joseph, M.D. University of Medicine & Dentistry of New Jersey-
Robert Wood Johnson Medical School
Alberg, Anthony J., Ph.D. Medical University of South Carolina
Albertson, Donna G., Ph.D. University of California, San Francisco
Albrecht, Terrance L., Ph.D. Wayne State University
Ambinder, Richard F., M.D., Ph.D. The Johns Hopkins University
Augenlicht, Leonard H., Ph.D. Albert Einstein College of Medicine of Yeshiva University

B

Bailey, Howard H., M.D. University of Wisconsin, Madison
Band, Hamid, M.D., Ph.D. University of Nebraska Medical Center
Bast, Robert C., M.D. Harvard University
Beckwith, Barbara J., M.A. The Ohio State University
Bepler, Gerold, M.D., Ph.D. Wayne State University
Bergan, Raymond C., M.D. Northwestern University
Berlin, Jordan D., M.D. Vanderbilt University Medical Center
Berwick, Marianne, Ph.D. The University of New Mexico
Bhalla, Kapil, M.D. The University of Kansas Center for Research
Black, Jennifer D., Ph.D. University of Nebraska Medical Center
Boyett, James M., Ph.D. St. Jude Children's Research Hospital
Brem, Steven, M.D. H. Lee Moffitt Cancer Center & Research Institute
Buchsbaum, Donald J., Ph.D. University of Alabama at Birmingham
Buckner, Jan C., M.D. Mayo Clinic

C

Carey, Thomas E., Ph.D. University of Michigan, Ann Arbor
Carson, William E., M.D. The Ohio State University
Chaudhary, Preet M., M.D., Ph.D. The University of Southern California
Chen, Moon S., Jr., Ph.D., M.P.H. University of California, Davis
Chow, Samson A., Ph.D. University of California, Los Angeles
Choy, Hak, M.D. The University of Texas Southwestern Medical Center
Chu, Edward, M.D. The University of Pittsburgh
Cinciripini, Paul M., Ph.D. The University of Texas MD Anderson Cancer Center
Clapper, Margie L., Ph.D. Fox Chase Cancer Center
Cooney, Kathleen A., M.D. University of Michigan, Ann Arbor

D

Debinski, Waldemar, M.D., Ph.D. Wake Forest University Health Sciences Center
 Dinney, Colin P.N., M.D. The University of Texas MD Anderson Cancer Center
 DiPaola, Robert S., M.D. University of Medicine & Dentistry of New Jersey-
 Robert Wood Johnson Medical School
 Djeu, Julie Y., Ph.D. H. Lee Moffitt Cancer Center & Research Institute
 Doetsch, Paul W., Ph.D. Emory University
 Dowlati, Afshin, M.D. Case Western Reserve University
 Duli, Anne, M.P.A. Case Western Reserve University

E

Eary, Janet F., M.D. Seattle Children’s Hospital
 Eckhardt, Sue G., M.D. University of Colorado, Denver
 El-Rifai, Wael, M.D., Ph.D. Vanderbilt University Medical Center
 Emanuel, Peter D., M.D. University of Arkansas for Medical Sciences, Little Rock
 Engleman, Edgar G., M.D. Stanford University
 Euhus, David M., M.D. The University of Texas Southwestern Medical Center
 Evans, Christopher P., M.D. University of California, Davis

F

Ferris, Robert L., M.D., Ph.D. The University of Pittsburgh
 Figlin, Robert A., M.D. Cedars-Sinai Medical Center
 Fisher, Richard I., M.D., Ph.D. University of Rochester
 Flynn, Brian S., Sc.D. The University of Vermont and State Agricultural College
 Fracasso, Paula M., M.D., Ph.D. University of Virginia
 Futscher, Bernard W., Ph.D. The University of Arizona

G

Gandara, David R., M.D. University of California, Davis
 Gapstur, Susan M., Ph.D. American Cancer Society
 Gerlach, Robert W., M.P.A. Dartmouth College
 Gerwick, William H., Ph.D. University of California, San Diego
 Ghandehari, Hamid, Ph.D. The University of Mississippi
 Gilbertson, Richard J., M.D., Ph.D. St. Jude Children’s Research Hospital
 Gillies, Robert J., Ph.D. H. Lee Moffitt Cancer Center & Research Institute
 Girotti, Albert, Ph.D. Medical College of Wisconsin
 Goodwin, W. Jarrad, M.D. University of Miami Miller School of Medicine
 Graham, Michael M., M.D., Ph.D. The University of Iowa
 Gudkov, Andrei V., Ph.D. Roswell Park Cancer Institute

H

Hallahan, Dennis E., M.D. Washington University in St. Louis
 Harpole, David H., M.D. Duke University
 Harrison, Anita L., M.P.A. Medical University of South Carolina

Appendix D-2: Consultants Serving as *Ad Hoc* Committee Members in FY2012

Hartmann, Lynn C., M.D.Mayo Clinic
Hecht, Stephen S., Ph.D. University of Minnesota, Twin Cities
Heslop, Helen E., M.D. Baylor College of Medicine
Hilsenbeck, Susan G., Ph.D. Baylor College of Medicine
Hoopes, Jack, Ph.D.Dartmouth College
Houghton, Janet A., Ph.D. Cleveland Clinic Lerner College of Medicine of
Case Western Reserve University
Howley, Peter M., M.D.Harvard University
Hsu, Edward W., Ph.D.The University of Utah
Hu, Jennifer J., Ph.D. University of Miami School of Medicine
Huang, Tim H.-M., Ph.D. The University of Texas Health Science Center at San Antonio
Hyslop, Terry, Ph.D.Thomas Jefferson University

I

Irwin, Melinda L., Ph.D. Yale University
Isom, Harriet C., Ph.D.The Pennsylvania State University, Milton S. Hershey
Medical Center
Israel, Mark A., M.D.Dartmouth College

J

Jaiswal, Anil K., Ph.D. University of Maryland, Baltimore
Jenkins, Robert B., M.D., Ph.D.Mayo Clinic
Jensen, Roy A., M.D. University of Kansas Medical Center
Jeruss, Jacqueline S., M.D., Ph.D.Northwestern University
Jones, Judy A., M.A.Cutaneous Lymphoma Foundation

K

Kane, Madeleine A., M.D., Ph.D.University of Colorado, Denver
Kaufman, Russel E., M.D. The Wistar Institute
Kerr, William G., Ph.D.College at Oneonta
Keyomarsi, Khandan, Ph.D.The University of Texas MD Anderson Cancer Center
Kibbe, Warren A., Ph.D.Northwestern University
Kleinman, Nanette, D.V.M. Case Western Reserve University
Klingemann, Hans, M.D., Ph.D. Tufts Medical Center
Kong, Ah-Ng Tony, Ph.D. Rutgers, The State University of New Jersey
Kumar, Nagi B., Ph.D.H. Lee Moffitt Cancer Center & Research Institute
Kung, Hsing-Jien, Ph.D. University of California, Davis
Kwon, Eugene D., M.D.Mayo Clinic

L

Larson, Steven M., M.D.Memorial Sloan-Kettering Cancer Center
Lee, Chung, Ph.D. University of California, Irvine
Li, King C., M.D.Wake Forest University Health Sciences Center
Liebermann, Towia A., Ph.D.Beth Israel Deaconess Medical Center

Liggitt, Harry D., D.V.M., Ph.D.University of Washington
Loffredo, Christopher A., Ph.D.Georgetown University
Loughran, Thomas P., M.D.The Pennsylvania State University, Milton S. Hershey
Medical Center

M

Malkas, Linda H., Ph.D. Beckman Research Institute of City of Hope
Manne, Sharon L., Ph.D.The Cancer Institute of New Jersey
Mao, Li, M.D. University of Maryland, Baltimore
McWeeney, Shannon K., Ph.D. Oregon Health & Science University
Mermelstein, Robin J., Ph.D.University of Illinois at Chicago
Meyer, William H., M.D.The University of Oklahoma Health Sciences Center
Meyn, Raymond E., Ph.D.The University of Texas MD Anderson Cancer Center
Miller, Kathy D., M.D.Indiana University-Purdue University, Indianapolis
Mitchell, Beverly S., M.D.Association of American Cancer Institutes
Moore, Malcolm J., M.D., Ph.D.Ontario Cancer Institute
Mukhtar, Hasan, Ph.D.University of Wisconsin, Madison
Mule, James J., Ph.D.H. Lee Moffitt Cancer Center & Research Institute
Mullen, Patricia D., M.P.H.The University of Texas Health Science Center at Houston
Munster, Pamela N., M.D.University of California, San Francisco

N

Naeve, Clayton W., Ph.D.St. Jude Children’s Research Hospital
Neugut, Alfred I., M.D., Ph.D.Columbia University
Newcomb, Polly A., Ph.D.Fred Hutchinson Cancer Research Center
Niland, Joyce C., Ph.D. Beckman Research Institute of City of Hope
Nishimura, Michael I., Ph.D.Loyola University, Chicago

O

O’Dorisio, M. Sue, M.D., Ph.D.The University of Iowa
Olshan, Andrew, Ph.D.The University of North Carolina at Chapel Hill
Ondrey, Frank G., M.D., Ph.D.University of Minnesota, Twin Cities
Ota, David M., M.D.Duke University
Ou, J.-H. James, Ph.D.The University of Southern California

P

Page, C. David, Ph.D.University of Wisconsin, Madison
Pasick, Rena J., Dr.P.H.University of California, San Francisco
Pestell, Richard G., M.D., Ph.D.Thomas Jefferson University
Piazza, Gary A., Ph.D.University of South Alabama
Porter, Peggy L., M.D.Fred Hutchinson Cancer Research Center
Powell, Robert S., M.B.A. Beckman Research Institute of City of Hope

Q

Quaranta, Vito, M.D.Vanderbilt University Medical Center
 Quelle, Dawn E., Ph.D.The University of Iowa

R

Raab-Traub, Nancy J., Ph.D.The University of North Carolina at Chapel Hill
 Rademaker, Alfred W., Ph.D.Northwestern University
 Ratliff, Timothy L., Ph.D.Purdue University, West Lafayette
 Reid, Mary E., Ph.D. Roswell Park Cancer Institute
 Ritz, Jerome, M.D. Dana-Farber Cancer Institute

S

Sacks, Peter G., Ph.D.New York University
 Sadler, Georgia R., Ph.D.University of California, San Diego
 Santana, Victor M., M.D.St. Jude Children’s Research Hospital
 Sarkar, Fazlul H., Ph.D.Wayne State University
 Sausville, Edward A., M.D., Ph.D. University of Maryland, Baltimore
 Schwartz, Stephen M., Ph.D.Fred Hutchinson Cancer Research Center
 Seewaldt, Victoria L., M.D.Duke University
 Seither, Richard L., Ph.D. Albert Einstein College of Medicine of Yeshiva University
 Shannon, Kevin M., M.D.University of California, San Francisco
 Shea, Thomas C., M.D.The University of North Carolina at Chapel Hill
 Shields, Peter G., M.D. The Ohio State University
 Shyr, Yu, Ph.D.Vanderbilt University Medical Center
 Siegfried, Jill M., Ph.D. The University of Pittsburgh
 Singh, Pomila, Ph.D. The University of Texas Medical Branch at Galveston
 Slingerland, Joyce M., M.D., Ph.D. University of Miami Miller School of Medicine
 Small, Eric J., M.D.University of California, San Francisco
 Smith, Jill P., M.D.The Pennsylvania State University, Milton S. Hershey
 Medical Center
 Snetselaar, Linda G., Ph.D.The University of Iowa
 Sosman, Jeffrey A., M.D.University of Illinois at Chicago
 Speicher, David W., Ph.D.The Wistar Institute
 Stadler, Walter M., M.D.The University of Chicago
 Stick, Roberta S., J.D.The Leukemia and Lymphoma Society
 Sukumar, Saraswati, Ph.D.The Johns Hopkins University

T

Tew, Kenneth D., Ph.D.Medical University of South Carolina
 Thompson, Ian M., M.D.The University of Texas Health Science Center at
 San Antonio

V

Van Breemen, Richard B., Ph.D. University of Illinois at Chicago
Van Etten, Richard A., M.D., Ph.D. Tufts Medical Center
Vuori, Kristiina, M.D., Ph.D. Sanford-Burnham Medical Research Institute

W

Warren, Edus H., M.D., Ph.D. Fred Hutchinson Cancer Research Center
Weiner, George J., M.D. The University of Iowa
Weiner, Louis M., M.D. Georgetown University
Weiss, Geoffrey R., M.D. University of Virginia
Wheatley, Barnarese P., M.P.H. Alameda County Medical Center
Wiley, Patti, M.B.A. On the Wings of Angels

Y

Yee, Douglas, M.D. University of Minnesota, Twin Cities
You, Ming, M.D., Ph.D. Medical College of Wisconsin
Yung, W. K. Alfred, M.D. The University of Texas MD Anderson Cancer Center

Z

Zutter, Mary M., M.D. Vanderbilt University Medical Center

Total number of Reviewers: 178

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

A

Abdulkadir, Sarki A., M.D., Ph.D.	Vanderbilt University
Abraham, George N., M.D., Ph.D.	University of Rochester
Abrams, Judith, Ph.D.	Wayne State University
Abrams, Scott I., Ph.D.	Roswell Park Cancer Institute
Adams, Peter D., Ph.D.	Glasgow University
Adams, Scott J., Ph.D.	University of Wisconsin, Madison
Adams, Sylvia, M.D.	New York University School of Medicine
Adams-Campbell, Lucile L., Ph.D.	Georgetown University
Agarwal, Rajesh, Ph.D.	University of Colorado, Denver
Aguilar, Zoraida P., Ph.D.	Covance, Inc.
Ahmad, Imran, Ph.D.	NeoPharm, Inc.
Ahmad, Nihal, Ph.D.	University of Wisconsin, Madison
Ahn, Chul W., Ph.D.	The University of Texas Southwestern Medical Center
Aisner, Joseph, M.D.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Ajani, Jaffer A., M.D.	The University of Texas MD Anderson Cancer Center
Akala, Emmanuel O., Ph.D.	The University of Utah
Akman, Steven A., M.D.	Wake Forest University
Alberts, David S., M.D., Ph.D.	The University of Arizona
Albertson, Donna G., Ph.D.	University of California, San Francisco
Alexandrow, Mark G., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Ali, Meser M., Ph.D.	Henry Ford Health System
Allegra, Carmen J., M.D.	University of Florida
Almasan, Alexandru, Ph.D.	Cleveland Clinic Lerner College of Medicine
Alonso, Alvaro, M.D., Ph.D., M.P.H.	University of Minnesota
Altieri, Dario C., M.D.	The Wistar Institute
Altman, Norman Harry, V.M.D.	University of Miami School of Medicine
Ambinder, Richard F., M.D., Ph.D.	The Johns Hopkins University
Anant, Shrikant, Ph.D.	The University of Kansas Medical Center
Andersen, Marin R., Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
Andersen, Peter A., Ph.D.	San Diego State University
Anderson, Carolyn, Ph.D.	The University of Pittsburgh
Anderson, James R., Ph.D.	National Childhood Cancer Foundation
Anderson, Michelle A., M.D.	University of Michigan, Ann Arbor
Anderson, Peter M., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Andrisani, Ourania M., Ph.D.	Purdue University, Indianapolis
Aplenc, Richard, M.D., Ph.D.	The University of Pennsylvania
Aplin, Andrew E., Ph.D.	Thomas Jefferson University
Appelhans, Bradley M., Ph.D.	Rush University Medical Center
Aragones, Abraham, M.D.	Memorial Sloan-Kettering Cancer Center
Archer, Kellie J., Ph.D.	Virginia Commonwealth University
Arenaz, Pablo, Ph.D.	Texas A&M International University
Argenbright, Keith E., M.D.	The University of Texas Southwestern Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Armstrong, Floyd D., Ph.D.	University of Miami School of Medicine
Arnold, Connie L., Ph.D.	Louisiana State University, Shreveport
Arteaga, Carlos L., M.D.	Vanderbilt University
Asanov, Alexander N., Ph.D.	TIRF Technologies, Inc.
Ashing-Giwa, Kimlin T., Ph.D.	Beckman Research Institute of City of Hope
Ashktorab, Hassan, Ph.D.	Howard University
Asmann, Yan W., Ph.D.	Mayo Clinic
Atasoy, Ulus, M.D.	University of Missouri, Columbia
Auerbach, Robert, Ph.D.	University of Wisconsin, Madison
Augenlicht, Leonard H., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Aung, Sandra, Ph.D.	UbiVac, LLC
Austin, Robert H., Ph.D.	Princeton University
Avantaggiati, Maria L., M.D.	Georgetown University
Avila-Tang, Erika, Ph.D.	The Johns Hopkins University
Awasthi, Y. Chandra, Ph.D.	University of North Texas Health Science Center

B

Backer, Marina V., Ph.D.	Sibtech, Inc.
Backes, Wayne L., Ph.D.	Louisiana State University, New Orleans
Backman, Vadim, Ph.D.	Northwestern University
Badr, Hoda J., Ph.D.	Mount Sinai School of Medicine
Bai, Wenlong, Ph.D.	University of South Florida
Baker, Amanda F., Ph.D.	The University of Arizona
Balch, Royal C., Ph.D.	Indiana University
Baldwin, Dee M., Ph.D.	The University of North Carolina at Charlotte
Balgley, Brian M., Ph.D.	Bioproximity, LLC
Ballman, Karla V., Ph.D.	Mayo Clinic
Baltezor, Michael J., Ph.D.	The University of Kansas
Band, Hamid, M.D., Ph.D.	University of Nebraska Medical Center
Bandera, Elisa V., M.D., Ph.D.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Banerjee, Sushanta, Ph.D.	Kansas City VA Medical Center
Baquet, Claudia R., M.D., M.P.H.	University of Maryland, Baltimore
Barbolina, Maria V., M.D., Ph.D.	University of Illinois
Baron, John A., M.D.	The University of North Carolina at Chapel Hill
Barry, Stephen E., Ph.D.	Alnis BioSciences, Inc.
Bar-Sagi, Dafna, Ph.D.	New York University School of Medicine
Barth, Rolf F., M.D.	The Ohio State University
Bartholomew, John B., Ph.D.	The University of Texas at Austin
Barton, Jennifer K., Ph.D.	The University of Arizona
Bastia, Deepak, Ph.D.	Medical University of South Carolina
Bastiaans, Glenn J., Ph.D.	Nanooptical Materials, Inc.
Bastian, Boris C., M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Basu, Hirak S., Ph.D.	University of Wisconsin, Madison
Batra, Surinder K., Ph.D.	University of Nebraska Medical Center
Batrakova, Elena, Ph.D.	The University of North Carolina at Chapel Hill
Bauer, Joshua A., Ph.D.	Vanderbilt University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Baum, Marianna K., Ph.D.	Florida International University
Baumann, William T., Ph.D.	Virginia Technologies, Inc.
Baxter-Lowe, Lee Ann, Ph.D.	University of California, San Francisco
Beck, George R. Jr., Ph.D.	Emory University
Becker, Christopher H., Ph.D.	Protein Metrics, Inc.
Beebe, Laura A., Ph.D., M.P.H.	The University of Oklahoma Health Sciences Center
Beebe-Dimmer, Jennifer L., Ph.D.	Wayne State University
Begley, Thomas J., Ph.D.	The State University of New York at Albany
Bellamkonda, Ravi V., Ph.D.	Georgia Institute of Technology
Bellamy, Scarlett, Sc.D.	The University of Pennsylvania
Bellen, Hugo J., D.V.M., Ph.D.	Baylor College of Medicine
Bellgrau, Donald, Ph.D.	University of Colorado, Denver
Bemis, Lynne T., Ph.D.	University of Colorado, Denver
Bender, Catherine M., Ph.D.	The University of Pittsburgh
Benedetti, Jacqueline, Ph.D.	University of Washington
Benedict, Michael K., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Ben-Jonathan, Nira, Ph.D.	University of Cincinnati
Bennett, Charles, M.D., Ph.D.	University of South Carolina, Columbia
Benz, Edward J., M.D.	Dana-Farber Cancer Institute
Berens, Michael E., Ph.D.	Translational Genomics Research Institute
Berezin, Mikhail Y., Ph.D.	Washington University in St. Louis
Berg, Stacey, M.D.	Baylor College of Medicine
Bergan, Raymond C., M.D.	Northwestern University, Chicago
Bergen, Harold R., Ph.D.	Mayo Clinic
Berger, Nathan A., D.V.M., M.D.	Case Western Reserve University
Berger, Shelley L., Ph.D.	The University of Pennsylvania
Bergers, Gabriele, Ph.D.	University of California, San Francisco
Bernstein, Irwin D., M.D.	Fred Hutchinson Cancer Research Center
Bernstein, Jonine L., Ph.D.	Memorial Sloan-Kettering Cancer Center
Bernstein, Steven H., M.D.	University of Rochester
Bernstein, Steven L., M.D.	Yale University
Berry, Donna L., Ph.D.	Dana-Farber Cancer Institute
Berti, Lorenzo, Ph.D.	University of California, Davis
Bertuch, Alison, M.D., Ph.D.	Baylor College of Medicine
Besmer, Peter, Ph.D.	Memorial Sloan-Kettering Cancer Center
Betancourt, Tania, Ph.D.	Texas State University, San Marcos
Betensky, Rebecca A., Ph.D.	Harvard School of Public Health
Bhansali, Shekhar, Ph.D.	Florida International University
Bhatia, Smita, M.D.	City of Hope National Medical Center
Bialous, Stella A., Ph.D.	Tobacco Policy International
Bickell, Nina A., M.D., M.P.H.	Mount Sinai School of Medicine
Biegon, Anat, Ph.D.	Brookhaven Science Associates-Brookhaven Laboratory
Bigatti, Silvia, Ph.D.	Purdue University, Indianapolis
Bikram, Malavosklish, Ph.D.	University of Houston
Billingsley, Melvin L., Ph.D.	The Pennsylvania State University, University Park
Birmann, Brenda M., Sc.D.	Brigham and Women's Hospital
Bishop, Gail A., Ph.D.	The University of Iowa
Black, Jennifer D., Ph.D.	University of Nebraska Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Blackstock, Arthur W., M.D.	Wake Forest University Health Sciences Center
Blalock, Janice A., Ph.D.	The University of Texas MD Anderson Cancer Center
Blankenberg, Francis G., M.D.	Stanford University
Bock, Cathryn H., Ph.D., M.P.H.	Wayne State University
Bodduluri, Haribabu, Ph.D.	University of Louisville
Bogler, Oliver, Ph.D.	The University of Texas MD Anderson Cancer Center
Bohorquez, Jose L., Ph.D.	Convergence Medical Devices, Inc.
Bokar, Joseph A., M.D., Ph.D.	Case Western Reserve University
Bold, Richard J., M.D.	University of California, Davis
Bollard, Catherine M., M.D.	Baylor College of Medicine
Boman, Bruce M., M.D., Ph.D.	Christiana Care Health Services, Inc.
Bonavida, Benjamin, Ph.D.	University of California, Los Angeles
Bondy, Melissa L., Ph.D.	Baylor College of Medicine
Boothman, David A., Ph.D.	The University of Texas Southwestern Medical Center
Borad, Mitesh, M.D.	Mayo Clinic, Arizona
Bordonaro, Michael, Ph.D.	The Commonwealth Medical College
Borgia, Jeffrey A., Ph.D.	Rush University Medical Center
Bosland, Maarten C., Ph.D.	University of Illinois at Chicago
Bostic, Chris, J.D.	Action on Smoking and Health
Boushey, Carol J., Ph.D., M.P.H.	The University of Hawaii at Manoa
Boyd, Douglas D., Ph.D.	The University of Texas MD Anderson Cancer Center
Boysen, Gunnar, Ph.D.	University of Arkansas, Little Rock
Bracci, Paige M., Ph.D., M.P.H.	University of California, San Francisco
Bradbury, Michelle S., M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Braithwaite, Dejana K., Ph.D.	University of California, San Francisco
Bram, Richard J., M.D., Ph.D.	Mayo Clinic
Branch, Craig A., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Brandt, Heather M., Ph.D.	University of South Carolina, Columbia
Brat, Daniel J., M.D., Ph.D.	Emory University
Braun, LaToya J., Ph.D.	University of Colorado, Denver
Braun, Terry A., Ph.D.	The University of Iowa
Braunschweig, Carol L., Ph.D.	University of Illinois
Braziel, Rita M., M.D.	Oregon Health & Science University
Breit, Jeffrey, Ph.D.	Bend Research, Inc.
Brenner, Malcolm K., M.D., Ph.D.	Baylor College of Medicine
Brewer, Molly A., D.V.M., M.D.	University of Connecticut Health Center
Brewer, Noel T., Ph.D.	The University of North Carolina at Chapel Hill
Bright, Robert K., Ph.D.	Texas Tech University Health Science Center
Briley, Margaret E., Ph.D.	The University of Texas at Austin
Bristow, Robert G., M.D., Ph.D.	University of Toronto
Broccoli, Dominique, Ph.D.	Memorial Health University Medical Center, Inc.
Brockbank, Kelvin G.M., Ph.D.	Cell and Tissue Systems, Inc.
Brockstedt, Dirk G., Ph.D.	Aduro BioTech
Brodbelt, Jennifer S., Ph.D.	Ohio University, Athens
Brodeur, Garrett M., M.D.	Children's Hospital of Philadelphia
Brody, Jerome S., M.D.	Boston University Medical Campus
Brown, Alan P., Ph.D.	Integrated Nonclinical Development Solutions, Inc.
Brown, David M., Ph.D.	Ambion Diagnostics, Inc.

Brown, H. Alex, Ph.D.	Vanderbilt University
Bruce, Jeffrey N., M.D.	Columbia University Health Sciences Campus
Bruchez, Marcel P., Ph.D.	Carnegie Mellon University
Brunengraber, Henri, M.D., Ph.D.	Case Western Reserve University
Bruner, Deborah W., Ph.D.	Emory University
Bubley, Glenn J., M.D., Ph.D.	Beth Israel Deaconess Medical Center
Buchbinder, David K., M.D.	University of California, Los Angeles
Burchiel, Scott W., Ph.D.	The University of New Mexico Health Sciences Center
Burgess, Diane J., Ph.D.	University of Connecticut, Storrs
Burgreen, Greg W., Ph.D.	Mississippi State University
Burhansstipanov, Linda, Ph.D.	Native American Cancer Research
Burns, Linda J., M.D.	University of Minnesota
Burt, Randall W., M.D.	The University of Utah
Bush, Jason A., Ph.D.	California State University, Fresno
Bushweller, John H., Ph.D.	University of Virginia
Butterfield, Lisa H., Ph.D.	The University of Pittsburgh
Byers, Tim E., M.D., Ph.D., M.P.H.	University of Colorado
Bylund, Carma L., Ph.D.	Memorial Sloan-Kettering Cancer Center
Byrd, John C., M.D., Ph.D.	The Ohio State University
Byzova, Tatiana V., Ph.D.	Cleveland Clinic Lerner College of Medicine

C

Caffrey, Michael S., Ph.D.	University of Illinois at Chicago
Cairo, Mitchell S., M.D.	New York Medical College
Calabretta, Bruno, M.D., Ph.D.	Thomas Jefferson University
Califano, Joseph A., M.D.	The Johns Hopkins University
Cameron, Carrie A., Ph.D.	The University of Texas MD Anderson Cancer Center
Cameron, Kenzie A., Ph.D., M.P.H.	Northwestern University
Campbell, Moray J., Ph.D.	Roswell Park Cancer Institute
Cannon, Martin J., Ph.D.	DCV Technologies, Inc.
Canoll, Peter D., M.D., Ph.D.	Columbia University Health Sciences Campus
Cao, Han, Ph.D.	BioNanomatrix, Inc.
Cao, Yue, Ph.D.	University of Michigan, Ann Arbor
Capobianco, Anthony J., Ph.D.	University of Miami Miller School of Medicine
Carbine, Nora E.	Cancer Information & Support Network
Carey, Robert, M.B.A.	RPC Associates, Inc.
Carlin, Bradley P., Ph.D.	University of Minnesota, Twin Cities
Carroll, Martin, M.D.	Children's Hospital of Philadelphia
Carroll, Raymond J., Ph.D.	Texas A&M University
Carter, Darrick A., Ph.D.	Protein Advances, Inc.
Castor, Trevor P., Ph.D.	Aphios Corporation
Cattaneo, Roberto B., Ph.D.	Mayo Clinic
Cave, William T., M.D.	University of Rochester School of Medicine
Celebi, Julide T., M.D.	Columbia University Health Sciences Campus
Celis, Esteban, M.D., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Cerhan, James R., M.D., Ph.D.	Mayo Clinic
Chaillet, J. Richard, M.D., Ph.D.	The University of Pittsburgh

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Chakravarti, Arnab, M.D.	American College of Radiology
Chamberlain, Marc C., M.D.	University of Washington
Chambers, Setsuko K., M.D.	The University of Arizona
Champlin, Richard E., M.D.	The University of Texas MD Anderson Cancer Center
Chan, Andrew T., M.D.	Massachusetts General Hospital
Chan, Cliburn C., Ph.D.	Duke University
Chandler, Dawn S., Ph.D.	The Research Institute at Nationwide Children's Hospital
Chandra, Joya, Ph.D.	The University of Texas MD Anderson Cancer Center
Chandran, Bala, Ph.D.	Rosalind Franklin University of Medicine and Sciences
Chang, Eric C., Ph.D.	Baylor College of Medicine
Chang, Susan M., M.D.	University of California, San Francisco
Chaplin, David D., M.D., Ph.D.	The University of Alabama at Birmingham
Chatham, John C., Ph.D.	The University of Alabama at Birmingham
Chellappan, Srikumar P., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Chen, George T.Y., Ph.D.	Massachusetts General Hospital
Chen, Herbert, M.D.	University of Wisconsin, Madison
Chen, Jason J., Ph.D.	University of Massachusetts Medical School, Worcester
Chen, Jiande, Ph.D.	Transtimulation Research Inc.
Chen, Jian Jennifer, Ph.D.	Novartis Institutes of Biomedical Research
Chen, Jinbo, Ph.D.	The University of Pennsylvania
Chen, Junjie, Ph.D.	The University of Texas MD Anderson Cancer Center
Chen, Kuang Y., Ph.D., M.P.H.	Rutgers, The State University of New Jersey
Chen, Moon S.C., Ph.D., M.P.H.	University of California, Davis
Chen, Taosheng, Ph.D.	St. Jude Children's Research Hospital
Chen, Wei, Ph.D.	Wayne State University
Chen, Xiaoli, M.D., Ph.D.	University of Minnesota
Chen, Yong Q., Ph.D.	Wake Forest University Health Sciences Center
Chen, Yu, Ph.D.	Massachusetts Institute of Technology
Chen, Yuan, Ph.D.	Beckman Research Institute of City of Hope
Chen, Zhiyuan, Ph.D.	University of Maryland, Baltimore County
Cheng, Iona, Ph.D.	University of Hawaii at Manoa
Cheng, Jin Q., M.D., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Cheng, Leo, Ph.D.	Massachusetts General Hospital
Cheng, Liang, M.D.	Indiana University
Cheng, Shi-Yuan, Ph.D.	Northwestern University, Chicago
Cheng, Tao, M.D.	The University of Pittsburgh
Chesney, Jason A., M.D., Ph.D.	University of Louisville
Cheung, Nai-Kong V., M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Chia, David S., Ph.D.	University of California, Los Angeles
Chiao, Elizabeth, M.D.	Baylor College of Medicine
Chiles, Thomas C., Ph.D.	Boston College
Chinnadurai, Govindaswamy, Ph.D.	Saint Louis University
Chishti, Athar H., Ph.D.	Tufts University
Chlebowski, Rowan T., M.D., Ph.D.	Harbor-University of California, Los Angeles Medical Center
Cho, Bongsup P., Ph.D.	The University of Rhode Island
Cho, Hyunyi, Ph.D.	Purdue University, West Lafayette
Cho, Kathleen R., M.D.	University of Michigan, Ann Arbor

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Chow, Gary, M.P.H.	American Cancer Society
Christensen, Brock C., Ph.D.	Dartmouth College
Christie, Debra W., M.B.A.	The University of Mississippi Medical Center
Chu, Wei-Sing, M.D.	American Registry of Pathology, Inc.
Church, Timothy R., Ph.D.	University of Minnesota
Ciccolo, Joseph T., Ph.D.	Brown University
Cittadine, Andrew J., M.B.A.	Diagnostic Photonics, Inc.
Claffey, Kevin P., Ph.D.	University of Connecticut School of Medicine
Clanton, Mark S., M.D., M.P.H.	American Cancer Society
Clarke, Jennifer P., Ph.D.	University of Miami Miller School of Medicine
Clary, Bryan M., M.D.	Duke University
Clary, Gregory J., Ph.D.	Advanced Digital Systems, Inc.
Clawson, Gary A., M.D., Ph.D.	The Pennsylvania State University, Milton S. Hershey Medical Center
Clayman, Marla L., Ph.D., M.P.H.	Northwestern University
Cleary, Michael L., M.D.	Stanford University
Clevenger, Charles V., M.D., Ph.D.	Northwestern University, Chicago
Clish, Clary B., Ph.D.	The Broad Institute of Harvard University
Cochran, Brent H., Ph.D.	Tufts University, Boston
Coe, Christopher L., Ph.D.	University of Wisconsin
Cohen, Edward P., M.D.	University of Illinois at Chicago
Cohen, Michael B., M.D.	The University of Utah
Cohn, Wendy F., Ph.D.	University of Virginia
Colcher, David M., Ph.D.	Beckman Research Institute of City of Hope
Colditz, Graham A., M.D., Dr.P.H.	Washington University in St. Louis
Cole, Bernard F., Ph.D.	The University of Vermont and State Agricultural College
Coleman, William B., Ph.D.	The University of North Carolina at Chapel Hill
Coller, Hilary A., Ph.D.	Princeton University
Colwell, Brian, Ph.D.	Texas A&M University Health Science Center
Comai, Lucio, Ph.D.	University of Southern California
Cooley, Philip C., M.S.	Research Triangle International
Coomber, Brenda L., Ph.D.	University of Guelph
Cooper, Priscilla K., Ph.D.	Lawrence Berkeley National Laboratory
Copelan, Edward A., M.D.	Cleveland Clinic Foundation
Copland, John A., Ph.D.	Mayo Clinic, Jacksonville
Corey, David R., Ph.D.	The University of Texas Southwestern Medical Center
Corey, Seth J., M.D., M.P.H.	Northwestern University
Corry, Peter M., Ph.D.	University of Arkansas Medical Science
Cote, Michele L., Ph.D., M.P.H.	Wayne State University
Coups, Elliot J., Ph.D.	University of Medicine and Dentistry of New Jersey- Robert Wood Johnson Medical School
Coussens, Lisa R., Ph.D.	Oregon Health & Science University
Cover, Timothy L., Ph.D.	Vanderbilt University Medical Center
Crane, Lori A., Ph.D., M.P.H.	University of Colorado, Denver
Crawford, Jason, Ph.D.	Yale University
Crawford, Susan E., M.D.	NorthShore University HealthSystem Research Institute
Crawford, Sybil L., Ph.D.	University of Massachusetts Medical School, Worcester
Cress, Anne E., Ph.D.	The University of Arizona

Crews, Phil, Ph.D.	University of California, Santa Cruz
Crino, Peter B., M.D., Ph.D.	The University of Pennsylvania
Cristofanilli, Massimo, M.D.	Fox Chase Cancer Center
Critchley-Thorne, Rebecca, Ph.D.	Cernostics, Inc.
Cronan, Thereasa A., Ph.D.	San Diego State University
Crooks, Gay Miriam, M.D.	University of California, Los Angeles
Crott, Jimmy W., Ph.D.	Tufts University, Boston
Culbertson, Christopher T., Ph.D.	Kansas State University
Curley, Steven A., M.D.	The University of Texas MD Anderson Cancer Center
Cutler, Stephen J., M.D., Ph.D.	The University of Vermont
Czerniak, Bogdan A., M.D., Ph.D.	The University of Texas Health Science Center
Czernin, Johannes, M.D.	University of California, Los Angeles

D

Daaka, Yehia, Ph.D.	University of Florida
Dadachova, Ekaterina, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Dagostino, Ralph B., Ph.D.	Wake Forest University Health Sciences Center
Dahiya, Rajvir, Ph.D.	Northern California Institute of Research & Education
Dai, Qi, M.D., Ph.D.	Vanderbilt University
Dai, Wei, Ph.D.	New York University School of Medicine
Daiss, John L., Ph.D.	First Wave Technologies, Inc.
Damodaran, Chendil, Ph.D.	Texas Tech University Health Science Center
Dancey, Janet E., M.D.	Ontario Institute for Cancer Research
Dang, Thao P., M.D.	University of Virginia
Das Gupta, Abhijit, Ph.D.	University of Maryland, College Park
Dash, Srikanta, Ph.D.	Tulane University
Datar, Rajiv V., Ph.D.	Synosys, Inc.
David, Gregory, Ph.D.	New York University School of Medicine
Davidson, Kelly M., M.D.	University of Virginia Health System
Davidson, Nancy E., M.D.	The University of Pittsburgh
Davis, Jean E., Ph.D.	Wayne State University
Davisson, Vincent J., Ph.D.	Purdue University, West Lafayette
De Assis, Sonia, Ph.D.	Georgetown University
Debinski, Waldemar, M.D., Ph.D.	Wake Forest University Health Sciences Center
DeCaprio, Anthony P., Ph.D.	Florida International University
DeCoster, Mark A., Ph.D.	Louisiana State University Health Sciences Center
De Los Santos, Carlos R., Ph.D.	The State University of New York at Stony Brook
Del Valle, Juan R, Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Demark-Wahnefried, Wendy, Ph.D.	The University of Alabama at Birmingham
Demetriou, Michael, M.D., Ph.D.	University of California, Irvine
Demirci, Utkan, Ph.D.	Brigham and Women's Hospital
Deng, Yibin, M.D., Ph.D.	University of Minnesota, Twin Cities
Denis, Gerald V., Ph.D.	Boston University Medical Campus
Denko, Nicholas C., M.D., Ph.D.	Stanford University
Dennis, Leslie K., Ph.D.	The University of Arizona
Denny, Christopher T., M.D.	University of California, Los Angeles
Desai, Pankaj B., Ph.D.	University of Cincinnati

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

De Shields, Mary S., M.D.	Eastern Shore Oncology, Inc.
Deshong, Philip, Sc.D.	University of Maryland, College Park
Deshpande, Anjali D., Ph.D., M.P.H.	Washington University in St. Louis
De Vere White, Ralph W., M.D.	University of California, Davis
Devine, Susan	The Hospital for Sick Children, Toronto
Dewhirst, Mark W., Ph.D.	Duke University Medical Center
De Winter, Alex, Ph.D.	Mohr Davidow Ventures
Dhanasekaran, Danny N., Ph.D.	University of Oklahoma Health Sciences Center
Diaz, Manuel O., M.D.	Loyola University, Chicago
Di Cristofano, Antonio, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Diefenbach, Michael A., Ph.D.	Mount Sinai School of Medicine
Diergaarde, Brenda B., Ph.D.	The University of Pittsburgh
Dignan, Mark B., Ph.D., M.P.H.	University of Kentucky
Ding, George Xiao, Ph.D.	Vanderbilt University
Ding, Wei-Qun, Ph.D.	The University of Oklahoma Health Sciences Center
Dino, Geri A., Ph.D.	West Virginia University
Dipersio, C. Michael, Ph.D.	Albany Medical College
Disis, Mary L., M.D.	University of Washington
Divgi, Chaitanya R., M.D.	Columbia University Health Sciences Campus
Djaballah, Hakim, Ph.D.	Memorial Sloan-Kettering Cancer Center
Djuric, Zora, Ph.D.	University of Michigan, Ann Arbor
Doerksen, Robert J., Ph.D.	The University of Mississippi
Doetsch, Paul W., Ph.D.	Emory University
Dohan, Daniel P., Ph.D.	University of California, San Francisco
Doherty, Gerard M., M.D.	Boston University Medical Center
Doktycz, Mitchel, Ph.D.	Oak Ridge National Laboratory
Dolnick, Bruce J., Ph.D.	Roswell Park Cancer Institute
Dong, Zigang, M.D.	University of Minnesota
Donovan, Maureen D., Ph.D.	The University of Iowa
Dooley, William C., M.D.	University of Oklahoma Health Science Center
Dorazio, John A., M.D., Ph.D.	University of Kentucky
Dorrestein, Pieter C., Ph.D.	University of California, San Diego
Dovichi, Norman J., Ph.D.	University of Notre Dame
Dowdy, Steven F., Ph.D.	University of California, San Diego
Dowlati, Afshin, M.D.	Case Western Reserve University
Doyle, Terrence W., Ph.D.	Vion Pharmaceuticals, Inc.
Dragomir, Anca D., Ph.D.	Georgetown University, Lombardi Cancer Center
Drake, Bettina F., Ph.D., M.P.H.	Washington University in St. Louis
Drake, Richard R., Ph.D.	Medical University of South Carolina
Driehuys, Bastiaan, Ph.D.	Medi-Physics, Inc.
Driscoll, Kimberly, Ph.D.	Florida State University
Dritschilo, Anatoly, M.D.	Georgetown University
Dropulic, Boro, Ph.D.	Lentigen Corporation
Dubbs, Robert M., J.D.	Obermayer Rebmann Maxwell & Hippel, LLP
Dubeau, Louis, M.D., Ph.D.	The University of Southern California
Duckett, Colin S., Ph.D.	University of Michigan, Ann Arbor
Duffy, Sonia A., Ph.D.	University of Michigan, Ann Arbor
Dunkel, Ira J., M.D.	Memorial Sloan-Kettering Institute Cancer Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Dutta, Anindya, Ph.D. University of Virginia
Dutton, Gareth R. Ph.D. The University of Alabama at Birmingham
Dwinell, Michael B., Ph.D. Medical College of Wisconsin

E

Earle, Craig C., M.D. Sunnybrook Health Sciences Centre
Eary, Janet F., M.D. Seattle Children's Hospital
Eckert, Richard L., Ph.D. University of Maryland, Baltimore
Eckhart, Walter, Ph.D. Salk Institute for Biological Studies
Edwards, D. Scott, Ph.D. SciFluor Life Sciences, LLC
Edwards, Jeremy S., Ph.D. The University of New Mexico
Eischen, Christine M., Ph.D. Vanderbilt University
El Fakhri, Georges, Ph.D. Massachusetts General Hospital
Eliason, James F., Ph.D. Wayne State University
Eliceiri, Brian P., Ph.D. University of California, San Diego
El Kouni, Mahmoud H., Ph.D. The University of Alabama at Birmingham
Ellerby, Lisa M., Ph.D. Buck Institute for Age Research
Ellingson, Benjamin M., Ph.D. University of California, Los Angeles
Elliott, John T, Ph.D. National Institute of Standards & Technology
Elliott, Thomas E., M.D. Duluth Clinic
Ellis, Lee M., M.D. The University of Texas MD Anderson Cancer Center
El-Rifai, Wael, M.D., Ph.D. Vanderbilt University Medical Center
Elson, Paul J., Sc.D. Cleveland Clinic Foundation
Elston, Robert C., Ph.D. Case Western Reserve University
Eltoum, Isameldin A., M.D. The University of Alabama at Birmingham
El-Zein, Randa A., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Emanuel, Peter D., M.D. University of Arkansas Medical Science, Little Rock
Emelianov, Stanislav Y., Ph.D. The University of Texas at Arlington
Emerson, Jane, M.D., Ph.D. The University of Southern California
Emrick, Todd S., Ph.D. University of Massachusetts, Amherst
Enders, Gregory H., M.D., Ph.D. Fox Chase Cancer Center
Erdei, Esther, Ph.D., M.P.H. The University of New Mexico Health Sciences Center
Erdmann, Christine A., Ph.D., M.P.H. Medical University of the Americas
Erlichman, Charles, M.D. Mayo Clinic
Escoffery, Ngoc-Cam, Ph.D., M.P.H. Emory University
Ewing, James R., Ph.D. Henry Ford Hospital

F

Fagerlin, Angela, Ph.D. University of Michigan, Ann Arbor
Fahey, Frederic H, Sc.D. Wake Forest University
Fajardo, Laurie L., M.D. University of Iowa
Fan, Chun-Yang, M.D., Ph.D. University of Arkansas Medical Science, Little Rock
Fan, Guang, M.D., Ph.D. Oregon Health & Science University
Fan, Rong, Ph.D. Yale University
Fan, Timothy M., D.V.M., Ph.D. University of Illinois at Urbana-Champaign
Fan, Weimin, M.D. Medical University of South Carolina

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Fan, Xudong, Ph.D.	University of Michigan, Ann Arbor
Fan, Zhen, M.D.	The University of Texas MD Anderson Cancer Center
Fang, Carolyn Y., Ph.D.	Fox Chase Cancer Center
Fantuzzi, Giamila, Ph.D.	University of Illinois
Farag, Sherif S., M.D., Ph.D.	Indiana University-Purdue University, Indianapolis
Fedorov, Andriy, Ph.D.	Brigham and Women's Hospital
Felton, James S., Ph.D.	University of California, Davis
Fenical, William, Ph.D.	University of California, San Diego
Fenniri, Hicham, Ph.D.	University of Alberta
Fenton, Jenifer I., Ph.D.	Michigan State University
Ferketich, Amy K., Ph.D.	The Ohio State University
Fernander, Anita F., Ph.D.	University of Kentucky
Ferrance, Jerome P., Ph.D.	J2F Engineering
Ferrando, Adolfo A., M.D., Ph.D.	Columbia University Health Sciences
Ferrer, Fernando A., M.D.	University of Connecticut School of Medicine
Ferris, Robert L., M.D., Ph.D.	The University of Pittsburgh
Ferrone, Soldano, M.D., Ph.D.	The University of Pittsburgh
Fessler, Jeffrey A., Ph.D.	University of Michigan, Ann Arbor
Fields, Alan P., Ph.D.	Mayo Clinic, Jacksonville
Figueiredo, Jane C., Ph.D.	The University of Southern California
Fine, Donald L., Ph.D.	DynPort Vaccine Company, LLC
Finkelstein, Dianne M., Ph.D.	Massachusetts General Hospital
Finn, Olivera J., Ph.D.	The University of Pittsburgh
Fishbein, James C., Ph.D.	University of Maryland, Baltimore County
Fisher, Christopher, Ph.D.	Nanovir, LLC
Fisher, Joy D., M.A.	The Johns Hopkins University
Fisher, Richard I., M.D., Ph.D.	University of Rochester
Fitzmaurice, Maryann, M.D., Ph.D.	Case Western Reserve University
Flemington, Erik K., Ph.D.	Tulane University
Flynn, Brian S., Sc.D.	The University of Vermont and State Agricultural College
Flynn, Patricia M., M.D.	The University of Tennessee Health Science Center
Flynn, Patrick J., M.D., Ph.D.	Park Nicollet Institute
Fonseca, Rafael, M.D.	Mayo Clinic Arizona
Fong De Los Santos, Luis E., Ph.D.	Mayo Clinic
Fontham, Elizabeth H., Ph.D., M.P.H.	Louisiana State University Health Sciences Center
Ford, Jennifer S., Ph.D.	Memorial Sloan-Kettering Cancer Center
Ford, John C., Ph.D.	Self Employed
Foreman, Kimberly E., Ph.D.	Loyola University, Chicago
Fornace, Albert J., M.D.	Georgetown University
Forsyth, Peter A., M.D.	University of South Florida
Fortini, Mark E., Ph.D.	Thomas Jefferson University
Foster, David A., Ph.D.	City University of New York
Fowke, Jay H., Ph.D., M.P.H.	Vanderbilt University
Francino, Maria P., Ph.D.	University of California, Merced
Frederickson, Christopher J., Ph.D.	The University of Texas Medical Branch, Galveston
Freedman, Matthew T., M.D.	Georgetown University
Freeman, Burgess B., Ph.D.	St. Jude Children's Research Hospital
Freeman, Carolyn R., M.D.	McGill University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Freeman, James W., Ph.D.	The University of Texas Health Science Center at San Antonio
Freeman, Michael R., Ph.D.	Cedars-Sinai Medical Center
Freeman, Richard B. Jr., M.D.	Tufts-New England Medical Center
Freemantle, Sarah J., Ph.D.	Dartmouth College
Freimuth, Robert R., Ph.D.	Mayo Clinic
Freitas, Michael A., Ph.D.	The Ohio State University
Fricke, Stanley T., Ph.D.	Children's National Medical Center
Friedman, Debra L., M.D.	Fred Hutchinson Cancer Research Center
Frisch, Steven M., Ph.D.	West Virginia University
Frost, Andra R., M.D.	The University of Alabama at Birmingham
Frueh, Klaus J., Ph.D.	Oregon Health and Science University
Fruh, Elaine, Ph.D.	Oregon Health and Science University
Fry, David C., Ph.D.	Hoffmann-La Roche, Inc.
Fu, Steven, M.D.	University of Minnesota, Twin Cities
Fuchs, Elaine, Ph.D.	Rockefeller University
Fuchs, Serge Y., M.D., Ph.D.	The University of Pennsylvania
Fueyo, Juan, M.D.	The University of Texas MD Anderson Cancer Center
Fukumura, Dai, M.D., Ph.D.	Massachusetts General Hospital
Fuloria, Jyotsna, M.D.	Ochsner Clinic Foundation
Fulton, Amy M., Ph.D.	University of Maryland, Baltimore
Furge, Kyle A., Ph.D.	Van Andel Research Institute
Furgeson, Darin Y., Ph.D.	The University of Utah

G

Gafken, Philip R., Ph.D.	Fred Hutchinson Cancer Research Center
Gaitas, Angelo, Ph.D.	Picocal, Inc.
Gajjar Amar, M.D.	St. Jude Children's Research Hospital
Galanis, Evanthia, M.D.	Mayo Clinic
Galipeau, Jacques, M.D.	Emory University
Gallagher, Carla J., Ph.D.	The Pennsylvania State University
Gallick, Gary E., Ph.D.	The University of Texas MD Anderson Cancer Center
Galloway, Robert L., Ph.D.	Vanderbilt University Medical Center
Gamcsik, Michael, Ph.D.	North Carolina State University, Raleigh
Ganapathi, Ram N., Ph.D.	Carolinas Healthcare System
Gandhi, Varsha, Ph.D.	The University of Texas MD Anderson Cancer Center
Ganju-Krishan, Awtar, Ph.D.	University of Miami Miller School of Medicine
Gannett, Peter M., Ph.D.	West Virginia University
Ganz, Patricia A., M.D.	University of California, Los Angeles
Gao, Shou-Jiang, Ph.D.	The University of Southern California
Gao, Tianyan, Ph.D.	University of Kentucky
Garza, Mary A., Ph.D., M.P.H.	University of Maryland, College Park
Gatewood, Joe M., Ph.D.	Acoustic Biosystems, Inc.
Gatsonis, Constantine A., Ph.D.	Brown University
Gaudet, Mia M., Ph.D.	American Cancer Society
Gaur, Rakesh, M.D., M.P.H.	Kansas City Clinical Oncology Program
Gautier, Jean, Sc.D., Ph.D.	Columbia University Health Sciences Campus
Gavai, Ashvinikumar, Ph.D.	Bristol-Myers Squibb Pharmaceutical Research Institute

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Geacintov, Nicholas E., Ph.D.	New York University
Gellibolian, Robert, Ph.D.	N-Abl Therapeutics, Inc.
Gelman, Irwin H., Ph.D.	Roswell Park Cancer Institute
Gendler, Sandra J., Ph.D.	Mayo Clinic, Arizona
Geng, Jason, Ph.D.	Xigen, LLC
Genkinger, Jeanine M., Ph.D.	Columbia University Health Sciences
Georger, Birgit, M.D., Ph.D.	Institut Gustave Roussy
Georgopoulos, Katia Ph.D.	Massachusetts General Hospital
Gerber, Scott A., Ph.D.	Dartmouth College
Gerend, Mary A., Ph.D.	Florida State University
Gervais, Debra A., M.D.	Massachusetts General Hospital
Gewirtz, David A., Ph.D.	Virginia Commonwealth University
Ghosh, Jagadananda, Ph.D.	Henry Ford Health System
Ghosh, Rita, Ph.D.	The University of Texas Health Science Center at San Antonio
Giam, Chou-Zen, Ph.D.	U.S. Uniformed Service University of Health Science
Giardina, Charles A., Ph.D.	University Of Connecticut, Storrs
Gibson, Laura F., Ph.D.	West Virginia University
Gilchrist, Gerald S., M.D.	Mayo Clinic
Gimotty, Phyllis A., Ph.D.	The University of Pennsylvania
Giovino, Gary A., Ph.D.	Roswell Park Cancer Institute
Gius, David, M.D, Ph.D.	Northwestern University, Chicago
Given, Barbara A., Ph.D.	Michigan State University
Glantz, Stanton A., Ph.D.	University of California, San Francisco
Glatstein, Eli J., M.D.	The University of Pennsylvania
Glazer, Robert I., Ph.D.	Georgetown University
Glazier, James A., Ph.D.	Indiana University, Bloomington
Glenn, Beth A., Ph.D.	University of California, Los Angeles
Glickson, Jerry D., Ph.D.	The University of Pennsylvania
Glorioso, Joseph C., Ph.D.	The University of Pittsburgh
Glunde, Kristine, Ph.D.	The Johns Hopkins Hospital
Glynn, Thomas J., Ph.D.	American Cancer Society
Go, Ronald S., M.D.	Gundersen Clinic, Ltd.
Go, Vay Liang W., M.D.	University of California, Los Angeles
Goddard, Katrina A., Ph.D.	Kaiser Foundation Research Institute
Godfrey, Tony E., Ph.D.	University of Rochester
Goldenring, James R., M.D., Ph.D.	Vanderbilt University Medical Center
Goldman, Radoslav, Ph.D.	Georgetown University
Golovlev, Val V., Ph.D.	Sci-Tec, Inc.
Gonzales, Melissa, Ph.D.	University of New Mexico
Gonzalez-Angulo, Ana M., M.D.	The University of Texas MD Anderson Cancer Center
Goodfellow, Paul J., Ph.D.	The Ohio State University
Goodman, Steven L., Ph.D.	Microscopy Innovations, LLC
Goss, Kathleen H., Ph.D.	University of Chicago
Gottschalk, Stephen, M.D.	Baylor College of Medicine
Govindan, Ramaswamy, M.D.	Washington University in St. Louis
Grandis, Jennifer R., M.D.	The University of Pittsburgh
Grando, Sergei A., M.D., Ph.D.	University of California, Irvine
Grann, Victor R., M.D., M.P.H.	Columbia University Health Sciences Campus

Grant, Marcia L., R.N.	City of Hope National Medical Center
Grant, Stephen G., Ph.D.	Nova Southeastern University
Gravekamp, Claudia, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Graves, Kristi D., Ph.D.	Georgetown University
Green, Michael R., M.D., Ph.D.	University of Massachusetts Medical School, Worcester
Greene, Mark I., M.D., Ph.D.	The University of Pennsylvania
Gregg, Jeffrey P., M.D.	University of California, Davis
Gregory, Richard I., Ph.D.	Children's Hospital Boston
Greis, Kenneth D., Ph.D.	University of Cincinnati
Greulich, Heidi, Ph.D.	Harvard University
Griffen, Ann L., D.D.S.	The Ohio State University
Griffin, Kenneth W., Ph.D., M.P.H.	Weill Cornell Medical College of Cornell University
Griffin, Robert J., Ph.D.	University of Arkansas Medical Science, Little Rock
Griffith, Derek M., Ph.D.	Vanderbilt University Medical Center
Grigsby, Perry W., M.D.	Washington University
Groden, Joanna L., Ph.D.	The Ohio State University
Grossman, Douglas, M.D., Ph.D.	The University of Utah
Grufferman, Seymour, M.D., Ph.D., M.P.H.	The University of New Mexico
Grupp, Stephan A., M.D., Ph.D.	Children's Hospital of Philadelphia
Gu, Li-Qun, Ph.D.	University of Missouri, Columbia
Guda, Chittibabu, Ph.D.	University of Nebraska Medical Center
Guidry, Jeffrey J., Ph.D.	Texas A&M University
Gulley, Margaret L., M.D.	The University of North Carolina at Chapel Hill
Gunter, Marc J., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Guo, Nancy L., Ph.D.	West Virginia University
Guo, Peixuan, Ph.D.	University of Kentucky
Gupta, Sanjeev, M.D.	Albert Einstein College of Medicine, Yeshiva University
Gur, David, Ph.D.	The University of Pittsburgh
Gutierrez-Hartmann, Arthur, M.D., Ph.D.	University of Colorado
Gutmann, David H., M.D., Ph.D.	Children's Tumor Foundation

H

Haab, Brian B., Ph.D.	Van Andel Research Institute
Hacker, Miles P., Ph.D.	University of Toledo
Hagedorn, Curt H., M.D.	The University of Utah
Hagensee, Michael E., M.D., Ph.D.	Louisiana State University Health Science Center
Hahn, Klaus M., Ph.D.	The University of North Carolina at Chapel Hill
Hakim, Iman A., M.D., Ph.D., M.P.H.	The University of Arizona
Haley, John D., Ph.D.	OSI Pharmaceuticals, LLC
Hamilton, Thomas A., Ph.D.	Cleveland Clinic Lerner College of Medicine
Hamilton, Thomas C., Ph.D.	Fox Chase Cancer Center
Hammons, George J., Ph.D.	Philander Smith College
Han, Misop, M.D.	The Johns Hopkins University
Han, Sang M., Ph.D.	The University of New Mexico
Hande, Kenneth R., M.D.	Vanderbilt University
Hanis, Craig L., Ph.D.	The University of Texas Health Science Center at Houston
Hankinson, Susan E., M.P.H.	University of Massachusetts, Amherst

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Hannink, Mark, Ph.D.	University of Missouri, Columbia
Hannun, Yusuf A., M.D.	The State University of New York at Stony Brook
Hansen, Marc F., Ph.D.	University of Connecticut School of Medicine
Hansen, Steen H., M.D., Ph.D.	Children's Hospital Boston
Haque, Reina, Ph.D., M.P.H.	Kaiser Foundation Research Institute
Hardman, Wanda E., Ph.D.	Marshall University
Hardy, Jerry L.	Self Employed
Harpole, David H., M.D.	Duke University
Harris, Lyndsay N., M.D.	Case Western Reserve University
Harris, Randall E., M.D., Ph.D.	The Ohio State University
Hartov, Alexander, Ph.D.	Hanover Medical Imaging Project, LLC
Hartshorn, Kevan L., M.D.	Boston Medical Center
Haugen, Bryan R., M.D.	University of Colorado, Denver
Haura, Eric B., M.D.	H. Lee Moffitt Cancer Center & Research Institute
Hawes, Stephen E., Ph.D.	University of Washington
Hawkins, Douglas S., M.D.	Seattle Children's Hospital
Hawley, Sarah, Ph.D.	University of Michigan, Ann Arbor
Hay, Nissim, Ph.D.	University of Illinois at Chicago
Hazlehurst, Lori A., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
He, Lin, Ph.D.	University of California, Berkeley
Heath, James R., Ph.D.	California Institute of Technology
Heber, David, M.D., Ph.D.	University of California, Los Angeles
Hei, Tom K., Ph.D.	Columbia University
Heisterkamp, Nora C., Ph.D.	Children's Hospital Los Angeles
Held, Kathryn D., Ph.D.	Massachusetts General Hospital
Hellstrom, Ingegerd E., M.D., Ph.D.	University of Washington
Hendershot, Linda M., Ph.D.	St. Jude Children's Research Hospital
Henderson, Eric R., Ph.D.	Iowa State University
Henry, Michael D., Ph.D.	The University of Iowa
Hergenrother, Paul, Ph.D.	University of Illinois at Urbana-Champaign
Herlyn, Meenhard F., D.V.M., Sc.D.	The Wistar Institute
Hermiston, Michelle L., M.D., Ph.D.	University of California, San Francisco
Herring, Amy H., Sc.D.	The University of North Carolina at Chapel Hill
Heslop, Helen E., M.D.	Baylor College of Medicine
Heston, Warren D., Ph.D.	Cleveland Clinic Foundation
Hettich, Robert L., Ph.D.	Oak Ridge National Laboratory
Heymach, John V., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Hiebert, Scott W., Ph.D.	Vanderbilt University
Higgins, Paul J., Ph.D.	Albany Medical College
Higuchi, Masahiro, Ph.D.	University of Arkansas Medical Science, Little Rock
Hilakivi-Clarke, Leena A., Ph.D.	Georgetown University
Hill, Elizabeth G., Ph.D.	Medical University of South Carolina
Hillner, Bruce E., M.D.	Virginia Commonwealth University
Hinds, Philip W., Ph.D.	Tufts Medical Center
Hines, Oscar J., M.D.	University of California, Los Angeles
Hiroi, Noboru, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Hlatky, Lynn, Ph.D.	Tufts University School of Medicine
Ho, Gloria, Y.F., Ph.D.	Albert Einstein College of Medicine of Yeshiva University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Ho, Shuk-Mei, Ph.D.	University of Cincinnati
Hochwald, Steven N., M.D.	University of Florida
Hockenbery, David M., M.D.	Fred Hutchinson Cancer Research Center
Hoffman, Aaron E., Ph.D.	Tulane University
Hogan, Michael E., Ph.D.	The University of Arizona
Hoh, Josephine, Ph.D.	Yale University
Hohenlohe, Paul A., Ph.D.	University of Idaho
Hohl, Raymond J., M.D., Ph.D.	The University of Iowa
Holiday, David B., Ph.D.	Research Triangle International
Holl, Mark R., Ph.D.	Arizona State University, Tempe
Hollingsworth, Michael A., Ph.D.	University of Nebraska Medical Center
Holsworth, Daniel, Ph.D.	Stemnext, LLC
Holt, Jeffrey T., M.D.	The Commonwealth Medical College
Hoopes, Jack, D.V.M., Ph.D.	Dartmouth College
Hoque, Ashraful, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Hord, Norman G., Ph.D.	Michigan State University
Horner, Ronnie D., Ph.D.	Duke University
Hortobagyi, Gabriel N., M.D.	The University of Texas MD Anderson Cancer Center
Horvath, Tamas L., D.V.M., Ph.D.	Yale University
Hossack, John A., Ph.D.	University of Virginia
Hostager, Bruce S., Ph.D.	University of Iowa
Houchen, Courtney W., M.D.	The University of Oklahoma Health Sciences Center
Houlette, Judy K, M.A.	Friend for Life Cancer Support Network
Howe, Louise R., Ph.D.	Weill Medical College of Cornell University
Howe, Philip H., Ph.D.	Medical University of South Carolina
Howell, Gillian M., Ph.D.	University of Nebraska Medical Center
Hoyo, Cathrine, Ph.D., M.P.H.	Duke University
Hrkach, Jeff, Ph.D.	Bind Biosciences, Inc.
Hu, Hong-Ming, Ph.D.	Providence Portland Medical Center
Hu, Jennifer J., Ph.D.	University of Miami Miller School of Medicine
Huang, Chuanshu, M.D., Ph.D.	New York University School of Medicine
Huang, Emina Hui-Na, M.D.	University of Florida
Huang, Jie, Sc.D.	Genentech, Inc.
Huang, Peng, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Huang, Songping D., Ph.D.	Kent State University
Huang, Suyun, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Huang, Tim H.-M., Ph.D.	The University of Texas Health Science Center at San Antonio
Huang, Xuefei, Ph.D.	Michigan State University
Hubbard, Karen, Ph.D.	City College of New York
Hughes, John R., M.D.	The University of Vermont and State Agricultural College
Hughes-Halbert, Chanita A., Ph.D.	Medical College of South Carolina
Humm, John L., Ph.D.	Memorial Sloan-Kettering Cancer Center
Hung, Mien-Chie, Ph.D.	The University of Texas MD Anderson Cancer Center
Hung, Paul J., Ph.D.	Cellasic Corporation
Hunter, Jennifer L., Ph.D., R.N.	University of Missouri, Kansas City
Hur, Chin, M.D.	Massachusetts General Hospital
Hursting, Stephen D., Ph.D., M.P.H.	The University of Texas at Austin
Huth, James F., M.D.	The University of Texas Southwestern Medical Center at Dallas

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Hutt-Fletcher, Lindsey M., Ph.D. Louisiana State University, Shreveport
Hyder, D.S. Fahmeed, Ph.D. Yale University
Hyland, Andrew, Ph.D. Roswell Park Cancer Institute
Hyslop, Terry, Ph.D. Thomas Jefferson University

I

Ibrahim, Jennifer K., Ph.D., M.P.H. Temple University
Ibrahim, Joseph G., Ph.D. The University of North Carolina at Chapel Hill
Iczkowski, Kenneth A., M.D. University of Colorado, Denver
Iftimia, Nicusor, Ph.D. Physical Sciences, Inc
Ingle, James N., M.D. Mayo Clinic
Intaglietta, Marcos, Ph.D. University of California, San Diego
Irudayaraj, Joseph M.K., Ph.D. Purdue University, West Lafayette
Issa, Jean-Pierre J., M.D. Temple University
Ittmann, Michael M., M.D., Ph.D. Baylor College of Medicine

J

Jackson, Kristina M., Ph.D. Brown University
Jackson, Twila A., Ph.D. University of Colorado, Denver
Jacobs, Russell E., Ph.D. California Institute of Technology
Jacobson, Brian C., M.D., M.P.H. Boston Medical Center
Jacobson, Geraldine M., M.D. West Virginia University
Jadvar, Hossein, M.D., Ph.D. University of Southern California
Jaiswal, Anil K., Ph.D. University of Maryland, Baltimore
Jay, Daniel G., Ph.D. Tufts University, Boston
Jay, Michael, Ph.D. Nanomed Pharmaceuticals, Inc.
Jeames, Sanford E., D.H.A. University of Massachusetts, Amherst
Jeffery, Elizabeth H., Ph.D. University of Illinois at Urbana-Champaign
Jelinek, Diane F., Ph.D. Mayo Clinic
Jen, Jin, M.D., Ph.D. Mayo Clinic
Jensen, Roy A., M.D. The University of Kansas Medical Center
Jensen, Todd R., Ph.D. Imaging Biometrics, LLC
Jeraj, Robert, Ph.D. University of Wisconsin, Madison
Jeruss, Jacqueline S., M.D., Ph.D. Northwestern University
Jewell, William R., M.D. University of Kansas Medical Center
Jhala, Nirag, M.D. The University of Alabama at Birmingham
Ji, Jiuping J., Ph.D. University of Medicine & Dentistry of New Jersey
Robert Wood Johnson Medical School
Jiang, Feng, M.D., Ph.D. University of Maryland, Baltimore
Jiang, Qing, Ph.D. Purdue University, West Lafayette
Jiang, Shi-Wen, M.D. Mercer University, Macon
Jimeno, Antonio, M.D., Ph.D. University of Colorado, Denver
Jing, Yongkui, Ph.D. Mount Sinai School of Medicine
Johnson, Bruce E., M.D. Dana-Farber Cancer Institute
Johnson, Katherine A., J.D. Virginia Commonwealth University
Johnstone, Peter A.S., M.D. Indiana University-Purdue University, Indianapolis

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Jones, Dean P., Ph.D. Emory University-Winship Cancer Center
Jones, Judy A. Cutaneous Lymphoma Foundation
Jones, Richard J., M.D. The Johns Hopkins University
Jones, Roy, M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Joyal, John L., Ph.D. Brigham and Women's Hospital
Junghans, Richard P., M.D., Ph.D. Roger Williams Hospital
Juon, Hee-Soon, Ph.D. The Johns Hopkins University
Jurisson, Silvia S., Ph.D. University of Missouri, Columbia

K

Kadlubar, Susan A., Ph.D. Roswell Park Cancer Institute
Kalinichenko, Vladimir V., M.D., Ph.D. Children's Hospital Medical Center, Cincinnati
Kalyanaraman, Balaraman, Ph.D. Medical College of Wisconsin
Kameoka, Jun, Ph.D. Texas A&M University
Kaminski, Joseph M., M.D. Mercy Hospital
Kane, Madeleine A., M.D., Ph.D. University of Colorado, Denver
Kane, Susan E., Ph.D. Beckman Research Institute of City of Hope
Kang, Duck-Hee, Ph.D., R.N., F.A.A.N. The University of Texas Health Science
Center at Houston
Kang, Yibin, Ph.D. Princeton University
Kannan, Raghuraman, Ph.D. University of Missouri, Columbia
Kaplan, Alan, Ph.D. University of Kentucky
Kapp, Julie M., Ph.D., M.P.H. University of Missouri, Columbia
Kapur, Ravi, Ph.D. George Mason University
Karczmar, Gregory S., Ph.D. University of Chicago
Karp, Judith, M.D. The Johns Hopkins University
Karp, Seth J., M.D. Vanderbilt University Medical Center
Kaskel, Frederick, M.D., Ph.D. Montefiore Medical Center
Kasper, Susan, Ph.D. University of Cincinnati
Kast, Wijbe R., Ph.D. The University of Southern California
Katiyar, Santosh K., Ph.D. The University of Alabama at Birmingham
Katsanis, Emmanuel, M.D. The University of Arizona
Katti, Kattesh V., Sc.D., Ph.D. University of Missouri, Columbia
Katz, Mira L., Ph.D., M.P.H. The Ohio State University
Katzenellenbogen, John A., Ph.D. University of Illinois at Urbana-Champaign
Kaufman, David G., M.D., Ph.D. The University of North Carolina at Chapel Hill
Kaumaya, Pravin T.P., Ph.D. The Ohio State University
Kaur, Balveen, Ph.D. The Ohio State University
Kaushik-Basu, Neerja, Ph.D. University of Medicine & Dentistry of New Jersey-
Robert Wood Johnson Medical School
Kay, Brian K., Ph.D. University of Illinois at Chicago
Keely, Patricia J., Ph.D. University of Wisconsin, Madison
Kelavkar, Uddhav P., Ph.D. Memorial Health Foundation, Inc.
Keller, Charles, M.D. Oregon Health & Science University
Keller, Evan T., D.V.M., Ph.D., M.P.H. University of Michigan, Ann Arbor
Kelly, Kimberly A., Ph.D. University of Virginia
Kelly, Kimberly M., Ph.D. West Virginia University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Kemp, Christopher, Ph.D.	Fred Hutchinson Cancer Research Center
Kemper, Katherine E., M.B.A.	Global Bridges
Kennedy, Brian K., Ph.D.	Buck Institute for Research on Aging
Keri, Ruth A., Ph.D.	Case Western Reserve University
Kernie, Steven G., M.D.	Columbia University Health Sciences
Kerr, Jacqueline, Ph.D.	University of California, San Diego
Kershaw, Erin E., M.D.	The University of Pittsburgh
Kessel, David, Ph.D.	Wayne State University
Khaled, Annette R., Ph.D.	University of Central Florida
Khalili, Kamel, Ph.D.	Temple University
Khayat, Anita F., Ph.D.	National Childhood Cancer Foundation
Khokhlova, Vera, Ph.D.	University of Washington
Khong, Hung T., M.D.	University of Utah, Huntsman Cancer Institute
Khuri, Fadlo R., M.D.	Emory University
Kieran, Mark W., Ph.D.	Dana-Farber Cancer Institute
Killackey, Maureen A., M.D.	Memorial Sloan-Kettering Cancer Center
Kilpatrick, Michael W., Ph.D.	Ikonisys, Inc.
Kim, Baek, Ph.D.	University of Rochester
Kim, Jae H., M.D., Ph.D.	Henry Ford Hospital
Kim, Seungchan, Ph.D.	Translational Genomics Research Institute
Kim, Youngmee, Ph.D.	University Of Miami
Kimler, Bruce F., Ph.D.	University of Kansas Medical Center
Kingston, David G.I., Ph.D.	Virginia Polytechnic Institute & State University
Kinter, Michael, Ph.D.	Oklahoma Medical Research Foundation
Kipreos, Edward T., Ph.D.	University of Georgia
Kirby, Brian J., Ph.D.	Cornell University
Kirk, James F., Ph.D.	Nanotherapeutics, Inc.
Kirkness, Ewen, Ph.D.	J. Craig Venter Institute
Kirschner, Marvin A., M.D.	University of Medicine & Dentistry of New Jersey- New Jersey Medical School
Kirshner, Julia Ph.D.	Purdue University, West Lafayette
Kitchell, Barbara E., D.V.M., Ph.D.	Michigan State University
Klassen, Ann C., Ph.D.	Drexel University
Klaunig, James E., Ph.D.	Indiana University, Bloomington
Klein, Alison P., Ph.D.	The Johns Hopkins University
Klein, Jonathan D., M.D., M.P.H.	American Academy of Pediatrics
Klein, Robert J., Ph.D.	Memorial Sloan-Kettering Cancer Center
Kleiner-Hancock, Heather E., Ph.D.	Louisiana State University Health Science Center, Shreveport
Klingelutz, Aloysius J., Ph.D.	University of Iowa
Klosky, James, Ph.D.	St. Jude Children's Research Hospital
Kluger, Harriet M., M.D.	Yale University
Knopp, Michael V., M.D., Ph.D.	The Ohio State University
Knowles, David W., Ph.D.	Lawrence Berkeley National Laboratory
Knudsen, Beatrice S., M.D., Ph.D.	Cedars-Sinai Medical Center
Knudsen, Karen E., Ph.D.	Thomas Jefferson University
Knutson, Keith L., Ph.D.	Mayo Clinic
Kobayashi, Susumu, M.D., Ph.D.	Beth Israel Deaconess Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Koh, James, Ph.D.Duke University
Kohman, Leslie J., M.D. The State University of New York, Health Science Center
Komarova, Natalia L., Ph.D. University of California, Irvine
Konety, Badrinath R., M.D.University of Minnesota
Kopelman, Raoul, Ph.D.University of Michigan, Ann Arbor
Koper, Olga B., Ph.D. Battelle Memorial Institute
Korc, Murray, M.D. Indiana University-Purdue University, Indianapolis
Kotyck, John J., Ph.D. Washington University in St. Louis
Koul, Hari K., Ph.D.University of Colorado, Denver
Koumenis, Constantinos, Ph.D.The University of Pennsylvania
Kousoulas, Konstantin G., Ph.D. Louisiana State University
Koutcher, Jason A., M.D., Ph.D. Memorial Sloan-Kettering Cancer Center
Kowalski, Jeanne, Ph.D. Emory University
Krasnykh, Victor, Ph.D.The University of Texas MD Anderson Cancer Center
Kraus, Manfred, Ph.D.Merck Research Laboratories
Kresty, Laura A., Ph.D. University of Miami Miller School of Medicine
Kreuter, Matthew W., Ph.D., M.P.H. Washington University in St. Louis
Krishnaswamy, Venkataramanan, Ph.D. Dartmouth College
Krizman, David B., Ph.D. Expression Pathology, Inc.
Krohn, Kenneth A., Ph.D.University of Washington
Krolewski, John J., M.D., Ph.D. University of Rochester
Kron, Stephen J., M.D., Ph.D. University of Chicago
Krupenko, Sergey A., Ph.D. Medical University of South Carolina
Krupinski, Elizabeth A., Ph.D. The University of Arizona
Kruse, Carol A., Ph.D. University of California, Los Angeles
Kufe, Donald W., M.D. Dana-Farber Cancer Institute
Kulesz-Martin, Molly F., Ph.D. Oregon Health & Science University
Kuller, Lewis H., M.D., M.P.H. The University of Pittsburgh
Kumar, Addanki P., Ph.D.The University of Texas Health Science Center at San Antonio
Kumar, Challa S., Ph.D. Louisiana State University and Agricultural & Mechanical College
Kun, Larry E., M.D.St. Jude Children's Research Hospital
Kung, Hsing-Jien, Ph.D. University of California, Davis
Kunicki, Thomas J., Ph.D. Children's Hospital of Orange County
Kuo, Calvin J., M.D., Ph.D. Stanford University
Kuo, Marcus T., Ph.D.The University of Texas MD Anderson Cancer Center
Kuppusamy, Periannan, Ph.D. The Ohio State University Medical Center
Kushi, Lawrence H., Sc.D. Kaiser Foundation Research Institute
Kyprianou, Natasha, Ph.D. University of Kentucky

L

Lacey, James V., M.P.H. Beckman Research Institute of City of Hope
Lacey, Michelle R., Ph.D. Tulane University
Lad, Thomas, M.D. Hektoen Institute for Medical Research, LLC
Laderoute, Keith R., Ph.D. Northwestern University
Ladisch, Stephan, M.D. Children's National Medical Center
LaFramboise, William A., Ph.D. The University of Pittsburgh
Laird, Beverly L., Ph.D. American Cancer Society

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Lam, Wan L., Ph.D.	British Columbia Cancer Research Centre
Lambert, Paul F., Ph.D.	University of Wisconsin, Madison
Landsittel, Douglas P., Ph.D.	The University of Pittsburgh
Lane, Timothy F., Ph.D.	University of California, Los Angeles
Languino, Lucia R., Ph.D.	Thomas Jefferson University
Lanier, Keith S., M.D.	Providence Portland Medical Center
Lannigan, Deborah, Ph.D.	University of Virginia
Lantz, Paula M., Ph.D.	George Washington University
Larson, Andrew C., Ph.D.	Northwestern University
Larson, Richard S., M.D., Ph.D.	The University of New Mexico Health Sciences Center
Lassman, Michael E., Ph.D.	Merck and Company
Lattime, Edmund C., Ph.D.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Lauffenburger, Douglas A., Ph.D.	Massachusetts Institute of Technology
Lawrence, David A., Ph.D.	Wadsworth Center
Lebovitz, Russell M., M.D., Ph.D.	Marval Biosciences, Inc.
Lechuga, Julia, Ph.D.	Cornell University
Lee, Amy S., Ph.D.	The University of Southern California
Lee, Cheng S., Ph.D.	University of Maryland, College Park
Lee, Chung, Ph.D.	University of California, Irvine
Lee, Francis Y.I., M.D., Ph.D.	Columbia University
Lee, Ji-Hyun, Dr.P.H.	H. Lee Moffitt Cancer Center & Research Institute
Lee, Ray F., Ph.D.	Princeton University
Lee, Robert J., Ph.D.	The Ohio State University
Lee, Stephen, Ph.D.	University of Ottawa
Lehman, John M., Ph.D.	East Carolina University
Lehrman, Mark, Ph.D.	The University of Texas Southwestern Medical Center
Leiby, Benjamin, Ph.D.	Thomas Jefferson University
Lelievre, Sophie A., D.V.M., Ph.D.	Purdue University, West Lafayette
Lemmon, Mark A., Ph.D.	The University of Pennsylvania
Lengerich, Eugene J., V.M.D.	The Pennsylvania State University, Milton S. Hershey Medical Center
Leong, Stanley P.L., M.D.	University of California, San Francisco
Lerner, Seth P., M.D.	Baylor College of Medicine
Lesniak, Maciej S., M.D.	The University of Chicago
Levchenko, Andre, Ph.D.	The Johns Hopkins University
Levenson, Richard M., M.D.	University of California, Davis
Levin, Albert M., Ph.D., M.P.H.	Henry Ford Health System
Levin, Ellis R., M.D.	University of California, Irvine
Levy, Laura S., Ph.D.	Tulane University School of Medicine
Lewis, Brian C., Ph.D.	University of Massachusetts Medical School, Worcester
Lewis, Jane, Dr.P.H.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Li, Ellen, M.D., Ph.D.	The State University of New York at Stony Brook
Li, Jia, Ph.D.	Henry Ford Health System
Li, Lei, Ph.D.	The University of Texas MD Anderson Cancer Center
Li, Shaoguang, M.D., Ph.D.	University of Massachusetts Medical School, Worcester
Li, Shulin, Ph.D.	The University of Texas MD Anderson Cancer Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Li, Xiaoxia, Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Li, Yan Chun, Ph.D.	The University of Chicago
Li, Yueming, Ph.D.	Memorial Sloan-Kettering Cancer Center
Li, Zihai, M.D., Ph.D.	Medical University of South Carolina
Liang, Jerome Z., Ph.D.	The State University of New York
Liau, Linda M., M.D., Ph.D.	University of California, Los Angeles
Libermann, Towia A., Ph.D.	Beth Israel Deaconess Medical Center
Liby, Karen T., Ph.D.	Dartmouth College
Licht, Jonathan D., M.D.	Northwestern University Feinberg School of Medicine
Lim, Unhee, Ph.D.	University of Hawaii Cancer Center
Lin, Anning A., M.D., Ph.D.	University of Chicago
Lin, Henry J., M.D.	University of California, Los Angeles
Lin, Jennifer H., Ph.D.	Brigham and Women's Hospital
Lin, Shiaw-Yih, Ph.D.	The University of Texas MD Anderson Medical Center
Lin, Xihong, Ph.D.	Harvard School of Public Health
Lin, Yan, Ph.D.	The University of Pittsburgh
Lin, Yong, M.D., Ph.D.	Lovelace Respiratory Research Institute
Lin, Young C., D.V.M., Ph.D.	The Ohio State University
Lipkin, Steven M., M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Listowsky, Irving, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Little, Julian, Ph.D.	University of Ottawa
Liu, Chen, M.D., Ph.D.	University of Florida
Liu, Chunming, Ph.D.	University of Kentucky
Liu, Hong, Ph.D.	University of Oklahoma
Liu, Yang, Ph.D.	University of Michigan
Livingston, David M., M.D.	Dana-Farber Cancer Institute
Lo, Roger S., M.D., Ph.D.	University of California, Los Angeles
Lochhead, Michael J., Ph.D.	MBio Diagnostics, Inc.
Locker, Joseph D., M.D., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Loh, Stewart N., Ph.D.	The State University of New York, Upstate Medical University
Lokeshwar, Bal L., Ph.D.	University of Miami Miller School of Medicine
Lokeshwar, Vinata B., Ph.D.	University of Miami
Lokshin, Anna E., Ph.D.	The University of Pittsburgh
London, Cheryl A., D.V.M., Ph.D.	The Ohio State University
London, Jack W., Ph.D.	Thomas Jefferson University
Long, Jirong, Ph.D.	Vanderbilt University
Lorusso, Patricia M., D.O.	Wayne State University
Lossos, Izidore S., M.D.	University of Miami Miller School of Medicine
Lothstein, Leonard, Ph.D.	The University of Tennessee Health Science Center
Low, Daniel A., Ph.D.	University of California, Los Angeles
Lowenstein, Pedro R., M.D., Ph.D.	University of Michigan, Ann Arbor
Lowery, Robert G., Ph.D.	BellBrooks Labs
Lowy, Andrew M., M.D.	University of California, San Diego
Lu, Karen H., M.D.	The University of Texas MD Anderson Cancer Center
Lu, Yi, Ph.D.	University of Tennessee Health Science Center
Lu, Zheng-Rong, Ph.D.	Case Western Reserve University
Lubman, David M., Ph.D.	University of Michigan, Ann Arbor

Luebke, Kevin J., Ph.D. The University of Texas Southwestern Medical Center
 Luo, Jun-Li, M.D. Scripps Research Institute
 Lurie, Galina, M.D. University of Hawaii Cancer Center

M

Ma, Chang-Ming C., Ph.D. Fox Chase Cancer Center
 Ma, Grace X., Ph.D. Temple University
 Ma, Jing, M.D., Ph.D. Brigham and Women’s Hospital
 Ma, Wen Wee, M.D. Roswell Park Cancer Institute
 Macleod, Kay F., Ph.D. The University of Chicago
 Madden, Kelley S., Ph.D. University of Rochester
 Madsen, Mark T., Ph.D. The University of Iowa
 Mahalingam, Meera, M.D., Ph.D. Boston University Medical Campus
 Mahmud, Salaheddin, M.D., Ph.D. University of Manitoba
 Mahvi, David M., M.D. Northwestern University
 Mai, Volker, Ph.D., M.P.H. University of Florida
 Maier, Stephan E., M.D., Ph.D. Harvard Medical School
 Maizels, Nancy, Ph.D. Yale University
 Maki, Wusi, Ph.D. Integrated Molecular Sensors, Inc.
 Malek, Sami N., M.D. University of Michigan, Ann Arbor
 Malemud, Charles J., Ph.D. Case Western Reserve University
 Malin, Jennifer L., M.D., Ph.D. University of California, Los Angeles
 Malkas, Linda H., Ph.D. Beckman Research Institute of City of Hope
 Mallik, Sanku, Ph.D. North Dakota State University
 Maluccio, Mary A., M.D., M.P.H. Indiana University-Purdue University, Indianapolis
 Mandelblatt, Jeanne, M.D., M.P.H. Georgetown University
 Mandrekar, Sumithra J., Ph.D. Mayo Clinic
 Manfredi, James J., Ph.D. Mount Sinai School of Medicine
 Mani, Sridhar, M.D. Albert Einstein College of Medicine of Yeshiva University
 Manjili, Masoud H., D.V.M., Ph.D. Virginia Commonwealth University
 Manne, Upender, Ph.D. The University of Alabama at Birmingham
 Mansbridge, Jonathan N., Ph.D. Advanced Tissue Sciences, Inc.
 Mao, Li, M.D. University of Maryland, Baltimore
 Mapes, James P., Ph.D. Rules-Based Medicine, Inc.
 Marcucci, Guido, M.D. The Ohio State University
 Markovic, Svetomir N., M.D., Ph.D. Mayo Clinic
 Marks, Jeffrey R., Ph.D. Duke University
 Marquez-Magana, Leticia M., Ph.D. San Francisco State University
 Martin, George R., Ph.D. Fibrogen, Inc.
 Martinez, Jesse D., Ph.D. The University of Arizona Cancer Center
 Maskarinec, Gertraud, M.D., Ph.D., M.P.H. The University of Hawaii at Manoa
 Mason, Christopher E., Ph.D. Weill Cornell Medical College of Cornell University
 Mason, Jeffrey T., Ph.D. Armed Forces Institute of Pathology
 Mason, Ralph P., Ph.D. The University of Texas Southwestern Medical Center
 Mathews, Herbert L., Ph.D. Loyola University
 Mathis, J. Michael, Ph.D. Louisiana State University, Shreveport
 Mattoussi, Hedi, Ph.D. Naval Research Laboratory

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Mawlawi, Osama, Ph.D.	The University of Texas MD Anderson Cancer Center
Mayer, Bruce J., Ph.D.	University of Connecticut Health Center
Mayo, Kevin H., Ph.D.	Actipep Biotechnology, Inc.
McAlpine, Shelli R., Ph.D.	San Diego State University
McCabe, George P., Ph.D.	Purdue University, West Lafayette
McCarthy, James B., Ph.D.	University of Minnesota, Twin Cities
McCarty, Owen J., Ph.D.	Oregon Health and Science University
McConkey, David J., Ph.D.	The University of Texas MD Anderson Cancer Center
McCormick, J. Justin, Ph.D.	Michigan State University
McCrary, Megan A., Ph.D.	Bastyr University
McDaid, Hayley M., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
McDonald, Brenna C., Psy.D.	Indiana University-Purdue University, Indianapolis
McGrath, Michael S., M.D., Ph.D.	Pathologica, LLC
McInnes, Campbell, Ph.D.	University of South Carolina
McIntyre, James O., Ph.D.	Vanderbilt University
McKinley, Randolph L., Ph.D.	Zumatek, Inc.
McLaren, Christine E., Ph.D.	University of California, Irvine
McMahon, Steven B., Ph.D.	Thomas Jefferson University
McNichols, Roger J., Ph.D.	Biotex, Inc.
Mecozzi, Sandro, Ph.D.	University of Wisconsin, Madison
Mehta, Anand S., Ph.D.	Drexel University College of Medicine
Melmed Shlomo, M.D.	Cedar Sinai Medical Research Institute
Mendell, Joshua T., M.D., Ph.D.	The University of Texas Southwestern Medical Center
Meneses, Patricio I., Ph.D.	Fordham University
Merad, Miriam, M.D., Ph.D.	Mount Sinai School of Medicine
Mermelstein, Robin J., Ph.D.	University of Illinois at Chicago
Mesri, Enrique A., Ph.D.	University of Miami School of Medicine
Messersmith, Wells A., M.D.	University of Colorado, Denver
Meyer, Charles R., Ph.D.	University of Michigan, Ann Arbor
Meyerhardt, Jeffrey A., M.D., M.P.H.	Dana-Farber Cancer Institute
Meyers, Craig M., Ph.D.	The Pennsylvania State University, Milton S. Hershey Medical Center
Meyn, Raymond E., Ph.D.	The University of Texas MD Anderson Cancer Center
Meyskens, Frank L., M.D.	University of California, Irvine
Meza, Jane, Ph.D.	University of Nebraska Medical Center
Michalek, Arthur M., Ph.D.	Roswell Park Cancer Institute
Mickey, Ruth, Ph.D., M.P.H.	The University of Vermont and State Agricultural College
Mignatti, Paolo, M.D.	New York University School of Medicine
Mikkelsen, Ross B., Ph.D.	Virginia Commonwealth University
Mikkelsen, Tom, M.D.	Henry Ford Health System
Miller, Carl W., Ph.D.	Cedars-Sinai Medical Center
Miller, Jeffrey S., M.D.	University of Minnesota
Miller-Halegoua, Suzanne M., Ph.D.	Fox Chase Cancer Center
Minchinton, Andrew I., Ph.D.	British Columbia Cancer Agency
Minderman, Hans, Ph.D.	Roswell Park Cancer Institute
Minn, Andy J., M.D., Ph.D.	The University of Pennsylvania
Mishra, Lopa, M.D.	The University of Texas MD Anderson Cancer Center
Mishra, Shiraz I., Ph.D.	The University of New Mexico Health Sciences Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Mitra, Robi D., Ph.D.	Washington University in St. Louis
Mitra, Sankar, Ph.D.	The University of Texas Medical Branch at Galveston
Mivechi, Nahid F., Ph.D.	Georgia Health Sciences University
Miyaoka, Robert S., Ph.D.	University of Washington school of Medicine
Modeste, Naomi N., D.P.H.	Loma Linda University
Mohapatra, Shyam S., Ph.D.	University of South Florida
Moley, Jeffrey F., M.D.	Washington University in St. Louis
Montaner, Silvia V., Ph.D., M.P.H.	University of Maryland, Baltimore
Mooberry, Susan L., Ph.D.	The University of Texas Health Science Center at San Antonio
Moore, Roland S., Ph.D.	Pacific Institute for Research & Evaluation
Moore, Stephen C., Ph.D.	Brigham and Women's Hospital
Moorthy, Bhagavatula, Ph.D.	Baylor College of Medicine
Morachis, Jose M., Ph.D.	Nanosort, Inc.
Morgan, Lee R., M.D., Ph.D.	Tigris Pharmaceuticals, Inc.
Mori, Motomi, Ph.D.	Oregon Health & Science University
Morin, Patrice J., Ph.D.	National Institute on Aging
Moritz, Robert L., Ph.D.	Institute for Systems Biology
Morris, David R., Ph.D.	University of Washington
Morris, Jeffrey S., Ph.D.	The University of Texas MD Anderson Cancer Center
Morton, Kathryn A., M.D.	The University of Utah
Moses, Ashlee V., Ph.D.	Oregon Health & Science University
Moskal, Joseph R., Ph.D.	Northwestern University
Motamedi, Massoud, Ph.D.	The University of Texas Medical Branch at Galveston
Mountz, James M., M.D., Ph.D.	The University of Pittsburgh
Moynihan, Jan A., Ph.D.	University of Rochester Medical Center
Moysich, Kirsten B., Ph.D.	Roswell Park Cancer Institute
Mucci, Lorelei, Sc.D.	Harvard School of Public Health
Muddiman, David C., Ph.D.	North Carolina State University, Raleigh
Mukherjee, Bhramar, Ph.D.	University of Michigan, Ann Arbor
Mukherjee, Priyabrata, Ph.D.	Mayo Clinic
Mukherji, Bijay, M.D.	University of Connecticut School of Medicine
Mukhtar, Hasan, Ph.D.	University of Wisconsin, Madison
Mullan, Patricia B., Ph.D.	University of Michigan
Mullen, Craig A., M.D., Ph.D.	University of Rochester
Muller, William, Ph.D.	McGill University
Mullersman, Jerald E., M.D., Ph.D., M.P.H.	East Tennessee State University
Munger, Karl, Ph.D.	Brigham and Women's Hospital
Munn, Lance L. Ph.D.	Massachusetts General Hospital
Munshi, Nikhil C., M.D.	Dana-Farber Cancer Institute
Munster, Pamela N., M.D.	University of California, San Francisco
Murff, Harvey J., M.D.	Vanderbilt University
Murnane, John P., Ph.D.	University of California, San Francisco
Murphy, Kate	C3: Colorectal Cancer Coalition
Murphy, William J., Ph.D.	University of Nevada, Reno
Murray, Nicole R., Ph.D.	Mayo Clinic Cancer Center
Murtaugh, Lewis C., Ph.D.	The University of Utah
Muschen, Markus, M.D.	University of California, San Francisco

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Musselman, Dominique L., M.D. University of Miami Miller School of Medicine
Mustian, Karen M., Ph.D., M.P.H. University of Rochester
Myers, Jeffrey N., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Myers, Steven R., Ph.D. University of Louisville

N

Nagar, Swati, Ph.D. Temple University
Nakshatri, Harikrishna, Ph.D. Indiana University-Purdue University, Indianapolis
Nana-Sinkam, Serge P., M.D. The Ohio State University
Nattinger, Ann B., M.D., M.P.H. Medical College of Wisconsin
Naugler, Christopher T., M.D. University of Calgary
Navarro, Ana M., Ph.D. University of California, San Diego
Navone, Nora M., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Needham, David, Ph.D. Duke University
Nelson, James C., Ph.D. Inanovate, Inc.
Nelson, Peter S., M.D. Fred Hutchinson Cancer Research Center
Nelson, Randall W., Ph.D. Arizona State University, Tempe
Nelson, William G., M.D., Ph.D. The Johns Hopkins University
Nemenoff, Raphael A., Ph.D. University of Colorado, Denver
Nemesure, Barbara, Ph.D. Stone Brook University Medical Center
Nephew, Kenneth P., Ph.D. Indiana University-Purdue University, Indianapolis
Nettles, Kendall W., Ph.D. Scripps Research Institute
Neuhouser, Marian L., Ph.D. Fred Hutchinson Cancer Research Center
Neumann, Carola A., M.D. Medical University of South Carolina
Neuwelt, Edward A., M.D. Vanderbilt University
Newburger, Peter E., M.D. University of Massachusetts Medical School
Newman, Edward M., Ph.D. Beckman Research Institute of City of Hope
Ng, Hanna, Ph.D. SRI International
Nghiem, Paul, M.D., Ph.D. Fred Hutchinson Cancer Research Center
Niaura, Raymond S., Ph.D. American Legacy Foundation
Nichols, Craig R., M.D. Oregon Health & Science University
Nickoloff, Jac A., Ph.D. Colorado State University, Fort Collins
Nicosia, Nancy, Ph.D. Rand Corporation
Nicosia, Santo V., M.D. University of South Florida
Niculescu, Mihai D., M.D., Ph.D. The University of North Carolina at Chapel Hill
Niedernhofer, Laura J., M.D., Ph.D. The University of Pittsburgh
Nikiforov, Mikhail, Ph.D. Roswell Park Cancer Institute
Ning, Ruola, Ph.D. University of Rochester
Nishimura, Michael I., Ph.D. Loyola University, Chicago
Nordstrom, Jeffrey L., M.D., Ph.D. Macrogenics, Inc.
Normolle, Daniel P., Ph.D. The University of Pittsburgh
Norris, James S., Ph.D. Medical University of South Carolina
Noy, Ariela, M.D., Ph.D. Memorial Sloan-Kettering Cancer Center
Nunn, Adrian D., Ph.D. Bracco Research USA, Inc.
Nunney, Leonard, Ph.D. University of California, Riverside
Nyati, Mukesh K., Ph.D. University of Michigan, Ann Arbor

O

O'Doherty, George A., Ph.D. Northeastern University
 O'Donnell, Joseph F., M.D. Dartmouth College
 O'Keefe, Stephen J.D., M.D., M.S.C. The University of Pittsburgh Medical Center
 O'Neill, Brian P., M.D. Mayo Clinic
 O'Reilly, Richard J., M.D. Memorial Sloan-Kettering Cancer Center
 Oberszyn, Tatiana M., Ph.D. The Ohio State University
 Obuchowski, Nancy, Ph.D. Cleveland Clinic Lerner College of Medicine of
 Case Western Reserve University
 Odunsi, Kunle O., M.D., Ph.D. Roswell Park Cancer Institute
 Oesterreich, Steffi, Ph.D. The University of Pittsburgh
 Oh, William K., M.D. Mount Sinai School of Medicine
 Ojima, Iwao, Ph.D. The State University of New York at Stony Brook
 Okada, Craig Y., M.D., Ph.D. Oregon Health & Science University
 Okunieff, Paul, M.D. University of Florida
 Oliver, Janet M., Ph.D. The University of New Mexico Health Sciences Center
 Olson, Karen, M.A. BalMed Group, LLC
 Oltz, Eugene M., Ph.D. Washington University School of Medicine
 Onar-Thomas, Arzu, Ph.D. St. Jude Children's Research Hospital
 Ondrey, Frank G., M.D., Ph.D. University of Minnesota, Twin Cities
 Orjuela, Manuela A., M.D. Columbia University
 Osheroff, Neil, Ph.D. Vanderbilt University
 Ostrowski, Michael C., Ph.D. The Ohio State University
 Ota, David M., M.D. Duke University
 Ouchi, Toru, Ph.D. Roswell Park Cancer Institute
 Oyajobi, Babatunde O., M.D., Ph.D. The University of Texas Health Science Center
 at San Antonio
 Ozbun, Michelle A., Ph.D. University of New Mexico

P

Paciorek, Christopher J., Ph.D. University of California, Berkeley
 Padilla, Geraldine V., Ph.D. University of California, San Francisco
 Pagoto, Sherry L., Ph.D. University of Massachusetts Medical School
 Pajonk, Frank, M.D., Ph.D. University of California, Los Angeles
 Palecek, Sean P., Ph.D. University of Wisconsin, Madison
 Paliwal, Bhudatt R., Ph.D. University of Wisconsin, Madison
 Palmer, J. Lynn, Ph.D. The University of Texas MD Anderson Cancer Center
 Pandey, Siyaram, Ph.D. University of Windsor
 Pandita, Tej K., Ph.D. The University of Texas Southwestern Medical Center
 Panin, Vladislav M., Ph.D. Texas A&M University
 Pankratz, V. Shane, Ph.D. Mayo Clinic
 Pannell, Lewis K., Ph.D. University of South Alabama
 Panyam, Jayanth, Ph.D. University of Minnesota
 Papavasiliou, F. Nina, Ph.D. Rockefeller University
 Papisov, Mikhail I., Ph.D. Massachusetts General Hospital
 Parent, Richard A., Ph.D. Consultox, Ltd.

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Park, John K., M.D., Ph.D.	National Institute of Neurological Disorders and Stroke
Park, Peter J., Ph.D.	Harvard University
Parsons, Barbara L. Ph.D.	Food and Drug Administration
Pasqualucci, Laura, M.D.	Columbia University Health Sciences
Patel, Nilesh, Ph.D.	Oakland University
Paterson, Yvonne J., Ph.D.	The University of Pennsylvania
Patterson, David, Ph.D.	University of Denver
Pearman, Timothy P., Ph.D.	Northwestern University
Pearse, Roger N., M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Pe'er, Dana, Ph.D.	Columbia University
Peehl, Donna M., Ph.D.	Stanford University School of Medicine
Pei, Zhiheng, M.D., Ph.D.	New York University School of Medicine
Pelizzari, Charles A., Ph.D.	The University of Chicago
Pelletier, Glenn J., M.D.	Self Employed
Pence, Barbara C., Ph.D.	Texas Tech University Health Science Center
Penichet, Manuel L., M.D., Ph.D.	University of California, Los Angeles
Perelman, Lev T., Ph.D.	Beth Israel Deaconess Medical Center
Perez-Soler, Roman, M.D.	Albert Einstein College of Medicine of Yeshiva University
Perkins, Archibald S., M.D., Ph.D.	University of Rochester
Perrotti, Danilo, M.D., Ph.D.	The Ohio State University
Petasis, Nicos A., Ph.D.	University of Southern California
Peter, Marcus E., Ph.D.	Robert H. Lurie Comprehensive Cancer Center
Peters, Edward S., D.M.D., Sc.D.	Louisiana State University Health Sciences Center
Petrocca, Fabio, M.D.	Harvard University School of Medicine
Petroni, Gina R., Ph.D.	University of Virginia
Petros, John A., M.D.	Emory University
Petty, Elizabeth M., M.D.	University of Michigan, Ann Arbor
Pfeifer, Gerd P., Ph.D.	Beckman Research Institute of City of Hope
Philip, Philip A., M.D., Ph.D.	Wayne State University
Phinney, Karen, Ph.D.	National Institute of Standards & Technology
Piazza, Gary A., Ph.D.	University of South Alabama
Pickworth, Wallace B., Ph.D.	Battelle Memorial Institute
Pierce, John P., Ph.D.	University of California, San Diego
Pignone, Michael P., M.D., M.P.H.	The University of North Carolina at Chapel Hill
Pili, Roberto, M.D.	Roswell Park Cancer Institute
Pinard, Courtney A., Ph.D.	University of Nebraska Medical Center
Pinilla, Javier, M.D., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Piper, Megan, Ph.D.	University of Wisconsin, Madison
Pirisi-Creek, Lucia A., M.D.	University of South Carolina, Columbia
Pishvaian, Michael J., M.D., Ph.D.	Georgetown University
Pizer, Stephen M., Ph.D.	The University of North Carolina at Chapel Hill
Plas, David R., Ph.D.	University of Cincinnati
Platanias, Leonidas C., M.D., Ph.D.	Northwestern University
Plate, Janet M.D., Ph.D.	Rush University Medical Center
Plymate, Stephen R., M.D.	University of Washington School of Medicine
Poisson, Laila M., Ph.D.	Henry Ford Health System
Pollak, Michael N., M.D.	McGill University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Polyak, Stephen J., Ph.D.University of Washington
Polychronakos, Constantin, M.D.McGill University
Pop, Mihai, Ph.D.University of Maryland, College Park
Porter, Peggy L., M.D.Fred Hutchinson Cancer Research Center
Potter, David A., M.D., Ph.D.University of Minnesota School of Medicine
Poynter, Jenny N., Ph.D., M.P.H.University of Minnesota, Twin Cities
Price, Nathan D., Ph.D.Institute for Systems Biology
Price, Ronald R., Ph.D.Vanderbilt University
Prins, Robert M., Ph.D.University of California, Los Angeles
Pulsipher, Michael A., M.D.The University of Utah

Q

Qian, Steven Y., Ph.D.North Dakota State University
Qin, Lidong, Ph.D.Methodist Hospital Research Institute
Quackenbush, John, Ph.D.Dana-Farber Cancer Institute
Quaranta, Vito, M.D.Vanderbilt University
Quesenberry, Peter J., M.D.Rhode Island Hospital
Quintiliani, Lisa, Ph.D.Boston Medical Center

R

Raab-Traub, Nancy J., Ph.D.The University of North Carolina at Chapel Hill
Raber, Jacob, Ph.D.J. David Gladstone Institutes
Rabius, Vance, Ph.D.The University of Texas MD Anderson Cancer Center
Radhakrishnan, Ravi, Ph.D.The University of Pennsylvania
Raffel, Corey, M.D., Ph.D.The Ohio State University
Raftery, Daniel, Ph.D.University of Washington
Ragin, Camille C., Ph.D., M.P.H.Institute for Cancer Research
Raich, Peter C., M.D.West Virginia University
Rajasekaran, Ayyappan K., Ph.D.A.I. Dupont Hospital for Children
Ramalingam, Tirunelveli, Ph.D.OCT Medical Imaging, Inc.
Ramchandran, Ramani, Ph.D.Medical College of Wisconsin
Ramesh, Aramandla, Ph.D.Meharry Medical College
Ramesh, Rajagopal, Ph.D.University of Oklahoma Health Science Center
Rampersaud, Arfaan, Ph.D.Columbus Nanoworks, Inc.
Rangaramanujam, Kannan, Ph.D.The Johns Hopkins University
Rangnekar, Vivek M., Ph.D.University of Kentucky
Ransom, Sean, Ph.D.Tulane University
Rao, Chinthalapally V., Ph.D.University of Oklahoma Health Sciences Center
Rao, Jasti S., Ph.D.University of Illinois at Chicago
Rao, J. Sunil, Ph.D.University of Miami Miller School of Medicine
Raphael, Benjamin, Ph.D.Brown University
Rauscher, Frank J. III, Ph.D.The Wistar Institute
Ray, Ranjit, Ph.D.Saint Louis University
Ray, Ratna B., Ph.D.Saint Louis University
Raylman, Raymond R., Ph.D.West Virginia University
Reader, Steven, Ph.D.University of South Florida

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Reaman, Gregory H., M.D.	National Childhood Cancer Foundation
Reder, Jake, Ph.D.	Celdara Medical, LLC
Redmond, Carol K., Sc.D., Ph.D.	The University of Pittsburgh
Reed, John C., M.D., Ph.D.	The Burnham Institute
Reeves, Anthony P., Ph.D.	Cornell University
Rehemtulla, Alnawaz, Ph.D.	University of Michigan, Ann Arbor
Reich, Daniel H., Ph.D.	The Johns Hopkins University
Reis, Isildinha R., Dr.PH.	University of Miami Miller School of Medicine
Rejniak, Katarzyna A., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Renne, Rolf F., Ph.D.	University of Florida
Reshef, Ran, M.D.	Hospital of The University of Pennsylvania
Revskoy, Sergei, M.D., Ph.D.	Northwestern University
Revzin, Alexander, Ph.D.	University of California, Davis
Rhodus, Nelson L., D.M.D.	University of Minnesota
Rice, Virginia H., Ph.D.	Wayne State University
Rich, Jeremy N., M.D.	Cleveland Clinic
Richards, Nigel G., Ph.D.	Indiana University-Purdue University, Indianapolis
Richards-Kortum, Rebecca R., Ph.D.	Rice University
Richmond, Ann, Ph.D.	Vanderbilt University
Ridner, Sheila H., Ph.D.	Vanderbilt University School of Nursing
Rigas, Basil, Sc.D., M.D.	The State University of New York at Stony Brook
Riggin, Ralph M., Ph.D.	Marcadia Biotech, Inc.
Riggins, Rebecca B., Ph.D.	Lombardi Comprehensive Cancer Center
Rigual, Nestor R., M.D.	Roswell Park Cancer Institute
Rippy, Daniel S., Ph.D.	Ripplecreek Partners, Inc.
Risinger, John, Ph.D.	Michigan State University
Ritter, Mark A., M.D., Ph.D.	University of Wisconsin, Madison
Roberson, Noma L., Ph.D.	Roberson Consulting International
Roberts, John D., M.D.	Virginia Commonwealth University
Roberts, Susan B., Ph.D.	Tufts University, Boston
Robertson, Fredika M., Ph.D.	The University of Texas MD Anderson Cancer Center
Robertson, Keith D., Ph.D.	Georgia Health Sciences University
Robertson, Michael J., M.D.	Indiana University-Purdue University, Indianapolis
Rodeck, Ulrich, M.D., Ph.D.	Thomas Jefferson University
Rodgers, William H., M.D., Ph.D.	Lenox Hill Hospital
Rodland, Karin D., Ph.D.	Battelle Memorial Institute
Rogatko, Andre, Ph.D.	Cedars-Sinai Medical Center
Rogers, Arlin B., D.V.M., Ph.D.	The University of North Carolina at Chapel Hill
Rogers, Laura Q., M.D.	Southern Illinois University
Rohr, Jurgen T., Ph.D.	University of Kentucky
Rom, William N., M.D., M.P.H.	New York University School of Medicine
Romano, Louis J., Ph.D.	Wayne State University
Romkes, Marjorie, Ph.D.	The University of Pittsburgh
Romo, Daniel, Ph.D.	Texas A&M University
Ronai, Ze'Ev A., Ph.D.	Sanford-Burnham Medical Research Institute
Roper, Michael G., Ph.D.	Florida State University
Rosenzweig, Steven A., Ph.D.	Medical University of South Carolina

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Roth, Monica J., Ph.D.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Rowe, Thomas C., Ph.D.	University of Florida College of Medicine
Rowling, Matthew J., Ph.D.	Iowa State University
Roy, Hemant K., M.D.	Northshore University Health System
Roy-Burman, Pradip, Ph.D.	Keck School of Medicine
Rozek, Laura S., Ph.D.	University of Michigan, Ann Arbor
Ruczinski, Ingo, Ph.D.	The Johns Hopkins University
Ruffin, Mack T., M.D., M.P.H.	University of Michigan, Ann Arbor
Runge-Morris, Melissa A., M.D.	Wayne State University
Runowicz, Carolyn D., M.D.	Florida International University
Runyan, Raymond B., Ph.D.	The University of Arizona
Russo, Jose, M.D.	Fox Chase Cancer Center
Ruvkun, Gary B., Ph.D.	Harvard Medical School

S

Saban, Ricardo, D.V.M., Ph.D.	The University of Oklahoma Health Sciences Center
Sabbadini, Roger A., Ph.D.	Lpath, Inc.
Sachs, George, M.D.	University of California, Los Angeles
Sadelain, Michel, M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Sadler, Georgia R., Ph.D.	University of California, San Diego
Saenger, Yvonne M., M.D.	Mount Sinai School of Medicine
Safa, Ahmad R., Ph.D.	Indiana University-Purdue University, Indianapolis
Safe, Stephen H., Ph.D.	Texas A&M AgriLife Research
Said, Jonathan W., M.D.	University of California, Los Angeles
Sakamoto, Kathleen M., M.D., Ph.D.	Stanford University
Salgia, Ravi, M.D., Ph.D.	The University of Chicago
Saltz, Joel H., M.D., Ph.D.	Emory University
Saluja, Ashok K., Ph.D.	University of Minnesota, Twin Cities
Sambanis, Athanassios, Ph.D.	Georgia Institute of Technology
Sampson, John H., M.D., Ph.D.	Duke University
Samson, Leona D., Ph.D.	Massachusetts Institute of Technology
Sanderson, Ralph D., Ph.D.	The University of Alabama at Birmingham
Sarkar, Devanand, Ph.D.	Virginia Commonwealth University
Sartor, Ryan B., M.D.	The University of North Carolina at Chapel Hill
Sartorius, Carol A., Ph.D.	University of Colorado, Denver
Sauk, John J., D.D.S.	University of Louisville
Sausville, Edward A., M.D., Ph.D.	University of Maryland, Baltimore
Savran, Cagri, Ph.D.	Purdue University, West Lafayette
Sawyers, Charles L., M.D.	Memorial Sloan-Kettering Cancer Center
Scadeng, Miriam, M.D.	University of California, San Diego
Scarpinato, Karin D., Ph.D.	Georgia Southern University
Schabath, Matthew B., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Schedin, Pepper J., Ph.D.	University of Colorado, Denver
Schensul, Jean J., Ph.D.	Institute for Community Research
Schepkin, Victor D., Ph.D.	Florida State University
Scheurer, Michael E., Ph.D., M.P.H.	Baylor College of Medicine

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Schiemann, William, Ph.D.	Case Western Reserve University
Schiff, Rachel, Ph.D.	Baylor College of Medicine
Schildkraut, Joellen M., Ph.D., M.P.H.	Duke University
Schmainda, Kathleen M., Ph.D.	Medical College of Wisconsin
Schmittgen, Thomas D., Ph.D.	The Ohio State University
Schootman, Mario, Ph.D.	Washington University in St. Louis
Schrag, Deborah, M.D., M.P.H.	Dana-Farber Cancer Institute
Schroeder, Joyce A., Ph.D.	The University of Arizona
Schuchter, Lynn M., M.D.	The University of Pennsylvania
Schuler, Linda A., D.V.M., Ph.D.	University of Wisconsin, Madison
Schulick, Richard D., M.D.	The Johns Hopkins University
Schulman, Kevin A., M.D.	Duke University
Schwartz, Cindy L. M.D.	Brown University
Schwartz, David A., Ph.D.	Solulink Biosciences
Schwartz, Gary G., M.D., Ph.D., M.P.H.	Wake Forest University Health Sciences Center
Schwartz, Gary N., M.D.	Dartmouth-Hitchcock Medical Center
Schwartz, Jeffrey L., Ph.D.	University of Washington
Schwartz, Joel L., D.M.D.	University of Illinois at Chicago
Schwartz, Lawrence H., M.D.	Columbia University
Schwertfeger, Kathryn L., Ph.D.	University of Minnesota
Scribner, Richard A., M.D., M.P.H.	Louisiana State University Health Sciences Center
Seewaldt, Victoria L., M.D.	Duke University
Segal, Rosalind A., M.D, Ph.D.	Dana-Farber Cancer Institute
Segall, Jeffrey E., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Selassie, Cynthia Rachel, Ph.D.	Pomona College
Seligmann, Bruce E., Ph.D.	High Throughput Genomics, Inc.
Servoss, Shannon L., Ph.D.	University of Arkansas, Fayetteville
Sequist, Lecia V., M.D.	Harvard University
Setaluri, Vijayasradhi, Ph.D.	University of Wisconsin, Madison
Seth, Prem, Ph.D.	Evanston Northwestern Hospital
Setiawan, Veronica Wendy, Ph.D.	University of Southern California
Sgouros, George, Ph.D.	The Johns Hopkins University School of Medicine
Shailubhai, Kunwar, Ph.D.	Institute for Hepatitis and Virus Research
Shankar, Sriram, Ph.D.	University of Virginia
Shannon, Jackilen, Ph.D., M.P.H.	Oregon Health & Science University
Shapiro, Benjamin, Ph.D.	University of Maryland, College Park
Shapiro, Charles L., M.D.	The Ohio State University
Sharma, Dipali, Ph.D.	The Johns Hopkins University
Sharma, Sherven, Ph.D.	University of California, Los Angeles
Sharma, Vijay, Ph.D.	Washington University
Sharp, John G., Ph.D.	University of Nebraska Medical Center
Sharp, Phillip A., Ph.D.	Massachusetts Institute of Technology
Shea, Thomas C., M.D.	The University of North Carolina at Chapel Hill
Sheikh, M. Saeed, M.D., Ph.D.	Upstate Medical University
Shen, Zhiyuan Shen, M.D., Ph.D.	Robert Wood Johnson Medical School
Sheng, Shijie, Ph.D.	Wayne State University
Sherman, Michael Y., Ph.D.	Boston University Medical Campus

Sherman, Scott, M.D., M.P.H.	New York University School of Medicine
Shi, Hua, M.D., Ph.D.	The State University of New York at Albany
Shi, Huidong, Ph.D.	Georgia Health Sciences University
Shibata, Darryl K., M.D.	The University of Southern California
Shi, Xianglin, Ph.D.	University of Kentucky
Shi, Yufang, D.V.M., Ph.D.	University of Medicine and Dentistry of New Jersey- Robert Wood Johnson Medical School
Shields, Anthony F., M.D., Ph.D.	Wayne State University
Shih, Ie-Ming, M.D., Ph.D.	The Johns Hopkins University
Shih, Wan Y., Ph.D.	Drexel University
Shillitoe, Edward J., Ph.D.	The State University of New York, Upstate Medical University
Showe, Louise C., Ph.D.	The Wistar Institute
Shpall, Elizabeth J., M.D.	The University of Texas MD Anderson Cancer Center
Shroyer, Kenneth R., M.D., Ph.D.	The State University of New York at Stony Brook
Shuman, Marc A., M.D.	University of California, San Francisco
Shung, K. Kirk, Ph.D.	The University of Southern California
Shureiqi, Imad, M.D.	The University of Texas MD Anderson Cancer Center
Shyr, Yu, Ph.D.	Vanderbilt University
Siddiqui, Aleem, Ph.D.	University of California, San Diego
Siegfried, Jill M., Ph.D.	The University of Pittsburgh
Siemann, Dietmar W., Ph.D.	University of Florida
Siminoff, Laura A., Ph.D.	Virginia Commonwealth University
Simmons, Vani N., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Simon, Julian A., Ph.D.	Fred Hutchinson Cancer Research Center
Simpson, Kit N., Dr.PH.	Medical University of South Carolina
Simson, Elkin, M.D.	Self Employed
Singh, Karan P., Ph.D.	The University of Alabama at Birmingham
Singh, Pomila, Ph.D.	The University of Texas Medical Branch at Galveston
Singh, Shivendra, Ph.D.	The University of Pittsburgh Cancer Institute
Sirica, Alphonse E., Ph.D.	Virginia Commonwealth University
Siu, Lillian L., M.D.	University of Toronto
Skapek, Stephen X., M.D.	The University of Texas Southwestern Medical Center
Skibola, Christine F., Ph.D.	University of California, Berkeley
Skordalakes, Emmanuel, Ph.D.	The Wistar Institute
Slager, Susan L., Ph.D.	Mayo Clinic
Slattery, Martha L., Ph.D., M.P.H.	The University of Utah
Slingluff, Craig L., M.D.	University of Virginia
Sloan, Jeff, Ph.D.	Mayo Clinic
Slominski, Andrzej T., M.D., Ph.D.	The University of Tennessee Health Science Center
Smith, Jennifer S., Ph.D., M.P.H.	The University of North Carolina at Chapel Hill
Snetselaar, Linda G., Ph.D.	The University of Iowa
So, Anthony D., M.D.	Duke University
Sohn, Lydia L., Ph.D.	University of California, Berkeley
Soliman, Amr, M.D., Ph.D., M.P.H.	University of Nebraska Medical Center
Solit, David B., M.D.	Memorial Sloan-Kettering Cancer Center
Solomon, William B., M.D.	The State University of New York, Downstate Medical Center
Sorkin, Alexander D., Ph.D.	University of Colorado Health Science Center
Sousa, Rui J., Ph.D.	The University of Texas Health Science Center at San Antonio

Spiegelman, Vladimir S., M.D., Ph.D.	AMC Cancer Research Center
Srivastava, Rakesh K., Ph.D.	The University of Kansas Medical Center
Srouf, Edward F., Ph.D.	Indiana University-Purdue University, Indianapolis
Stack, Mary S., Ph.D.	University of Notre Dame
Stampfer, Martha R., Ph.D.	Lawrence Berkeley National Laboratory
Steck, Susan E., Ph.D., M.P.H.	University of South Carolina, Columbia
Steel, Jennifer L., Ph.D.	The University of Pittsburgh Medical Center
Steinberg, Bettie M., Ph.D.	Long Island Jewish Medical Center
Stevens, Victoria L., Ph.D.	American Cancer Society
Stewart, Clinton F., Pharm.D.	St. Jude Children's Research Hospital
Stewart, Sheila A., Ph.D.	Washington University in St. Louis
Stick, Roberta S., J.D.	Leukemia and Lymphoma Society
Stillman, Frances A., Ed.D.	The Johns Hopkins University
Storer, Barry E., Ph.D.	Fred Hutchinson Cancer Research Center
Strair, Roger K., M.D., Ph.D.	University of Medicine & Dentistry of New Jersey- Robert Wood Johnson Medical School
Strasser, Andrew, Ph.D.	The University of Pennsylvania
Street, Richard L., Ph.D.	Baylor College of Medicine
Stroobant, Paul, Ph.D.	Differential Proteomics, Inc.
Sturgeon, Susan R., Dr.P.H.	University of Massachusetts, Amherst
Su, Ying-Hsiu, Ph.D.	Drexel University College of Medicine
Sukumar, Saraswati, Ph.D.	The Johns Hopkins University
Sullivan, Debra K., Ph.D.	The University of Kansas Medical Center
Sullivan, Mark A., Ph.D.	University of Rochester
Suman, Vera J., Ph.D.	Mayo Clinic
Sun, Jieli, Ph.D.	Wake Forest University School of Medicine
Sun, Peiqing, Ph.D.	The Scripps Research Institute
Sun, Shumei S., Ph.D.	Virginia Commonwealth University
Sutcliffe, Siobhan, Ph.D.	Washington University in St. Louis
Sutphen, Rebecca, M.D.	University of South Florida
Svenson, Sonke, Ph.D.	Cerulean Pharma, Inc.
Swaminathan, Sankar, M.D.	The University of Utah
Sweeney, Carol, Ph.D.	The University of Utah
Symanowski, James T., Ph.D.	Carolinas Healthcare System
Szmacinski, Henryk, Ph.D.	University of Maryland, Baltimore

T

Tabar, Viviane, M.D.	Memorial Sloan-Kettering Cancer Center
Taichman, Russell S., D.M.D., D.M.Sc.	University of Michigan School of Dentistry
Tainsky, Michael A., Ph.D.	Wayne State University
Taioli, Emmanuela, Ph.D., M.D.	The State University of New York, Downstate Medical Center
Tajbakhsh, Jian, Ph.D.	Cedars-Sinai Medical Center
Tamanai, Fuyuhiko, Ph.D.	University of California, Los Angeles
Tan, Ming T., Ph.D.	Georgetown University
Tang, Li, M.D., Ph.D.	Roswell Park Cancer Institute
Tanjasiri, Sora P., Dr.PH.	California State University, Fullerton

Tannenbaum, Charles S., Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Taouli, Bachir, M.D.	Mount Sinai School of Medicine
Tautz, Lutz, Ph.D.	Sanford-Burnham Medical Research Institute
Taylor, Kathryn L., Ph.D.	Georgetown University Medical Center
Taylor, Maureen, Ph.D.	Imperial College of Science, Technology and Medicine
Taylor, Richard E., Ph.D.	University of Notre Dame
Teegarden, Dorothy, Ph.D.	Purdue University, West Lafayette
Teitell, Michael A., M.D., Ph.D.	University of California, Los Angeles
Tenen, Daniel G., M.D.	Beth Israel Deaconess Medical Center
Terrin, Norma C., Ph.D.	Tufts Medical Center
Thangaraju, Muthusamy, Ph.D.	Medical College of Georgia
Thayer, Julian F., Ph.D.	The Ohio State University
Thomas, Nancy E., M.D., Ph.D.	The University of North Carolina at Chapel Hill
Thomas-Tikhonenko, Andrei, Ph.D.	Children’s Hospital of Philadelphia
Thompson, Cheryl L., Ph.D.	Case Western Reserve University
Thompson, E. Aubrey, Ph.D.	Mayo Clinic, Jacksonville
Thompson-Carino, Patricia A., Ph.D.	The University of Arizona
Thomson, Cynthia A., Ph.D.	The University of Arizona
Thorburn, Andrew M., Ph.D.	University of Colorado Health Science
Threadgill, David W., Ph.D.	North Carolina State University, Raleigh
Thulborn, Keith R., M.D., Ph.D.	University of Illinois at Chicago
Tockman, Melvyn S., M.D., Ph.D.	University of South Florida
Tolbert, Thomas J., Ph.D.	The University of Kansas, Lawrence
Tolley, Luke, Ph.D.	Southern Illinois University, Carbondale
Tomalia, Donald A., Ph.D.	Dendritic Nanotechnologies, Inc.
Topp, Elizabeth M., Ph.D.	Purdue University, West Lafayette
Topsakal, Erdem, Ph.D.	Mississippi State University
Torchilin, Vladimir P., Sc.D., Ph.D.	Northeastern University
Toretsky, Jeffrey A., M.D.	Georgetown University
Torti, Suzy V., Ph.D.	Wake Forest University Health Sciences Center
Tosteson, Tor D., Sc.D.	Dartmouth College
Townsend, Alan J., Ph.D.	Wake Forest University School of Medicine
Tracy, J. Kathleen, Ph.D.	University of Maryland, Baltimore
Travis, Lois B., Sc.D., M.D.	University of Rochester
Triche, Timothy J., M.D., Ph.D.	Children’s Hospital Los Angeles
Tricot, Guido J., M.D., Ph.D.	The University of Iowa
Troyer, Dean A., M.D.	Eastern Virginia Medical School
Trump, Donald L., M.D.	Roswell Park Cancer Institute
Tucker, Thomas C., Ph.D., M.P.H.	University of Kentucky
Tung, Ching-Hsuan, Ph.D.	Weill Medical College of Cornell University
Turchi, John J., Ph.D.	Indiana University-Purdue University, Indianapolis
Turker, Mitchell S., Ph.D., J.D.	Oregon Health and Science University
Turner, Barbara J., Ed.D., M.D.	The University of Pennsylvania
Tworek, Cindy, Ph.D.	West Virginia University
Tycko, Benjamin, M.D., Ph.D.	Gordon Research Conferences
Tyler, Jessica K., Ph.D.	The University of Texas MD Anderson Cancer Center

U

Upendran, Anandhi, Ph.D.Nanoparticle Biochem, Inc.

V

Vail, David M., D.V.M.University of Wisconsin, Madison
 Valerie, Kristoffer C., Ph.D.Virginia Commonwealth University
 Van Besien, Koen W., M.D., Ph.D. Weill Cornell Medical College of Cornell University
 Vanderheyden, Jean-Luc E., Ph.D. JLVMI Consulting, LLC
 Van De Rijn, Jan Matt, M.D., Ph.D.Stanford University Medical Center
 Van Deursen, Jan M., Ph.D.Mayo Clinic
 Van Ness, Brian G., Ph.D.University of Minnesota, Twin Cities
 Vannier, Michael W., M.D.The University of Chicago
 Vasmatzis, George, Ph.D.Mayo Clinic
 Vaughan, Andrew T., Ph.D. Loyola University, Chicago
 Vaughan, John T., M.D., Ph.D.University of Minnesota, Twin Cities
 Vera, David R., Ph.D.University of California, San Diego
 Verschraegen, Claire F., M.D.The University of Vermont and State Agricultural College
 Vidrine, Damon J., Dr.P.H.The University of Texas MD Anderson Cancer Center
 Vile, Richard G, Ph.D.Mayo Clinic
 Visovsky, Constance G., Ph.D., R.N.University of South Florida
 Volkman, Brian F., Ph.D.Medical College of Wisconsin
 Vosburgh, Kirby G., Ph.D.Brigham and Women’s Hospital
 Vournakis, John J., Ph.D.Marine Polymer Technologies, Inc.
 Vujaskovic, Zeljko, M.D., Ph.D.Duke University
 Vykoukal, Jody V., Ph.D.The University of Texas MD Anderson Cancer Center

W

Wagner, David H. Jr., Ph.D.University of Colorado at Denver
 Wagner, Kay-Uwe, Ph.D.University of Nebraska Medical Center
 Wahl, Richard L., M.D.The Johns Hopkins University
 Wakil, Salih J., Ph.D.Baylor College of Medicine
 Walker, Ellen A., Ph.D.Temple University
 Walkosz, Barbara, Ph.D.Klein Buendel, Inc.
 Waller, Edmund K., M.D., Ph.D.Emory University
 Walsh, Martin J., Ph.D.Mount Sinai School of Medicine
 Walter, Roland Bruno, M.D., Ph.D.University of Washington School of Medicine
 Wan, Yu-Jui Yvonne, Ph.D.University of Kansas Medical Center
 Wands, Jack R., M.D.Rhode Island Hospital
 Wang, Bingcheng, Ph.D.Case Western Reserve University
 Wang, Chiayeng, Ph.D.University of Illinois, Chicago
 Wang, Catharine, Ph.D.Fox Chase Cancer Center
 Wang, Edwin, Ph.D.National Research Council Canada
 Wang, Henry Y., Ph.D.University of Michigan, Ann Arbor
 Wang, Hong-Gang, Ph.D.The Pennsylvania State University,
 Milton S. Hershey Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Wang, Judy H., Ph.D.	Georgetown University
Wang, Liang, Ph.D.	Medical College of Wisconsin
Wang, Quntian, Ph.D.	University of Illinois at Chicago
Wang, Rongfu, Ph.D.	Methodist Hospital Research Institute
Wang, Shan X., Ph.D.	Stanford University
Wang, Weiqun G., Ph.D.	Kansas State University
Wang-Rodriguez, Jessica, M.D.	University of California, San Diego
Ward, Dianne S., Ed.D.	The University of North Carolina at Chapel Hill
Wargovich, Michael, Ph.D.	The University of Texas Health Science Center at San Antonio
Warrick, Cynthia A., Ph.D.	Howard University
Washington, Mary K., M.D., Ph.D.	Vanderbilt University
Wattenberg, Brian W., Ph.D.	University of Louisville
Weber, Michael J., Ph.D.	University of Virginia
Weber, Patricia C., Ph.D.	Imiplex, LLC
Webster, Thomas J., Ph.D.	Brown University
Wei, Alexander, Ph.D.	Purdue University, West Lafayette
Weier, Heinz-Ulrich G., Ph.D.	Lawrence Berkeley National Laboratory
Weinberg, Irving, M.D., Ph.D.	Naviscan PET Systems, Inc.
Weinmann, Sheila A., Ph.D., M.P.H.	Kaiser Foundation Research Institute
Weintraub, Bruce D., M.D.	Trophogen, Inc.
Weiss, Heidi L., Ph.D.	The University of Texas Medical Branch at Galveston
Weiss, Joseph F., Ph.D.	Department of Energy
Weiss, Robert H., M.D.	University of California, Davis
Weiss, Stephen Joseph, M.D.	University of Michigan
Weissbach, Herbert, Ph.D.	Florida Atlantic University
Welford, Scott Michael, Ph.D.	Case Western Reserve University
Wen, Patrick Y., M.D.	Dana-Farber Cancer Institute
Wernli, Karen J., Ph.D.	Group Health Cooperative
West, Dee W., Ph.D.	Cancer Prevention Institute of California
Westphall, Michael S., Ph.D.	University of Wisconsin, Madison
Wetzler, Meir, M.D.	Roswell Park Cancer Institute
Wheatley, Barnarese P., Ed.D., M.P.H.	Alameda County Medical Center
White, Eileen, Ph.D.	Rutgers University
White, Emily, Ph.D.	Fred Hutchinson Cancer Research Center
Whiteside, Theresa L., Ph.D.	The University of Pittsburgh
Whitewolf, Celeste C., J.D.	Native People's Circle of Hope
Wieneke, Jacqueline, M.D.	Food and Drug Administration
Wiggins, Charles L., Ph.D.	The University of New Mexico Health Sciences Center
Wilcox, Adam B., Ph.D.	IHC Health Services, Inc.
Wiley, Patti, M.B.A.	On The Wings of Angels
Wilgus, Traci A., Ph.D.	The Ohio State University
Willey, James C., M.D.	Medical College of Ohio
Williams, David M., Ph.D.	Brown University
Williams, Karen Patricia, Ph.D.	Michigan State University
Williamson, Jeffrey F., Ph.D.	Virginia Commonwealth University
Wilson, Bridget S., Ph.D.	University of New Mexico Health Sciences Center
Wilson, David M., Ph.D.	National Institute on Aging
Wilson, Keith T., M.D.	Vanderbilt University Medical Center

Wilson-Sanders, Susan E., D.V.M.	The University of Arizona
Windle, Brad E., Ph.D.	Virginia Commonwealth University
Wingard, John R., M.D.	University of Florida
Winn, Robert A., M.D.	University of Colorado, Denver
Wistuba, Ignacio Ivan, M.D.	The University of Texas MD Anderson Cancer Center
Witt, Whitney P., Ph.D., M.P.H.	University of Wisconsin, Madison
Wolf, Wendy A., Ph.D.	Children's Hospital Boston
Wong, Ho-Lun, Ph.D.	Temple University
Wong, Lucas, M.D.	Oregon Health & Science University
Wong, Melissa H., Ph.D.	Oregon Health & Science University
Wong, Season S.S., Ph.D.	AI Biosciences, Inc.
Wong, Stephen T.C., Ph.D.	The Methodist Hospital System in Houston, Texas
Wood, Charles, Ph.D.	University of Nebraska
Wood, Marie E., M.D.	The University of Vermont and State Agricultural College
Woodle, Martin C., Ph.D.	Aparna Biosciences Corporation
Worsham, Maria J., Ph.D.	Henry Ford Health System
Woster, Patrick M. Ph.D.	Medical University of South Carolina
Wray, Susan, Ph.D.	National Institute of Neurological Disorders and Stroke
Wright, Kenneth L., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Wright, Michael E., Ph.D.	The University of Iowa
Wroblewski, Dariusz, Ph.D.	Bioformatix, Inc.
Wu, Tong, M.D., Ph.D.	Tulane University
Wu, Xifeng, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Wyatt, Christopher L., Ph.D.	Virginia Polytechnic Institute and State University
Wyatt, Gwen K., Ph.D., R.N.	Michigan State University

X

Xiao, Hua, M.D., Ph.D.	Michigan State University
Xing, Lei, Ph.D.	Stanford University
Xu, Tian, Ph.D.	Yale University
Xu, Xiangxi Mike, Ph.D.	University of Miami School of Medicine
Xu, Yan, Ph.D.	Indiana University-Purdue University, Indianapolis
Xu, Yang, Ph.D.	University of California, San Diego

Y

Yamamoto, Masato, M.D., Ph.D.	University of Minnesota
Yan, Cong, Ph.D.	Indiana University School of Medicine
Yang, Chung S., Ph.D.	Rutgers, The State University of New Jersey
Yang, Hushan, Ph.D.	Thomas Jefferson University
Yang, Ping, M.D., Ph.D.	Mayo Clinic Foundation
Yang, Yu-Chung, Ph.D.	Case Western Reserve University
Yannelli, John R., Ph.D.	University of Kentucky
Yao, Zhi Q., M.D., Ph.D.	East Tennessee State University
Yarema, Kevin J., Ph.D.	The Johns Hopkins University
Yaroch, Amy L., Ph.D.	AMC Cancer Research Center
Yeap, Beow Y., Sc.D.	Harvard Medical School

Yeger, Herman, Ph.D.	University of Toronto
Yen, Yun, M.D., Ph.D.	Beckman Research Institute of City of Hope
Yeo, Yoon, Ph.D.	Purdue University, West Lafayette
Yi, Qing, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Yost, David A., Ph.D.	Innovative Biosensors, Inc.
You, Ming, M.D., Ph.D.	Medical College of Wisconsin
Young, Jeanne P.	Childhood Brain Tumor Foundation
Yu, Gang, Ph.D.	The University of Texas Southwestern Medical Center
Yu, Qin, Ph.D.	Mount Sinai School of Medicine
Yu, Xue-Zhong, M.D.	University of South Florida
Yuan, Junying, Ph.D.	Harvard Medical School
Yuan, Zhi-Min, M.D., Ph.D.	The University of Texas Health Science Center at San Antonio
Yung, K. W. Alfred, M.D.	The University of Texas MD Anderson Cancer Center

Z

Zablotska, Lydia B., M.D., Ph.D.	University of California, San Francisco
Zaia, John A., M.D.	Beckman Research Institute of the City of Hope
Zaia, Joseph, Ph.D.	Boston University Medical Campus
Zaika, Alexander I., Ph.D.	Vanderbilt University
Zaren, Howard A., M.D.	John H. Stroger, Jr. Hospital
Zarnegar, Rasa, M.D.	Weill Cornell Medical College of Cornell University
Zarour, Hassane M., M.D.	The University of Pittsburgh
Zhang, David Y., M.D., Ph.D., M.P.H.	Mount Sinai School of Medicine
Zhang, Heping, Ph.D.	Yale University School of Medicine
Zhang, Huang-Ge, D.V.M., M.D., Ph.D.	The University of Alabama at Birmingham
Zhang, Jing, Ph.D.	University of Wisconsin
Zhang, Luwen, Ph.D.	University of Nebraska
Zhang, Ruiwen, M.D., Ph.D.	Texas Tech University Health Science Center
Zhang, Wei, Ph.D.	The University of Texas MD Anderson Cancer Center
Zhang, Weizhou, Ph.D.	University of California, San Diego
Zhang, Xiaoliu, M.D., Ph.D.	Baylor College of Medicine
Zhang, Yuesheng, M.D., Ph.D.	Roswell Park Cancer Institute
Zhang, Zuo-Feng, M.D., Ph.D., M.P.H.	University of California, Los Angeles
Zhao, Hongyu, Ph.D.	Yale University
Zhao, Zhizhuang J., Ph.D.	University of Oklahoma Health Sciences Center
Zheng, Bin, Ph.D.	The University of Pittsburgh
Zheng, Bin, Ph.D.	Columbia University Health Sciences Campus
Zheng, Yi, Ph.D.	Children's Hospital Medical Center
Zhou, Daohong, M.D.	University of Arkansas, Little Rock
Zhou, Gang, Ph.D.	College of William and Mary
Zhou, Jin-Rong, Ph.D.	Harvard Medical School
Zhou, Pengbo, Ph.D.	Cornell University
Zhou, Rong, Ph.D.	The University of Pennsylvania
Zhu, Haidong, M.D., Ph.D.	Georgia Prevention Institute
Zhu, Jianzhong, Ph.D.	The University of Pittsburgh
Zhu, Yong, Ph.D.	Yale University
Zhu, Yong, M., Ph.D.	Proteomtech, Inc.

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2012

Zhu, Yuan-Shan, M.D., Ph.D. Weill Cornell Medical College of Cornell University
Zi, Xiaolin, M.D., Ph.D. University of California, Irvine
Zondlo, Neal J., Ph.D. University of Delaware
Zou, Lee, Ph.D. Massachusetts General Hospital
Zutter, Mary M., M.D. Vanderbilt University

Total number of Reviewers: 1,770

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at <http://deainfo.nci.nih.gov/flash/awards.htm>.

C Series: Research Construction Programs

C06	Research Facilities Construction Grants To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.
------------	---

D Series: Training Projects

D43	International Training Grants in Epidemiology To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in foreign countries through support of training programs for foreign health professionals, technicians, and other health care workers.
------------	---

F Series: Fellowship Programs

F31	Predocctoral Individual National Research Service Award (NRSA) To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	Predocctoral Fellowship—Minority Students A fellowship award that provides predoctoral minority students with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	National Research Service Award for Individual Postdoctoral Fellows To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F32	National Research Service Award for Individual Postdoctoral Fellows To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F33	National Research Service Award for Senior Fellows To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Series: Career Development Programs

K01	<p>The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00)</p> <p>A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.</p>
K01	<p>Mentored Career Development Award for Underrepresented Minorities</p> <p>To support scientists committed to research who are in need of both advanced research training and additional experience.</p>
K05	<p>Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Research</p> <p>To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.</p>
K07	<p>Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award</p> <p>To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.</p>
K08	<p>Mentored Clinical Scientists Development Award</p> <p>To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.</p>
K08	<p>Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology</p> <p>A specialized type of Mentored Clinical Scientist Developmental Award (K08) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.</p>

K12	<p>Institutional Clinical Oncology Research Career Development Award</p> <p>To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.</p>
K22	<p>The NCI Transition Career Development Award for Underrepresented Minorities</p> <p>To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.</p>
K22	<p>The NCI Scholars Program</p> <p>To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this Program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.</p>
K23	<p>Mentored Patient-Oriented Research Career Development Award</p> <p>To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.</p>
K23	<p>Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities</p> <p>To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.</p>
K24	<p>Mid-Career Investigator Award in Patient-Oriented Research</p> <p>To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.</p>
K25	<p>Mentored Quantitative Research Career Development Award</p> <p>This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the necessary training and career development required to become involved in multidisciplinary cancer research.</p>

K99/ R00	<p>NIH Pathway to Independence (PI) Award</p> <p>The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to postdoctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.</p>
P Series: Research Program Projects and Centers	
P01	<p>Research Program Projects</p> <p>To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.</p>
P20	<p>Exploratory Grants</p> <p>To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.</p>
P30	<p>Center Core Grants</p> <p>To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to assure greater productivity than that provided through the separate projects and Program Projects.</p>
P50	<p>Specialized Center Grants</p> <p>To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.</p>

R Series: Research Projects	
R01	<p>Research Project</p> <p>Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.</p>
R03	<p>Small Research Grants</p> <p>Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.</p>
R13	<p>Conferences</p> <p>The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.</p>
R15	<p>The NIH Academic Research Enhancement Awards (AREA)</p> <p>To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' faculty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.</p>
R21	<p>Exploratory/Developmental Grants</p> <p>To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)</p>
R24	<p>Resource-Related Research Projects</p> <p>To support research projects that will enhance the capability of resources to serve biomedical research.</p>

R25E	<p>Cancer Education Grant Program (CEGP)</p> <p>A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured short-term research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH, and are dedicated to areas of particular concern to the National Cancer Program.</p>
R25T	<p>Cancer Education and Career Development Program</p> <p>To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but should also be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.</p>
R33	<p>Exploratory/Developmental Grants, Phase II</p> <p>To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33.</p>
R37	<p>Method to Extend Research in Time (MERIT) Award</p> <p>To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of review of competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.</p>

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral research area as described in the solicitations

below. Support under the SBIR program is normally provided for 6 months/\$100,000 for Phase I, and 2 years/\$500,000 for Phase II. However, applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	<p>STTR Grants, Phase I To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount; to establish the technical merit and feasibility of ideas that have potential for commercialization.</p>
R42	<p>STTR Grants, Phase II To support in-depth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.</p>
R43	<p>SBIR Grants, Phase I To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.</p>
R44	<p>SBIR Grants, Phase II To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.</p>
R55	<p>James A. Shannon Director's Award To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications.</p>
R56	<p>High-Priority, Short-Term Project Award Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.</p>

S Series: Research-Related Programs	
SC1	<p>Research Enhancement Award</p> <p>Individual investigator-initiated research projects aimed at developing researchers at minority-serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (R01 or equivalent).</p>
SC2	<p>Pilot Research Project</p> <p>Individual investigator-initiated pilot research projects for faculty at minority-serving institutions (MSIs) to generate preliminary data for a more ambitious research project.</p>
S06	<p>Minority Biomedical Research Support (MBRS)</p> <p>To strengthen the biomedical research and research training capability of ethnic minority institutions, and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.</p>
S07	<p>Biomedical Research Support Grants (NCRR BRSG)</p> <p>As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the BRSG program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institution after the award period ends. Awardees also are required to collaborate with other institutions conducting human subjects research and are not currently funded under this program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it is administered by the National Center for Research Resources (NCRR).</p>
S10	<p>Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)</p> <p>The National Center for Research Resources (NCRR) initiated its competitive Shared Instrumentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide support for expensive state-of-the-art instruments utilized in both basic and clinical research. This program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of the program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described.</p>
S21	<p>Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building</p> <p>To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.</p>

T Series: Training Programs	
T15	Continuing Education Training Grants To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.
T32	NIH National Research Service Award—Institutional Research Training Grants To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.
U Series: Cooperative Agreements	
U01	Research Projects—Cooperative Agreements To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.
U10	Cooperative Clinical Research—Cooperative Agreements To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators, and are usually conducted under established protocols.
U13	Conference—Cooperative Agreements To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.
U19	Research Program—Cooperative Agreements To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.
U24	Resource-Related Research Projects—Cooperative Agreements To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U54	Specialized Center—Cooperative Agreements To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program projects in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.
U56	Exploratory Grants—Cooperative Agreements To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.

Appendix F: Glossary of Acronyms

AHRQ	Agency for Healthcare Research and Quality	DCLG	Director's Consumer Liaison Group
AIDS	Acquired Immune Deficiency Syndrome	DPC	Division of Cancer Prevention
AISB	Applied Information Systems Branch	DCTD	Division of Cancer Treatment and Diagnosis
ARA	Awaiting Receipt of Application	DEA	Division of Extramural Activities
AREA	Academic Research Enhancement Award	DEAS	Division of Extramural Activities Support
ARRA	American Recovery and Reinvestment Act	DHHS	U.S. Department of Health and Human Services (now HHS)
BRSRG	Biomedical Research Support Grant	DOC	Division/Office/Center
BSA	Board of Scientific Advisors	EPMC	Extramural Program Management Committee
BSC	Board of Scientific Counselors	eRA	Electronic Research Administration
C&A	Certification and Accreditation	ESA	Extramural Support Assistant
CAM	Complementary and Alternative Medicine	FACA	Federal Advisory Committee Act
CBIIT	NCI Center for Biomedical Informatics and Information Technology	FDA	Food and Drug Administration
CCCT	Coordinating Center for Clinical Trials	FIC	Fogarty International Center
CCR	Center for Cancer Research	FLARE	Fiscal Linked Analysis of Research Emphasis
CCSB	Centers for Cancer Systems Biology	FNLCR	Frederick National Laboratory for Cancer Research
CCSG	Cancer Center Support Grant	FOA	Funding Opportunity Announcements
CCT	Center for Cancer Training	FOIA	Freedom of Information Act
CD	Career Development	FY	Fiscal Year
CDC	Centers for Disease Control and Prevention	GSS	General Support System
CEGP	Cancer Education Grant Program	HHS	Department of Health and Human Services (replaces DHHS)
CIT	Center for Information Technology	I2E	IMPAC II Extensions
CMO	Committee Management Office	IC	Institute/Center
CSO	Common Scientific Outline	ICRP	ICR Partners
CSR	Center for Scientific Review	IMPAC	Information for Management, Planning, Analysis, and Coordination
CSSI	Center for Strategic Scientific Initiatives	IRG	Initial Review Group
CTAC	Clinical Trials and Translational Research Advisory Committee	IRM	Information Resources Management
CTEP	Clinical Trials Evaluation Program	IT	Information Technology
DCB	Division of Cancer Biology	LOI	Letter of Intent
DCCPS	Division of Cancer Control and Population Sciences	LRP	Loan Repayment Program
DCEG	Division of Cancer Epidemiology and Genetics	MBRS	Minority Biomedical Research Support
		MERIT	Method to Extend Research in Time
		MSI	Minority-Serving Institution

NCAB	National Cancer Advisory Board	PCRB	Program Coordination and Referral Branch
NCCAM	National Center for Complementary and Alternative Medicine	PHS	Public Health Service (HHS)
NCI	National Cancer Institute	PI	Principal Investigator
NCRR	National Center for Research Resources	PRESTO	Program Review and Extramural Staff Training Office
NCTN	National Clinical Trials Network	RAEB	Research Analysis and Evaluation Branch
NDPA	NIH Director Pioneer Award	R&D	Research and Development
NFAC	NCI Frederick Advisory Committee	RFA	Request for Applications
NFRP	NCI Funded Research Portfolio	RFP	Request for Proposals
NIA	National Institute on Aging	RIO	Research Integrity Officer
NIBIB	National Institute of Biomedical Imaging and Bioengineering	RO	Referral Officer
NICHD	Eunice Kennedy Shriver National Institute of Child Health and Human Development	RPRB	Research Programs Review Branch
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases	RTRB	Resources and Training Review Branch
NIH	National Institutes of Health	RUG	Review Users Group
NIMH	National Institute of Mental Health	SBIR	Small Business Innovation Research
NRSA	National Research Service Award	SBIRDC	SBIR Development Center
OAR	Office of AIDS Research	SEER	Surveillance, Epidemiology, and End Results
OBF	Office of Budget and Finance	SEP	Special Emphasis Panel
OBSSR	Office of Behavioral and Social Sciences Research	SGE	Special Government Employee
OCAM	Office of Complementary and Alternative Medicine	SIC	Special Interest Category
OD	Office of the Director	SIG	Shared Instrumentation Grant
OEA	Office of Extramural Applications	SITE	Organ Site Codes
OER	Office of Extramural Research	SPECS	Strategic Partnering to Evaluate Cancer Signatures
OFACP	Office of Federal Advisory Committee Policy	SPL	Scientific Program Leadership
OHAM	Office of HIV and AIDS Malignancies	SPORE	Specialized Program of Research Excellence
OPERA	Office of Policy for Extramural Research Administration	SPRS	Secure Payee Reimbursement System
ORRPC	Office of Referral, Review, and Program Coordination	SREA	Scientific Review and Evaluation Activities
PA	Program Announcement	SRLB	Special Review and Logistics Branch
PAR	Reviewed Program Announcement	SRO	Scientific Review Officer (formerly Scientific Review Administrator)
PAT	Process Analytic Technologies	STTR	Small Business Technology Transfer Research
PCP	President's Cancer Panel	T&E	Training and Education
		TEAG	Trans-NCI Extramural Awareness Group

Appendix G: Cancer Information Sources on the Internet

NCI Website

The National Cancer Institute maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at <http://www.cancer.gov/>.

DEA Websites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

<http://deainfo.nci.nih.gov/index.htm>

DEA home page links to the individual DEA Web pages listed below; mission of the Division; contact information for DEA staff.

Advisory Boards and Groups

<http://deainfo.nci.nih.gov/advisory/boards.htm>

Links to the home page of each NCI Advisory Board, Committee, etc.

<http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm>

President's Cancer Panel Charter; meeting agendas, meeting minutes, annual reports.

<http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>

National Cancer Advisory Board Charter; members of subcommittees, meeting agendas.

<http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>

NCAB meeting summaries.

<http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>

Board of Scientific Advisors Charter; members of subcommittees, meeting agendas.

<http://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm>

BSA meeting summaries.

<http://deainfo.nci.nih.gov/advisory/fac/fac.htm>

Charter, minutes, members, and agendas of the NCI Frederick Advisory Committee

<http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm> and

<http://deainfo.nci.nih.gov/advisory/bsc/cse/cse.htm>

Board of Scientific Counselors Charter; members of subcommittees.

<http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm>

Clinical Trials and Translational Research Advisory Committee Charter; members, minutes, and agendas.

<http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm>

NCI Director's Consumer Liaison Group Charter; meeting schedules, agendas, minutes, and meeting summaries.

<http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>

Program Review Group reports.

<http://deainfo.nci.nih.gov/advisory/irg/irg.htm>

Initial Review Group Charter; subcommittee members.

<http://deainfo.nci.nih.gov/advisory/sep/sep.htm>

Special Emphasis Panel Charter; rosters of recent meetings.

Funding Opportunities/Policies

<http://deainfo.nci.nih.gov/funding.htm>

Comprehensive information about funding for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; downloadable application forms.

<http://deais.nci.nih.gov/Public/RFA-PA.jsp?nt=P>

Active PAs, with links to detailed descriptions.

<http://deais.nci.nih.gov/Public/RFA-PA.jsp>

Active RFAs, with links to detailed descriptions.

<http://deainfo.nci.nih.gov/grantspolicies/>

Links to full-text NCI and NIH policies related to grants and grant review (e.g., Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications).

<http://deainfo.nci.nih.gov/flash/awards.htm>

Grant Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links to PAs, RFAs, guidelines, and supplemental materials).

http://grants.nih.gov/grants/new_investigators/index.htm

New and Early Stage Investigator Policies.

<http://www.cancer.gov/researchandfunding/training>

The Center for Cancer Training (CCT).

Other Websites

<http://report.nih.gov/index.aspx>

Research Portfolio Online Reporting Tools (RePORT). Reports, Data, and Analyses of NIH Research Activities.

<http://fundedresearch.cancer.gov>

NCI Funded Research Portfolio: A visitor can search the database for information about extramural research grant and contract awards as well as intramural grants made by the NCI.

Other NIH Websites

<http://www.nih.gov>

<http://grants.nih.gov/grants/ElectronicReceipt/>

<http://grants.nih.gov/grants/policy/policy.htm>

<http://grants.nih.gov/grants/guide/index.html>

<http://grants.nih.gov/training/extramural.htm>

<http://report.nih.gov>

**An electronic version of this document can be viewed and downloaded
from the Internet at <http://deainfo.nci.nih.gov/>**



NATIONAL[®]
CANCER
INSTITUTE

December 2013